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Nanotechnology is one of the main drivers of the current scientific advancements. Indeed, 
by engineering materials in the nanoscale range, materials may acquire unique properties 
that allow the development of novel and innovative applications for sometimes well-known 
materials. Distinct nanoparticles enjoy widespread popularity as they are being exploited by 
various industries, such as the automotive, aerospace, chemical, textile and cosmetic 
industry. In this spirit, the use of organic and inorganic nanoparticles (NPs) is also being 
avidly explored for biomedical use. NPs can be applied to improve biomarker detection, 
enhance imaging-mediated diagnosis or improve treatment strategies. Overall organic 
nanoparticles have evolved further in their clinical development, whereas the elusive safety 
profiles of inorganic nanoparticles hinder their clinical implementation. In this thesis we will 
look into the origin of the questionable safety of inorganic NPs and how the optimization of 
nanotoxicity testing may bring solace. First, we look into the use of organic particles as 
nanocarriers for nucleic acids (NA), and how their delivery potential could be enhanced using 
low molecular weight adjuvants. 
The therapeutic potential of nucleic acids has been well established for a myriad of 
disorders. In contrast, few NA-based therapeutics managed to transfer to the clinic. This can 
mainly be attributed to delivery challenges, as NA require delivery to their cytosolic or 
nuclear site of action to evoke a therapeutic effect. Nanocarriers were initially believed to be 
the magic bullet towards efficient delivery of NA. However, the intracellular endo-lysosomal 
entrapment upon endocytosis severely hampers their delivery efficiency. Indeed, only a 
minor fraction of the internalized NA dose manages to reach its intracellular site of action, 
whereas the bulk is destined for lysosomal degradation. Hence, escape to the cytosol 
remains a major intracellular hurdle, which we aim to tackle by improving cytosolic NA 
release through the repurposing of cationic amphiphilic drugs (CADs).  
This method was initially investigated in the context of small interfering (si)RNA delivery, 
using dextran nanogels (NG) as a model nanocarrier. In Chapter 1 we provide a general 
introduction to NA delivery by nanocarriers, focussing on the abovementioned NGs. In 
addition, we discuss the molecular RNA interference pathway, which is triggered upon 
AIM & OUTLINE 
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successful cytosolic delivery of siRNA and allows sequence-specific post-transcriptional gene 
silencing. Finally, we introduce the use of CADs as low molecular weight adjuvants and 
explain their molecular action, which is hypothesized to improve siRNA delivery. In Chapter 2 
we review literature on the use of low molecular weight adjuvants to improve NA delivery. 
More specifically, we describe how the delivery by distinct nanocarriers or the transfection 
efficiency of certain NA can be improved through the action of specific small molecules.   
In Chapter 3 we investigated whether CADs could be repurposed to improve the cytosolic 
siRNA delivery upon transfection with NGs in cancer cells. We furthermore assessed the 
effect of the CADs on the endo-lysosomal compartment in an attempt to elucidate how 
CADs facilitate siRNA transfer to the cytosol. Moreover, we evaluated whether additional 
CAD treatments at later time points could further induce cytosolic delivery of siRNA, thereby 
exploiting the lysosomes as an intracellular NA depot. Finally, we established the therapeutic 
potential of the adjuvant approach by enhancing the effect of an anti-cancer siRNA in non-
small cell lung cancer cells. 
Given the promising observations in Chapter 3, we aimed to establish the broader 
applicability of the adjuvant approach in terms of the adjuvant, NA cargo and nanocarrier. 
More specifically, in Chapter 4 we examined if additional low molecular weight molecules 
without CAD properties could equally improve siRNA delivery. In addition, we assessed 
whether CADs could improve messenger RNA delivery and looked into the effect of CADs on 
the delivery by lipid-based formulations and a cholesterol-siRNA conjugate. 
Several inorganic nanoparticles can equally be applied as delivery vehicles. Iron oxide 
(IO)NPs are for instance being developed for magnetism-guided drug delivery and gold and 
silica NPs are investigated for their NA delivery potential. Additional potential applications 
comprise imaging, biomarker detection and cancer treatment (through hyperthermia). 
Despite the large body of research on the potential biomedical use of distinct inorganic NPs, 
few are currently applied in the clinic. Overall, the main setback towards clinical translation 
remains the questionable safety, which can at least in part be attributed to the publication 
of conflicting and inconsistent data. Hence, standardization of in vitro nanotoxicity 
assessments became a hot topic with various research groups pinpointing drawbacks in the 
current testing paradigm and identifying parameters that require optimization. We aimed to 
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contribute to the optimization effort by assessing the importance of the applied cell model 
in mechanistic nanotoxicity evaluations and NP optimization studies.  
In Chapter 5 we first provided a general introduction into the field of nanotoxicity by 
discussing several mechanisms through which inorganic NPs may affect the cell homeostasis 
and the conventional in vitro assays applied to study cell-NP interactions. Moreover, intrinsic 
shortcomings to these methods are highlighted and recently developed assays are 
introduced. Finally, we provide insights into how the in vitro cell model complexity affects 
NP uptake and toxicity. 
In Chapter 6 we studied the interaction of iron oxide (IO)NPs with six related neural cell 
types, namely neural stem cells, a neural progenitor cell line and neuroblastoma cell line 
derived from both humans and mice. In short, we assessed the IONP-induced cytotoxicity, 
production of reactive oxygen species and the impact of IONPs on the calcium homeostasis, 
mitochondrial health and cell morphology. Hereby, we aimed to unveil whether the cell type 
and species extensively influence the outcome of in vitro nanotoxicity studies and if the cell 
model should be standardized, just like many other elements of the in vitro nanotoxicity 
testing paradigm. In a follow-up study, presented in Chapter 7, we investigated if the 
selected cell model affects the nanosafety optimization of inorganic NPs for biomedical use. 
Hereto we evaluated cell-NP interactions in the same setup as described in Chapter 6 and 
looked into the cell-NP interaction of differentially coated IONPs. 
Thus in this thesis we aim to tackle an important short coming to of both organic and 
inorganic NPs, being the low delivery efficiency and the optimization of nanotoxicity 
assessments, respectively. In a final chapter (Chapter 8) we discuss the broader international 
context and commercial incentive towards the use of both types of NPs. Finally, we look into 
the clinical development of inorganic NPs and nanoconstructs for siRNA delivery and discuss 
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RNA interference (RNAi) is a highly conserved biological process applied by the cell to 
regulate gene expression in a sequence specific fashion at the post-transcriptional level. Ever 
since the discovery of this phenomenon, researchers have set out to use it to their 
advantage as a lab tool or a novel therapeutic strategy. In this thesis we triggered the RNAi 
pathway with short interfering RNA (siRNA). Given the issues connected to nucleic acid 
delivery, an appropriate carrier was applied to obtain intracellular siRNA delivery. More 
specifically, we applied dextran nanogels in the majority of the experiments. In this general 
introduction we supply the reader with background information on the RNAi pathway, its 
effectors – including siRNA – and the nanocarriers that can be applied to deliver siRNA, with 
a focus on dextran nanogels. In a final section, we focus on the use of functional inhibitors of 




1. RNA INTERFERENCE 
RNA interference (RNAi) is a mechanism through which gene expression can sequence-
specifically be modulated at the post-transcriptional level. This process is highly evolutionary 
conserved, given its important function in the endogenous regulation of gene expression and 
the defense against viral infections and foreign genetic material, such as transposons.1-3 
RNAi was first witnessed in plants in 1990.4 Nearly a decade later Fire and Mello showed that 
exogenous double stranded RNA (dsRNA) silenced an endogenous gene in a sequence 
specific way in C. elegans.5 For their pioneer work, both gentleman were rewarded the 
Nobel Prize for Physiology and Medicine in 2006. Soon after these observations, RNAi was 
shown to modulate gene expression in mammalian cells.6 From this point onwards, research 
into this pathway with regard to both the elucidation of the molecular mechanism and the 
potential applications fiercely increased. The first report on RNAi-mediated gene silencing in 
human cells appeared in 2004.7 One year earlier, a first successful in vivo study was 
published, which systemically applied naked siRNA in a murine acute liver failure model.8 In 
2004, Acuity Pharmaceuticals commenced a first Phase I clinical trial where naked siRNA 
targeting the VEGF pathway was injected intravitreally for the treatment of age-related 
macular degeneration.9 Soon afterwards stable nucleic acid lipid nanoparticles (SNALP) were 
applied to deliver 1-2.5 mg/kg siRNA via an intravenous injection in non-human primates, 
leading to >90% apolipoprotein B silencing in the liver 48h post injection.10 Intranasally 
administrated siRNA was reported to be safe and well tolerated in 2008.11 The final glass 
ceiling was breached in 2010 with the report on the first clinical Phase I study in humans 
providing a proof-of-concept that systemically administrated siRNAs can silence target genes 
in human beings.12 
As a lab tool RNAi can be applied to elucidate protein functions or to create knock-down 
models mimicking certain disorders.13, 14 More importantly, RNAi modulators can be applied 
as a therapeutic strategy for a vast diversity of disorders, such as viral infections, hereditary 
and autoimmune diseases or cancer.15, 16 In this section we will introduce the RNAi pathway 
as well as its effectors.  
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1.1. Mechanism 
The RNAi pathway can be triggered by different categories of effector molecules, including 
microRNA (miRNA) and short interfering RNA (siRNA). Although both groups share certain 
steps in the pathway, both their biogenesis and final effect on the target messenger RNA 
(mRNA) differ (Figure 1.1).17 
 
Figure 1.1. miRNA biogenesis and the RNAi molecular pathway followed by miRNA (left) and siRNA 






First, siRNA is mainly exogenous in source whereas miRNA stem from endogenously 
expressed transcripts.19 Primary miRNA (pri-miRNA) is generated through transcription by 
RNA polymerase II and folded into a stem-loop structure with bulges due to occasional base 
pair mismatches.20 This pri-miRNA is subsequently transferred to the microprocessor 
complex, where Drosha cleaves the pri-miRNA into a shorter precursor miRNA (pre-
miRNA).17, 21 Next, pre-miRNA is shuttled from the nucleus to the cytosol by Exprotin-5.22-24 
Once in the cytosol, the pre-miRNA is processed by Dicer, which produces mature ˜22 
nucleotides long miRNA duplexes and removes the loop structure.20   
Where miRNA mainly stems from endogenously expressed transcripts, siRNA generally 
enters the cytosol as a long dsRNA molecule upon a viral infection. As for pre-miRNA, the 
dsRNA is cleaved by Dicer at ˜22 nucleotide intervals to generate mature siRNA duplexes 
with 2 nucleotide overhangs at the 3’ end.25 In contrast to miRNA, the base pairs in the 
siRNA molecule show complete complementarity wherefore no bulges are present in the 
mature duplexes.17, 20  
From this point onwards, both the mature siRNA and miRNA follow similar processing down 
the RNAi pathway. First, Argonaute 2 (Ago2) associates with the RNase complex containing 
Dicer to facilitate transfer of the mature siRNA or miRNA duplex to Ago2 in the so-called pre-
RNA-induced silencing complex (pre-RISC). Here, the mature duplexes are unwound in an 
ATP-dependent process.17 Next, the guide strand is selected based on the thermodynamic 
stability of both strands, with the strand with the more stable base pairs at its 5’ end being 
more likely to become the passenger strand.25, 26 The latter is subsequently discarded from 
pre-RISC or cleaved by Ago2 in case of miRNA or siRNA, respectively, whereby activated 
RISC* is obtained.27, 28 The guide strand subsequently directs RISC* towards the target 
mRNA, which is recognized through Watson and Crick base pairing.17   
From this point onwards the pathways for siRNA- and miRNA-mediated gene silencing once 
again diverge. In general, siRNA shows complete complementarity with its target mRNA and 
the phosphodiester bond of the target nucleotides associated with nucleotide 10 and 11 of 
the siRNA guide strand (counting from the 5’ end) is cleaved by Ago 2.29 Hereby, unprotected 
ends are created in the mRNA strand, which leaves it vulnerable to further degradation by 
exonucleases in the cytosol.30 
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Complete complementarity is in contrast not a prerequisite for miRNA-mediated gene 
silencing, as the target mRNA is generally recognized through complementarity with bases 2 
to 8 of the miRNA guide strand, also known as the seed region.31 Consequently, the target 
mRNA will either be degraded or its translation will be inhibited, based on the extent of base 
complementarity in the miRNA-mRNA duplex.20, 32 In case of complete complementarity, 
Ago2 cleaves the mRNA similar to silencing by siRNA.29, 33 However, in most cases incomplete 
complementarity leads to bulges in the mRNA-miRNA duplex, which hampers cleaving by 
Ago2. The consequent mechanism of gene silencing is still under debate. One possibility may 
be the inhibition of translation initiation by blocking the association of the 40S and 60S 
ribosome subunits.34 The mRNA may in turn be shuttled towards the processing bodies (p-
bodies) where it can be deadenylated and degraded.17, 20 
This last distinction between siRNA- and miRNA-mediated gene silencing implicates that 
siRNA will theoretically silence a single target gene whereas a single miRNA can affect the 
expression of multiple genes.15 An overview of the distinctions between siRNA and miRNA is 
provided in Table 1.1. SiRNA was selected for our work given its increased specificity.  
Table 1.1. Distinctions between siRNA and miRNA source, processing and effect. 
 siRNA miRNA 
Source 
Exogenous 
 Viral, transposons 
 Synthetic dsRNA or siRNA 
Endogenous 
 Transcription by RNA 
polymerase II 
Processing Dicer: dsRNA -> siRNA  
Drosha: Pri-mirNA -> pre-miRNA  
Dicer:    Pre-miRNA -> miRNA  
Structure mature 
duplex 
˜22 base pairs  
3’ 2 nucleotide overhang 
Complete complementarity 
18-25 base pairs  
3’ 2 nucleotide overhang 
Incomplete complementarity 
Target recognition Complete complementarity Complementarity in seed region 
# mRNA targets One Multiple 
Mechanism of 
gene silencing 
Ago2 cleaves target mRNA  
Ago2 cleaves target mRNA 
Repress initiation translation 




1.2. RNAi triggers 
Based upon the current knowledge of the RNAi pathway, several RNAi triggers could be 
developed. These include plasmid DNA (pDNA) or synthetic siRNA molecules, being either 
dsRNA or ˜22 base pair duplexes.15 Of note, by synthesizing RNAi triggers with the proper 
sequence any given mRNA molecule can theoretically be targeted. 
In case of pDNA, transcription of the transgene renders a short hairpin (sh)RNA molecule 
mimicking the pre-miRNA intermediate in the miRNA biogenesis. This shRNA is subsequently 
processed like miRNA but will cleave the target mRNA similar to siRNA.35, 36 Interestingly, 
prolonged gene silencing can be achieved via this method when stable transgene expression 
is obtained.37 Despite the fact that this strategy can be interesting for chronic disorders, this 
method also poses several challenges. First, in order to influence the target gene expression, 
the shRNA has to run through the entire miRNA pathway wherefore the extent of the effect 
largely depends on the kinetics of the various enzymes necessary for shRNA processing. 
Competition of the shRNA with endogenous pre-miRNA for exportin-5 and additional 
downstream enzymes may consequently affect the cellular RNAi homeostasis and cause 
severe adverse effects.22, 38 Secondly, pDNA nuclear entry is a predicament for a successful 
therapy. Hence, the nuclear envelope needs to be crossed for successful delivery, which is 
one of the more difficult biological barriers to overcome during transfection.39, 40   
Overall, the use of synthetic siRNA and especially that of ˜22 base pair duplexes is the 
preferred strategy. Such oligonucleotides can be easily produced on a large scale and are 
more easily transfected into the cytosol. Chemical modifications can furthermore reduce 
potential adverse events and improve the stability.16, 41 Initially 25 to 27 base pair ‘Dicer-
ready’ duplexes were applied. However, these duplexes still required Dicer mediated 
cleaving, which is not the case when applying synthetic ˜22 base pair duplexes mimicking 
mature siRNA molecules.42 Hence, the latter are the overall selected weapon of choice. 
Indeed, by applying an effector that only enters the pathway at its final stage, a minimum 
effect on the cellular RNAi homeostasis is anticipated.42 
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2. NANOCARRIERS 
Naked unmodified siRNA duplexes, as applied in preliminary work, largely failed to strongly 
influence gene expression. Two main factors were held responsible: namely the limited 
stability and the physicochemical properties of the duplex. Indeed, unmodified siRNA is 
prone to nuclease-mediated degradation and the large size and negative charge limit cellular 
siRNA internalization through passive diffusion.43 The issue of siRNA degradation was in part 
resolved by chemical modifications of the siRNA bases whereas nanoparticles, the so-called 
nanocarriers, are most often applied to ensure internalization. In this section we provide a 
short overview of avidly applied nanoparticles for siRNA delivery, with a focus on the 
dextran nanogels (dex-NGs) used in the majority of the experimental work presented in the 
first part of this thesis.  
2.1. Overview 
Nanoparticles for nucleic acid delivery, from here on forward referred to as nanocarriers, 
can be divided into two main subgroups: viral and non-viral nanocarriers. Viral vectors allow 
great transfection efficiencies, but their use has been correlated with insertional 
mutagenesis and immunogenicity.44  Non-viral vectors are in contrast considered to be a 
safer alternative although the main limitation remains their limited transfection efficiency. 
Thus, no ideal nanocarrier exists as of today.  
Since the applied dex-NGs belong to the non-viral carriers, this subgroup will be further 
highlighted. In general, non-viral carriers can be subdivided in lipid-based, polymer-based 
and inorganic nanocarriers, all of which have shown potential to deliver siRNA.2 Here, we 
provide a short introduction to the different nanocarriers for siRNA delivery. For more 
detailed information and extensive reviews on distinct formulations, the reader is referred 
to various recent reviews.2, 3, 9, 41, 45 
Lipid-based carriers are most widely applied and have advanced furthest in their 
development.41 Concurrently, most siRNA-formulations evaluated in clinical trials are lipid-
based.16, 41, 46, 47 The in vitro standard for siRNA transfection is Lipofectamine RNAiMAX, 
where lipids and siRNA are mixed to form lipoplexes.2 Amphiphilic lipids are furthermore 
often applied as they spontaneously arrange in micellar or liposomal structures when 




constituents to ensure siRNA complexation.49, 50 Helper lipids can furthermore be included to 
improve the LPS stability (cholesterol) or endosomal escape efficiency (DOPE).2, 49, 51 Many 
different synthetic and naturally occurring lipids (e.g. phospholipids, sphingolipids, 
cholesterol, etc.) can be applied to synthesize LPS, explaining the plethora of reported 
formulations.2 Efforts on formulation optimization lead to the development of stable nucleic 
acid lipid particles (SNALP). This LPS consists of lipids that become charged in an acidic 
environment to promote escape and encapsulates the siRNA in its aqueous core. The LPS is 
furthermore stabilized by polyethylene glycol (PEG) and is readily degradable. In general, 
good in vitro and in vivo transfection results were obtained with SNALP, explaining its avid 
use in clinical trials.10, 52, 53 More recently, Akinc et al. developed biodegradable lipid-like 
molecules, the so-called ‘lipidoids’.54 More than 1200 lipidoids could be created by 
combining hydrophobic alkylacrylate or –acrylamide chains of different lengths (C10-18) 
with various primary or secondary amine structures. A screening approach revealed the 
most efficient lipidoid-based carrier for siRNA delivery, which successfully induced gene 
silencing in hepatocytes in vitro, in mice and in non-human primates.55, 56  
A second ominously applied strategy is the use of polymer-based nanocarriers.3 Such carriers 
come in distinct structures depending on the applied polymer, with the most frequently 
reported ones being polyplexes, polymeric micelles, dendrimers and nanospheres.2, 41 First, 
polyplexes are - similar to lipoplexes - prepared by simply mixing nucleic acids with the 
cationic polymer. The first polymer to be applied in this context was poly-L-lysine.57, 58 
Probably the best-known polymer applied in this way is polyethylene imine (PEI). The many 
amine groups are suggested to act as a proton sponge in the endosomal environment, which 
facilitates endosomal escape.59, 60 However, the strong positive charge responsible for PEI-
related cytotoxicity reduces its applicability.61 Consequently, recent reports rather 
incorporate PEI into a formulation (lipid-based, polymer-based or inorganic nanocarriers) to 
enhance the escape properties of the latter rather than applying it on its own.41, 62, 63 
Secondly, polymeric micelles are generally prepared through self-assembly by introducing 
amphiphilic polymers (mainly tri-block polymers) into an aqueous milieu.41 A third category 
comprises of dendrimers, which are repetitively branched molecules, with the most well-
known example being the poly(amidoamine) (PAMAM) dendrimers. These are reported to 
promote endosomal escape through a proton sponge mechanism, but are on the downside 
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not biodegradable and are reported to evoke adverse effects.2, 41 A final main category 
consists of the nanospheres, where the nucleic acids are electrostatically attached to the 
polymer throughout the entire sphere.3 A popular polymer applied to prepare nanospheres 
is poly(lactic-co-glycolic acid) (PLGA). The biodegradable feature of this FDA-approved 
polymer allows to synthesize controlled release formulations, which consequently show 
excellent biocompatibility.64, 65 The downsides of this polymer are its anionic charge and 
hydrophobic nature implying the necessity to introduce a cationic element to ensure NA 
complexation.2, 41 The nanogels applied in this thesis furthermore belong to this category 
and will be discussed in detail in section 2.2. 
In addition to the use of the abovementioned synthetic polymers various groups apply 
naturally occurring polymers.2, 3 The polysaccharide chitosan is for instance avidly used given 
its excellent biocompatibility and abundance of amine groups allowing siRNA 
complexation.66 Secondly, the cyclic oligosaccharides, also known as cyclodextrins, can be 
applied for siRNA delivery.66, 67 A final category comprises the cell penetrating peptides 
(CPP). In this regard, a large variety of CPPs has been reported since the structure and size 
can be tuned by varying the amino acid number and composition.68, 69 
Finally, inorganic nanoparticles (NPs) are considered interesting delivery vehicles, as their 
size and surface properties are to a large extent tunable.2, 45 Nowadays these NPs are 
employed either alone or in combination with lipids or polymers. In the latter case, the NPs 
can either be the core of the construct or be present at the surface of the polymer- or lipid-
based carrier. Overall, gold and mesoporous silica NPs are chiefly reported as NA delivery 
vehicles.2, 45 Interestingly, gold NPs bind the NA through thiol linkages, which are revoked in 
the reducing cellular environment.70 The mesoporous silica NPs are in turn applied for their 








The dex-NGs can be classified as nanospheres and more specifically as hydrogels. They 
consist of 2-(methacryloyloxy)ethyl)trimethylammonium chloride (TMAEMA) and dextran 
hydroxyethyl methacrylate (dex-HEMA) monomers that are cross-linked via an inverse 
emulsion photopolymerization method (Figure 1.2A).66 The obtained dex-NGs are a 3D 
hydrophilic network, which can absorb large quantities of water and the positive charge, 
necessary to allow siRNA loading stems from the TMAEMA monomers.66 
 
Figure 1.2. (A) Chemical structures of the dex-HEMA and TMAEMA monomers, and the three-
dimensional nanogel network of dex-HEMA copolymerized with TMAEMA (dex-HEMA-co-TMAEMA) 
 
(B) Overview of the nanogel degradation process under physiological conditions (pH 7,4; 37°C). This 
figure is adapted from Raemdonck et al.66, 73 © John Wiley & Sons 2009 and Elsevier 2010. 
Previous work from our group highlighted the potential of these dex-NGs as a nanocarrier 
for siRNA delivery.66, 74 They showed a high loading capacity, as up to 50 pmol siRNA can be 
complexated to 1 μg of lyophilized dex-NGs.66, 74 The positive charge furthermore ensures 
good cellular uptake.74 Once inside the cell, the carbonate ester linkages in the dex-HEMA 
monomers are prone to hydrolysis, especially at physiological pH (Figure 1.2B). Hydrolysis is 
in contrast slowed down in the acidic environment of the endo-lysosomes, thereby 
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protecting the dex-NGs and its siRNA cargo from rapid degradation.74 Due to this hydrolysis, 
increasing amounts of water dilate the pores in the gel network, causing the particle to 
swell, degrade and release siRNA. Interestingly, this biodegradation can be tuned by varying 
the crosslinking degree in the dex-HEMA monomers.66 Hence, dex-NGs with a proper 
crosslinking density can potentially be applied as a depot for prolonged intracellular siRNA 
release.  
Previous work showed that the dex-NGs are internalized through endocytosis, stimulated by 
the interaction between the cationic dex-NGs and the negative membrane lipids. The 
majority of the internalized dex-NGs are subsequently trafficked to the lysosomal 
compartment.74 During this process a certain amount of siRNA is able to reach the cytosol 
and induce gene silencing. However, relatively large siRNA doses are required to obtain the 
desired effect as cytosolic delivery remains incomplete. Hence, we evaluated if cytosolic 
siRNA delivery could be enhanced by a small molecular adjuvant strategy.  
3. FUNCTIONAL INHIBITORS OF ACID SPHINGOMYELINASE 
The evaluated small molecular adjuvants to boots siRNA delivery are functional inhibitors of 
the acid sphingomyelinase (ASM, FIASMA). FIASMAs are structurally diverse compounds 
from distinct drug classes. However, all known FIASMAs are cationic amphiphilic drugs 
(CADs), which implies that they contain a basic amine group and a hydrophobic segment. 
Hence, all FIASMAs are characterized by a pKa of at least 7.4 and a LogP > 3.75, 76  
Due to these physicochemical properties, CADs preferentially accumulate in the acidic 
organelles. Indeed, the lysosomes can contain up to 100-fold higher CAD concentrations 
than the cytosol. It is in these lysosomes that the FIASMAs inhibit ASM.75ASM is a positively 
charged membrane bound enzyme that is anchored to the abundant negatively charged 
bis(monoacylglycero)phosphate (BMP) through electrostatic interactions. ASM requires this 
interaction for its protection against enzymatic degradation as well as its enzymatic action, 





Upon lysosomal accumulation, the FIASMAs insert into the lysosomal membrane through 
their hydrophobic segment. They preferentially accumulate at the negative BMP regions due 
to electrostatic interactions with their positive amine groups. Upon sufficient accumulation, 
the electrostatic anchoring of ASM is perturbed and the latter is released from the 
membrane, followed by enzymatic degradation in the lysosomal lumen (Figure 1.3).78 Hence, 
the FIASMA do not inhibit ASM through a key-lock mechanism, but sufficiently high  
concentrations are required to ensure functional inhibition, which is obtained through the 
lysomotrophic nature of the compounds. Consequently, sphingomyelin accumulates leading 
to a perturbed lipid balance with an increased sphingomyelin/ceramide ratio. This in turn 
causes lysosomal membrane destabilization and even permeabilization.79, 80 
 
Figure 1.3. ASM is electrostatically anchored to the negative BMP region of the lysosomal membrane. 
FIASMAs insert into the membrane and interfere with the electrostatic interaction between BMP and 
ASM. Functional inhibition is obtained through ASM is release into the lysosomal lumen followed by 
cathepsin-mediated degradation. This figure is adapted from Kornhuber et al.78 © Elsevier 2014. 
Cancer cells are reported to be more sensitive towards perturbation of the lysosomal 
compartment.80, 81 Due to their enhanced metabolic needs, cancer cells contain more and 
enlarged lysosomes, which are less stable and have a higher cathepsin content. In addition, 
cancer lysosomes contain less sphingomyelin and express lower ASM levels. Hence, lower 
FIASMA concentrations are required to functionally inhibit ASMs.80 Indeed, several reports 
revealed CAD-mediated cancer-cell selective lysosomal membrane permeabilization (LMP). 
82, 83 In turn, we investigated whether this phenomenon could be applied to induce cytosolic 
siRNA delivery of lysosomally accumulated siRNA.  
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CHAPTER 2 
Boosting non-viral nucleic acid delivery and transfection efficiency: 
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There is no doubt regarding the great therapeutic potential of nucleic acids (NA). To be 
functional, NA require delivery into the cytosol or nucleus of the target cell. To first ensure 
cellular internalization, NA are generally packaged into nanomedicines. However, many 
nanomedicines largely fail to deliver the bulk of their NA cargo to its intracellular site of 
action. Indeed, escape from the endosomal lumen following nanomedicine uptake through 
endocytosis, remains an inefficient process. Interestingly, increasing evidence exists that 
major NA delivery hurdles can in part be overcome through helpful biological functions of 
distinct classes of small molecules. Our literature study revealed how various (classes of) 
small molecular compounds can intervene at distinct stages of the delivery pathway. Small 
molecules are reported to influence processes including nanomedicine internalization, 
endosomal escape, intracellular trafficking and transgene expression. Of note, a number of 
compounds exert their effect by simultaneously affecting several of these elements. 
Interestingly, the small molecular adjuvants were incorporated into the nanocarrier, 
conjugated to the nucleic acid or added before, during or after nanocarrier administration, 






The potential of nucleic acid (NA) therapeutics to treat a plethora of disorders has been 
clearly established in the course of the past three decades.1 For instance, plasmid (p)DNA 
and messenger (m)RNA can be administered to restore protein expression. Splice switching 
oligonucleotides (SSO) in turn correct aberrant pre-mRNA splicing or induce alternative 
splicing to restore protein function.2 Furthermore, antisense oligonucleotides (ASO) and RNA 
interference (RNAi) triggers, such as small interfering (si)RNA, short hairpin (sh)RNA and 
micro (mi)RNA, can be applied to silence disease-promoting genes.3 However, relatively few 
NA drugs were successfully translated from bench to bedside.4 This can mainly be attributed 
to the difficulty of safely and effectively delivering NA therapeutics to the desired 
(intracellular) target site, given the many extra- and intracellular barriers (Figure 2.1).1, 5 
NA therapeutics encounter various extracellular barriers upon systemic administration. For 
one, most naked NA are readily attacked by nucleases present in the blood stream and can 
induce an innate immune response.1 In addition, smaller NA are prone to glomerular 
filtration and renal elimination. Hence, naked NA suffer from rapid clearance, as evidenced 
by their short half-life of ˜10 minutes.1 Both issues of the enzymatic degradation and the 
immunogenic character could at least in part be tackled by chemical modifications.3, 6 
However, such modifications do not affect the NA size to reduce rapid clearance. Hence, 
suitable delivery agents are required to prolong the circulation time and ensure NA 
internalization. Both viral and non-viral nanocarriers are being developed in parallel, but only 
the latter is discussed in this overview. Although non-viral nanocarriers protect the NA cargo 
from nucleases in the bloodstream and rapid renal clearance, the nanocarrier itself faces 
several extra- and intracellular obstacles that hamper efficient delivery.5 Upon systemic 
administration, proteins rapidly adsorb onto the nanocarrier surface. Via this protein corona, 
nanocarriers are recognized and internalized by macrophages of the mononuclear phagocyte 
system (MPS).5 Next, the nanocarrier needs to reach its target through extravasation, unless 
endothelial or circulating cells are targeted.7, 8 The ease of extravasation is in part 
determined by the size of the endothelial fenestrations. The latter are reported to be 
enlarged in for instance inflamed tissues and solid tumors, which facilitates passive 
targeting.1, 5 The nanocarrier should subsequently be distributed throughout the target 
tissue, which is influenced by the interstitial pressure, cell density and extracellular matrix.5 
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Figure 2.1. Intra- and extracellular barriers limit successful in vivo NA delivery via non-viral carriers. 
The latter need to overcome extracellular barriers, such as (i) degradation by serum endonucleases, 
(ii) immune detection, (iii) renal clearance and (iv) nonspecific interactions. Subsequently, the carriers 
must in most cases extravasate to reach their target tissue. Next, The nanocarriers should have 
sufficient mobility in the tissue extracellular matrix to reach the target cells. From this point onwards 
the cell membrane and entrapment in the endo-lysosomes pose major intracellular barriers. Finally, 
following endosomal escape, the NA need to reach their site of action. For siRNA and miRNA mimics 
this implies loading into the RNA-induced silencing complex (RISC), mRNA must interact with the 
translational machinery and DNA needs to cross the nuclear envelope in order to exert its function. 




Once the nanocarrier has successfully reached the target cell, it additionally encounters 
several (intra)cellular barriers. The first is the cell membrane over which the nanocarrier is 
generally internalized via endocytosis. Consequently, the nanocarrier is captured in 
endosomal vesicles and will chiefly be trafficked to the lysosomes, where the acidic pH and 
lysosomal hydrolases can degrade both the carrier and cargo.1 In contrast, NA require 
cytosolic or even nuclear localization to exert their function. Unfortunately, even for state of 
the art delivery systems endosomal escape remains a major bottleneck.9, 10 For those NA 
that require nuclear translocation, the nuclear envelope presents a final important barrier 
towards successful transfections.1  
Overall, the low delivery efficiency of non-viral carriers remains the major bottleneck. To 
meet this impediment, several strategies were suggested to overcome various extra- and 
intracellular barriers. An ideal carrier size range was for instance defined to improve their 
pharmacokinetic profile. Indeed, nanocarriers with a diameter below 20 nm are prone to 
renal clearance, while nanocarriers larger than 200 nm undergo hepatic clearance or are 
more easily removed by MPS.1 Potentially the most widely applied strategy to arm the 
nanocarrier against rapid clearance by MPS, is to avoid opsonization with a polyethylene 
glycol (PEG) coating.5 Moreover, targeting ligands were included to increase the tissue 
specificity. Such active targeting approaches theoretically improve carrier uptake via 
receptor-mediated endocytosis. However, a recent sobering report indicated that only a 
limited delivery advantage is obtained by actively targeting solid tumors.11 On the 
intracellular level, many groups in turn focused on improving endosomal escape. Among 
others, such methods include the use of nanocarriers containing positively charged polymers 
or lipids with a high buffer capacity to induce the so-called proton sponge effect. In turn, 
fusogenic or lysogenic lipids or peptides and cell penetrating peptides are applied to increase 
the permeability of the endosomal membrane.10, 12  
As an alternative to the abovementioned strategies, small molecules can be applied to 
improve NA delivery. Since the very start of LNP-mediated pDNA transfections, several 
groups experimented with the concept of low molecular weight adjuvants to increase the 
transfection efficiency. For instance, Fraley and colleagues were the first to report enhanced 
pDNA transfection in vitro upon a chloroquine (CLQ) pretreatment in 1981.13 In 1994, 
Malone et al. found subcutaneous dexamethasone injections to improve the transfection by 
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intrahepatically injected pDNA.14 Despite an initial wave of promising results, this concept 
left the foreground of the delivery field. However, many groups did combine low molecular 
weight drugs and NA as a possible anti-cancer treatment.15 Here, the NA aid the drug 
through a synergistic effect on cell viability or reverting multidrug resistance. In recent years, 
the interest in the use of low molecular weight adjuvants to improve NA delivery was 
renewed, with several large-scale compound screenings identifying novel NA delivery 
enhancers.16-18 This chapter bundles both the initial and recent reports to provide a general 
overview on low molecular weight adjuvants improving the therapeutic potential of NA.  
2. SMALL MOLECULES IMPROVE NUCLEIC ACID UPTAKE 
First, literature revealed that small molecules can boost NA internalization. On the one hand, 
adjuvants can enhance carrier distribution throughout the tumor tissue. On the other hand, 
small molecules can be incorporated in the nanocarrier as targeting ligands to boost uptake 
through receptor-mediated endocytosis. Furthermore, carbohydrates stimulate the cell to 
more avidly internalize NA. Finally, small molecules can modify the physicochemical 
properties of the carrier, thereby improving its uptake kinetics.  
2.1. Small molecules enhance tumor penetration 
The therapeutic potential of systemic NA therapies to treat cancer is widely investigated. To 
achieve an optimal therapeutic effect, the carrier needs to be evenly distributed throughout 
the tumor tissue. However, the mobility of nanocarriers in the tumor interstitium following 
extravasation is severely hindered by the high cell density, dense fibrotic extracellular matrix 
and high interstitial pressure, especially in solid tumors.19, 20 Indeed, Kataoka’s group showed 
that 70 nm micelles are confined to the vicinity of the tumor vessels, whereas 30 nm 
micelles can penetrate deeper into the tumor tissue.21 Unfortunately, the size of most 
nanocarriers largely exceeds 30 nm, thereby severely limiting their tumor penetration.  
Matrix modifiers, such as relaxin and bacterial collagenase, were initially investigated as 
penetration enhancers to improve delivery to solid tumors.20 However alternative small 
molecules were evaluated, given the reported toxicity and the increased risk of tumor 
progression of the former. Losartan was for instance put forward due to its antifibrotic 




intratumoral collagen I production in mice. Consequently, the tumor penetration and 
accumulation of intravenously (i.v.) or intratumorally (i.t.) injected 100 nm fluorescent 
nanoparticles (NPs) was significantly increased in three different tumor models. In contrast, 
NPs were found at the i.t. injection site or in the periphery of the untreated tumors following 
i.v. administration.20 Losartan pretreatment clearly enhanced the in vivo efficacy of Doxil® 
liposomes (LPS) and could equally improve the delivery of NA loaded nanocarriers. 
In addition, the group of Jessie Au introduced the concept of tumor priming. Here, tumors 
are pretreated with an apoptosis inducing agent to improve delivery.22 More specifically, a 
single paclitaxel (PTX) administration prior to the nanocarrier treatment induces apoptosis in 
>10% of the tumor cells. Consequently, the cell density is reduced and the interstitial space 
is enlarged, becomes more porous and less tortuous in favor of interstitial nanocarrier 
transport. In addition, a PTX pretreatment increases the blood vessel radius, thereby 
improving tumor perfusion and increasing the nanocarrier supply.19 This strategy was initially 
applied to successfully improve the efficacy of protein-bound drugs and Doxil® LPS.19, 22 
More recently, Wong et al. showed that PTX pretreatment enhanced the depth of LPS 
penetration in a 3D spheroid and tumor fragment histoculture.23 A PTX pretreatment in turn 
improved the siRNA-mediated gene silencing in mice thereby reducing tumor growth and 
increasing survival, which underscored the therapeutic potential of tumor priming.24, 25 In 
confirmation, docetaxel pre- or co-treatment improved the tumor distribution of LNPs in a 
mouse xenograft model.26 
2.2. Small molecules improve NA internalization 
2.2.1. The application of small molecules as targeting ligands 
The success of a systemic NA therapeutic furthermore depends on its targeting efficiency. To 
date, satisfactory delivery could chiefly be obtained in the liver and spleen, given the 
preferential accumulation of most nanocarriers.27-29 Unfortunately, many carriers fail to 
identify their target tissue, which results in nonspecific accumulation in off-target tissues.30, 
31 To overcome this impediment, it was proposed to apply targeting moieties. In theory, 
active targeting improves tissue specific biodistribution by enhancing interactions with the 
target cell surface and subsequent receptor-mediated endocytosis.3 Initial targeting 
approaches mainly applied antibodies, peptides or antibody- or peptide-fragments. 
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However, several drawbacks included immune responses upon repeated administration, 
expensive manufacturing processes and non-straightforward formulation and 
characterization. Subsequently, small molecules were put forward as an alternative since 
they are less immunogenic, show better biodegradability and are easier to manufacture, 
characterize and integrate into a formulation.31 In this regard, the small molecule can either 
be present on the nanocarrier surface or directly conjugated to the NA.  
Probably, the best-known low molecular weight targeting ligand is folate. It is often applied 
to obtain cancer cell-specific uptake, as the folate receptor is overexpressed on the cell 
surface of various tumor cell types compared to normal tissue. Tumor targeting with folate 
can be obtained via many different strategies, as elaborately reviewed elsewhere.30, 32 
A second popular targeting approach is the use of carbohydrates. For instance, mannose 
targets the lectin-like receptor on tumor cells, galactose and lactose interact with the 
asialoglycoprotein receptor to facilitate uptake in hepatocytes and stellate cells and fructose 
improves targeting of the hepatic Kupffer cells.30 Furthermore, Akinc et al. synthesized a 
trivalent N-acetylgalactosamine (GalNAc) cluster, which can be conjugated to LNP or siRNA 
(Figure 2.2). GalNAc avidly binds the asialoglycoprotein receptor thereby promoting 
receptor-mediated uptake of the complex in hepatocytes in mice.33 The GalNAc-siRNA 
conjugate recently advanced into Phase III clinical evaluation.34 However, reanalysis of the 
Phase II data revealed higher mortality in the GalNAc-conjugate treated group, wherefore 
the Phase III study was prematurely terminated.35 
Figure 2.2. Molecular structure of a GalNAc-siRNA conjugate. This figure is reproduced from Kanasty 
et al.36 ©Nature publishing group 2013.  
Appropriate small molecular ligands are furthermore suggested to target tumors 
overexpressing the sigma receptor at their cell surface. For instance, Mukherjee et al. 




for pDNA delivery and clearly observed improved transgene expression for the targeted 
formulation compared to the untargeted LPS or Lipofectamine® 2000. In addition, this 
improvement was blocked by treatment with free haloperidol and no differences in 
transgene expression were obtained for targeted and non-targeted LPS in CHO cells, which 
express low sigma receptor levels.37 Subsequently, the group of Leaf Huang proposed the 
use of anisamide as a sigma-1 receptor ligand.38 Incorporation of anisamide into their lipid-
based carrier, improved siRNA delivery by 4-fold in B16F10 murine melanoma cells. These 
results were confirmed in mice, as tumor-specific uptake was obtained along with 70-80% 
luciferase silencing.39 A follow-up study underscored the potential of this approach since 
anisamide-targeting of a carrier containing siRNA against MDM2, c-myc and VEGF markedly 
reduced lung metastasis and prolonged the mean animal survival time with 30%.40 
Nakagawa et al. furthermore conjugated a trivalent anisamide construct to SSO, which 
enhanced both the internalization and the biological effect of this complex in vitro.41 
However, the use of anisamide was recently put to question, as the interaction between the 
intracellular sigma-1 receptor and surface-bound anisamide may be unlikely and given the 
variable in vivo efficacy of anisamide-decorated nanocarriers.42 Of note, the efficiency of 
active solid tumor targeting strategies was generally questioned since a recent meta-analysis 
revealed that active targeting moieties could not strongly augment the median internalized 
NA dose compared to non-targeted nanocarriers.11 
Finally, Tam et al. recently reported a screening of 800 compounds to identify LNP uptake 
enhancers. Out of the 7 components that most significantly improved LNP uptake in HeLa 
cells by their presence during transfection, 3 were cardiac glycosides. These molecules bind 
to the extracellular region of the Na+/K+ ATPase pump, which induces endocytosis of the 
latter. Thus, the glycoside co-treatment likely improved LNP uptake via increased plasma 
membrane turnover. Accordingly, when strophanthindin (a cardiac glycoside) was 
incorporated into the LNP bilayer, the carrier internalization and gene silencing were 
improved in vitro. Given the general recurrence of the Na+/K+ ATPase pump throughout the 
body, the authors argued that this strategy could potentially be applied as a generic strategy 
to improve LNP uptake.43 However, the limited selectivity could likewise imply the induction 
of off-target effects, thereby limiting the applicability of this approach for systemically 
administered nanocarriers. 
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2.2.2. Additional methods to improve nucleic acid uptake 
In 1981, Fraley et al. showed that carbohydrates can additionally stimulate nanocarrier 
endocytosis.13 Much more recently, Han et al. applied a similar approach to improve ASO 
delivery in muscle cells of a Duchenne muscular dystrophy mouse model. More specifically, 
intramuscular (i.m.) co-injection of ASO and a mixture of 2.5% glucose and 2.5% fructose 
enhanced the exon skipping activity of the former, resulting in a remarkable functional 
improvement at low ASO doses. The cellular metabolism of the injected hexoses produced 
excess ATP that subsequently supported the energy-dependent ASO uptake in energy 
deficient muscle cells. Of note, this approach could potentially be generally applicable to 
stimulate NA uptake in muscles and other energy-dependent tissues.44 
In addition, several small molecules boost NA uptake through direct interaction with the 
carrier or NA, thereby altering the physicochemical characteristics in favor of cellular 
internalization. For instance, Osborn et al. identified Guanabenz (WytensinTM) as a delivery 
enhancer for cholesterol-conjugated siRNA (chol-siRNA). Guanabenz markedly improved 
chol-siRNA uptake in an siRNA sequence-independent, but NA-specific way, hypothetically 
by shielding the negative siRNA charge. However, the independent modulation of cellular 
processes involved in chol-siRNA uptake by Guanabenz could not be excluded.18 Likewise, 
Gilleron et al. identified several hit compounds that significantly improved chol-siRNA uptake 
upon co-incubation through unidentified mechanisms. The same accounted for LNP, 
although little overlap was found between the hits for both constructs. Interestingly, a 
number of molecules improved LNP uptake when the molecules were added to the LNP 
dispersion prior to the transfection. An overnight incubation allowed direct interaction 
between the small molecule and the LNP, resulting in LNP size reduction and improved 
uptake kinetics.16 
3. SMALL MOLECULES ENHANCE ENDOSOMAL ESCAPE 
As mentioned in the introduction, NA enclosed in a nanocarrier are mainly internalized 
through endocytosis and become sequestered in the endosomal compartment. However, NA 
need to reach the cytosol or nucleus in order to achieve a therapeutic effect. Unfortunately, 
the amount of NA effectively reaching its intracellular site of action is dramatically low and 




the lysosomes.9, 45 Hence, timely escape of the NA, preferably from the endosomal 
compartment to avoid exposure to lysosomal hydrolases, is one of the biggest challenges in 
the delivery field. In an effort to overcome this hurdle, various physical and chemical 
techniques were proposed to promote release by inducing a burst of the endosome, creating 
pores in the endosomal membrane or fusion of the carrier with the endosomal membrane 
(Figure 2.3).10  
Figure 2.3. Nanocarriers are taken up by endocytosis and sequestered in the endosomal compartment 
(blue vesicle). From here on, vesicles gradually acidify (orange vesicle) and the cargo can be released 
through a burst of the endosomal membrane, the formation of pores or fusion of the lipid-based 
carrier with the endosomal membrane. This figure is adapted from Martens et al.10 ©Elsevier 2014. 
Interestingly, several small molecules were recently proposed to positively influence 
endosomal escape and reduce the chances of lysosomal entrapment. Yu et al. showed that 
exposure of the endosomal membrane to amphotericin B promotes endosomal escape 
through the formation of pores in the endosomal membrane. Upon inclusion of the 
compound in a micelle, siRNA delivery was markedly enhanced. In contrast, free 
amphotericin B failed to improve siRNA delivery and elicited toxicity, most probably by 
damaging the plasma membrane.46 Furthermore, the plant glycoside SO1861 (known to 
trigger cytosolic delivery of the plant toxin saporin) improved the endosomal escape of 
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plasmid (p)DNA, mini circle (mc)DNA and siRNA delivered by lipid- and peptide-based 
carriers. Of note, siRNA-mediated gene silencing was to a lesser extent improved than 
transgene expression. Additionally, only a glycoside treatment post transfection positively 
influenced siRNA delivery, whereas glycoside presence during or after transfection as well as 
incorporation into the carrier improved DNA delivery. The glycoside was proposed to 
improve delivery via interactions with the endosomal membrane, though this remains to be 
experimentally confirmed.47 
In an effort to identify small molecules that reduce the cytotoxic effect of bacterial toxins, 
Retro-1 was discovered. This molecule blocks retrograde trafficking by interfering with the 
shuttling from the late endosomes to the Golgi apparatus. Subsequently, Ming et al. 
evaluated the potential of this molecule to improve NA delivery and found that Retro-1 
treatment post transfection improved NA release by preferential destabilization of the late 
endosomal compartment. Of note, Retro-1 improved the action of SSO and ASO but not of 
siRNA, which could potentially be attributed to limited uptake of the unstabilized siRNA. 
Furthermore, Retro-1 improved the in vivo activity of SSO in mice.48 In a follow-up screening, 
more than 100.000 compounds were evaluated for their potential to improve the delivery of 
SSO, ASO and chol-siRNA. The identified hits improved the action of all three NA tested and 
were more potent than Retro-1. Similar to Retro-1, the hit compounds targeted the late 
endosomes to facilitate cytosolic NA release. However, only partial release was obtained 
since the bulk of the internalized NA dose remained entrapped in the late endosomes. It was 
not clear whether only a specific subset of endosomes was affected or if all endosomes were 
equally affected to a limited extent. Despite the fact that the exact impact on the endosomal 
membrane remains to be elucidated, the hits were proposed to enhance escape by (i) 
inducing defects in vesicle fusion, (ii) destabilizing the endosomal membrane or (iii) 
increasing the rate or extent of tubulation and budding of the carrier-containing vesicles.17 In 
turn, the screening performed by Gilleron et al. furthermore identified hits that improved 
the escape of the LNP-encapsulated siRNA or chol-siRNA. Hit compounds could be 
subdivided according to their effect on the endosomal system, which was correlated to the 
possible mechanism through which escape was improved. These included: (i) interference 
with endosomal vesicle acidification or maturation, (ii) effects on intracellular trafficking or 




4. SMALL MOLECULES INTERFERE WITH INTRACELLULAR TRAFFICKING 
Upon internalization through endocytosis, nanocarriers are sequestered in the early 
endosomes. From this point onwards, intracellular trafficking determines the cellular 
location of the carrier and its cargo. Initially the early endosomes mature to late endosomes, 
wherefrom the carrier is mainly trafficked to the lysosomes.9, 45 The minor fraction of NA 
that is able to escape these compartments in turn needs to travel through the cytosol to 
reach its site of action. Small RNA molecules, such as siRNA, can freely diffuse through the 
dense cytosol, whereas NA larger than 2000 bases require active transport mechanisms.49 In 
general, the cytosolic transport of both larger NA and endo-lysosomal vesicles containing 
NA-loaded nanocarriers occurs via microtubules.50 Hence, scientists investigated whether 
microtubule (de)stabilizing agents can influence NA delivery.  
The first report on this hypothesis was published in 1996, where Chowdhury et al. evaluated 
if a single intraperitoneal (i.p.) colchicine injection 30 minutes prior to the i.v. injection of a 
pDNA-asialoglycoprotein-polylysine complex improved the hepatic transgene expression in 
rats. Colchicine, which disrupts the microtubule network, increased the residence time of 
the delivered pDNA in the liver, accompanied by prolonged transgene expression up to 14 
weeks compared to 48h in control rats.51 Subsequently, Hasewaga et al. observed that a 60-
minute nocodazole (microtubule disruptor) or taxol (microtubule stabilizer) pretreatment 
altered the cellular lipoplex (LPX) distribution. In untreated cells, the internalized LPX were 
trafficked over the microtubuli to the lysosomes, which in turn concentrated in the 
microtubule-organizing center (MTOC). Upon nocodazole treatment, the LPX and lysosomes 
were freely distributed throughout the cytosol without co-localization. In case of taxol, the 
LPX still preferentially resided in the perinuclear region without co-localizing with the 
lysosomes or the MTOC. Thus, the 2-fold improved transgene expression obtained with 
either compound could be explained by the prevention of lysosomal degradation due to 
alternate intracellular trafficking.50 These findings were recently corroborated, as 
nocodazole pretreatment improved transgene expression by 8- and 40-fold, respectively, for 
Lipofectamine and LPX-mediated delivery via altering the LPX transport and intracellular 
destination.52 In turn, Lindberg et al. confirmed the results on nocodazole whereas no 
improvement could be obtained with taxol.53 The potential to enhance transgene expression 
was furthermore shown to be cell type-dependent: colchicine increased the LPS-mediated 
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pDNA transfection to varying extents in A549, H1299 and Chang Liver cells whereas PTX, 
which stabilizes the microtubuli, only enhanced transfection in the A549 cells.54 
Wang and MacDonald evaluated a larger set of molecules known to specifically bind tubulin 
and inhibit its polymerization, namely colchicine, vinblastine, vincristine, nocodazole and 
podophyllotoxin. Pretreatment with each molecule dramatically enhanced the transgene 
expression (from 25- up to 39-fold) following transfection with cationic LPX.55 The greater 
enhancement compared to Hasegawa et al. could potentially be explained by the prolonged 
pre-incubation time (3h vs 1h), the distinct cell type or differences in LPX compositions. 
Interestingly, colchicine failed to enhance transgene expression when present during 
transfection. Of note, inhibition of actin polymerization by cytochalasin B did not affect the 
transfection efficiency, underscoring that vesicle and pDNA transport occurs on 
microtubules. Interestingly, three molecules known to prevent endo-lysosomal fusion 
through distinct mechanisms improved the transfection efficiency, highlighting the 
importance of avoiding lysosomal sequestration.55  
In addition, microtubule-stabilizing agents improve transgene expression following 
electroporation or microinjection. Indeed, the presence of taxol immediately after 
electroporation increased transgene expression by 4.5-fold, while nocodazole remained 
without effect.56 Vaughan et al. furthermore hypothesized that histon deacetylase 6 
(HDAC6) inhibitors influence cytosolic pDNA transport. The latter enhance microtubule 
acetylation, which improves the microtubule stability and results in the attraction of motor 
proteins. In confirmation, pDNA was trafficked to the nucleus remarkably quicker in a HDAC6 
knock down model. Furthermore, taxol and the HDAC6 inhibitor NCT-10b had a similar 
positive effect on transgene expression following pDNA delivery via electroporation.57  
The presence of microtubule stabilizing agents during polymer-mediated transfection also 
augmented transgene expression. For example, a 40-fold increased luciferase expression 
was obtained in PC3 cells with the HDAC6 inhibitor tubacin. This was correlated to the 
altered intracellular polyplex distribution, as the polyplexes were diffusely present in the 
cytosol in tubacin treated cells in contrast to the perinuclear condensation to the MTOC in 
untreated cells.58 Similarly, PTX significantly enhanced transgene expression when present 




depolymerization by cytochalasin B had no influence on the transfection efficiency. Of note, 
microtubule disruption by colchicine strongly reduced the delivery efficiency of the PEI 
polyplexes in contrast to the significant improvement observed for lipid-based carriers.59 The 
opposite effects of microtubule (de)stabilizing agents for lipid- and polymer-based carriers 
can presumably be explained by their intrinsic differences in intracellular trafficking and 
escape mechanism. PEI-based polyplexes likely require a certain extent of intracellular 
trafficking and vesicle acidification to facilitate pDNA release, which could be hampered by 
microtubule depolymerization. In turn, PTX promotes vesicle trafficking without advancing 
to endo-lysosomal fusion.50 Thus, endosomal escape could still occur followed by improved 
pDNA transport to the nucleus over stabilized microtubuli.59  
Although all molecules are applied to improve the transfection efficiency by preventing 
trafficking to the lysosomes, the effect of microtubule (de)stabilizing agents on transgene 
expression clearly depends on the cell type, carrier and applied small molecule. For lipid-
based carriers, pretreatment with microtubule destabilizing agents provides the best results 
whereas polymer-based carriers require co-incubation with compounds that promote 
microtubule stability.  
In addition, certain kinases influence intracellular trafficking. Consequently, pre-inhibition of 
protein kinase A with H89 promoted the transfection efficiency of branched PEI polyplexes 
2- to 3-fold by inhibiting trafficking to the lysosomes. Although H89 pretreatment equally 
altered the trafficking pattern of linear PEI polyplexes and Lipofectamine, no influence on 
transfection efficiency could be detected for these carriers.60  
Next to lysosomal routing, the carrier and cargo can be recycled to the extracellular milieu 
by exocytosis. Of note, up to 70% of the internalized siRNA dose can be exported, which is in 
part controlled by the endo-lysosomal Niemann-Pick C1 (NPC1) membrane protein.45 
Accordingly, NPC1 inhibition by NP3.47 delayed the recycling, which enhanced the silencing 
potential up to 4-fold in HeLa cells. The improved therapeutic potential was explained in 
terms of increased chances of endosomal escape by the prolonged cellular retention and 
reduced trafficking to the lysosomes.61  
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5.  SMALL MOLECULES BOOST TRANSGENE EXPRESSION 
When free pDNA in the cytosol is able to cross the nuclear envelope, the negatively charged 
pDNA associates with positive histones to form nucleosomes.62 This inclusion of exogenous 
pDNA into the nuclear chromatin structure hampers efficient transgene expression and 
explains the gradual transgene silencing.63 From this point onwards, the transgene 
expression is furthermore subjected to epigenetic regulation mechanisms.64 Histone 
hyperacetylation is typically associated with gene expression by facilitating access of 
transcription factors and RNA polymerase to the unwound DNA.38, 65 In contrast, histone 
deacetylation and methylation of a pDNA promoter region silences transgene expression.66 
Hence, various studies report on the use of epigenetic expression modulators in an effort to 
improve transgene expression. Of note, in contrast to the cytosolic HDAC6, the HDAC 
inhibitors described in this section target nuclear HDACs. 
In 2000, Yamano and colleagues were the first to report the beneficial effect of the HDAC 
inhibitor depsipeptide on transgene expression. Co-exposure to LPS and depsipeptide 
significantly enhanced transgene expression in vitro through improved transcription, without 
affecting the number of pDNA copies in the nucleus. Transgene expression was additionally 
improved in vivo upon i.t. co-injection. However, a separate i.p. depsipeptide injection or 
inclusion of depsipeptide into the LPS failed to enhance transgene expression.67 
Subsequently, Liu et al. showed that i.v. co-injection of PEI:pDNA polyplexes and 
depsipeptide improved transgene expression in the liver, spleen and lungs of healthy mice. 
In tumor bearing mice, the expression was in turn preferentially enhanced in the metastatic 
breast cancer cells without affecting normal cells.38 Besides depsipeptide, trichostatin A 
(TSA) and cyclic hydroxamic acid containing peptide 31 (CHAP31) improved transgene 
expression in vitro more efficiently in the human keratinocyte cell line (HaCaT) than in 
normal human keratinocytes. The expression in normal dermal fibroblast was to an even 
greater extent improved.62, 65, 67 The enhanced transgene expression was cell type-
dependent, which was explained by variations in the basal transgene expression levels and 
the availability of the transcription apparatus.67 In addition, HDAC inhibitors enhanced 
transgene expression to a greater extent in more rapidly dividing cells, which can be 




dividing cells acquire more nuclear pDNA copies that are prone to enhanced transcription 
upon HDAC inhibition. 
Additional studies report on the combination of various HDAC inhibitors with different 
delivery vehicles in diverse cell models. For instance, post transfection treatment with TSA, 
valeric acid, caproic acid, 4-phenyl butyric acid and butyric acid enhanced transgene 
expression following LPS-mediated pDNA delivery in CHO cells.69 Kim et al. in turn found TSA, 
sodium butyrate and valproic acid to improve GFP expression in embryonic stem cells 
following transfection with the commercial carriers Lipofectamine® 2000 and FuGENE®.70 A 
valproic acid treatment post transfection furthermore improved expression of a transgene 
delivered via PEI complexes in CHO cells.71 Finally, the presence of etinostat during and post 
transfection with different polymer-based carriers enhanced luciferase expression up to 25-
fold in bladder and prostate cancer cells.62  
In general, these HDAC inhibitors increased the expression of successfully delivered but 
poorly expressed transgenes. They are suggested to improve expression through (i) the 
prevention of histone deacetylation, (ii) the acetylation (activation) of transcription factors 
and (iii) their influence on the expression of genes that in turn regulate transgene 
expression.38, 65, 67 Thus, HDAC inhibition increases mRNA levels without affecting pDNA 
uptake, stability or translocation to the nucleus. This is a general phenomenon, independent 
of the applied promoter region or carrier. Initiation of adjuvant treatment more than 24 
hours post transfection did not result in enhanced transgene expression.63 Presumably, the 
applied molecules mainly keep the de novo synthesized histones, needed to form 
nucleosomes, acetylated.69 When treatment initiation is delayed, many of the histones may 
have undergone deacetylation, leaving no room for a potential adjuvant effect. 
Besides histone (de)acetylation, epigenetic gene regulation involves additional processes like 
DNA methylation, which is involved in gradual silencing of stably and transiently transfected 
genes.66, 72 Consequently, Choi et al. showed that 5-aza-2’-deoxycytidine (5A2dC), a DNA 
methyl transferase (DNMT) inhibitor, could reactivate the transcription of stably transfected 
genes. Of note, the combination of 5A2dC with sodium butyrate or TSA resulted in a 
synergistic reactivation of the transgene.72 Interestingly, 5A2dC could also improve the 
therapeutic potential of DNA vaccines both in vitro and in vivo. Indeed, a 5A2dC treatment 
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prior to vaccine delivery by gene gun increased the expression of the transgene-encoded 
antigen, resulting in reduced tumor growth and prolonged survival.73 This strategy was 
furthermore tested in the context of polymer-based pDNA delivery. Backliwal et al. 
evaluated the potential of 4 HDAC inhibitors and 4 DNMT inhibitors to enhance transgene 
expression in CHO and HEK293 cells. Small molecule treatment was initiated 3 hours post 
transfection with PEI:DNA polyplexes. HDAC inhibitors were more efficient than DNMT 
inhibitors in HEK293 cells, whereas both groups equally efficient improved transgene 
expression in the CHO cells. Here, HDAC inhibitor and DNMT inhibitor combinations resulted 
in additive enhancement of gene expression. The variations between both cell types were 
explained in terms of relative abundance of HDAC and DNMT. In turn, histon deacetylation is 
a reversible process whereas DNA can only be demethylated upon replication, which may 
explain the variations in efficacy for both inhibitors observed in the HEK293 cells.64  
Finally, Ishiguro and Sartorelli defined two additional (classes of) molecules with the 
potential to enhance transgene expression when added post transfection. The first molecule 
is phorbol 12-myristate 13-acetate, which presumably affects transgene transcription 
through the activation of protein kinase C. The second group – consisting of hexamethylene 
bisacetamide, diazepam, hypoxantine and 6-thioguanine – promotes the initiation of 
transcription potentially by destabilizing the chromatin structure.63, 74  
6. ALTERNATIVE MECHANISMS TO IMPROVE THE TRANSFECTION EFFICIENCY 
An additional major issue to NA delivery is the induction of an innate immune response upon 
recognition of the cationic carrier or NA cargo by pattern recognition receptors on the cell 
membrane or in the endo-lysosomes.75-77 This immune response is reported to decrease the 
magnitude and duration of the NA effect, thereby severely reducing the therapeutic 
potential.75, 77 Consequently, various groups evaluated the potential of small molecules to 
mitigate the immune response by blocking key proteins involved in NA recognition.75 
However, a successfully reduced innate immune response was not always clearly correlated 
to improved transfection efficiencies.78-80 In contrast, Awe et al. applied BAY11 during and 
post transfection with RNAiMAX® to enhance mRNA-mediated reprogramming of adult 
human skin cells to pluripotency. BAY11 inhibits the NF-κβ-based immune response 




encoded reprogramming factors. Of note, the effect could be retained upon sustained 
BAY11 exposure. The exact mechanism for the enhanced trans-mRNA expression remains to 
be elucidated, although an enhanced mRNA stability (due to reduced immune response-
mediated decay), improved translation and/or transfection efficiency were proposed.81 
In addition, NA are subjected to degradation by endo-lysosomal nucleases. Indeed, Howell et 
al. showed that the success of pDNA transfection was reduced or enhanced in DNAse II 
overexpressing or knock out cells, respectively.82 In corroboration, the naturally occurring 
endo-lysosomal DNAse II inhibitor, DMI-2, improved the expression of chloramphenicol 
acetyl transferase in vitro. Of note, the expression was 10-fold enhanced upon transfection 
with protein-A-poly-lysine conjugates, whereas the expression was only 1.5-fold improved 
upon lipofection and the transfection potential of calcium phosphate precipitates was not 
altered.83 Hence, the adjuvant effect of the DNAse inhibitor DMI-2 was clearly carrier 
specific, potentially depending on (i) the ability of the carrier to shield the NA and (ii) the 
amount of NA released from the carrier available for degradation by endo-lysosomal 
nucleases. 
Since many kinases are known to regulate different cellular processes that may influence the 
NA therapeutic efficiency, such as endocytosis, cell proliferation and gene transcription, 
Christensen et al. hypothesized that certain kinase inhibitors may positively influence 
transgene delivery and expression.84 Kinase inhibitors with a positive impact on transgene 
expression affected cell cycle kinases, signal transducers and growth factor receptors. The 
Polo-like kinase 1 (PLK1) inhibitors altered the polyplex distribution from confinement in the 
MTOC to a diffuse presence in the cytosol. In addition, PLK1 inhibitors induced cell cycle 
arrest in the G2/M phase, where cells are more susceptive to transfection given the 
compromised nuclear membrane.84 Likewise, synchronization of the cells in the G2/M phase 
prior to transfection can be applied to improve the pDNA transfection efficiency. Indeed, 
when removing the reversible inhibitor of cyclin-dependent kinase 1 (RO-3306) during 
transfection, the cells synchronously enter mitosis. During mitosis the nuclear envelope is 
compromised, which allows increased nuclear translocation of the pDNA followed by 
enhanced transgene expression.68  
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Finally, Kendall et al. reported that several small molecules improve ASO-mediated exon 
skipping in Duchenne muscular dystrophy. Most identified hits were compounds known to 
modulate the intracellular calcium level. More specifically, three compounds target the 
ryanodine receptor thereby potentially altering the calcium homeostasis in the nucleus in 
favor of exon skipping. Of note, the most potent adjuvant, dantrolene, enhanced exon 
skipping both in vitro and in vivo, leading to rescue of muscle function in mice.85 
7. SMALL MOLECULES AS A NANOCARRIER 
A nanocarrier should fulfill several functions, namely (i) tightly package the NA cargo, (ii) 
ensure stability in a biological environment, (iii) selectively deliver the payload to the target 
tissue, (iv) interact with the cell surface to initiate internalization and (v) induce endosomal 
escape.86, 87 To meet these requirements, nanocarriers are often complex formulations 
consisting of several components, each with a specific function. For instance, cationic lipids 
or polymers are included to complex the NA, a hydrophilic polymer (e.g. PEG) assures 
colloidal stability and mitigates unspecific interactions, and ligands at the nanocarrier 
surface improve interaction with the cell surface and initiate receptor-mediated 
endocytosis.88 In contrast, Gooding et al. proposed to apply a simple small molecule carrier 
(SMoC), with the small molecule consisting of cationic guanidine groups linked to a biphenyl 
backbone. This positively charged low molecular weight construct binds negatively charged 
NA and shields its charge.89 The structure of the SMoC is based on cell penetrating peptides 
(CPP), which enter the cell through macropinocytosis upon binding of glycosaminoglycan 
chains of the proteoglycans on the cell surface. The guanidine rich SMoC mimics this CPP 
feature to ensure cellular internalization. The functionality of this SMoC for siRNA delivery 
was demonstrated in vitro by similar transfection efficiencies for both the SMoC and 






8. PLEIOTROPIC ADJUVANTS 
Finally, several molecules are able to improve the potential of NA therapeutics through 
various mechanisms. The previously mentioned molecule TSA belongs to this group, as it 
improves transgene expression through inhibition of nuclear HDAC and interferes with 
trafficking by inhibition of the cytosolic HDAC6.57, 73 CLQ is potentially the most well-known 
compound in this category, besides dexamethasone and other steroids.  
8.1. Chloroquine 
Many reports can be found on the use of CLQ as an enhancer for NA delivery. In 1981, Fraley 
et al. were the first to report that CLQ pretreatment of glycerol-stimulated cells enhanced 
liposome-mediated pDNA delivery in vitro.13 Combined efforts from different groups 
elucidated the mechanisms through which CLQ influences transgene expression. On the one 
hand, CLQ intercalates double stranded NA structures. This facilitates displacement from the 
carrier, prevents enzymatic degradation and recognition by toll like receptor 9 (TLR9), 
thereby preventing the initiation of an innate immune response. On the other hand, CLQ is 
reported to buffer the endosomes. Consequently, both the NA recognition by TLR9 and NA 
progression to the degrading lysosomal compartment are hampered, as they require an 
acidic pH.90, 91  
The group of John Fabre showed the potential of a CLQ treatment during transfection to 
improve transgene expression in various cell models, such as corneal endothelial cells, 
primary rat neural cells and primary vascular smooth muscle cells.92-95 In turn, Zhang et al. 
showed improved transfection of poly-lysine-pDNA complexes by CLQ co-incubation in 
HepG2 liver cells in vitro as well as in the rat liver in vivo.96 A follow up study revealed that 
several animals showed 10- to 30-fold enhanced expression while others stayed without 
effect with the maximal tolerable dose scheme. In addition, 0.6 mg/L appeared to be the 
cut-off CLQ serum concentration whereupon effects on delivery were observed. In contrast, 
the improvement in transgene expression could not be linearly correlated to the CLQ serum 
levels. It was furthermore not possible to reach maximum transgene expression with the in 
vivo applicable CLQ doses, as previously observed in vitro. Thus, the in vivo applicability of 
CLQ as a small molecular adjuvant is hampered by its systemic dose-limiting toxicity.97 
Accordingly, the interest in the use of CLQ as a transfection enhancer faded in the following 
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years. More recently, CLQ was once again applied to enhance siRNA-mediated gene 
silencing. For instance, Stremersch et al. showed that a CLQ treatment post transfection with 
exosome-like vesicles markedly improved chol-siRNA mediated gene silencing in non-small 
cell lung cancer cells in vitro.98 Accordingly, CLQ treatment during siRNA-loaded micelle 
transfection increased gene silencing by approximately 30%. Of note, CLQ did not affect 
gene silencing by Lipofectamine®. In turn, pretreatment with bafilomycin (a V-ATPase 
inhibitor) to prevent endosome acidification, completely abolished gene silencing. The 
authors argued that solely preventing endosome acidification is likely not sufficient to 
improve NA delivery although they did not question if the uptake was altered upon 
bafilomycin pretreatment.99 Notably, a CLQ pretreatment significantly decreased LNP-
mediated siRNA delivery.9 Overall, the adjuvant effect depends on both the carrier and the 
moment of the adjuvant treatment relative to the transfection. Accordingly, the moment of 
CLQ treatment post transfection with PEI-coated mesoporous silica NPs determines the 
extent of the transfection efficiency enhancement. In case of adjuvant treatment 8 hours 
post transfection, the siRNA-mediated silencing was significantly enhanced whereas a CLQ 
treatment 36 hours post transfection failed to improve gene silencing. Since this impediment 
could be countered by the use of nuclease-stabilized siRNA, lysosomal siRNA degradation is 
potentially an important contributing factor (Figure 2.4).100 Finally, both pDNA and siRNA 
delivery by mesoporous silica NPs was enhanced upon introduction of CLQ into the 
carrier.101 Thus, despite the dose-limiting systemic toxicity of CLQ, this approach may 





Figure 2.4. Mesoporous silica NPs coated with PEI (MSN_siRNAPEI) enter the cell through endocytosis. 
Upon timely endosomal escape functional siRNA reaches the cytosol. When CLQ is added early post 
transfection, escape of functional siRNA is enhanced. When CLQ is added 36 hours post transfection, 
siRNA is degraded in the lysosomes prior to release. Applying nuclease-stabilized siRNA circumvents 
this. Hence, even when added 36 hours post transfection, CLQ can induce release of the internalized 
nuclease-stabilized siRNA. This figure is reproduced from Wang et al.100 ©Elsevier 2013. 
8.2. Dexamethasone and other steroids 
Already in 1994 it was believed that dexamethasone could improve the therapeutic potential 
of NA due to its anti-inflammatory and immune suppressive action.14 Indeed, 
dexamethasone pretreatment enhanced luciferase expression in hepatocytes both in vitro 
and in vivo independent of the applied promoter sequence on the plasmid. Additionally, 
histological sections of treated rat livers showed reduced inflammation and an increased 
number of luciferase expressing hepatocytes.14 Moreover, an i.p. dexamethasone injection 
reduced the secretion of tumor necrosis factor α and interleukin-1β in mouse lungs after i.v. 
injection of lipid-protamine-pDNA complexes and the level of transgene expression was 
inversely correlated to the cytokine levels.102 A dexamethasone pretreatment can 
furthermore improve the in vivo therapeutic window of siRNA-loaded LNP in mice by 
suppressing pro-inflammatory gene expression, cytokine secretion and mitogen-activated 
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protein kinase phosphorylation without negatively affecting siRNA-mediated gene 
silencing.103 Overall, the anti-inflammatory effect enhances the therapeutic efficiency of 
different NA regardless of applied the carrier or cargo. 104, 105 
Further in vitro studies revealed an additional aspect of the mechanism by which 
dexamethasone enhances transgene expression. For one, the adjuvant effect of 
dexamethasone could be abolished by pretreatment with a steroid receptor agonist 
(RU38486), implicating the necessity of glucocorticoid receptor (GR) binding.104, 105 In 
addition, Kelly et al. observed increased plasmid translocation to the nucleus, which could be 
explained in terms of dexamethasone-mediated GR activation.105 This leads to rapid 
translocation of the receptor-ligand complex to the nucleus and subsequent nuclear pore 
dilation, facilitating nuclear entry of the pDNA.106  
Hence, this concept of facilitating shuttling to the nucleus was further explored by either 
conjugating dexamethasone to pDNA or the incorporation into a nanocarrier. For instance, 
Rebuffat et al. directly coupled dexamethasone to pDNA to enhance nuclear accumulation 
(Figure 2.5). However, the presence of dexamethasone sterically hindered the transcription 
initiation of nuclear pDNA.107 In turn, Gruneich et al. successfully incorporated a 
dexamethasone-spermine conjugate into a liposomal formulation. Compared to 
Lipofectamine®, this construct induced transgene expression more efficiently combined with 
less inflammation in vitro and in vivo.108 The delivery potential of PAMAM dendrimers could 
also be improved by dexamethasone conjugation.109 In addition, conjugation of 
dexamethasone to PEI even outperformed dexamethasone pretreatment.110 Of note, similar 
results could be obtained in vitro and in vivo by dexamethasone inclusion into a PEI-based 
vector, underscoring the general nature of the adjuvant effect.111, 112 However, the 
therapeutic applicability of this strategy is somewhat limited by the tumor-promoting nature 





Figure 2.5. (1) Dexamethasone-pDNA conjugates are internalized over the plasma membrane (PM). 
(2) Dexamethasone facilitates the interaction of the pDNA-dexamethasone conjugate with the 
glucocorticoid receptor (GR). (3) This complex is transferred to the nucleus, where the GR facilitates 
dilation of the nuclear pore complex (NPC) to allow pDNA to cross the nuclear envelope (NE). This 
figure is reproduced from Rebuffat et al.107 ©Nature Publishing group 2001. 
 
Besides dexamethasone, other steroids are able to activate the GR and consequently 
improve transgene expression. Indeed, when cortisol is mixed with a plasmid prior to 
complexation with PEI, reporter gene expression is doubled. Cortisone, which is not able to 
activate the GR, did not influence the transfection efficiency, confirming the requirement of 
GR activation for improved translocation to the nucleus.113 Furthermore, the presence of 
methylprednisolone during lipofection enhanced transgene expression up to 100-fold. Of 
note, even greater expression levels were achieved when methylprednisolone was included 
in the lipoplex.114 In addition, methylprednisolone tripled luciferase expression in mice 
muscles, although the expression could not be prolonged compared to the control group.104 
Finally, estradiol increased both the number of transfected cells and the extent of reporter 
gene expression when applied during Lipofectamine® transfection.115, 116 Besides improving 
cellular uptake, estradiol increased transgene translocation to the nucleus through an 
estrogen receptor-independent mechanism.114, 116 Similar to methylprednisolone, estradiol 
inclusion into a lipoplex improved transgene expression to the greatest extent in both 
bronchial epithelial cells in vitro and in nasal and lung epithelium in mice. However, the in 
vivo efficiency was not as high as anticipated based on in vitro results, indicating that 
additional barriers need to be overcome.  
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9. CONCLUSION AND PERSPECTIVES 
In conclusion, we provided a general overview of small molecular adjuvants that can be 
applied to enhance the NA delivery and/or transfection efficiency, thereby ultimately 
improving their therapeutic potential. The use of low molecular weight adjuvants provides 
an exciting alternative to conventional NA delivery approaches, which mainly focus on 
carrier design. Of note, the discussed small molecular adjuvants form a heterogeneous 
group and exert their effect by affecting specific aspects of NA delivery. For one, several 
compounds alter the biodistribution of a nanocarrier through active targeting or enhance 
tissue penetration. Other adjuvants have the ability to modulate intracellular trafficking or 
improve endosomal escape, which all prevent lysosomal sequestration and degradation of 
the carrier and cargo. Finally, some molecules mitigate the innate immune response or 
enhance the transfection efficiency directly by enhancing transgene expression or 
influencing cell cycle progression. For most categories of NA transfection enhancers, both in 
vitro and in vivo studies highlighted their adjuvant potential. Earlier reports mostly 
document on molecules capable of improving pDNA transfection, while more recent studies 
describe low molecular weight adjuvants improving the effect of additional NA therapeutics 
(Table 2.1).  
The pleiotropic molecules CLQ and dexamethasone could generally improve NA transfection 
efficiencies. In contrast, most identified adjuvants aiming to avoid lysosomal sequestration 
only positively influenced the transfection efficiency under specific circumstances. Here, the 
beneficial effect strongly depended on the moment of small molecule treatment relative to 
the transfection, the applied carrier as well as the NA cargo and the cell model. In addition, 
the beneficial effect of microtubule (de)stabilizing agents depended on the uptake, 
trafficking and escape mechanism of the nanocarrier.  
Overall, a better understanding of cellular internalization pathways, endosomal escape and 
intracellular trafficking will aid in rationally combining small molecular adjuvants with the 
desired NA and/or nanocarrier. Indeed, potentially thousands of proteins are involved in the 
abovementioned processes and could be targeted with the proper (combination of) 
adjuvants. In addition more research should be performed on the impact of reducing the 




The applicability of the proposed adjuvant strategies requires in vivo evaluation in terms of 
efficacy and safety. Despite the fact that various adjuvants were able to enhance NA delivery 
in vivo, the in vivo transfection efficiencies were often lower than expected based on the in 
vitro data. This indicates that the more complex in vivo environment poses additional 
barriers to those mimicked in vitro. An integrated approach combining several small 
molecules that improve delivery at various levels, could potentially more firmly boost the in 
vivo therapeutic potential of NA. In the best possible scenario, a combination of small 
molecules would synergistically improve the transfection efficiency. Furthermore, the safety 
of the proposed approaches needs to be addressed, as for instance the use of CLQ is limited 
by its systemic toxicity. In this regard, the tissue specificity of the delivery strategy and its 
general impact should be taken into account. In turn, the inclusion of the proposed 
adjuvants into a nanocarrier alongside the NA or the use of NA-conjugates could pose a 
solution to potential toxicity questions.  
Overall, this review highlights the potential of small molecules to improve NA transfections. 
It is clear that the use of low molecular weight adjuvants is a promising strategy to improve 
the therapeutic potential of NA, which will be further explored in the near future. 
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Table 2.1. Small molecules adjuvants that improve NA delivery grouped according to their mechanism of action. 
 
Mechanism of improved 
delivery 









Small molecules improve NA uptake 
Tumor penetration Fibrinolytic agent Losartan  
pre X X Doxil LPS  20 
Tumor priming Paclitaxel  pre X X LNP:siRNA 
23-25 
Active targeting 
Target asialoglycoprotein receptor GalNAc  conjugate X X LNP:siRNA  
33 
Target sigma receptor 
 
Haloperidol  in carrier X  LNP:DNA 37 
Anisamide  in carrier 
X X LNP:siRNA 39, 40 
X  siRNA conjugate 41 




Stimulate endocytosis Glycerol  post X  LNP:DNA 
13 
ATP produced by metabilization 
needed for energy-dependent NA 
uptake  
Hexoses  





Direct interaction with 
the NA or carrier 
Shield siRNA charge 
Improved cell association 




Reduce size LNP Hit compounds  pre X X LNP 
16 
Small molecules improve endosomal escape 
 Create pores in late endosomal 
membrane 





Interaction with endosomal 
membrane 








pDNA, mcDNA, siRNA  
47 
Block retrograde trafficking from 
endosomes to Golgi apparatus 
Retro-1  post 




(i) destabilize membrane 
(ii) defect vesicle formation 
(iii) increase the rate or extent of  
       tubulation and budding of the  
       carrier-containing vesciles 





Different mechanism for hits:  
(i) hinder acidification/maturation 
(ii) interfere with trafficking  
(iii) destabilize endosomal  
       membrane 
Hit compounds  co X  Chol-siRNA 
LNP:siRNA 
16 
Small molecules interfere with intracellular trafficking 
 
Microtubule depolymerization 
 Prevent degradation in  
      lysosomes 
Colchicine  pre 
X  LPS:DNA 
54 






pre X  LPS:DNA 55 
Taxol  pre X  LPS:DNA 
50 
Nocodazole pre X  LPS:DNA 
50, 52, 
53 
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Improved pDNA trafficking over 
stabilized microtubules 




Microtubule stabilization  
prevent vesicle fusion 
PTX  
pre X  LPS:DNA 
55 




 Stabilizes microtubuli by  
      acetylation 





Tubacin  co X  Polyplex:DNA 
58 
Protein kinase A inhibitor H89 pre X  Branched PEI:DNA 
60 
NPC1 inhibitor (prevent recycling) NP3.47 co X  LNP:siRNA 
61 
Small molecules boost transgene expression 
 
HDAC inhibitor  
(i) prevent of histon  
    deacetylation 
(ii) acetylation (activation) of  
      transcription factors  
(iii) influence the expression of  
       genes that regulate the  
       expression of transgenes 
Depsipeptide  
co  X LPS:DNA 
67 
co   X PEI:DNA 
38 
post X  LPS:DNA 
65 
post X  CaP:DNA 
65 
Trichostatin A  
post X  LPS:DNA 
65 




post X  PEI:DNA 
64 
post X  CaP:DNA 
65 
post X  electroporation 
56 
Valproic acid 
post X  PEI:DNA  
64 





Sodium butyrate  
post X  PEI:DNA 
64 
post X  electroporation 
56 
CHAP 31  post 
X  LPS:DNA 
CaP:DNA 
65 





X  PEI-DNA 
62 
DNMT inhibitor 













post X  LPS-DNA  
63, 74 
Activate protein kinase C PMA  post X  PLS-DNA 
63, 74 
Alternative mechanisms to improve the transfection efficiency 
 
Reduce innate immune response BAY11 
co 
post 
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Reduce degradation by  
endo-lysosomal DNAse 





CDK1 inhibitor RO-3306 pre X  PEI:pDNA 
68 
Enhance exon skipping Dantrolene post X X ASO 
85 
Small molecule as nanocarrier 
 
More compact complex  
Shielding of siRNA charge 
Guanidine groups 
linked to a biphenyl 
system 




Intercalate NA   
(i) improve release from carrier 
(ii) prevent degradation 
(iii) prevent recognition by TLR9 
 
Prevent acidification  
(i) prevent endo-lysosome fusion 
(ii) prevent degradation 
(iii) prevent TLR9 activation 
Chloroquine 
pre X  LPS:pDNA 
13 












post X  Micelle:siRNA 
99 
post X  MSN-PEI:siRNA 
100 
in carrier X  MSN:siRNA:CLQ 
101 
Steroids  
(i) Reduce innate immune response 
(ii) Bind glucocorticoid receptor  
         - facilitate transport to nucleus  




 X pDNA 
14 
post X  LPS:pDNA 
14 












pre X  Lipofectamine:pDNA 105 
in carrier X  Dexa-pDNA conjugate 
107 
in carrier X X LPS-dexa:pDNA 
108 
in carrier X  PAMAM-dexa:pDNA 
109 
in carrier X  PEI-dexa:pDNA 
110 
in carrier  X PEI-dexa:pDNA 
111 
in carrier X X Au-PEI:pDNA:PEI-dexa 
112 
Cortisol 
pre X  Lipofectamine:pDNA 
105 
in carrier X  PEI:dexa-pDNA 
113 
Methylprednisolone 
co X  LNP:pDNA 
114 







 X pDNA 
104 
Improve uptake 
Improve nuclear translocation  
Estradiol 
co X  Lipofectamine:pDNA 
115, 116 
co X  LNP:pDNA 
114 
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The great therapeutic potential of RNAi has since long been recognized, yet its clinical 
translation lags behind. Among other limiting factors, the efficient delivery of RNAi-triggers 
into the cytosol remains a major bottleneck. When an RNAi-effector, such as small 
interfering (si)RNA, is enclosed in a nanocarrier, uptake generally occurs through endocytosis 
whereupon the bulk of the cargo remains inactive within the endo-lysosomal compartment. 
Thus, current suboptimal delivery strategies require optimization in terms of efficiency. We 
hypothesized that the sequential addition of small molecules following transfection could 
substantially ameliorate the silencing potential of siRNA-loaded dextran nanogels. We show 
that carvedilol, desloratadine, nortriptyline and salmeterol, all FDA-approved cationic 
amphiphilic drugs (CAD), can be repurposed to this end. The four CADs improved gene 
silencing in a concentration dependent fashion with almost complete silencing at the highest 
concentration tested. This is the result of the reduced lysosomal stability induced by 
lysosomal swelling, as the CAD-mediated inhibition of acid sphingomyelinase causes 
sphingomyelin, cholesterol and phospholipid accumulation. Consequently, the lysosomal 
membrane is destabilized followed by limited membrane permeabilization. This in turn 
allows siRNA release into the cytosol and subsequent gene silencing. Of note, the lysosomes 
could be applied as a depot for prolonged and triggered siRNA release by multiple CAD 






The cytosolic delivery of RNA interference (RNAi)-effectors, such as small interfering (si)RNA, 
triggers the RNAi pathway to efficiently and specifically induce posttranscriptional gene 
silencing.1, 2 In theory any gene of interest can be targeted, making siRNAs promising 
therapeutic candidates for a myriad of genetic disorders and cancer.3, 4 
Since their negative charge and relatively high molecular weight hinder passive diffusion 
over the cell membrane, siRNA is generally enclosed in a nanocarrier to ensure cellular 
uptake.5 Such carriers are internalized by cells via one or more endocytic pathways and 
consequently confined to the early endosomes. Next, the nanocarriers are progressively 
trafficked to the late endosomes and finally lysosomes, where both the carrier and its cargo 
face degradation. However, as cytosolic siRNA delivery is a prerequisite to trigger the RNAi 
pathway and reduce gene expression, lysosomal entrapment is generally regarded as a non-
functional dead end for siRNA therapeutics.5 To avoid lysosomal degradation, current cell 
delivery methods aim to stimulate endosomal escape prior to fusion of the endosomes with 
the lysosomes.6, 7 Unfortunately, the rapid trafficking towards the lysosomes strongly limits 
the time-window to induce release.8 In addition, current escape strategies target early or 
late endosomes since the induction of severe lysosomal membrane damage is believed to 
trigger cell death.6, 9 Despite extensive efforts, state-of-the-art cytosolic delivery strategies 
largely fail to deliver, as the bulk of the internalized siRNA dose remains entrapped in the 
lysosomes.10, 11  
Opposed to the current paradigm, we propose to exploit the lysosomes for timely cytosolic 
siRNA delivery by repurposing cationic amphiphilic drugs (CADs). CADs are pharmacologically 
diverse compounds that preferentially accumulate in lysosomes given their amphiphilic and 
weak basic properties.12 Here, protonated CADs insert in lysosomal membranes with their 
hydrophobic segment, causing the detachment of the membrane-associated acid 
sphingomyelinase (ASM) and its subsequent degradation in the lysosomal lumen (Figure 
3.1).13 Thus, many CADs are known as functional inhibitors of ASM (FIASMAs).12, 14 Active 
ASM catalyzes the hydrolysis of sphingomyelin (SM) to ceramide, thereby playing an 
important role in the maintenance of the lipid homeostasis and lysosomal membrane 
integrity. Indeed, SM accumulation upon ASM inhibition is associated with reduced 
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membrane stability and induction of lysosomal membrane permeabilization (LMP) in cancer 
cells (Figure 3.1).13, 15, 16  
 
Figure 3.1. Acid sphingomyelinase (ASM) is a membrane bound enzyme present in the lysosomes that 
contributes to lipid homeostasis. Cationic amphiphilic drugs (CADs) insert in the lysosomal 
membranes and cause electrostatic repulsion of ASM, thereby inducing ASM release into the 
lysosomal lumen followed by degradation. As a result, lipids accumulate in the lysosomes, leading to 
lysosomal swelling and membrane permeabilization.13, 17 
 
To evaluate this hypothesis we selected four structurally diverse, FDA-approved CADs with a 
distinct pharmacological activity, namely carvedilol (a β-blocker), desloratadine (an 
antihistamine), nortriptyline (an antidepressant) and salmeterol (a β2-agonist) (Figure 3.2). 
All compounds have an estimated logP > 3 and pKa > 7.4 and can thus be classified as 
lysosomotropic drugs, CADs and FIASMAs.12, 14 As a model nanomedicine, we applied siRNA-
loaded cationic dextran nanogels (siNGs) that have demonstrated high uptake and gene 
silencing efficiency in cancer cells.18, 19 To unambiguously assess the adjuvant effect, the 




 Figure 3.2. The drug class, logP, pKa values and molecular structure of carvedilol, desloratadine, 
nortriptyline and salmeterol.20  
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2. MATERIALS AND METHODS 
2.1. siRNA duplexes 
The 21 nucleotide siRNA duplex targetting the enhanced green fluorescent protein (eGFP; 
sieGFP) and the control siRNA duplex (siCTRL) were purchased from Eurogentec (Belgium). 
For uptake experiments, the siCTRL duplex was labeled with a Cy5 dye at the 5´ end of the 
sense strand (Eurogentec, Belgium). In addition, nuclease-stabilized versions of the siEGFP 
and siCTRL duplexes (Dharmacon, USA) were applied in experiments regarding triggered 
siRNA release. The siGLO green transfection indicator (Dharmacon, USA) was furthermore 
used. Finally, custom-designed siRNA with the siSTABLE modification targeting polo-like 
kinase 1 (siPLK1) was obtained from Dharmacon (USA). The sequences and modifications of 
the applied siRNA duplexes are summarized in Table 3.1.  
Table 3.1. Applied siRNA sequences and duplex modifications. 
siRNA Modification Manufacturer 
Sequencea 
Sense strand (5’ -> 3’) Antisense strand (5’ -> 3’) 
siCTRL
b 










Dharmacon UAGCGACUAAACACAUCAAUU UUGAUGUGUUUAGUCGCUAUU 
sieGFP
e 





Dharmacon CAAGCUGACCCUGAAGUUCUU GAACUUCAGGGUCAGCUUGUU 
siGLO FAM-labelled
f 





Dharmacon CAACCAAAGUCGAAUAUGAUU UCAUAUUCGACUUUGGUUGUU 
a
 Capital and lower case letters respectively represent ribonucleotides and 2′-deoxyribonucleotides; 
b
 negative 
control scrambled duplex; 
c
 the siCTRL duplex was labeled with a Cy5 dye at the 5´ end of the sense strand;  
d
 siSTABLE RNA strand modification by Dharmacon for use in nuclease-rich environments; 
e 
siRNA duplex 
targeting enhanced green fluorescent protein; 
f
 Fluorescent siCTRL duplex modified to translocate to the 
nucleus upon successful transfection; 
g
 siRNA duplex targetting polo-like kinase 1. 
 
2.2. NG complexation 
The cationic dextran nanogels (NGs) were prepared via an inverse mini-emulsion 
photopolymerization method.18, 19 Before the NGs were loaded with siRNA, a 2 mg/mL 
dispersion of a lyophilized stock was prepared in ice-cooled nuclease free water and 
sonicated briefly (amplitude 10%). Subsequently, equal volumes of appropriate NG and 




(pH 7.4, 20 mM) were mixed to a final volume of 100 µL and were allowed to complexate for 
15 minutes at room temperature. The same volume of HEPES buffer was added to this 
dispersion, followed by Opti-MEM® (Invitrogen, Belgium) to a final volume of 1 mL. 300 µL of 
this dispersion was applied per well during transfection. Hence, three technical replicates 
were performed for each condition. This complexation procedure was applied for all cell-
based experiments and resulted in a 30 µg/mL NG dispersion loaded with 2 nM siRNA (= 
0.06 pmol siRNA/µg NGs or 0.6 pmol siRNA/well).  
2.3. Cell lines and cell culture conditions 
All experiments were performed on the non-small cell lung carcinoma cell line H1299 of 
which both the wild type (H1299-WT) and the eGFP-expressing variant (H1299-eGFP) were 
applied. Complete cell medium was prepared by supplementing RPMI 1640 culture medium 
with 10% fetal bovine serum (FBS, HycloneTM, Thermo Fisher Scientific, Belgium), 2 mM L-
Glutamine and 100 U/mL penicillin/streptomycin. The cell lines were cultured in a 
humidified atmosphere containing 5% CO2 at 37 °C and culture medium was renewed every 
other day unless the 80% confluence level was reached. In this case, the cells were split 
using 0.25% trypsin-EDTA. All products were purchased from Invitrogen (Belgium) unless 
specifically mentioned otherwise.  
2.4. siNG transfection and sequential adjuvant treatment 
Cells were transfected with 300µL of the 30 µg/mL NG dispersion loaded with 2 nM siRNA 
per well during four hours at 37 °C in a humidified atmosphere containing 5% CO2. 
Subsequently, the siNG dispersion in Opti-MEM was removed, the cells were washed once 
with phosphate buffered saline (PBS, Invitrogen, Belgium) and received fresh cell medium. In 
case of CAD treatment, cell medium containing 10, 20 or 40 µM carvedilol,  desloratadine 
(DL), nortriptyline (NT) or salmeterol was applied. Furthermore, 5 µM NT and DL were tested 
alone as well as in the following combinations: 5 µM + 5 µM, 10 µM + 10 µM and 20 µM + 20 
µM. Furthermore, dextromethorphan was tested in the following concentration range: 10, 
20, 40, 80, 120, 160 and 200 µM. In additional experiments, we applied cell medium 
containing 10, 20 or 40 µM chloroquine, 30 µM U18666A or 300 µM 2-hydroxy oleic acid, 
the latter either alone or in combination with 10 µM DL. Figure 3.3 shows the molecular 
structure, logP and pKa values of the additionally applied adjuvants. All small molecules 
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were obtained from Sigma-Aldrich (Belgium) and the stock solutions were prepared in 
sterile-filtered BioPerformance Certified dimethyl sulfoxide (DMSO, Sigma-Aldrich, Belgium). 
The final DMSO concentration brought onto the cells did not exceed 0.16 vol% and this 
condition was additionally tested for potential off-target effects.  
 
Figure 3.3. The drug category, logP, pKa values and molecular structure of dextrometorphan, 
chloroquine, U18666A and 2-hydroxy oleic acid.20 
 
All adjuvant treatments were performed in complete cell medium and lasted 20 hours, 
unless specifically mentioned otherwise. Afterwards, the small molecule-containing cell 
medium was removed and cells were kept in 1 mL fresh cell medium for an additional 24 
hours until analysis. In a final set of experiments regarding the triggered siRNA release from 
the lysosomal compartment, the DL incubation time was reduced to 2 hours without further 
changes to the protocol timeline. This treatment time was also applied in the experiment 
where cells were exposed daily or every other day to DL over a period of 6 days. 
2.5. Measuring the siNG transfection efficiency 
For silencing experiments, H1299-eGFP cells were seeded in 24 well plates at a density of 
35000 cells/well and were allowed to settle overnight. Subsequently, the cells were 
transfected with 0.6 pmol siRNA/well (300 µL siNG dispersion) and treated with 0.5 mL cell 
medium containing a small molecular adjuvant. Note that for every sieGFP or siPLK1 




SiNG-mediated eGFP silencing was determined by flow cytometry 48h after the transfection. 
Sample preparation consisted of washing the cells with PBS, followed by detachment with 
0.25% trypsin-EDTA. The cells were collected, centrifuged 5 minutes at 300g, resuspended in 
300 µL flow buffer and kept on ice until analysis. For each sample the forward and side 
scatter as well as the green fluorescent signal were measured for at least 15000 cells. The 
samples were excited with the 488 laser line and the signal was detected with the 530/30 
filter using the FACSCalibur™ flow cytometer (BD Biosciences, Belgium) and BD CellQuest™ 
acquisition software. Finally, data analysis was performed using the FlowJo software (Tree 
Star Inc.) and the calculated percentage eGFP expression is presented as the mean ± 
standard error of the mean (SEM) for four biological replicates. 
When probing the evolution of the eGFP signal over an extended period of time, the eGFP 
signal was measured daily. Hereto, treated cells were passaged every other day and 
reseeded in new 24 well plates during sample preparation for the flow cytometry 
measurements.  
The silencing potential of siPLK1-NGs was established through evaluating the cell viability. 
Hereto, we applied the CellTiter GLO® assay (Promega, Belgium). Before initiating the assay, 
the culture plates and reconstituted assay buffer were placed at room temperature for 30 
minutes. Next, the culture medium was replaced by 250 µL fresh cell medium and an equal 
volume of assay buffer was added. To induce complete cell lysis, the plates were shaken 
during 2 minutes and the signal was allowed to stabilize for 10 minutes. 100 µL from each 
well was subsequently transferred to an opaque 96-well plate, which was measured with a 
GloMax® 96 Microplate Luminometer (Promega, Belgium). Three biological replicates were 
performed and data are expressed as the mean cell viability (%) ± SEM.    
2.6. Cell viability 
The H1299-eGFP cells were seeded, transfected and treated with the CADs similar to the 
silencing experiments. Please note that we only applied siCTRL-loaded NGs in this set of 
experiments. Again, the CellTiter GLO assay was performed as described above in three 
biological replicates (data are expressed as the mean ± SEM).    
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2.7. Release of FITC-dextrans and oligonucleotides  
H1299-WT cells were seeded at 105000 cells/dish in 35mm diameter glass bottom 
microscopy dishes (Greiner Bio-One GmbH, Germany) and were allowed to settle overnight. 
To visualize the FITC-dextran (FD) release,cells were exposed to 1 mL of a 1 mg/mL 
dispersion of 10 kDa FD (Sigma-Aldrich, Belgium) in complete cell medium during 1 hour at 
37 °C in a humidified atmosphere containing 5% CO2. To assess oligonucleotide (ON) escape, 
the NGs were first loaded with 100 nM Alexa Fluor 647-labelled ON (Eurogentec, Belgium) 
according to the procedure described for siRNA complexation and 900 µL of the ON-NG 
dispersion was added to each dish. Of note, these oligonucleotides transfer to the nucleus 
upon release into the cytosol.21 Following four hours of ON-NG transfection or 1h incubation 
with FD, the cells were washed with PBS and received 1.5 mL fresh cell medium with or 
without 10, 20 or 40 µM DL. After an additional incubation period of 20 hours, the cell 
medium was removed and nuclei were labeled with Hoechst (Molecular ProbesTM, Belgium) 
in cell medium during 15 minutes at 37 °C. Finally, the Hoechst solution was removed, fresh 
cell medium was added and cells were kept at 37 °C in a humidified atmosphere containing 
5% CO2 until imaging.  
The samples were imaged using a laser scanning confocal microscope (LSCM, C1si, Nikon) 
and a 60x oil immersion Plan Apo objective (Nikon, Belgium). The 408, 488 and 633 laser 
lines were applied to respectively excite the Hoechst labeled nuclei, the FD and ON. During 
data analysis with ImageJ, both the total cell number and amount of cells with a diffuse FD 
labeling or ON-positive nuclei were counted. Data are represented as the percentage of cells 
with a diffuse FD signal for minimum 225 cells per condition in 10 images and the 
percentage of cells with ON-positive nuclei for at least 180 cells in 10 images.  
2.8. Lysosome detection using flow cytometry 
H1299-eGFP cells were seeded, transfected and treated with the CADs as described for the 
cell viability experiments. Following 20 hours of CAD treatment, the lysosomes were labeled 
with the LysoTracker® Deep Red (LDR) probe (Molecular Probes™, Belgium) through 
incubation with 1 mL 75 nM LDR in cell medium for 30 minutes at 37 °C. Further sample 
preparations were carried out as previously described for the silencing experiments. Using 
the FACSCalibur™ flow cytometer and BD CellQuest™ acquisition software, the LDR signal 




15000 cells per sample. Experiments were performed in biological triplicate and fold changes 
in LDR signal intensity are expressed as the mean ± SEM. 
2.9. Visualizing lysosomes with confocal microscopy 
H1299-WT cells were seeded as specified for the FD release experiment and transfected with 
siNGs followed by a 20-hour DL treatment. After removal of the DL-containing cell medium, 
cells were washed with PBS and incubated with 75 nM LysoTracker® Red DND-99 (Molecular 
Probes™, Belgium) in cell medium during 30 minutes at 37 °C. Next, the dye was removed, 
cells were washed with PBS and fixed with 4% paraformaldehyde (PFA) during 15 minutes at 
room temperature. Finally, the cells were washed twice with PBS, covered with Vectashield 
antifade mounting medium containing DAPI (Vector Laboratories, USA) and stored at 4 °C 
until imaging. A LSCM and 100x oil immersion Plan Apo objective (Nikon, Belgium) objective 
were applied for imaging. The 408 and 561 laser lines respectively excited the DAPI-labeled 
cores and LysoTracker® Red DND-99-stained lysosomes. The LysoTracker® Red DND-99 signal 
intensity and area were determined using the ImageJ in at least 115 cells from minimum 11 
images.  
2.10. Phospholipidosis detection with LipidTOXTM red 
H1299-WT cells were seeded and allowed to settle overnight as detailed previously. Next, 
the cells were incubated with a mixture of a 1/1000 dilution of the LipidTOX™ red 
phospholipidosis detection reagent (Thermo Fisher Scientific, USA) and the desired CAD in 
complete cell medium. Upon 20h incubation, the cells were fixed with 4% PFA and stored at 
4° covered in Vectashield antifade mounting medium containing DAPI. Imaging occurred 
with a LSCM and a 100x oil immersion objective. DAPI and the LipidTOX™ red 
phospholipidosis dye were respectively excited with the 406 and 561 laser lines.   
2.11. Cholesterol detection with filipin 
Following H1299-WT cell seeding, transfection and DL treatment, the cells were washed 
once with PBS and fixed with 3% PFA during 1 hour. After washing the samples with PBS, the 
remnant PFA was quenched with a 1.5 mg/mL glycine solution in PBS during 10 minutes. 
Next, a 0.1 mg/mL filipin solution in PBS containing 10% FBS was applied for 2 hours. 
Afterwards, the cells were washed once with PBS containing FBS, once with PBS and finally 
stored at 4 °C in Vectashield without DAPI (Vector Laboratories, USA). All steps of this 
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labeling procedure were executed at room temperature. The samples were imaged with a 
LSCM and a 100x oil immersion objective following excitation with the 406 laser line.  
2.12. Sphingomyelin detection with lysenin 
Cell seeding, transfection and DL treatment of the H1299-WT cells occurred similar to the 
previous microscopy experiments. The subsequent staining procedure was carried out at 
room temperature. Following one wash step with PBS, the cells were fixed with 4% PFA 
during 15 minutes. The fixative was removed, the cells washed twice with PBS and 
permeabilized with 0.5% Tween 20 for 15 minutes. Next, the cells were washed twice with 
blocking buffer (BB, 2 wt% bovine serum albumin (Amresco, USA) in PBS) and kept in BB 
during 30 minutes. Upon removal, the cells were incubated 2 hours with a 1 µg/mL lysenin 
(Sigma-Aldrich, Belgium) solution in BB. The cells were subsequently washed twice with PBS 
before 1 hour incubation with the lysenin rabbit anti-human antiserum (1:500 in BB, 
Peptanova, Germany). Before and after the subsequent 1-hour incubation period with the 
secondary goat anti-rabbit AF 647 antibody (1:500 in BB, Molecular ProbesTM, Belgium), cells 
were washed with BB. Finally the cells were washed with PBS and stored at 4 °C covered 
with Vectashield containing DAPI. Using the 408 and 633 laser lines the nuclei and 
sphingomyelin were excited respectively and detected with a LSCM and a 60x oil immersion 
objective.  
2.13. Transfection with siGLO green transfection indicator   
H1299-WT cells were seeded as described previously. For this experiment, NGs were 
complexated with 100 nM green fluorescent siRNA (siGLO, Dharmacon, USA). Following 
transfection and 40 µM DL treatment, the cells were fixed with 4% PFA and stored in 
Vectashield containing DAPI. The samples were imaged with a LSCM and a 100x oil 
immersion objective following excitation with the 406 and 488 nm laser line to visualize the 
DAPI and siGLO signal, respectively.  
2.14. Statistical analysis 
Statistical analysis was performed using the 6th version of the GraphPad Prism software. 
One-way ANOVA combined with the post-hoc Dunnett test was applied to compare multiple 





3.1. CAD treatment enhances siRNA-mediated gene silencing 
First, we evaluated if an adjuvant treatment with carvedilol (CD), desloratadine (DL) 
nortriptyline (NT) or salmeterol (ST) enhanced the gene silencing potential of suboptimal 
siRNA-loaded dextran nanogels (siNGs, 2 nM siRNA) in a non-small cell lung cancer cell line 
(H1299) that stably expresses the enhanced green fluorescent protein (eGFP).  
In line with earlier observations, the suboptimal siRNA-loaded nanogels (siNGs) were 
efficiently internalized by the H1299 cells (Figure 3.4A) and induced ~25% eGFP silencing 
under the given experimental conditions (Figure 3.4C).18, 19 Notably, the sequential 
treatment by each compound markedly improved the siNG silencing potential in a similar 
concentration dependent fashion (Figure 3.4C, Figure 3.4D). Compared to the siNGs alone, 
10 µM CAD induced a significant increase in eGFP silencing and almost complete gene 
silencing was obtained with 40 µM. It was verified that the solvent, DMSO, did not influence 
the siNG-mediated gene silencing (Figure 3.4B). When a combination of CADs was applied, 
additive effects on gene silencing were observed and no significant variations were detected 
between the combination of DL and NT or double the concentration of each compound 
separately (Figure 3.5A). In turn, not all CADs were active in the same dose range. For 
instance, 10-fold higher concentrations of dextromethorphan were required to obtain a 
similar adjuvant effect (Figure 3.5C). Our adjuvant approach was furthermore compared to 
the gold standard for siRNA transfections, ie. Lipofectamine® RNAiMAX lipoplexes. When the 
latter was applied according to the manufacturers guidelines (5 pmol siRNA per well) 
maximal gene silencing was obtained (Figure 3.5B). However, when the lipoplexes were 
diluted to obtain a similar siRNA concentration per well as with the suboptimal siNGs (0.6 
pmol siRNA/well or 2nM siRNA) ˜55% gene silencing was obtained, compared to >90% 
silencing for the siNG-CAD combination (Figure 3.5B). Note that, as compared to 
Lipofectamine RNAiMAX, the same level of knockdown can be achieved with a 10-fold 
lower dose of siRNA by the sequential addition of a CAD to siNG-transfected cells. Finally, 
sequential addition of the endosomal escape enhancer chloroquine (CLQ) improved siNG-
mediated silencing to a similar extent as the first four CADs tested (Figure 3.5D). However, 
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the use of CLQ as a delivery enhancer is limited by its systemic toxicity, while other CADs, for 
instance antihistamines, may provide a safer alternative.22 
 
Figure 3.4. (A) Representative scatter plots showing the forward scatter (FSC) and the intensity of the 
fluorescent Cy5-labeled siRNA measured at 661 nm ± 16 (FL4) from untreated H1299-eGFP cells and 
cells exposed to 30 µg/mL siNGs. The scatter plots unambiguously indicate that all cells avidly 
internalize the siRNA-loaded NGs when a concentration of 30 µl/mL siNGs is applied. (B) % eGFP 




exposure to the highest DMSO concentration applied in all CAD experiments (white). Thus, the solvent 
does not influence the sieGFP-NG mediated gene silencing in H1299-eGFP cells. (C) Transfection of 
H1299-eGFP cells with suboptimal siNGs resulted in ˜75% eGFP expression. Sequential carvedilol, 
desloratadine, nortriptyline or salmeterol addition caused significant additional silencing of the stably 
expressed eGFP in a concentration dependent manner. (D) The mean fluorescence intensity (MFI) for 
the H1299-eGFP cells transfected with siCTRL-loaded NGs (black) and siEGFP-NGs (white) followed by 
adjuvant treatment with 10, 20 or 40 µM nortriptyline (NT), salmeterol (ST), carvedilol (CD) or 
desloratadine (DL). This graph is a representative graph for four independent experiments. Data are 
represented as mean ± the standard error of the mean (SEM) for minimum three independent 
biological replicates. Statistical significance, with respect to NG transfection alone, is indicated when 
appropriate (* p<0.05, ** p<0.01,  *** p<0.005).  
 
 
Figure 3.5. (A) Combinations of desloratadine (DL) and nortriptyline (NT) evoked additive effects on 
eGFP silencing. (B) Comparison of eGFP knockdown between siNGs and lipofectamine RNAiMAX. (C) 
Dextrometorphan (DX) does not influence gene silencing in the same dose range. (D) Endosomal 
escape enhancer chloroquine (CLQ) improves gene silencing to a similar extent as the initial molecules 
tested. Data are represented as mean ± the standard error of the mean (SEM) for minimum three 
independent biological replicates. Statistical significance, with respect to NG transfection, is indicated 
when appropriate (* p<0.05, ** p<0.01,  *** p<0.005). Statistical significance between NG + 40 DL 
and RNAiMAX is indicated by xxx (p<0.005). (NG = siNG transfection without sequential adjuvant 
treatment, CAD = cationic amphiphilic drug) 
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3.2. CAD treatment affects cell viability to a minor extent 
Next, we evaluated the impact of the CAD treatment alone or sequential to the siNG 
transfection on cell viability. Figure 3.6A, which shows the viability of H1299-eGFP cells (%) 
following CAD treatment, indicates that the CADs were fairly well tolerated in the applied 
concentration range with CD and DL being the least and most biocompatible, respectively. 
The NG transfection reduced the cell viability to ˜80% (Figure 3.6B), which is an acceptable 
toxicity level. None of the CADs induced significant additional cytotoxicity at a concentration 
of 10 µM (Figure 3.6B). For both ST and CD, significant additional cytotoxicity was detected 
starting from 20 µM, while this was only the case for 40 µM NT or DL. Of note, only for ST 
and CD did the cytotoxicity observed at 40 µM exceed the sum of the effects from each 
separate component. Again, DL was best tolerated with ˜60% viability.   
 
Figure 3.6. Cell viability of H1299-eGFP cells following CAD treatment alone (A) or sequential NG 
transfection and 20 hours CAD addition (B). Data reflect the mean ± SEM (n = 3) and statistical 
significance is indicated when appropriate (* p<0.05, ** p<0.01, *** p<0.005). In (B) the black * 
represent significant variations relative to the untreated control (NTC), whereas the grey * resemble 
significant differences with respect to the cells transfected with siCTRL-NGs. (NTC = not treated 
control, NG = nanogels, CAD = cationic amphiphilic drug, NT = nortriptyline, ST = salmeterol, CD = 




3.3. Desloratadine improves the cytosolic delivery of macromolecules 
Based on current literature13, we hypothesized that the sequential CAD treatment improved 
the siNG silencing potential by facilitating the siRNA transfer to the cytosol, through the 
induction of lysosomal membrane permeabilization (LMP). To visualize LMP as a function of 
CAD treatment, the H1299-WT cells were first incubated with FITC-labeled dextrans (FD, 10 
kDa), being a fluid-phase marker to label the endo-lysosomes. Upon leakage of FD to the 
cytosol due to LMP, the affected cells show a diffusely stained cytosol in contrast to the 
typical punctate pattern indicative of endo-lysosomal sequestration.23 As expected, the 
punctate pattern was observed in the bulk of the untreated cells (Figure 3.7). Upon DL 
adjuvant treatment, we observed a concentration dependent increase in the percentage of 
cells with a diffuse FD labeling, reaching up to ~26% with 40 µM DL.  
 
Figure 3.7. Representative confocal images from the intracellular FITC-dextran distribution in 
untreated H1299-WT cells or cells incubated with 10, 20 or 40 µM desloratadine (DL) following FITC-
dextran uptake via endocytosis. The values below the images correspond to the percentage of cells 
with a diffuse FITC-dextran labeling. The scale bar corresponds to 50 µM.  
 
Subsequently, we confirmed the improved release for our model carrier by applying NGs 
loaded with Cy5-labeled oligonucleotides (ON), which translocate to the nucleus upon 
escape.21 ON were detected in the nuclei of ~1% of the transfected cells. In contrast, ~30% 
of the cells showcased positive nuclei following a 40 µM DL treatment (data not shown). 
Although the percentage of positive cells correlates well for both methods, it was lower than 
anticipated based on the silencing results. This may be explained by the fact that upon 
release of a limited amount of FD or ON, the labels are diluted in the cytosol or nuclei, 
respectively, with the fluorescence falling well below the detection limit of a standard 
fluorescent confocal microscope.11  
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3.4. The lysosomal compartment is affected by CAD treatment 
Since CADs were suggested to induce lysosomal siRNA release, we examined the impact of 
the CAD treatment on the lysosomal compartment of siNG-transfected cells by labeling the 
endo-lysosomes with LysoTracker® Deep Red (LDR) and quantification through flow 
cytometry. Figure 3.8A shows that all four CADs alone evoked a similar significant 
concentration-dependent signal increase compared to the untreated cells. In addition, siNGs 
transfection alone caused a significant two-fold raise with respect to the untreated control 
(Figure 3.8B). Importantly, upon sequential CAD treatment, the LDR signal was additionally 
significantly elevated for all CADs in nearly all concentrations tested.  
These observations could visually be confirmed by confocal microscopy following labeling of 
the endo-lysosomes with LysoTracker® Red. siNG endocytosis explained the two-fold 
increase in endo-lysosomal volume for NG-transfected cells, as we witnessed an elevation in 
the number of labeled organelles without notable alterations in their appearance (Figure 
3.8C). In turn, the additional LDR signal increase upon sequential CAD treatment coincided 
with a marked enlargement of the labeled vesicles, which was confirmed by quantification of 
the LysoTacker® Red signal area (Figure 3.8D).  
This CAD-induced lysosomal swelling in turn increased the cellular granularity, which was 
corroborated by the augmented side scatter (SSC) signal. Upon NG transfection, a minor 
shift towards higher SSC values could be noted and this trend continued with mounting CAD 
concentrations (Figure 3.8F). Indeed, for 40 µM DL a clear shift of the cell population, which 
resulted in a 1.8-fold increase in the mean SSC signal (Figure 3.8E). Similar trends were 
obtained for NT, ST and CD (Figure 3.9A). The combination of CADs resulted in additive SSC 
increases and no significant variations were detected between the single compounds and 
the combination of half of their doses (Figure 3.9B). In line with the concentration-
dependent effect of dextromethorphan on siNG-induced gene silencing (Figure 3.5C), only 
doses above 80 µM significantly augmented the SSC signal (Figure 3.9C), although the effect 
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Figure 3.8. (A) and (B) Fold change in LDR signal measured via flow cytometry for H1299-eGFP  cells 
treated only with the CADs (A) or the combination of siNGs and CADs (B). (C) Representative confocal 
images showing the endo-lysosomal compartment (red) following LysoTracker® red labeling for 
untreated H1299-WT cells, NG-transfected cells or cells transfected with siNGs followed by 10, 20 or 
40 µM DL treatment. The scale bar corresponds to 20 µm. (D) Fold increase in signal area relative to 
the untreated control quantified from the confocal images for transfected cells with and without DL. 
(E) Fold change in side scatter induced by NG transfection or sequential treatment with DL. (F) 
Representative scatter plots for untreated cells, NG-transfected cells or cells transfected with siNGs 
followed by 10, 20 or 40 µM DL treatment. Data are represented as the mean ± SEM (n = 3) and 
statistical significance is indicated when appropriate, in black when referring to the untreated control 
and in gray when compared to NG transfected cells (* p<0.05, ** p<0.001, *** p<0.005). (NTC = not 
treated control, LDR = LysoTracker® Deep Red, CAD = cationic amphiphilic drug, NG = nanogels, NT = 
nortriptyline, ST = salmeterol, CD = carvedilol, DL = desloratadine; FSC = forward scatter, SSC = side 
scatter) 
 
Figure 3.9. (A) Fold increase in side scatter (SSC) signal with respect to the untreated control H1299-
eGFP cells by NG transfection alone or with additional CAD treatment. (B) Fold change increase of the 
SSC signal upon siNG transfection of H1299-eGFP cells whether or not followed by treatment with 10, 
20 or 40 µM DL or NT or their combination. (C) Fold change of the SSC signal as a consequence of 
siNG transfection of H1299-eGFP cells in combination with dextromethorphan treatment (10, 20, 40, 
80, 120, 160 or 200 µM). Data are represented as the mean ± SEM (n = 3) and statistical significance 
is indicated when appropriate in black with reference to the untreated cells and in gray with respect 
to the NG-transfected cells (* p<0.05, ** p<0.001, *** p<0.005). (NTC = not treated control, NG = 





3.5. CADs induce a lysosomal storage disease-like phenotype 
Since CADs are known lysosomotropic agents and phospholipidosis (PLD) inducers, we 
subsequently explored whether the enlargement of the lysosomal compartment could be 
attributed to phospholipid accumulation. Labeling CAD-treated cells with the PLD detection 
reagent LipidTox Red (Figure 3.10A), revealed that DL treatment induced PLD in a 
concentration dependent fashion. The lipids accumulated in vesicular structures, which 
enlarged and became more numerous as a function of the DL concentration. Furthermore, 
only higher doses of dextromethorphan (≥ 80 μM) clearly induced vesicular phospholipid 
accumulation, corroborating earlier observations.  
Such lipid accumulation is a general phenotypical feature of lysosomal lipid storage 
disorders.24 However, in this case we did not experimentally verify whether the lipids 
effectively accumulated in lysosomal structures. Further experiments applying phospholipid 
and lysosomal markers following detection by confocal microscopy or transmission electron 
microscopy could offer more definite proof of the lysosomal lipid accumulation.  
Interestingly, several groups applied CADs to induce a Niemann-Pick disease (NPD) 
phenotype.25 NPD is a lysosomal storage disorder caused by either a depletion of the 
cholesterol transport protein NPC1 (NPD type C) or a genetic defect in the acid 
sphingomyelinase enzyme (ASM, NPD type A). Both NPD type A and C present a similar 
phenotype that is characterized by enlarged lysosomes due to the accumulation of 
cholesterol and sphingolipids, including sphingomyelin (SM).26, 27 To experimentally confirm 
whether the induction of a NPD phenotype enhances siRNA-mediated gene silencing, we 
first compared the CAD adjuvant effect to that of U18666A, a structurally different (Figure 
3.3) and often applied small molecular inducer of the NPD phenotype. Compared to siNG-
transfected cells sequentially treated with 40 µM DL, the cellular granularity was augmented 
to an even greater extent by 30 µM U18666A (Figure 3.10C). Moreover, U18666A clearly 
improved siNG-mediated gene silencing (Figure 3.10B), albeit to a lesser extent than 40 µM 
DL.  






Figure 3.10. (A) Representative confocal images from the phospholipid distribution in H1299-WT cells 
visualized with LipidTox Red PLD detection reagent in untreated cells and cells treated with 10 or 40 
µM DL or 10, 40, 80 or 200 µM DX. The scale bar corresponds to 30 µm. (B) The eGFP silencing 
induced by adjuvant treatment with 30 µM U18666A compared to siNG transfection alone. (C) 
Representative scatter plots from untreated cells and siNG-transfected cells receiving sequential 
treatment with 40 µM DL or 30 µM U18666A. (D) Representative confocal images from the 
intracellular cholesterol distribution in untreated H1299-WT cells or transfected cells treated with 10, 
20 or 40 µM DL. The scale bar corresponds to 30 µm. (E) Representative confocal images showing the 
intracellular sphingomyelin distribution in untreated H1299-WT cells or transfected cells additionally 
treated with 10, 20 and 40 µM DL. The scale bar corresponds to 30 µm. (F) The % eGFP expression in 
H1299-eGFP cells following transfection with the siNGs alone or in combination with 300 µM 2OHOA, 
10 µM DL or the combination of both. Data are represented as the mean ± SEM (n = 3) and statistical 
significance is indicated when appropriate (*** p<0.005) (NG = nanogels, DL = desloratadine, FSC = 
forward scatter, SSC = side scatter, 2OHOA = 2-hydroxy oleic acid) 
 
Next, we imaged the cellular cholesterol distribution following siNG transfection and 
sequential CAD treatment (Figure 3.10D). In the untreated cells, the cholesterol appears to 
be mainly diffusely present in the cell membrane as well as in the perinuclear region. Upon 
DL treatment, cholesterol is redistributed to vesicular structures, which enlarge in a 
concentration dependent fashion. This observation correlates well with our results on endo-
lysosomal swelling (Figure 3.8C) and phospholipid accumulation (Figure 3.10A), although co-
labeling experiments should be performed to confirm this hypothesis. In addition, we 
observed similar alterations in the SM distribution upon CAD treatment (Figure 3.10E, 
supporting the notion that the CADs negatively influence the ASM activity and cause SM 
accumulation. To confirm that interference with the SM metabolism contributed to the 
enhanced siNG-mediated gene silencing, we combined 10 µM DL and 300 µM 2-hydroxy 
oleic acid (2OHOA), a known activator of the SM synthetase. The additive effect of 2-OHOA 
on the siRNA-mediated gene silencing indeed suggests an involvement of the SM 
homeostasis in the improved cytosolic siRNA delivery (Figure 3.10F). More definite proof 
could be provided by performing ASM-activity studies prior to and post CAD exposure.12 
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3.6. The impact of the DL incubation time and multiple DL treatments 
All experiments described above involved a 20-hour CAD treatment. Since a 20-hour DL 
incubation period reduced the cell viability to ˜60%, we evaluated whether a reduction of 
the exposure time from 20 to 2 hours could reduce the toxicity levels in order to obtain a 
more applicable strategy to improve siRNA release in vivo. Figure 3.11A shows that both a 2h 
and 20h incubation improved siNG-mediated gene silencing to a similar extent. Of note, the 
SSC signal was significantly lower in cells exposed 2h to DL (Figure 3.11B), which suggests 
that the induced PLD phenotype is only transiently present. Interestingly, a 2h DL incubation 
period did not cause any additional cytotoxicity compared to the siNGs alone (Figure 3.11C). 
Thus, the more rapid recovery from the PLD state appears to have a positive effect on cell 
viability.  
Figure 3.11. (A) The percentage eGFP expression in H1299-eGFP cells following transfection with the 
siNGs alone or in combination with a 2h or 20h DL treatment. (B) Fold change in SSC induced by siNG 
transfection or sequential treatment with siNGs and 2h or 20h DL. (C) Percentage viable cells 
following siNG transfection whether or not combined with 2h or 20h DL. Data are represented as 
mean ± SEM (n = 3) and statistical significance is indicated when appropriate by black * when 
referring to the untreated control and gray * when compared to NG transfected cells (* p<0.05, ** 
p<0.001, *** p<0.005). Finally, statistical significance between the 2h and 20h condition is indicated 
by the black x (xx p<0.01, xxx p<0.005). 
 
Next, we investigated whether DL treatment influenced the kinetics of the siNG-mediated 
gene silencing. Since the compounds are dissolved in DMSO, we first ensured that the 
presence of DMSO did not alter the siNG-induced eGFP silencing over time (Figure 3.12A). A 
DL concentration dependent improvement of initial gene silencing (Figure 3.12B)  was 
obtained in correspondence to previous results (Figure 3.4C). From day 2 onwards, the 
relative eGFP expression steadily increased and at day 7 expression levels reached 100% in 





Figure 3.12. (A) Kinetics of the eGFP knockdown in H1299-eGFP cells transfected with siNGs (black) 
and a single time exposed to 0.16% DMSO in cell medium (gray). This graph shows that the presence 
of DSMO does not influence the siNG-mediated eGFP silencing. (B) Kinetics of eGFP knockdown in 
cells transfected with siNGs (circle) and treated with 10 (square), 20 (upwards triangle) or 40 µM 
(downwards triangle) DL. 
 
Interestingly, confocal images of cells transfected with NGs encapsulating labeled siRNA 
(siGLO green transfection indicator) revealed enlarged siGLO-NG containing vesicles in DL 
treated cells (Figure 3.13A), indicating that not all internalized and presumably lysosomally 
accumulated siRNA is released upon a single adjuvant treatment. The effective lysosomal 
accumulation is assumed based upon previous co-localization studies from our group18, but 
would ideally be experimentally confirmed. Based on the siGLO data, we investigated if 
multiple DL treatments could induce additional siRNA release at later time points. Since we 
applied nuclease-stabilized siRNA for this experiment to avoid siRNA degradation, we first 
confirmed the comparable silencing potential of both siRNA molecules (Figure 3.13B). Most 
interestingly, we observed that upon multiple 2h DL treatments additional siRNA could be 
released. Of note, additional cell viability experiments are required to estimate the safety of 
this approach. In any case, the additional exposure to DL allowed us to maintain minimal 
eGFP expression levels up to four days post transfection, after which eGFP expression levels 
gradually augmented to reach basal levels at day 9 following similar kinetics compared to a 
single DL addition (Figure 3.13C). In comparison, the expression levels reached 100% at day 3 
post transfection in case of a suboptimal siNG transfection alone. Despite the retained PLD 
phenotype by DL treatments after day 4 (Figure 3.13D), the adjuvant treatments failed to 
provide further prolongation of the maximal gene silencing. 
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Figure 3.13. (A) Cellular distribution of the siGLO signal in H1299-WT cells transfected with siGLO-NGs 
alone or subjected to the sequential 40 µM DL treatment. (B) % eGFP expression following NG-
mediated siRNA delivery of unmodified siRNA (black) and stabilized siRNA (white) in combination with 
10, 20 or 40 µM DL in H1299-eGFP cells. Data are represented as the mean ±SEM (n=3) and the 
statistical significance is indicated when appropriate. (C) Kinetics of eGFP knowckdown in cells 
transfected with siNGs (black line) and treated once with 40 µM DL (green line), daily (pink line) or 
every other day (blue line) until day six post transfection. (D) The evolution of the side scatter signal in 
H1299-eGFP cells transfected with siNGs followed by a single DL treatment (green) or repeated 
exposure, namely daily (pink) or every other day (blue) until day 6 after transfection.  (NG = nanogels, 




3.7. DL improves therapeutic siRNA delivery 
Finally, we applied our adjuvant strategy to improve delivery of a therapeutic siRNA 
targeting polo-like kinase 1 (PLK1). Reducing PLK1 expression halts the cell cycle and induces 
apoptosis in certain cancer cells, such as the applied H1299 cell line.28, 29 Hence, reducing 
PLK1 expression is currently avidly investigated as a potential anti-cancer strategy. 
NGs loaded with control siRNA reduced the cell viability to approximately 80% in any 
condition tested (Figure 3.14A), corroborating previous experiments (Figure 3.6B). Thus, an 
increase in siRNA dose or DL treatment(s) did not additionally affect cell viability. NGs loaded 
with 1 and 10 nM siPLK1 did not affect cell viability, while 100 nM siPLK1 reduced the cell 
viability to ˜60% (Figure 3.14B). The DL adjuvant treatment enhanced siPLK1-mediated 
cytotoxicity for all siPLK1 doses tested. (Figure 3.14B) Once again, repeating the adjuvant 
incubation (2h, 40 µM DL) further reduced cell viability (Figure 3.14C). The most extensive 
adjuvant effect was observed for 10 nM siPLK1 where a maximal effect on cell viability was 
obtained with a single DL treatment (Figure 7A). For both 10 and 100 nM siPLK1 a second DL 
treatment did not further reduce the cell viability (Figure 3.14D). 
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Figure 3.14. (A) H1299-eGFP cell viability measured upon transfection with siCTRL-NGs as control 
during the siPLK1 transfection. No significant variations in cell viability could be detected between the 
various treatment groups. (B) Percentage viable H1299-eGFP cells following transfection with siPLK1-
loaded NGs whether or not subjected to a sequential 40 µM DL treatment. (C) % viable cells of cells 
solely transfected with 1 nM siPLK1-NGs or subjected to one or two 40 µM DL treatments. (D) Relative 
H1299-eGFP cell viability indicative of PLK1 silencing for cells transfected with 10 or 100 nM siPLK1 
and treated not, once or twice with 40 µM DL. A second DL treatment could not further improve the 
siPLK1 effect. Data are presented as the mean ± SEM (n = 3) and statistical significance is indicated 







The successful application of siRNA therapeutics faces multiple delivery challenges. 
Formulation into nanoparticles is often proposed to guide the siRNA across extra- and 
intracellular barriers. However, endocytic uptake of nanomedicines by target cells typically 
leads to endo-lysosomal sequestration, explaining the poor cytosolic siRNA delivery 
efficiency of available nanomedicines.6, 7 In order to avoid lysosomal degradation of the 
nanocarrier and its cargo, the general consensus states that endosomal escape should occur 
as soon as possible upon internalization. However, the time frame in which release 
strategies can be of benefit is rather narrow, as nanocarriers can be trafficked to the 
lysosomes within the hour after internalization.8 Moreover, it is believed that membrane-
destabilizing agents should ideally avoid acting on lysosomes, as lysosomal membrane 
permeabilization (LMP) is considered a hallmark of lysosomal cell death.9 The data presented 
in this work argue against this leading paradigm, as we propose to target the lysosomes to 
enhance cytosolic siRNA delivery.  
We applied cationic dextran nanogels (NGs) as a model nanocarrier given their siRNA 
delivery potential in various cell types, endo-lysosomal entrapment following internalization 
and progressive lysosomal accumulation.18 CADs were selected as adjuvants given their 
potential to destabilize the lysosomal compartment through their reported FIASMA activity 
and ability to induce PLD.13 We selected four model CADs to evaluate their adjuvant effect 
on siRNA delivery, namely carvedilol, desloratadine (DL), nortriptyline and salmeterol. 
Although the four selected molecules differed in drug class and molecular structure, all 
compounds markedly improved the siNG silencing potential to a similar extent 20 Moreover, 
the additive effect on gene silencing is in line with the reported additive ASM inhibition.12 
However, not all CADs were active in a similar dose range, for instance 10-fold higher 
dextrometorphan doses were required to obtain an adjuvant effect. This may be attributed 
to variations in the molecular structure with the basic amine not being spatially separated 
from the hydrophobic ring structure, therefore potentially being less available to functionally 
inhibit ASM.20, 26  
Throughout the literature, several CADs are applied to induce a Niemann-Pick disease (NPD) 
phenotype.30-32 NPD is a lysosomal storage disorder either caused by a lack of functional 
ASM (type A) or a deficient Niemann-Pick C1 cholesterol transporter (type C). Overall NPD 
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type A and C show similar phenotypes, characterized by enlarged and less stable lysosomes, 
which are more prone to LMP.26, 27 In corroboration, the NPC1 inhibitor U18666A, which is 
avidly applied to evoke a NPD phenotype, ameliorated siRNA-mediated gene silencing 
similar to the CADs. In corroboration, Sahay et al. showed that gene silencing was enhanced 
in NPC1-/- cells and upon NPC1 inhibition by NP3.47, which was explained by increased 
chances of siRNA escape through inhibited exocytosis of the carrier.8, 33 Likewise, CADs 
potentially reduced the siNG recycling since FIASMAs are reported to inhibit vesicle fusion27, 
although this was not experimentally verified. Overall, this data set suggests that the 
induction of a NPD phenotype may positively affect siRNA delivery. In our case, the FIASMAs 
are suggested to induce (endo-)lysosomal swelling due to the accumulation of 
phospholipids, cholesterol and sphingomyelin. This is in turn reported to destabilize the 
lysosomal membrane, thereby causing LMP, which may in turn facilitate siRNA release. 
However, additional experiments are required to provide a more stringent confirmation of 
the suggested mechanism of improved cytosolic siRNA delivery. For one, to probe the ASM 
activity in function of the CAD concentration will allow confirmation of the FIASMA effect.12 
The effect of CADs in a cathepsins knock out model would allow to estimate the importance 
of ASM degradation for the observed improved release. A confirmation of lysosomal lipid 
accumulation can be provided by labeling both the lysosomes (LAMP-1) and the 
phospholipids in a single experiment. Indeed, as Lysotracker probes will label acidic 
organelles, we currently cannot refute the possibility that some of the release is also linked 
to late endosomes. Finally, the extent of LMP could be estimated by evaluating the release 
of differentially sized dextrans or quantification of the cytosolic cathepsin concentration.23 
Similar to previous reports10, 11, we noted that not all internalized siRNA is released upon a 
single DL treatment. Hence, we evaluated whether we could induce additional siRNA release 
with multiple CAD treatments. The NGs are an ideal carrier for this purpose given their 
biodegradability but relative stability at acidic pH, implying slow siRNA release from the NGs 
in the lysosomal compartment where the NGs progressively accumulate following 
transfection.19 Of note, a potential influence of the CADs on intracellular trafficking may 
slightly alter the intracellular distribution and requires experimental confirmation. Strikingly, 
up to day 3 post transfection we could induce additional siRNA release, highlighting the 




from day 4, additional DL treatments remained without effect. This may be attributed to the 
consequent cell divisions that may have diluted the siNG-containing lysosomes to such an 
extent that minor additional siRNA release could no longer extend the maximal gene 
silencing.  
An optimal endosomal escape strategy should merge efficiency and safety. Maximal gene 
silencing was obtained with siNGs encapsulating 2 nM siRNA combined with the highest CAD 
concentration tested, whereas siRNA doses exceeding 50 nM would otherwise be required. 
Such a dose sparing strategy could strongly reduce the risk of siRNA-related adverse effects. 
In addition, any negative impact on cell viability could be avoided for DL by reducing the 
exposure time. Interestingly, the side scatter signal accordingly decreased, indicative of the 
reversible nature of the PLD phenotype.14, 34 In corroboration, the occurrence of drug-
induced PLD is only rarely correlated to organ toxicity in vivo.35 The limited cytotoxicity 
furthermore implies that improved cytosolic siRNA release did not coincide with severe LMP, 
which typically evokes cell death through excessive leakage of lysosomal cathepsins.9, 36 In 
contrast, Petersen et al. witnessed cancer cell death through severe LMP induction by 
siramesine.13 Such strong LMP inducers might be suitable delivery adjuvants when applied at 
lower doses. The suggested ‘minor’ LMP allowing improved siRNA release furthermore 
suggests that small pores are created in the lysosomal membrane, which solely allow 
uncomplexed siRNA to transfer to the cytosol. Similarly, Wittrup et al. reported that free 
siRNA escapes the endosomal compartment rather than the entire lipoplex.10 This 
hypothesis may be confirmed by evaluating the release of differentially sized dextrans.23  
Finally, to confirm the enhanced delivery in a therapeutic setting, siRNA targeting polo-like 
kinase 1 (PLK1) was delivered in the H1299 non-small cell lung cancer cell model, which is 
particularly sensitive to PLK1 suppression due to its p53 deficiency.37, 38 DL markedly boosted 
NG-mediated siPLK-1 delivery, resulting in significantly greater cytotoxicity. This approach 
requires further confirmation in a relevant in vivo model. However, systemically 
administered NGs show limited stability and are rapidly cleared from the circulation.39 Their 
intratumoral administration to a murine xenograft model may furthermore not be advisable 
given the limited predictive power towards the clinical outcome in human tumors.40 Hence, 
the in vivo evaluation of the small molecule adjuvant approach will require the 
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administration of appropriate siRNA delivery vehicles in more complex tumor models that 
more closely represent the human tumor pathophysiology.  
In this work we aimed to repurpose CADs with an acceptable clinical safety profile to boost 
cytosolic siRNA delivery. In this context, CAD antihistamines were recently repurposed as 
adjuvants to enhance the efficacy of anti-cancer drugs, evidenced by reduced mortality in 
patients using antihistamines while receiving chemotherapy.41 Importantly, it can be 
rationalized that this CAD adjuvant approach may enhance siRNA delivery to cancer cells in 
vivo. For one, cancer cell lysosomes are generally less stable, show an altered membrane 
composition and lower ASM activity.13, 16, 42 In addition, CADs were recently reported to 
induce LMP in cancer cells in vivo.13, 16 Moreover, sufficiently high concentrations may be 
reached in tissues given the extremely high distribution volumes of CADs. This may 
especially be true for cancer cells since CADs are suggested to preferentially accumulate at 
the more acidic tumor sites.41 Physiologically based pharmacokinetic modeling could 
furthermore provide information on in vivo ADME processes and will allow us to estimate 
whether the CADs will accumulate in sufficiently high concentrations to allow improved 
release and in which tissues the effect will preferentially occur. Overall, to use of a 
benchmark therapy as a positive control in both in vitro and in vivo experiments would allow 






In conclusion, we demonstrated that cationic amphiphilic drugs (CADs) can be repurposed to 
stimulate cytosolic delivery of siRNA in cancer cells. Indeed CADs induced the accumulation 
of phospholipids, cholesterol and sphingomyelin, which is assumed to result in the 
enlargement of the endo-lysosomal compartment and the induction of minor lysosomal 
membrane permeabilization (LMP) followed by enhanced siRNA release. Importantly, our 
results suggest that this acquired lysosomal storage disorder-phenotype is responsible for 
the improved siRNA delivery when CADs were sequentially applied to siNG transfected 
cancer cells. Most importantly, further CAD treatments could be applied to induce additional 
siRNA release of the accumulated siRNA, which was not released by the initial CAD 
treatment. Overall, we believe this is a highly interesting approach, which requires further 
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CHAPTER 4 
Exploring the broader applicability of a low molecular weight adjuvant  
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Research efforts in the past few decades revealed the enormous therapeutic potential of 
distinct nucleic acids (NA). Unfortunately, many NA therapeutics are yet to transfer to the 
clinic, as efficient delivery to their intracellular target site remains a major stumbling block. 
In Chapter 3 we showed that cationic amphiphilic drugs (CADs) improve the siRNA-mediated 
gene silencing in nanogel (NG) transfected cells, which coincided with a transient 
phospholipidosis (PLD) phenotype. It was suggested that the accumulated phospholipids 
caused transient lysosomal membrane destabilization and minor lysosomal membrane 
permeabilization (LMP), thereby allowing enhanced siRNA release to the cytosol. Here we 
explore the broader applicability of this method in terms of the applied transfection method, 
NA cargo and small molecular adjuvant. Tobramycin induced PLD but was unable to improve 
siRNA delivery whereas the therapeutic range of disulfiram was too narrow. Moreover, CADs 
could not significantly improve mRNA delivery. A sequential CAD treatment was equally 
unable to strongly enhance the delivery potential of various liposomal formulations, a 
cholesterol-siRNA conjugate or RNAiMAX. We were able to introduce a CAD as a liposomal 
building block, but it failed to contribute to the delivery potential of the formulation. Hence, 
the proposed adjuvant strategy may not be very broadly applicable. However, these data 
revealed key factors requiring further investigation to allow future rational combinations of 





In Chapter 3 we investigated the potential of cationic amphiphilic drugs (CADs) to improve 
the gene silencing potential of siRNA-loaded dextran nanogels (siNGs). This improved 
silencing potential was suggested to be attributed to the inhibition of acid sphingomyelinase 
(ASM) by the CADs, although this was not experimentally verified. Indeed, the reported 
lysosomotropic nature of the CADs would ensure lysosomal accumulation and allow 
functional inhibition of ASM (FIASMA).1, 2 This suggested interaction was corroborated by the 
accumulation of sphingomyelin, cholesterol and other phospholipids. We subsequently 
hypothesized that this lipid imbalance destabilized the lysosomal membrane3, 4, thereby 
improving siRNA release to the cytosol. Again, this lysosomal siRNA release could be 
assumed based on the provided data set but remains to be experimentally confirmed. In any 
case, we obtain promising results on the potential adjuvant effects of CADs on the 
therapeutic potential of nucleic acids (NA).  Here, we set out to establish the broader 
applicability of this adjuvant approach in terms of the applied small molecular adjuvant, NA 
cargo and nanocarrier.  
The adjuvant potential of the CADs coincided with a phospholipidosis (PLD) phenotype. 
Based on this observation we investigated if small molecules without CAD-properties and 
FIASMA activity, but known to induce PLD could equally improve siRNA delivery. Hereto, we 
selected tobramycin (TM), which is reported to induce PLD in the kidney upon systemic 
administration.5 Results in Chapter 3 additionally suggested that the siRNA could escape to 
the cytosol through the destabilization and permeabilization of the lysosomal membrane 
due to the phospholipid accumulation. Hence, evaluated whether disulfiram (DSF) was able 
to boost the silencing potential of siNGs. DSF was selected since it has no CAD properties or 
FIASMA activity but is suggested to destabilize the lysosomes, leading to lysosomal cell death 
in cancer cells.6, 7 Thus, we investigated if the FIASMA activity of the CADs is essential for 
their adjuvant effect.  
Besides siRNA, multiple distinct therapeutic NA are being investigated, such as plasmid DNA, 
messenger RNA (mRNA), antisense oligonucleotides (ASO), splice switching oligonucleotides 
(SSO) and microRNA. Each NA drug has specific therapeutic applications, according to its 
mode of action. In contrast, most NA face the same delivery challenges, as they require 
nanocarriers to protect them from nucleases, to improve their in vivo biodistribution and to 
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ensure transport over the cell membrane. In addition, the NA need to escape the endo-
lysosomal compartment in an efficient way to reach their intracellular target site.8, 9 
Therefore we evaluated if our CAD adjuvant approach could similarly improve the delivery of 
other NA therapeutics, besides siRNA. To contrast the relatively small siRNA duplexes (˜21 
base pairs), we selected mRNA, being long single stranded NA (˜1000 bases) that may 
arrange in secondary structures due to self-complementarity. The delivery of mRNA is 
mainly pursued in the context of protein replacement therapies or as a vaccination strategy 
for the treatment of infectious diseases or for cancer immunotherapy.9 In protein 
replacement therapies, mRNA outperforms pDNA since mRNA is translated in the cytosol 
and does not require translocation to the nucleus. This implies that mRNA transfections are 
not associated with the risk of genomic integration.10 The efficiency of mRNA is in turn 
limited by the transient nature of its effect and its immunogenic properties, leading to 
mRNA degradation and further reduction of the therapeutic protein expression levels.11 
However, this immunogenic potential is considered advantageous in the context of the 
abovementioned vaccination strategies.11 Similar to siRNA delivery, mRNA delivery is 
severely hampered by entrapment in the endo-lysosomes. Hence, to apply the lysosomes as 
a depot for mRNA release (Figure 3.13C) could be a major advantage to tackle the transient 
nature of the mRNA effect and gain control over therapeutic protein levels. 
The nanogels (NG) applied in Chapter 3 are polymeric nanocarriers. A second prominent 
group comprises lipid-based nanocarriers (Chapter 1). Such lipid nanoparticles (LNP) 
generally consist of amphiphilic lipids, which arrange in micellar or lamellar structures in a 
hydrophilic milieu. Cationic lipids are additionally included to ensure NA complexation, 
whereas neutral helper lipids may enhance the LNP rigidity (e.g. cholesterol) or improve the 
endosomal escape efficiency (e.g. 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, DOPE). 
The LNPs are believed to promote NA endosomal escape through fusion events with the 
endo-lysosomal membrane. Although fusogenic lipids may stimulate fusion events, a large 
fraction of the internalized NA dose fails to reach its intracellular target site and remains 
entrapped in the late endo-lysosomal compartment.12, 13 Thus, we assessed whether a 
sequential CAD treatment could improve the siRNA delivery potential of several lipid-based 
formulations. Furthermore, we evaluated if a CAD could be included as a liposomal building 




2. MATERIALS & METHODS 
2.1. Nucleic acids 
We applied the scrambled control siRNA (siCTRL), eGFP-targeting siRNA (sieGFP), nuclease-
stabilized and Cy-5-labeled duplexes as described in Chapter 3 (Table 3.1). Furthermore, cells 
were transfected with nuclease-stabilized siRNA covalently linked to cholesterol 
(Dharmacon, USA) (Table 4.1). In a final set of experiments, eGFP-expressing mRNA was 
applied. The latter was produced by in vitro transcription from the T7 promoter-containing 
pGEM4Z-GFP-64A plasmid, which was purified and linearized using respectively the QIAquick 
PCR purification kit (Qiagen, The Netherlands) and Spe I restriction enzymes (Promega, The 
Netherlands). The linearized plasmid subsequently served as a template for the in vitro 
transcription reaction carried out with the T7 mMessage mMachine kit (Ambion, Belgium), 
which additionally capped and polyadenylated the mRNA. The obtained mRNA was purified 
with the RNeasy Mini Kit (Qiagen, Netherlands) and the mRNA concentration and purity 
were determined by respectively measuring the absorbance at 260 nm and the 260/280 nm 
absorbance ratio with the NanoDrop 2000c spectrophotometer (Thermo Scientific, USA). 
 
Table 4.1. Applied siRNA sequences and duplex modifications. 
siRNA Modification Manufacturer 
Sequencea 










Dharmacon CAAGCUGACCCUGAAGUUCUU GAACUUCAGGGUCAGCUUGUU 
a 5’ end of the sense strand modified with a cholesteryl-tetraethyleneglycol linker; b siSTABLE RNA 
strand modification by Dharmacon for use in nuclease-rich environments. 
 
2.2. NG synthesis and complexation 
Cationic dextran nanogel (NG) synthesis occurred through an inverse mini-emulsion 
photopolymerization method.14, 15 Actual complexation to siRNA-loaded NGs (siNGs) 
occurred according to the procedure described in Chapter 3 (section 2.2). In case of 
complexation with mRNA, 100 µL of a 0.6 mg/mL NG dispersion was added to 100 µL of an 
appropriate mRNA dilution. Following 15 minutes of complexation at room temperature, 
800 µL Opti-MEM was added and 300 µL of the dispersion was brought onto the cells. The 
mRNA concentrations per well were 0.1; 0.25 and 0.5 µg mRNA.  
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2.3. Liposome preparation and complexation 
Various liposomes (LPS) were prepared via the lipid film hydration method. All lipids were 
obtained from Avanti Polar Lipids (USA) as solutions in chloroform. First, we prepared (2,3-
dioleoyloxy-propyl)-trimethylammonium (DOTAP)–cholesterol LPS by mixing appropriate 
volumes of the lipid solutions in a round bottom flask to obtain a 1:1 mass ratio. Through 
rotary evaporation under vacuum at 40°C, a lipid film was created and subsequently 
hydrated using 1 mL HEPES buffer (pH 7.4, 20 mM). The obtained mixture was vortexed and 
sonicated 1 minute at 10% amplitude to obtain a monodisperse 2 mg/mL LPS dispersion. A 
similar protocol was applied to prepare DOTAP-DOPE (1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine) LPS in a 1:1 molar ratio. Finally, we prepared DOPE-nortriptyline (NT) 
LPS with a 1:1 mass ratio. Hereto, a 1 mg DOPE lipid film was hydrated with a 1 mg/mL NT 
solution in HEPES buffer to prepare a 2 mg/mL LPS dispersion.  
The LPS were complexed with siRNA immediately before the transfection. Hereto, 
appropriate dilutions of the LPS in HEPES buffer were added to a propper siRNA dilution. 
This mixture was allowed to complex at room temperature for 30 minutes prior to further 
dilution in Opti-MEM and transfection. In case of DOTAP-chol LPS, cells were transfected 
with a 5 or 10 μg/mL LPS dispersion respectively carrying 2.5 and 5 nM siRNA. 10 and 20 
μg/mL DOPE-NT LPS were applied to transfect the cells with 12.5 and 25 nM siRNA, 
respectively. Finally DOTAP-DOPE LPS were complexated with siRNA at a charge ratio equal 
to 8 and the applied siRNA concentrations per well were 0.1; 0.5; 1; 5 and 10 nM. 
2.4. Complexation of commercial carriers 
Both Lipofectamine® MessengerMAX and RNAiMAX (Invitrogen, Belgium) were applied 
according to the manufacturers guidelines. Equal volumes mRNA or siRNA dilutions and 
MessengerMAX or RNAiMAX dispersions, respectively, were mixed and allowed to 
complexate during 5 minutes at room temperature. Subsequently, the obtained lipoplexes 
(LPX) were added to the appointed wells, whereupon transfection occurred in Opti-MEM. 
According to the guidelines, 0.5 µg mRNA and 5 pmol siRNA were applied per well to obtain 
optimal protein expression and gene silencing, respectively. To mimic the siRNA 
concentration applied for a suboptimal siNG transfection, the RNAiMAX LPX were 
additionally diluted, to allow a more straightforward comparison of both transfection 




Table 4.2. Applied siRNA concentration in terms of nM siRNA/30 µg/mL NGs  
or pmol siRNA/well. 




2.5. Dynamic Light Scattering and zeta-potential 
A Zetasizer Nano ZS (Malvern), equipped with Dispersion Technology Software, was applied 
to perform dynamic light scattering and ζ-potential measurements to determine the 
hydrodynamic size and surface charge of the nanocarriers before and after complexation. 
Appropriate dilutions of the carrier or complexes were prepared in HEPES buffer (20 mM, pH 
7.4) right before the measurement. 
2.6. Gel retention assay 
The The capacity of the NGs to complex mRNA was evaluated through a gel retention assay 
using a 1.5% agarose (Invitrogen, Belgium) gel containing gelred (1/1000, Biotium, USA) for 
mRNA visualization. The gel was prepared in TBE buffer (10.8 g/L Tris base, 5.5 g/L boric acid, 
0.74 g/L Na2EDTA.2H2O). Next, increasing amounts of mRNA were allowed to complex with 
a fixed NG concentration. Subsequently, a gel loading solution (Ambion, Belgium) was added 
to each sample prior to transfer to the gel well. Finally, electrophoresis was performed at 
100 V during 40 minutes, followed by UV transillumination and gel photography.  
2.7. Cell culture 
SiRNA- mediated gene silencing was evaluated in the H1299-eGFP cell line whereas the wild 
type variant (H1299-WT) was applied for microscopy experiments and to investigate mRNA 
expression. Both cell lines were cultured as described in Chapter 3 (Section 2.3). Cells were 
seeded in 24 well plates at a density of 35000 cells/well for uptake and gene silencing or 
protein expression experiments. For the phospholipidosis detection with confocal 
microscopy, we seeded the H1299-WT cells in glass bottom 35 mm diameter microscopy 
dishes (Greiner Bio-One GmbH, Germany) at 105000 cells per dish.  
  CHAPTER 4 
 123 
2.8. Transfection and adjuvant treatment 
The transfection protocol described in Chapter 3 (section 2.4) was applied for all carrier and 
nucleic acid combinations, whereupon an adjuvant treatment was executed according to 
experimental needs. In case of desloratadine (DL), 0.5 mL cell medium containing 10, 20 or 
40 µM was applied. 40 µM chloroquine (CLQ) and nortriptyline (NT) were respectively tested 
in combination with chol-siRNA and mRNA-NGs or messengerMAX. Tobramycin (TM) was 
tested as an adjuvant to siNG delivery in the following concentrations: 100 and 500 µM, 1, 2, 
3 and 4 mM. In a similar setup disulfiram (DSF) was added either alone (5, 10, 25 or 50 µM) 
or in combination with ZnCl2: 5 and 10 µM DSF were combined with 5 µM ZnCl2, and 25 and 
50 µM DSF were combined with 10 µM ZnCl2. Finally, we tested the combination of 25µM 
DSF with 20 µM DL and 10 µM ZnCl2. All small molecules (Figure 4.1) were obtained from 
Sigma-Aldrich (Belgium) and the stock solutions were prepared in sterile-filtered 
BioPerformance Certified dimethyl sulfoxide (DMSO, Sigma-Aldrich, Belgium), except for 
ZnCl2, which was dissolved in sterile water. Most adjuvant treatments lasted 20 hours, 
except for the combination of mRNA-NGs and DOTAP-DOPE LPS with NT and DL, 
respectively, where a 2-hour incubation time was applied. 
Figure 4.1. The drug class, logP, pKa and molecular structures of tobramycin, disulfiram, 




2.9. Quantifying nanocarrier uptake 
To allow fluorescent detection of nanocarrier uptake, 10% of the siCTRL duplex was replaced 
by Cy5-labeled siCTRL. Subsequent to 4 hours of transfection, the cells were washed with 
PBS containing 0.1 mg/mL dextran sulphate sodium salt (Sigma-Aldrich, Belgium) to remove 
the surface-bound siRNA and allow detection of the effectively internalized siNGs. Next, the 
cells were detached using 0.25% trypsin-EDTA, collected in flow tubes and centrifuged 5 
minutes at 300g. Finally, the cell pellet was suspended in 300 µL FACS buffer and samples 
were kept on ice until analysis. The latter occurred with a FACSCaliburTM flow cytometer (BD 
Biosciences, Belgium) and BD CellQuest™ acquisition software, collecting 10000 events per 
sample. The Cy5-labelled siRNA was exited using the red laser line and the fluorescent signal 
was detected with the 661 nm ± 16 filter. Finally, data analysis was performed using the 
FlowJo software (Tree Star Inc.), where both the percentage of cells showing carrier uptake 
as well as their mean fluorescent intensity (MFI) were determined. 
2.10. Evaluation of the transfection efficiency 
SiRNA-mediated gene silencing and mRNA (eGFP) expression were both evaluated using the 
FACSCalibur™ flow cytometer as described in Chapter 3 (section 2.5). Through data analysis 
we determined the percentage eGFP expression in case of siRNA-mediated gene silencing or 
both the percentage of cells expressing eGFP and their MFI following mRNA transfection. 
2.11. Phospholipidosis detection 
To allow labeling of the phospholipids in the H1299-WT cells, the latter were co-exposed to 
the small molecular adjuvant and a 1/1000 dilution of the LipidTOX™ red phospholipidosis 
detection reagent (Thermo Fisher Scientific, USA) in complete cell medium. The samples 
were fixed, covered in Vectashield antifade mounting medium containing DAPI (Vector 
Laboratories, USA) and imaged as detailed in Chapter 3 (section 2.10).  
2.12. Statistics 
Size and ζ-potential data are represented as the mean ± the standard deviation (SD) of three 
measurements. Flow cytometry results are represented as the mean ± the standard error to 
the mean (SEM). Statistical analysis was performed with the 6th version of the GraphPad 
Prism software using one-way ANOVA combined with the post-hoc Dunnett test to compare 
multiple groups.  
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3. RESULTS 
3.1. Distinct small molecular adjuvants do not equally improve siRNA delivery 
3.1.1. Tobramycin 
By sequentially applying tobramycin (TM), a phospholipidosis (PLD)-inducer but no a cationic 
amphiphilic drug (CAD), we assessed whether the induction of a PLD phenotype is sufficient 
to improve siRNA-mediated gene silencing. Figure 4.2A shows that TM had no effect on the 
siRNA-mediated gene silencing by siRNA-loaded NGs (siNGs) in H1299-eGFP cells. Even the 
highest TM concentrations, known to induce PLD, remained without an adjuvant effect. In 
contrast, TM concentrations >1 mM significantly elevated the side scatter (SSC) signal with 
respect to the siNG-transfected cells (Figure 4.2B), indicative of increased cell granularity. 
The extent of the augmentation could however not be compared to the prominent increase 
observed upon CAD treatment (Figure 3.9A). Figure 4.2C reveals the accumulation of 
phospholipids for the highest dose tested. Opposed to earlier observations in CAD-treated 
cells (Figure 3.10A), were the accumulated phospholipids to a large extent located in the 





Figure 4.2. (A) % eGFP expression in H1299-eGFP cells following siNG transfection alone or combined 
with a 20h tobramycin (TM) adjuvant treatment. (B) Fold change in the side scatter (SSC) signal upon 
siNG transfection whether or not combined with TM. Data are represented as the mean ± SEM for 3 
technical replicates. Statistical significance is represented with reference to the untreated control 
(NTC) by the grey * or with respect to the siNG transfected cells by the black *. (ns  = not significant, * 
p < 0.05, ** p < 0.01, *** p < 0.005). (C) Representative confocal images of the phospholipid 
distribution visualized with the LipidTOXTM Red phospholipidosis detection reagent for untreated cells 
and cells treated 20 hours with 100 or 4000 μM TM. The scale bar corresponds to 30 μm. 
 
3.1.2. Disulfiram 
Next, we evaluated whether disulfiram (DSF) could potentiate siRNA delivery in cancer cells. 
Figure 4.3A shows that a 20h DSF treatment significantly improved siRNA-mediated gene 
silencing for all DSF concentrations tested. However, the extent of the effect was limited, 
with ˜45% eGFP expression remaining at 50 μM DSF, versus almost complete eGFP silencing 
with 40 μM desloratadine (DL) (Figure 3.4C). The reduced eGFP expression at 50 μM DSF was 
furthermore accompanied by cell stress, as suggested by the increased mean fluorescent 
intensity (MFI) in the cells transfected with a control siRNA duplex (siCTRL) (Figure 4.3B). 
Concurrently, only the highest DSF dose induced a significant increase in the SSC signal with 
respect to the siNG transfected cells (Figure 4.3C). 
DSF is show to induce apoptosis in cancer cells due to its ionophore activity.7 This DSF-
induced apoptosis coincides with cytosolic cathepsin presense, wherefore DFS is suggested 
to induce lysosomal cell death.6 The propensity of DSF to evoke cancer cell death is indeed 
correlated to the Zn2+ concentration in the extracellular milieu, as an increased number of 
apoptotic cells were detected when supplementing the cell culture medium with 20 μM 
Zn2+.7 Since our objective is to destabilize the lysosomes to allow siRNA release without 
evoking severe cell stress, we applied the combination of 5 or 10 μM DSF with 5 μM ZnCl2. 
However, no significant differences were detected in gene silencing as a function of ZnCl2 
supplementation (Figure 4.3D). Next, we combined higher DSF doses (25 or 50 μM) with 10 
μM ZnCl2. Figure 4.3E shows the MFI of H1299-eGFP cells transfected with siCTRL (black) or 
eGFP-targeting siRNA (sieGFP, white) for the different adjuvant combinations. For 25 μM 
DSF, the MFI in the sieGFP sample additionally decreased upon co-incubation with 10 μM 
ZnCl2, indicative of enhanced silencing. This coincided with cell stress, as evidenced by the 
increased MFI in the concurrent siCTRL sample. Both siCTRL and sieGFP transfected cells 
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treated with the combination of 50 μM DSF and 10 μM ZnCl2 in turn showed a pronounced 
drop in eGFP expession levels, indicative of severe cell stress and cell death.  
Finally, we evaluated the combination of DSF and desloratadine (DL). Given the different 
mechanism through which LMP is induced, an additive or even synergistic destabilising 
effect on the lysosomal membrane was anticipated. However, similar eGFP expression levels 
were observed in the 20 μM DL and 25 μM DSF + 20 μM DL sample (Figure 4.3F), implying 
that supplementing DL with DSF was not of added value. In contrast, when 10 μM ZnCl2 was 
additionally applied, a strong cytotoxic response was noted similar to the combination of 50 
μM DSF and 10 μM ZnCl2.  
 
Figure 4.3. (A) % eGFP expression in H1299 cells upon siNG transfection whether or not combined 
with mounting disulfiram (DSF) concentrations for 20 hours. (B) Representative plot of the mean eGFP 
fluorescence intensities (MFI) of cells treated with NGs loaded with siCTRL (black bars) or siEGFP 
(white bars) as a function of the DSF concentration. (C) Fold change in the side scatter (SSC) signal as 
a function of the applied DSF concentration additive to siNG transfection. The fold change was 
calculated relative to the untreated control (NTC). (D) % eGFP expression for cells transfected with 
siNGs followed by exposure to to DSF alone (black bars) or DSF in combination with 5 μM ZnCl2 
(blocked bars). (E) A representative MFI plot for siNG transfected cells with siCTRL (black) or sieGFP 
(white) followed by 25 or 50 μM DSF alone or in combination with 10 μM ZnCl2. (F) A representative 
MFI plot for siCTRL-NGs (black) or siEGFP-NGs (white) transfected cells exposed to different 
combinations of 25 μM DSF, 20 μM desloratadine (DL) and 10 μM ZnCl2. (A), (C) and (D) Data are 
represented as the mean ± SEM for 3 technical replicates in a single biological replicate. Statistical 
significance is represented by grey * with reference to the untreated control (NTC) or by black * with 




3.2. The therapeutic potential of mRNA  is not strongly enhanced by CADs 
Next, we evaluated whether CADs could improve the therapeutic effect of larger mRNA 
molecules (˜ 1000 bases, as determined with agarose gel electrophoresis) upon mRNA-NG 
transfection. First, we showed that the NGs completely complexed the mRNA in all 
evaluated ratios (Figure 4.4A). The size and ζ-potential furthermore remained unaltered 
upon complexation (Table 4.3). 
 
Figure 4.4. (A) NGs completely complex 0.1, 0.25 and 0.5 μg mRNA as evaluated with an agarose gel 
retention assay. (B) and (C) The transfection efficiency in terms of the percentage of transfected 
H1299 cells (B) and the eGFP mean fluorescent intensity (MFI) of the transfected cells (C) for mRNA-
NG transfected cells alone (black bars) or combined with a 20h 40 μM nortriptyline (NT) treatment 
(grey bars). (D) and (E) The transfection efficiency in terms of the percentage of transfected cells (D) 
and the eGFP MFI (E) of cells transfected with messengerMAX (black bars) with or without 40 μM NT 
(grey bars). The data are represented as the mean ± SEM for 3 technical replicates. Statistical 
significance is indicated when appropriate. (ns = not significant, * p < 0.05, *** p < 0.005). 
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Table 4.3. The hydrodynamic size (nm) and surface charge (mV) of NGs in HEPES buffer 
before and after complexation with mRNA. 
 Size (nm) PDI ζ-potential (mV) 
NG 196.2 ± 1.2 0.133 23.2 ± 0.1 
NG + 0.1 μg mRNA 196.7 ± 0.8 0.167 22.7 ± 0.8 
NG + 0.25 μg mRNA 195.5 ± 0.7 0.133 22.3 ± 0.7 
NG + 0.5 μg mRNA 195.7 ± 2.4 0.171 22.9 ± 0.6 
 
Subsequently, we evaluated the transfection efficiency of the mRNA-NGs in terms of the 
number of transfected cells as well as the eGFP expression levels (Figure 4.4B and 4.4C). 
Overall, a low number of cells was successfully transfected by the mRNA-NGs, as values no 
higher than ˜ 6% were obtained for each mRNA concentration. An adjuvant treatment with 
40 μM nortriptyline (NT) induced a significant, though only minor augmentation of the 
percentage of transfected cells (up to ˜ 10%). Concurrently, protein expression remained 
low and was not significantly elevated by 40 μM NT.  
The mRNA-NG transfection was additionally compared to the commercial gold standard for 
mRNA transfections, i.e. messengerMAX™. When the latter was applied according to the 
manufacturers’ guidelines, the entire cell population was successfully transfected and high 
protein expression levels were observed (Figure 4.4D and 4.4E). A NT adjuvant treatment did 
neither alter the percentage of transfected cells nor the eGFP expression levels.  
3.3. Lipid-based transfection methods are less prone to the CAD adjuvant effect 
3.3.1. Cholesterol-siRNA 
One strategy to circumvent the necessity of a carrier for the systemic administration of 
siRNA is the use of cholesterol-siRNA (chol-siRNA) conjugates. Here, cholesterol facilitates 
siRNA transport across the cell membrane and protects the siRNA against nuclease-
mediated degradation.17, 18 Figure 4.5A shows that the intrinsic silencing potential of the 
chol-siRNA was low, with less than 10% eGFP silencing at 100 nM chol-siRNA. The 
application of 40 μM desloratadine (DL) or chloroquine (CLQ) had little impact on the 
transfection efficiency (Figure 4.5A), despite the clear increase of the SSC signal (Figure 





Figure 4.5. The percentage eGFP expression (A) and fold change in side scatter (SSC) signal relative to 
the untreated control (B) upon transfection with 50 or 100 nM chol-siRNA alone (black bars) or in 
combination with 40 μM desloratadine (DL, light grey bars) or chloroquine (CLQ, dark grey bars). Data 
are represented as the mean ± SEM for 3 technical replicates. (NTC = untreated control) 
 
3.3.2. DOTAP-cholesterol liposomes 
Next, we evaluated the potency of CADs to boost DOTAP-cholesterol liposome (LPS)-
mediated siRNA delivery. At the applied charge ratio, all siRNA is complexed by the LPS.19 
DLS measurements furthermore revealed desirable lipoplex characteristics, namely a 
hydrodynamic size of ~100 nm and a positive surface charge to stimulate internalization 
through interaction with the negatively charged cell surface  (Table 4.4). 
Table 4.4. The hydrodynamic size (nm) and surface charge (mV) of DOTAP-chol LPS in 
HEPES buffer before and after siRNA complexation. 
 Size (nm) PDI ζ-potential (mV) 
DOTAP-chol 119.8 ± 1.0 0.295 58.5 ± 0.9 
DOTAP-chol + siRNA 116.8 ± 0.1 0.293 57.9 ± 2.9 
 
Similar to experiments by Dakwar et al., the transfection efficiency of the DOTAP-chol LPS 
was evaluated in both Opti-MEM and serum containing cell medium (i.e. full medium).20 
Figure 4.6A and 4.6E indicate that the entire cell population internalized the DOTAP-chol LPS 
irrespective of the applied transfection medium. However, the extent of LPS uptake 
increased for the higher LPS concentration upon transfection in full medium, whereas the 
uptake did not vary between both LPS concentrations in Opti-MEM  (Figure 4.6B and 4.6F). 
 






Figure 4.6. (A) and (E) Representative of scatter plots showing the forward scatter (FSC) as a function 
of the FL4 signal indicating LPS uptake in the entire cell population in Opti-MEM (A) and serum 
containing cell medium (E). (B) & (F) Mean fluorescent intensity (MFI) of the Cy5-labeled siRNA upon 
LPS uptake as a function of the LPS concentration (μg/mL) for cells transfected in Opti-MEM (B) or 
complete cell medium (F). (C) & (G) % remnant eGFP expression as a function of the LPS concentration 
upon transfection with LPS alone (black bars) or combined with 40 μM desloratadine (DL) (grey bars) 
with the transfection performed in Opti-MEM (C) or complete cell medium (G). (D) & (H) Fold chance 
in the side scatter (SSC) signal relative to the untreated control as a function of the LPS concentration 
with (grey bars) or without (black bars) 40 μM desloratadine (DL) adjuvant treatment with the 
transfection performed in Opti-MEM (D) or full medium (H). Data are represented as the mean ± SEM 
for 3 technical repeats and statistical significance is indicated when appropriate. (ns = not significant, 
* p < 0.05, ** p < 0.01, *** p < 0.005) 
 
Following transfection in Opti-MEM, nearly maximal eGFP gene silencing was obtained for 5 
and 10 μg LPS/mL, repsectively carrying 2.5 and 5 nM siRNA (Figure 4.6C). Interestingly, 
despite similar or even improved uptake of the highest LPS dose in full medium, the 
transfection efficiency was significantly lower with only ˜10% and ˜15% eGFP silencing for 
respectively 5 μg and 10 μg LPS/mL (Figure 4.6G). 40 μM DL caused a slight, though 
significant additional reduction in eGFP expression for 5 μg LPS/mL in Opti-MEM (Figure 
4.6C), while this effect was not observed for the highest LPS concentration in Opti-MEM, 
despite the clear increase in the SSC signal (Figure 4.6C and 4.6D). However, the near 
optimal results of the LPS transfection alone did not allow much room for improvement. 
Here, the suboptimal transfection in full medium was significantly enhanced (Figure 4.6G), 
concurrent to the increased SSC signal (Figure 4.6H). 
To exclude potential effects of lysosomal siRNA degradation following LPS-mediated 
delivery, this set of experiments was repeated for DOTAP-chol LPS loaded with nuclease-
stabilized siRNA (siSTABLE). The LPS showed similar uptake behavior in Opti-MEM and full 
medium irrespective of the applied siRNA (data not shown). The transfection of siSTABLE-LPS 
was slightly less efficient compared to LPS encapsulating unmodified siRNA in both 
transfection media (Figure 4.7). Overall the adjuvant treatment had no or only a minor effect 
on the transfection efficiency. Overall, the slight improvement in siRNA delivery obtained for 
the DOTAP-chol LPS as a result of DL treatment is by no means comparable to the vast effect 
observed for the siNGs.  
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Figure 4.7. % GFP expression as a function of the LPS concentration following DOTAP-cholesterol LPS 
transfection in Opti-MEM (A) and (B) or full medium (C) and (D) with LPS loaded with unmodified 
siRNA (A) & (C) or siSTABLE (B) & (D). Graphs show the transfection efficiency of the LPS alone (black 
bars) or combined with 40 μM desloratadine (DL, grey bars). Data are represented as the mean ± SEM 
for 3 technical replicates and statistical significance is indicated when appropriate. (ns = not 
significant, * p < 0.05, ** p < 0.01) 
 
3.3.3. DOTAP-DOPE liposomes 
Besides DOTAP-chol LPS, we evaluated DOTAP-DOPE LPS, in which the fusogenic helper lipid 
DOPE replaces the stabilizing cholesterol. Again, previous data from our group demonstrated 
that the LPS show complete siRNA complexation at a charge ratio (+/-) of 8.21 DLS 
measurements indicate that complexes a hydrodynamic size of ˜100 nm and a strong 
positive surface charge of ˜60 mV were obtained. 
Figure 4.8A and 4.8B respectively show the LPS uptake in terms of the percentage of positive 
cells and the silencing potential of DOTAP-DOPE LPS as a function of the siRNA 
concentration. 1 nM siRNA was selected for further testing, given its uptake in nearly 100% 
of the cells and its suboptimal silencing potential (˜20%). When we subsquently combined 
the DOTAP-DOPE LPS with a 10, 20 or 40 μM DL, no significant improvement of the eGFP 





Figure 4.8. (A) Uptake of siRNA-loaded DOTAP-DOPE LPS in terms of the percentage of positive cells. 
(B) The transfection efficiency of DOTAP-DOPE LPS as a function of the applied siRNA concentration. 
(C) The influence of 20 hours adjuvant treatment with 10, 20 or 40 μM desloratadine (DL) on the 
transfection efficiency of suboptimal siRNA-loaded DOTAP-DOPE LPS. Data are represented as the 
mean ± SEM for 3 technical replicates and statistical significance is indicated when appropriate. (ns 
not significant, *** p < 0.005) 
 
3.3.4. DOPE-nortriptyline liposomes 
A potential disadvantage of the proposed CAD adjuvant strategy is the need for relatively 
high CAD doses. Hence, we explored the potential of introducing a CAD adjuvant as a 
building block of the nanocarrier by combining NT and DOPE. Interestingly, DLS data indicate 
liposome formation (Table 4.5), although the inclusion of NT into the LPS was not further 
verified.  
Table 4.5. The hydrodynamic size (nm) and surface charge (mV) of DOPE-NT LPS in HEPES 
buffer before and after siRNA complexation. 
 Size (nm) PDI ζ-potential (mV) 
DOPE-NT 105.5 ± 0.1 0.269 30.9 ± 0.8 
DOPE-NT + siRNA 112.9 ± 1.0 0.184 30.7 ± 0.5 
 
The The transfection efficiency of the DOPE-NT LPS was compared to the DOTAP-DOPE LPS. 
Both LPS were internalized by the entire cell population (Figure 4.9A), although the 
corresponding MFI was significantly higher for the DOTAP-DOPE LPS (Figure 4.9B). The 
DOPE-NT LPS evoked a concentration-dependent eGFP silencing, albeit to a lesser extent 
than the DOTAP-DOPE LPS (Figure 4.9C). However, the succesfull transfection by the DOPE-
NT LPS was not accompanied by an elevation of the SSC signal as witnessed with free NT 
(Figure 4.9D, Figure 3.9A).  
  CHAPTER 4 
 135 
 
Figure 4.9. (A) and (B) Uptake of DOTAP-DOPE (white bars) and DOPE-NT (black bars) LPS in terms of 
the percentage of positive cells (A) and the mean fluorescent intensity (MFI) of the positive cells (B). 
(C) The transfection efficiency in terms of the percentage eGFP expression in H1299-eGFP cells 
transfected with DOTAP-DOPE (white bars) and DOPE-NT (black bars) LPS, as a function of the applied 
LPS concentration. (D) The fold change of the side scatter (SSC) signal relative to the untreated 
control for cells transfected with DOTAP-DOPE (white bars) or DOPE-NT (black bars) LPS. Data are 
represented as the mean ± SEM for 3 technical replicates and statistical significance between DOTAP-
DOPE or DOPE-NT LPS is indicated when appropriate. (ns = not significant, *** p < 0.005) 
 
3.3.5. Commercial lipofection reagent RNAiMAX 
Finally, we evaluated the combination of DL and the commercial lipid-based carrier 
RNAiMAX, which is considered the gold standard for siRNA transfections. Two siRNA doses 
were applied, namely 0.6 and 5 pmol siRNA/well. Figure 4.10 shows nearly complete gene 
silencing at the highest dose tested whereas 0.6 pmol siRNA/well only reached up to ˜55% 
gene silencing. Similar to the results obtained with messengerMAX, 40 μM DL did not 





Figure 4.10. Percentage eGFP expression upon transfection with RNAiMAX as a function of the siRNA 
concentration per well for cells solely transfected with RNAiMAX (black bars) or combined with a 2-
hour 40 μM desloratadine (DL) treatment (grey bar). Data are represented as the mean ± SEM for 3 
technical replicates and statistical significance between RNAiMAX with and without adjuvant 
treatment is indicated when appropriate. (ns = not significant) 
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4. DISCUSSION 
In Chapter 3 we established that a sequential treatment with a cationic amphiphilic drug 
(CAD) improves siRNA-mediated gene silencing in NG transfected cells. Additionally, we 
showed that CADs induce a phospholipidosis (PLD) phenotype, with the accumulation of 
phospholipids, sphingomyelin and cholesterol, which is believed to destabilize the lysosomal 
membrane thereby allowing siRNA transfer the cytosol. Here, we evaluated the wider 
applicability of this method in terms of the small molecular adjuvant, the nucleic acid cargo 
and the nanocarrier. It must be noted that all experiments were performed in a single 
biological replicate with the graphs showing the mean ± the standard error to the mean of 
three technical replicates. Hence, data interpretation should occur with caution and the 
trends should ideally be confirmed by additional biological replicates. 
4.1. Distinct small molecular adjuvants do not equally improve siRNA delivery 
First, we evaluated tobramycin (TM) given its reported potential to induce phospholipidosis 
(PLD) in renal tubular cells in vivo without being a cationic amphiphilic drug (CAD). 5, 22 
Despite the fact that TM contains various basic amines, with the strongest base being 
characterized by a pKa value of 9.83, TM cannot be classified as a CAD given its strong 
hydrophilic nature (logP = -5.8).16 Consequently, TM cannot be considered to functionally 
inhibit acid sphingomyelinase (ASM, FIASMA), but induces PLD by binding phospholipids in 
the acidic environment of the late endosomes/lysosomes thereby preventing degradation by 
lysosomal phospholipases.5, 23  
The induction of PLD with high TM doses could be visualized upon LipidTOXTM red labeling 
(Figure 4.2C), in accordance to previous reports.24 The high TM doses required to evoke this 
phenotype could be explained in terms of the less favorable physicochemical properties for 
cellular uptake through passive diffusion. Despite the induction of PLD, no concurrent 
improvement in siRNA-mediated gene silencing could be detected (Figure 4.2A). Of note, the 
deviating cellular distribution of the accumulated phospholipids could explain the 
differences in the extent of SSC increase for TM (Figure 4.2B) and DL (Figure 3.8A) and may 
potentially clarify the lack of adjuvant effect for TM.   
These results suggest that accumulation of specific lipids is likely required to improve the 




applicability of non-CAD PLD-inducers as small molecular adjuvants, additional compounds 
require evaluation. In any case would the adjuvant application of an antibiotic like TM be 
less advisable given the issue of antibiotic resistance. TM furthermore induces tissue specific 
PLD in renal tubular cells in vivo, which limits the general applicability, but may reduce off-
target adverse events.5  
Subsequently, we evaluated the adjuvant potential of the alcohol deterrent disulfiram (DSF). 
DSF is characterized by a high logP value (3.88), but does not contain a protonatable amine 
group.16 Hence, it is neither a lysosomotropic compound nor a FIASMA.2, 16 Interestingly, 
recent literature showed that DSF causes apoptosis combined with elevated cytosolic 
cathepsin levels, which strongly suggest the induction of lysosomal cell death through 
lysosomal membrane permeabilization (LMP). DSF indeed induced apoptotic cell death in 
many, but not all, cell and xenograft models tested and this effect is tightly connected to the 
availability of Zn2+- or Cu2+-ions.6, 7, 25 By its ionophore activity, DSF transports these bivalent 
ions into the cell, leading to a sudden increase of the cellular Zn2+ or Cu2+ concentration. As a 
protective measure, the DSF-ion complexes are rapidly shuttled to the lysosomal 
compartment. Consequently, the proteasome is inhibited, which is suggested to affect the 
lysosomal function,  thereby allowing cathepsin release and apoptosis induction.26 In 
addition, the lysosomes are no longer confined to the perinuclear region.6, 25 Overall, the 
DSF-mediated augmentation of the lysosomal Zn2+ or Cu2+ concentration is assumed to cause 
lysosomal dysfunction, potentially leading to LMP.7, 26 Here, we evaluated whether this 
lysosome destabilizating capacity could be applied to our advantage to improve siRNA 
delivery in cancer cells.  
Although DSF an sich significantly improved siRNA-mediated gene silencing (Figure 4.3A), the 
extent of the effect could not be compared to that of the initially evaluated FIASMAs (Figure 
3.2). Since the DSF activity is related to the extracellular Zn2+ concentration, we combined 
both components. Where 5 μM Zn2+ failed to potentiate the effect of DSF (Figure 4.3D), 10 
μM Zn2+ enhanced the adjuvant effect of 25 μM DSF (Figure 4.3E). In contrast, a strong 
cytotoxic response was noted with the combination of 50 μM DSF and 10 μM Zn2+ (Figure 
4.3E). Although the effect on the lysosomal compartment was not experimentally explored, 
we hypothesize that this combinated perturber the lysosomes to such an extent that the 
potential adjuvant effect was overruled by cytotoxicity. Lysosomal cell death is of course a 
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desirable outcome in the light of an anti-cancer therapy. Hence, the strong cytotoxicity 
observed for the combination of DSF, DL and Zn2+ (Figure 4.3F) is a highly interesting 
observation since the cytotoxic effect of DSF could be potentiated by the relatively safe DL. 
Taken together, we can assume that not all lysosome perturbing compounds will be equally 
applicable as delivery enhancers given the disparity between efectuating siRNA release and 
inducing cytotoxicity.  
4.2. The therapeutic potential of mRNA  is not strongly enhanced by CADs 
Secondly, we investigated whether mRNA expression could be by a sequential CAD 
treatment. To vary a single factor at a time, we applied the NGs as a delivery vehicle for the 
eGFP-encoding mRNA. Although the number of negative charges for mRNA largely exceeds 
that of siRNA ( ˜1000 for the applied mRNA molecules versus ˜42 for an siRNA duplex) the 
NG complexation capacity was not exceeded by the notably lower mRNA doses, which 
explains the observed complete complexation (Figure 4.4A).14 However, only limited eGFP 
expression levels were obtained (Figure 4.4B and C) with the mRNA dose recommended for 
optimal transfection with messengerMAX (0.5 μg mRNA/well) with or without a sequential 
CAD treatment. Hence, we hypothesized that the mRNA may be less easily released from the 
NGs and/or the endosomes. Since it is assumed that only the free NA cargo transfers to the 
cytosol, the enhanced NA-carrier interaction may in turn explain the limited potentiating 
effect of the sequential CAD treatment. A second possible explanation for the limited 
transfection efficiency is that the mRNA molecule may be too large to cross the endo-
lysosomal membrane. In corroboration, CADs were not able to significantly enhance mRNA 
expression upon transfection with messengerMAX.  
These data suggest that our approach may not allow improved transfection of larger NA, 
leaving many questions unanswered on the level of the NA cargo. To firmly establish the 
adjuvant potential, we should evaluate the impact of NA dissociation from the carrier and 






4.3. Lipid-based transfection methods are less prone to the CAD adjuvant effect 
In Chapter 3 we applied a polymeric nanocarrier to achieve siRNA transfection. Here, we 
evaluated if our proposed CAD adjuvant method can be applied to additional transfection 
methods, such as siRNA-cholesterol conjugates, lipid nanoparticles and a commercial lipid-
based transfection reagent. 
4.3.1. Cholesterol-siRNA conjugate 
A cholesterol-siRNA conjugate (chol-siRNA) was the first construct to successfully induce 
hepatic gene silencing in vivo following i.v. injection.17 The efficacy was attributed to the 
increased half-life and the enhanced internalization at the target site compared to naked 
siRNA. Indeed, the cholesterol moiety protects the siRNA duplex against nucleases and 
ensures the connection to lipoprotein particles in the blood stream. This in turn improves 
the chol-siRNA biodistribution by avoiding rapid renal clearance and stimulating chol-siRNA 
uptake in the liver through endocytosis upon recognition by the lipoprotein receptor.13, 27 
Our group previously observed good uptake and gene silencing by a chol-siRNA conjugate in 
the H1299-eGFP cells.28 However, we were not able to confirm these results (Figure 4.5A). 
Most importantly, the suboptimal silencing could not be improved by DL or chloroquine 
(CLQ) (Figure 4.5A) despite the induction of a PLD phenotype (Figure 4.5B). Besides low chol-
siRNA uptake, the lack of the adjuvant effect may be explained in terms of a different uptake 
pathway for chol-siRNA compared to the siNGs. Indeed, binding to lipoprotein particles is a 
prerequisite for the receptor-mediated endocytosis observed in vivo, but is unlikely to occur 
upon transfection in Opti-MEM. Consequently, chol-siRNA may not be predominantly 
trafficked to the endo-lysosomal compartment 29, although this was not experimentally 
verified in our setup. In contrast, both Ming et al. and Gilleron et al. were able to improve 
the silencing potential of chol-siRNA by effectuating release from the late endosomal 
compartment, which suggests at least partial endo-lysosomal chol-siRNA entrapment.30, 31 
The induction of a Niemann-Pick disease (NPD) phenotype may in turn not be an ideal 
strategy to improve chol-siRNA delivery since cholesterol shuttling by the Niemann-Pick C1 
(NPC1) protein is inhibited in NPD cells32, 33, thereby potentially reducing the chances of chol-
siRNA escape.  
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4.3.2. Liposomes and commercial transfection reagents 
Overall, LNP are most frequently applied as drug delivery vehicles and have advanced 
furthest in their clinical development8, 34, which is of interest towards the translation of our 
adjuvant approach. Hence, we evaluated if DL could enhance the gene silencing potential by 
relatively simple siRNA-loaded DOTAP-DOPE and DOTAP-cholesterol liposomes (LPS) to 
establish whether our adjuvant approach is applicable to lipid-based nanocarriers. 
In case of the DOTAP-cholesterol LPS, a sequential 40 μM DL treatment had no significant or 
only a very limited effect regardless of the transfection medium, despite the induction of a 
PLD phenotype (Figure 4.6H). This could not be attributed to siRNA degradation (Figure 4.7). 
Likewise, no significant improvement of suboptimal DOTAP-DOPE LPS could be achieved 
(Figure 4.9).  
Many reports indicate that LPS are internalized through endocytosis, followed by 
intracellular trafficking to the lysosomal compartment. For liposomal formulations, 
endosomal escape is believed to occur via fusion of the LPS with the endo-lysosomal 
membrane35, 36, which can be stimulated by the application of fusogenic lipids like DOPE.37, 38 
However, even for the most effective carriers only a small fraction of the internalized NA 
dose reaches the cytosol, while the majority of the LPS and their NA cargo are progressively 
sequestered in the lysosomes.13 PLD induction by DL was not able to induce additional siRNA 
release in our setup, which may be attributed to differences in siRNA release from the LPS. 
As of today, relatively little is known regarding nanocarrier degradation and/or NA 
decomplexation in the endo-lysosomes. Since de Duve stated the lysosomes to be the cell’s 
recycling bins39, it is generally assumed that carriers and cargo reaching this organelle 
undergo degradation. Free nucleic acids are indeed rapidly degraded in the lysosomes and 
NA inclusion in a lipid- or polymer-based carrier clearly reduced and delayed NA hydrolysis40, 
suggesting slow and incomplete NA detachment from the carrier. Since this release is in all 
probability imperative to our adjuvant strategy, it can be rationalized that the adjuvants fail 
to potentiate the siRNA-loaded LPS due to slower siRNA release from the carrier. Lipid-based 
carriers are suggested to be degraded by phospholipases, which show substrate preference 
for phosphatidylcholine and -ethanolamine groups.41 However, the cationic surface charge 
and multilamellar configuration of the LPS do not favor degradation42, thereby potentially 




significantly enhance the transfection potential of commercial lipid-based transfection 
reagents (Figure 4.4E and 4.10). Hence, future experiments should be set up to study the 
carrier degradation. It should also be confirmed that CADs do not negatively affect LPS 
degradation by a secondary inhibition of the lysosomal phospholipases.  
Finally, we evaluated if a CAD as a liposomal building block could improve the therapeutic 
potential of the formulation. If so, this would allow using lower CAD doses and would 
potentially minimize off-target effects of the free drug. DLS results indicated successful LPS 
formation for the combination of DOPE and NT. This implies that NT was inserted in the 
lipid-bilayer, as the conical lipid DOPE is not able to form lamellar structures by itself. 
However, the extent of NT inclusion in the bilayer and the core of the LPS warrants further 
research. Compared to the DOTAP-DOPE LPS, uptake for the DOPE-NT LPS was lower in 
terms of the mean fluorescent signal of the positive cells. This may be explained by the 
stronger positive charge of the DOTAP-DOPE LPS, which may allow enhanced interaction 
with the negative cell membrane. However, since the fluorescent signal stems from the Cy5-
labeled siRNA, the differences likely stem from variations in siRNA complexation. The latter 
was not experimentally determined for the DOPE-NT LPS. We obtained suboptimal silencing 
results with the DOPE-NT LPS. Of note, the induced silencing was not accompanied by an 
increased SSC signal. Hence, siRNA release is in all probability rather a consequence of the 
fusogenic properties of DOPE than the FIASMA activity of NT. The absence of an increased 
SSC signal suggests that an insufficient amount of NT is released from the bilayer or the 
hydrophilic core to induce the PLD phenotype.   
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5. CONCLUSION 
Despite the great potential of a CAD adjuvant treatment to enhance siRNA-mediated gene 
silencing upon siNG transfection as show in Chapter 3, similar results could not be obtained 
with alternate small molecular adjuvants, nucleic acid cargos, nanocarriers or transfection 
reagents. It is anticipated that the cellular internalization, intracellular trafficking and 
lysosomal degradation of the carrier and/or NA decomplexation are of major importance to 
whether a CAD adjuvant approach will have a potentiating effect. Elucidation of these events 
may provide an explanation to why an adjuvant approach may or may not be successful and 
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Assessing nanoparticle toxicity with cell-based assays:  
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The number of newly engineered nanomaterials is vastly increasing along with their 
applications. Despite the fact that a lot of interest and effort are being put into the 
development of nano-based biomedical applications, the level of translational clinical output 
remains limited due to uncertainty on the toxicological profiles of the nanoparticles (NPs). As 
NPs used in biomedicines are likely to directly interact with cells and biomolecules, it is 
imperative to rule out any adverse effect before they can be safely applied. The initial 
nanosafety screening is preferably performed in vitro, but extrapolation to the in vivo 
outcome remains challenging. In addition, generated in vitro and in vivo data are often 
conflicting, which consolidates the in vitro-in vivo gap and impedes the formulation of 
unambiguous conclusions on NP toxicity. Consequently, more consistent and relevant in 
vitro and in vivo data need to be acquired in order to bridge this gap. This is in turn in conflict 
with the incentive to reduce the number of animals used for in vivo toxicity testing. 
Therefore the need for more reliable in vitro models with a higher predictive power, 
mimicking the in vivo environment more closely, becomes more prominent. In this review 
we will discuss the current paradigm and routine methods for nanosafety evaluations, and 
give an overview of adjustments that can be made to the cultivation systems in order to 
optimise current in vitro models. We will also describe various novel model systems and 







Since the 1980’s the field of nanotechnology has increasingly gained importance, leading to 
a large number of applications since the 1990’s. Today, inorganic nanoparticles (NPs) are 
applied in various technological applications and consumer goods. For example, zinc oxide 
(ZnO)NPs are used in sunscreens and toothpastes and silver (Ag)NPs can be found in food 
packages, deodorants and are applied as a preservative in cosmetics.1-3 Given the ever 
increasing use of NPs and the high interest of exploiting the exceptional features of NPs in 
biomedical applications, it is expected that both intentional and unintentional exposure will 
become more frequent.4, 5 Consequently, the increasing implementation of nanotechnology 
in our daily lives is joined with raising concerns on potential adverse effects towards human 
health.6 It is therefore recommended that the safety of these products, towards consumers 
and workers at the production site, is carefully evaluated before the introduction to the 
market.4, 5, 7 However, there are currently only very limited regulations on the use and the 
safety criteria for nanomaterials in industrial applications or consumer goods. Major 
obstacles on the route to an appropriate legislation are the broad nature of nanotechnology, 
the incredible pace at which the field keeps advancing and the enormous variety in types of 
nanomaterials, each with different physicochemical properties and specific applications.7 
This legislation should cover all aspects of nanotechnology without any material or 
application being left out, which is, from a practical point of view, extremely hard to obtain. 
In order to try and overcome this predicament, the European Commission has launched a 
recommendation on a definition of nanomaterials in 2011 that states that a nanomaterial is: 
“A natural, incidental or manufactured material containing particles, in an unbound state or 
as an aggregate or as an agglomerate and where, for 50% or more of the particles in the 
number size distribution, one or more external dimensions is in the size range from 1 - 100 
nm. In specific cases and where warranted by concerns for the environment, health, safety 
or competitiveness the number size distribution threshold of 50 % may be replaced by a 
threshold between 1 and 50 %.”8 As every definition has its limitations and introduces 
technical challenges, regulatory bodies have not yet come to a global agreement on the 
correct definition, but the most used criterion is the size limitation.9-11 Nanotechnology is 
subsequently defined as the manipulation and application of particles and systems with at 
least one dimension below 100 nm.10 For nanomedicine purposes these technologies are 
used to develop applications for diagnosis,12, 13 imaging,14, 15 treatment 16, 17 and prevention 
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of diseases.18-20 A recent novelty in nanomedicine is the concept of theranostics, where 
particles combine diagnostic and therapeutic features in a single construct.21, 22 For example, 
Kirui et al. created immunotargeted gold-coated iron oxide (IO)NPs to visualize colorectal 
tumors by magnetic resonance imaging followed by treatment with hyperthermia.23  
It is on the one hand due to the minute dimensions of the NPs that they exhibit many unique 
properties (e.g. IONPs are superparamagnetic24 and gold (Au)NPs have a localized surface 
plasmon resonance25) because of which they can be implemented in novel innovative 
applications.26 These dimensions are on the other hand often the cause of adverse health 
effects through the higher surface area to volume ratio and enhanced surface reactivity.27, 28 
The fact that both the great potential and the high risk lie in the miniature dimensions of the 
NPs is referred to as the nanomaterial-paradox and underscores the importance of a 
thorough toxicological analysis.9 Even though nanotechnology has been evolving since the 
1980’s, it was only in 2004 that Donaldson et al. mentioned the importance of 
nanotoxicology - as a subcategory of toxicology - to enable the further development of safe 
and sustainable nanotechnology.29 Nanotoxicology is referred to as the study on interactions 
between NPs and biological systems with an emphasis on establishing a relationship, if any, 
between the physicochemical properties of the NP and the toxicological responses.30 It is 
crucial that nanotoxicology is regarded as a distinct category of toxicology since standard 
toxicity assays, initially developed for the evaluation of chemical substances, are often 
inadequate for nanotoxicity assessment. This can be attributed to the different mechanisms 
leading to nanocytotoxicity, the specific behavior of the NPs in culture media and the 
possible interference of NPs with various toxicity assays.9, 31-33 Therefore the classical 
toxicity-testing paradigm needs to be optimized to be applicable for nanosafety evaluation. 
The experimental design is, besides the assays, also subject to optimization, as it is clear 
from literature that it has the potential to influence the uptake and/or the observed 
toxicological effects.34-37 
This chapter provides an overview of current methods used for nanosafety evaluations and 
factors related to the cell model that are likely to influence the outcome of the experiments. 
Furthermore we will propose adjustments that can be made to the cultivation system in 
order to minimize artifacts and resemble the in vivo situation more closely, as illustrated by 






2.1. Common mechanisms of nanocytotoxicity  
As mentioned above, nanotoxicology should be regarded as a specific subcategory of 
toxicology since the general toxicology paradigm cannot completely cover NP-induced 
cytotoxicity.29 Of note, generally higher levels of toxicity are observed for NPs in comparison 
to their bulk material,20, 30 which is attributed to the higher surface area to volume ratio, 
possible surface reactivity and susceptibility to NP degradation and ion leaching.27, 38 In 
addition, most chemicals induce cell damage through interactions with specific 
biomolecules, whereas a single NP may cause cytotoxicity via a combination of adverse 
events.  
A true general paradigm on how NPs evoke cell injury remains to be elucidated. However, it 
can be stated that cytotoxicity can be elucidated via 4 distinct categories of events: (i) 
effects related to induction of reactive oxygen species (ROS), (ii) effects due to direct 
interactions of the NPs with biomolecules, (iii) effects from leached ions and (iv) effects 
related to the protein corona.  
Nel et al. have put ROS induction forward as one of the main mechanisms through which 
inorganic NPs induce cytotoxicity, as this effect has been observed in a multitude of in vivo 
and in vitro studies.39-43 It is proposed that ROS can be induced either through intrinsic ROS 
generating properties of the NP or cell-mediated ROS generation. In the latter category, NPs 
can interfere with the anti-oxidative defense mechanism by reducing the activity of the anti-
oxidative defense enzymes.44 Furthermore NPs can activate several signaling pathways 
through interaction with cell surface receptors.45 Hereby stress-dependent signaling 
pathways are activated, which alter gene expression of the anti-oxidant response element, 
leading to ROS overproduction.46 In addition, NPs can cause increased ROS production in the 
mitochondria through interference with the respiratory chain.46, 47 Finally, several NPs are 
capable of activating NADPH oxidase, thereby inducing ROS production.48, 49 In the first 
category (intrinsic ROS generating properties), NPs are intrinsically capable of generating 
ROS through the presence of reactive surface groups or surface bound radicals.27 In addition, 
transition metals present on the surface or leached from the NP in the acidic environment of 
the endo-lysosomes can generate ROS via Fenton chemistry.27, 45 Overall, ROS induction can 
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be a consequence of a single or a combination of the abovementioned events. Furthermore, 
Nel et al. proposed a tired response of the cells to elevated ROS levels, which has been 
confirmed in in vitro and in vivo studies for different NPs. In general limited ROS levels 
induce an anti-oxidative response, medium ROS levels evoke a proliferative and 
inflammatory response and persistently high levels of oxidative stress induce apoptotic and 
necrotic signaling pathways.27  
The induction of ROS can have a multitude of downstream effects. Indeed, ROS is known to 
induce general cell damage, as it can interact with DNA, proteins, lipids and organelles.27 
First, oxidative DNA damage influences gene expression or can induce mutagenesis or 
apoptosis in case of insufficient repair mechanisms.50 Secondly, proteins can be activated or 
inactivated as a consequence of ROS presence.51 ROS can furthermore cause actin stress 
fiber formation and therefore alter the cell’s morphology, motility and adhesion.52, 53 
Persistent ROS induction will trigger a stress response leading to the production of cytokines 
and the induction of an inflammatory response. If ROS is not neutralized in a timely fashion, 
a feed-forward loop keep stimulating both ROS and cytokine production leading to 
immunotoxicity.27  
Due to lipid peroxidation, membranes can be damaged, which in turn leads to 
malfunctioning organelles. Indeed, the mitochondria, endoplasmatic reticulum (ER) and 
lysosomes are reported to suffer from ROS.54 This secondary ROS damage can in turn lead to 
downstream effects such as altered signaling and a perturbed calcium homeostasis.54 In 
addition, both ER stress and lysosomal destabilization can induce autophagy and an 
inflammatory response.55  
Of note, this ROS paradigm does not account for all NPs: cerium oxide (CeO2)NPs, for 
example, were found not to induce ROS but on the contrary even showed a protective effect 
against ROS damage in vivo as well as in vitro.56, 57 Furthermore, Harris et al. could not detect 
increased ROS levels upon IONP exposure in a high content screening (HCS).58 In addition, 
IONPs were shown to exhibit an intrinsic peroxidase-like activity in a cell free environment as 
well as in mesenchymal stem cells, where they even promoted cell proliferation.59, 60 Of 
note, only unimpaired IONPs displayed this peroxidase-like activity. Importantly, when IONPs 





induces ion leaching. Upon saturation of the cell’s iron homeostasis, excess iron ions 
subsequently cause increased ROS production through Fenton chemistry.61 This feature 
underscores the complexity of NP-cell interactions and highlights the importance of the 
intracellular localization of the NPs.  
The second main mechanism through which NPs induce adverse effects is by interacting 
directly with biomolecules, such as DNA, proteins and lipids, which in turn leads to 
downstream effects. Notably, most ROS-related events may also occur through direct NP-
biomolecule interactions. For instance, NPs can alter gene expression via interactions with 
signal transduction pathways, interference with epigenetic gene regulation or the 
transcriptional or translational machinery through their perinuclear localisation.50, 51, 62 In 
addition, very small NPs with a diameter below 5 nm may directly interact with DNA to alter 
its expression.63 Studies furthermore show that NPs can interact with components of the 
cytoskeleton thereby potentially altering cell morphology as well as signal transduction.64-66 
In addition, NPs were shown to interfere with receptor-ligand interactions and signalling 
pathways.67, 68 Comparable to ROS-induced damage; NPs are capable of damaging 
membranes and organelles such as the mitochondria and lysosomes. This may in turn evoke 
autophagy or an inflammatory response.51, 69 Of note, some NPs were also shown to induce 
an immune response through interaction with the Toll Like Receptor 4.70 Finally, NPs are also 
capable of directly evoking ER stress, which in turn leads to autophagy, increased calcium 
levels and potentially inflammation or apoptosis.69, 71  
The third general element causing NPs to induce toxicity is their susceptibility to 
degradation. Depending on the uptake mechanisms and subsequent trafficking many NPs 
end up in the acidic and degrading environment of the lysosomes.45, 72 This environment can 
cause degradation or even dissolution of the NP, resulting in the leaching of free ions or an 
increase in reactive surface groups.45 The following impact on cell wellbeing depends on the 
chemical composition of the NP. For cadmium (Cd)-containing quantum dots (QDs), for 
example, the leaching of highly toxic Cd2+-ions is considered to be the main cause of any 
observed toxicity.73, 74 It has been shown for several NPs that the induced toxicity is more 
severe for the nanoparticulate form than its ionic counterpart. This is called the “Trojan 
Horse effect” as it can likely be contributed to a more efficient uptake of the NP through 
  CHAPTER 5 
157 
 
endocytosis compared to the free ionic form, which consequently leads to elevated 
intracellular ionic concentrations.51  
Finally, it is known that NPs avidly bind serum proteins to their surface, creating a protein 
corona.75 The nature of this corona depends on the NPs physicochemical properties and the 
composition of the microenvironment (e.g. cell culture media) surrounding the NPs.30, 76 The 
binding of serum proteins to the NP surface is an important determinant in how the cells 
‘see’ the NPs and therefore influences NP uptake and toxicity.77-79 Additionally, proteins 
incorporated in this corona can undergo conformational changes and because of which the 
cell may recognize them as an antigen and initiate an immune response.20, 29 An immune 
response can furthermore be triggered by direct interactions of NPs with immune cells, 
complement activation and facilitation of antigen-specific hypersensitivity reaction through 
interactions with T lymphocytes or the release of chemokines and cytokines. Here, the 
mechanism of immunotoxicity appears to be both cell- and NP-dependent.80 
Overall, in the current nanotoxicity paradigm ROS induction has been proposed as the main 
toxic effect, which can lead to a plethora of downstream effects. Yet this section highlights 
the need for a multiparametric nanosafety evaluation at sublethal NP doses to thoroughly 
investigate the effect on cell homeostasis. The uptake mechanism and ultimate intracellular 
location of the NPs must also be taken into account as these parameters co-determine the 
extent and mechanism of the NP-induced injury.  
2.2. Routine methods for nanotoxicity testing  
In the NP development process nanosafety is primarily evaluated in vitro.81, 82 It is essential 
to note that, prior to any toxicity testing, the NPs must be thoroughly characterized with 
respect to the purity and physicochemical properties. NP characterization should be 
performed both on the dry and wet state, with the latter ideally being a relevant medium 
such as the cell culture medium or a biological fluid.82, 83 NP characterization will not be 
elaborately discussed here, but further information can be found via alternative literature.83-
86 This section summarizes the main methodological principles of in vitro nanosafety 





2.2.1. Routine in vitro methods 
In vitro assays are mainly the first to be conducted in a toxicological evaluation.87 Most in 
vitro studies are conducted in classical 2D monocultures of cancer or long-lived cell lines 
although the use of stem cells or primary cells is steadily increasing. The selection of a 
relevant cell type generally depends on the expected in vivo target organ and application of 
the NP and/or the expected exposure.88 In a vast majority of the studies the cells are 
exposed to the NP dispersion during a single incubation period, which mostly ranges from 3 
up to 48 hours.87, 89, 90 The induced toxicity is subsequently evaluated using mainly 
biochemical assays, including enzymatic assays and enzyme-linked immunoassays with a 
fluorometric or spectrophotometric read-out. Such assays remain popular given their 
relatively short duration, the uncomplicated detection principle and straightforward data 
processing.91 Furthermore, the possibility of up scaling and automation of the execution, 
detection and data processing makes these assays highly convenient in regard to a high 
throughput approach.91, 92 Another popular method is to stain specific cellular components 
with fluorescently labeled antibodies or molecular probes.45, 87, 93 This approach allows 
detection via a plate reader or flow cytometry or is combined with microscopy-based 
analysis. The latter is an important tool for the evaluation of morphological features like cell 
spreading and organelle behavior, but will also increasingly be applied in high content 
screening (HCS) approaches to evaluate cellular processes.94, 95  
Finally specialized techniques are used to evaluate specific parameters. For example, ion 
leaching can be detected in cell-free conditions using specialized buffers and the intactness 
of stem cell functionality can be evaluated by observing the efficiency of cellular 
differentiation induced by specific protocols.45, 96   
2.2.2. Issues with routine in vitro methods 
Up until now, many conflicting data have been generated as shown in reviews on the toxicity 
of a specific NP or the correlation between the NPs physicochemical properties and the 
evoked effects.28, 97-99 This led to an increasing awareness that the routine in vitro testing 
paradigm may not be as appropriate for nanosafety assessments as initially assumed.100, 101 
Nel et al. first raised this thought in 2006, emphasizing on the necessity to optimize several 
elements of the testing paradigm.27 We believe that the major issues with the current in 
vitro methods are (i) the (mostly) incomplete NP characterization, (ii) the lack of consensus 
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on the dose metric, (iii) the possibility of NPs interfering with the assays, (iv) the 
shortcomings inherent to the most used classical 2D monocultures and (v) the lack of 
standardization and guidelines on how to perform an in vitro nanosafety evaluation.11, 100-103 
Thus, classic assays may be appropriate for nanotoxicity elements but factors such as the 
preparation of the NP dispersion and the inclusion of additional controls to avoid the effect 
of assay interference should be optimized.  
a. NP characterisation 
A first shortcoming to the current nanotoxicity testing strategy paradigm is the often 
incomplete characterization of the NPs. Thorough NP characterization is imperative, as 
different physicochemical properties could potentially influence the outcome of nanosafety 
studies. In this regard, a consensus should be reached on which parameters to characterize 
as well as on the methods that should be applied. Combined efforts from multiple groups, 
overviewed by the European Commission, lead to the identification of NP parameters that 
should be characterized as well as to guidelines on appropriate methods. With regard to the 
latter, it is recognized that additional efforts are needed since some methods are only 
applicable to a subset of NPs, novel methods are required to asses certain parameters and 
several methods still require standardization.104 Furthermore, it is proposed to obtain 
information on the physical characteristics (size distribution, shape and aspect ratio, 
agglomeration/aggregation and porosity), the chemical properties (chemical composition 
and crystallinity), the NP surface properties (charge, photocatalysis and surface reactivity) 
and parameters relevant for fate and exposure (zeta potential, dustiness and water 
solubility/dispersibility/dissolution kinetics).105 
Importantly, NPs should be characterized both in dry and wet state. In addition, it is crucial 
to characterize the NPs in the applied exposure medium since cell media applied for in vitro 
studies often contain high salt and protein concentrations, which can respectively induce NP 
aggregation and form a protein corona on the NP surface. Both factors can in turn have an 
impact on NP size, charge and colloidal stability. 106 Hence, info on NP properties in the 






A final hurdle is the difficulty to retrieve reliable conclusions on the effect of a single 
physicochemical parameter on nanosafety. This originates from the fact that altering one 
parameter, for example surface charge, without affecting any other (hydrodynamic size, 
colloidal stability, nature of the coating…) is not an easy task.103 In addition, when changing a 
single parameter, scientist should take into account how this parameter may change when 
the NP is dispersed in the applied culture medium.  
b. NP concentration  
Besides the NPs physicochemical parameters, NP concentration is an additional element that 
requires optimization. Here, a consensus is needed on methods to determine the 
concentration as well as the dose metric 107, 108109, 110since currently various studies apply 
different dose metrics, which reduces the inter-study comparability.107, 108 Most often, NP 
concentration is expressed in terms of mass/volume. This option requires the least thorough 
characterization to determine the NP concentration and is considered the most 
straightforward. However, it is not always the most relevant metric, as smaller NPs often 
evoke a stronger toxic response in comparison to their larger counterparts at similar 
mass/volume doses.37, 103 Logically, the number of NPs present is much higher for smaller 
NPs than for their larger counterpart at similar mass doses. In addition, this dose metric does 
not allow easy comparison of the effects induced by NPs consisting of materials with 
different densities.  
Wittmaack considers particle number/volume to be the best dose metric.109 Other groups 
believe that the concentration should be expressed in terms of surface area/volume since 
both particle size and number are contained in this metric.110, 111 Of note, these metrics are 
not influenced by differences in particle density, which is the case for the mass/volume 
metric. Thus, it was suggested that if authors should prefer to use the NP mass/volume ratio 
to express the concentration, it should be combined with the NP number/volume 
concentration to provide sufficient information in order to enable interpretation of the 
toxicity data between different studies.40, 107, 112  
The applicability of the surface area/volume unit has been demonstrated by Rushton et al. 
who found a significant correlation between the in vitro oxidative response and the 
inflammatory response in vivo for nine different NPs with distinct physicochemical 
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properties when the concentration was expressed in surface area/volume.113 When the 
same group applied this method to a previous data set, in which no in vitro-in vivo 
correlation could be observed, a clear correlation was now established.113, 114 
c. Assay interference 
A third major issue is the potential of NPs to interfere with classical biochemical assays.101, 
115 NPs with optical properties can, for instance, alter the outcome of an assay based on a 
spectrophotometric or fluorometric read-out.32 Such read-outs can furthermore be altered 
by changes in the fluorescence or absorbance characteristics of the indicator due to direct 
interaction with the NPs.116, 117 Additionally, NPs may interact with enzymes or substrates 
because of their high absorbance capacity and/or catalytic activity and change their 
structure and/or function.101, 102, 115 Kroll et al. looked into the interference of 24 well-
characterised NPs with four frequently used in vitro assays and observed concentration-, NP- 
and assay-dependent interferences.31 More recently, Ong et al. showed that NP interference 
could not be predicted based on NP-assay component interactions and our current 
understanding of NP behaviour.115 Consequently it is imperative to validate the assays for 
each specific type of NP by assuring that the measured toxicity, or the lack thereof, is indeed 
caused by the NP and is not merely a consequence of assay interference.115, 118, 119 Therefore 
appropriate controls should be introduced: besides a negative (no treatment) and positive 
(maximum effect) control, the positive control should be tested in combination with the 
NPs. Test reagents should also be incubated with the NPs to rule out any possible interaction 
with its components.64 Furthermore, every single parameter should ideally be evaluated 
with multiple assays, which supply complementary information and have a different assay- 
and detection principle, to validate the obtained results.120  
Finally, strategies to determine cellular uptake levels and intracellular localization are 
correlated to the type of NP tested and may therefore differ for different types of NPs. 
However, adapting a NP to enable detection by a specific technique may not be the most 
suitable approach, as linking a fluorescent probe to the particle may influence the formation 
of the protein corona or the NP-biomolecule interactions and therefore alter its behaviour 





d. Shortcomings to classical 2D monocultures 
Regarding the cell models applied for nanosafety testing, the most frequently applied 
monocultures are static models with a reduced level of complexity in contrast to the 
complex and dynamic in vivo environment and therefore show several important 
shortcomings.30, 121 Importantly, the cell model determines in which state 
((un)differentiated, (un)polarized) the cells are exposed to the NPs as well as the contact 
time, which can in turn influence the nanosafety profile.  
For most in vitro assessments a single cell type is selected to represent the desired target 
organ in an attempt to predict an in vivo effect.37 Hereto, most often the parenchymal cell 
type is selected, which can in turn be represented by either a (cancer or long-lived) cell line 
or primary cells. Of note, this first selection has already been shown to influence the 
nanosafety profile since several groups have shown that NP-induced effects differ in 
different cell lines or primary cells representing the same tissue.122-124 Variations between 
culturing methods and extensive in vitro culturing can furthermore affect the phenotype and 
potentially influence the cell-NP interactions, but such factors are often overlooked during 
data interpretation. An important example is the use of antibiotics in culture media to 
prevent bacterial contamination since their presence has been reported to alter the cell 
biochemistry.125   
Since organs consist of multiple differentiated cell types, all with their specific function, 
modeling the in vivo response by using a single cell type is furthermore nearly impossible.126 
Hence, the impact of intercellular communication between different cell types cannot be 
taken into account in such simplified models, which is believed to be a major factor 
contributing to the large discrepancies between in vitro and in vivo data (Section 5). 
Next, most studies apply monolayer cultures or cell suspensions for their nanosafety 
assessment. However, these 2D cultures generally fail to reproduce cell polarization, 
differentiation and specific architecture as observed at the organ level (Section 6). In 
addition, the extracellular matrix (ECM) produced by cells in a monolayer is less dense and 
incomplete in comparison to the one found in vivo.127 This ECM is a very important factor as 
it is a key regulator in homeostasis and phenotype expression and forms a natural barrier 
with small pores, limiting NP diffusion into the tissue.128 
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Taken together, oversimplified 2D models fail to reconstitute the in vivo microenvironment 
as they offer a reductionist approach with spatial limitations leading to expression of a 
different cellular phenotype and consequently to the vast in vitro-in vivo gap.129  
e. Standardisation of in vitro nanotoxicology methods 
Given the many shortcomings mentioned in the previous sections, we believe that in vitro 
nanosafety assessments would tremendously benefit from a standardization of the entire 
testing paradigm. Regarding NP characterization, we previously mentioned the need of 
standardization of both the parameters to be evaluated as well as the methods through 
which this should be performed. Subsequently a consensus should be reached on how NP 
dispersions in relevant exposure media should be prepared. Various groups simply disperse 
the NPs in the culture media and let agglomeration and/or aggregation take its course, 
whereas others by numerous means try to avoid such events. Hereto, surface modification, 
addition of surfactants or methods like sonication are applied but were in turn shown to 
influence the nanosafety profile.130-132 For instance, altering the duration and intensity of 
sonication affects the physicochemical properties and dissolution kinetics of copper oxide 
NPs and subsequently their toxicity profile.133 In addition, results from a study by 
Oberdörster et al. using surfactant stabilized dispersions have been put to question since the 
observed toxicity might have been caused by surfactant residuals.134 We believe that it is 
better not to alter the dispersion state and to strive for a medium resembling the in vivo 
tissue microenvironment as close as possible to mimic relevant exposure scenarios.135, 136  
In a next step, attention should be paid to standardization of incubation conditions, as 
overexposure levels should be avoided. The importance thereof becomes clear when 
evaluating genotoxicity for example: acute toxicity at overexposure conditions can 
mistakenly be interpreted for genotoxicity since apoptosis is associated with DNA 
fragmentation.137, 138 Therefore, genotoxicity and other effects on cell homeostasis should 
be evaluated at sublethal doses. In addition, the determination of relevant dose ranges is 
severely hampered by the lack of exposure data and doses required for specific applications. 
Therefore, in vitro nanotoxicity testing currently focuses on the determination of the No 
Observed Adverse Effect Level (NOAEL) values instead of evaluating realistic exposure 
scenarios or dosages.37 Furthermore, nanosafety should be evaluated of functional NP 





With regard to incubation conditions, several treatment regiments should be defined to 
mimic acute and long-term exposure, as different toxicity profiles have already been 
obtained for both exposure regiments.140 
Nanosafety testing should additionally look beyond live/dead scoring in order to develop a 
more predictive paradigm towards adverse in vivo outcomes. Hence, a shift could be 
observed towards the evaluation of cell function and effects on cellular homeostasis at 
sublethal NP doses.141, 142 In this regards, we believe that the interstudy comparability could 
be increased by a standardization in terms of which assays should be applied as well as at 
which time points evaluation should be performed. Ideally, several assays would be applied 
to assess the same parameter to improve the robustness of the assessment.120 In addition, 
the selected parameters should be evaluated over an extended time course to obtain 
information on possible long-term effects of NP exposure.61, 143 
Finally, we believe that the applied cell models should be standardized. We propose to 
define a set of cell lines representing different organs for screening purposes, whereas more 
intricate models should be applied for thorough in vitro nanosafety assessments. When 
applying cell lines, researches should furthermore avoid to evaluate NP-cell interactions in 
cells showing senescence due to extensive passaging in vitro. Besides, the cell phenotype 
may alter due to extensive in vitro culturing. Hence, cells should be characterized prior to 
the nanotoxicity study to ensure the quality of the cell model. Finally, cell culture 
parameters should be standardized as the application of distinct culture media, whether or 
not containing antibiotics, may alter the phenotype and heavily impact the outcome of 
nanotoxicity evaluations. Overall, all culture parameters that could potentially influence the 
outcome (cell seeding density, culture medium composition, etc.) should be defined to 
counter the generation of conflicting results. 
In conclusion, further research regarding method optimization of the entire in vitro 
nanosafety testing paradigm is highly recommended in order to obtain reproducible data 
that would allow to draw firm conclusions regarding NP toxicity. 
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2.2.3. Novel methods for toxicity testing  
In order to overcome certain shortcomings as well as to meet emerging challenges, several 
novel methodologies were developed in the last few years, of which an overview is provided 
in this section.  
a. Particokinetics 
NP dosimetry poses challenges in terms of the selection of the proper dose metric. In 
addition, it has been proposed that the dose to which the cells are exposed is not necessarily 
correctly represented by the initial concentration of the NP dispersion due to events as NP 
agglomeration and/or aggregation and subsequent sedimentation. To meet this challenge, 
Teeguarden et al. proposed the concept of particokinetics to model the solution dynamics of 
the NPs.110 They marked diffusion, sedimentation and aggregation as predominant processes 
determining the NP dispersion. Additionally, they suggested a distinction between the 
administered, delivered and cellular dose respectively being the dose added to the cell 
culture, the dose reaching the cell surface and the dose reaching the interior of the cell 
(Figure 5.1). The latter is the most interesting for nanosafety studies but is also the most 
difficult to determine. They proposed to calculate the delivered dose combining the 
administrated dose and the NPs particokinetics.110 Recently the initial model was optimized 
and is now referred to as the In vitro Sedimentation, Diffusion and Dosimetry model 
(ISDD).144 However, some debate on the applicability of the model remains, as it has been 
stated that the calculated doses will be underestimated for monodisperse NP suspensions 
since ISDD does not take convectional forces that develop in most solutions into account.145 
In contrast, Ahmad Khanbeigi et al. found measured cellular doses to correlate well with 
computed delivered doses for several NPs in various exposure conditions, indicating the 
applicability of the model.146 
 
Figure 5.1. Schematic representation of the concept of administered dose (A), delivered dose (B) and 






b. Label-free methods 
One of the major drawbacks of classical toxicity assays is the possible interference of the NPs 
with either the assay components or the read-out. Hence, label-free methods have been put 
forward as an alternative to evaluate nanotoxicity in vitro. Here, the read-out is based on 
physical qualities, such as impedance, refractive index and viscoelasticity.147 Since label-free 
methods are non-invasive, there is no need to sacrifice the cells to perform the end-point 
measurement as is the case for biochemical methods. Thus, label-free methods allow 
continuously monitoring the cellular response and establishing the dynamics of cell-NP 
interactions.148, 149 Such techniques typically allow evaluating parameters that are related to 
cell adhesion, such as cell proliferation, viability, morphology, migration and detachment. In 
contrast, label-free methods are not able to provide information on the mechanism through 
which NPs induce adverse events. Several label-free methods were developed over the past 
few years and are extensively reviewed elsewhere.147  
A popular example of a label-free method is electro-chemical impedance sensing. Here, cells 
are cultured on culture plates with integrated microelectrodes, which continuously measure 
the electrical impedance signal.150 This method is mainly applied to evaluate acute 
cytotoxicity but can also provide information on cell morphology.147 In the last few years, 
several groups found good correlations between impedance-based acute toxicity 
measurements and data obtained with classical cell viability assays for different NPs in 
various cell types, underscoring the broad applicability of this method.148, 149, 151 In addition, 
real time cell analyzers can be applied in a high throughput setting,149, 151 which makes this 
method a good candidate for initial large scale safety screenings to identify the least acute 
cytotoxic NPs for a certain application.  
c. Multiparametric nanosafety evaluation 
Since it was observed that NPs can cause multiple effects via different mechanisms, 
awareness has risen on the necessity to evaluate nanotoxicity in vitro by a multiparametric 
method.91, 152 Endpoints such as acute toxicity, ROS induction, morphological alterations, 
genotoxicity and NP degradation have been put forward as important parameters that 
should be included.45, 120, 153 Even though no consensus on the optimal design of this 
multiparametric method has been reached yet, several examples have been proposed 
recently.64, 152 We believe that methods to evaluate the effect on cell homeostasis should 
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preferably be biochemical or microscopy-based assays, as they are easily amendable for a 
screening approach.120 Most importantly, positive and negative controls should be included 
during analysis and toxicity thresholds must be defined to allow appropriate interpretation 
of the observed effects. In addition, such schemes require the definition of and 
extrapolation to potential in vivo adverse events.  
d. Screening approaches 
Despite many recent efforts in the field of nanotoxicology, this discipline is not yet able to 
keep up with the tremendous pace of the development of new nanomaterials. In order to 
overcome this impediment, several groups have proposed to apply high throughput or high 
content screening approaches to assess nanosafety.45, 149, 154 The use of screening techniques 
is imperative to enable simultaneous testing of multiple doses in different cell types by using 
various assays in a reasonable amount of time.120, 153 When combined with a 
multiparametric approach, high content imaging is a highly promising tool as it allows the 
extraction and evaluation of multiple parameters simultaneously in thousands of cells for 
every evaluated condition.155, 156 Consequently, such techniques can be implemented for NP 
toxicity fingerprinting as well as to prioritize NPs for in vivo evaluations.154 Finally, several 
groups also suggest the implementation of omic-techniques to screen for genotoxicity, 
alterations in protein expression or biomarkers related to cellular pathways.92, 157 
e. Assessments at single cell level 
Most assays and techniques provide a single end point value for the entire cell population. 
However, it has been shown that NP uptake is often not homogeneous. In contrast, NP 
uptake can vary quite extensively between different cells in the same population depending 
on the size of the cell, the cell cycle phase during NP contact and on the NP agglomeration 
state.158, 159 The recently developed high content techniques have enabled the analysis of 
cell-NP interactions at the single cell level, which showed that the evoked responses can be 
correlated to the intracellular NP dose.158, 159 For instance, Manshian et al. divided the cells 
into different groups based on the intracellular QD dose and obtained different cellular 
responses in these groups. Low intracellular doses could be correlated with cytoprotective 
events, whereas cells with a high QD loading experienced cytotoxicity, which combined lead 





f. QSAR and in silico models 
Screening approaches will generate a vast amount of data at a high pace, causing the 
bottleneck of nanotoxicity testing to shift from the assay execution to data processing. 
Therefore bio-informatics are gaining importance as automated data analysis will be 
necessary to keep up with the rapidly evolving field of nanotechnology.160  
A popular subject in bio-informatics is the setup of an in silico approach to nanotoxicity with 
the development of quantitative structure-activity relationships (QSAR) as the ultimate goal. 
These QSARs will in turn allow the prediction of the toxicity of newly engineered NPs based 
on their physicochemical properties, enabling an even faster evolution of nanotechnology 
through a safety-by-design approach.160 The development of in silico models and HCS go 
hand in hand as on the one hand the development of a reliable in silico model requires a 
large amount of data, which can be provided by HCS and bio-informatic tools are on the 
other hand indispensable for an efficient processing of HCS data.160 Recently, Puzyn et al. 
developed a QSAR that predicts the toxicity of metal oxide NPs in E. Coli based on the effect 
of 17 different metal oxide NPs.161 However, many obstacles still need to be overcome 
before the implementation of the first QSAR that allows the prediction of the adverse effects 
of any NP towards human health. Therefore, clear correlations between the NPs 
physicochemical properties and observed effect must be found, large-scale comparative 
studies should be performed and the QSARs must be validated, which requires the 
identification of reference nanomaterials with well-known effects.45, 91  
3. THE NATURE OF CELL TYPE-DEPENDENT EFFECTS 
In vitro studies are mostly performed on cancer cell lines or long-lived cell lines, as these are 
readily available, relatively inexpensive and easy to cultivate due to their enhanced 
proliferative capacity. Yet, it is known that cancer cells have a disturbed apoptotic balance 
and a higher metabolic activity to sustain their high proliferation rate.162 Overall, cancer cells 
express an altered phenotype compared to primary cells characterized by a loss of normal 
cell features, enlarged irregular nuclei, a small cytoplasmic volume and an irregular cell size, 
shape and arrangement.163 Long lived cell lines in turn express a phenotype that is not 
entirely stable, as changes may have been induced intentionally during their immortalization 
or unintentionally by the long cultivation time and extensive in vitro manipulation.164, 165 
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These alterations may include changes in cellular homeostasis, growth potential, biological 
responses, signal transduction etc. Hence, doubts have been raised on whether these cell 
lines are a reliable representation of the in vivo situation and on their usefulness for general 
in vitro nanosafety evaluations. Subsequently, the use of primary cells or stem cells has been 
put forward as an alternative since it is assumed that these cells mimic the in vivo cellular 
situation more closely.165, 166 However, these cells are not always easily obtained and require 
specific handling, making them a less suitable cell model for screening approaches. In 
addition, primary cells may in turn suffer from batch-to-batch differences, which could lead 
to a reduced reproducibility that is not an issue for cell lines. The use of pooled stocks may 
be a good strategy to overcome these interbatch differences and allows taking 
interindividual variations into account, which is in turn not possible when applying cell lines. 
This section summarizes several studies that verified whether various cell types differ in 
their way of handling administered NPs in terms of NP uptake and cytotoxicity. 
3.1. Effect of the cell type on nanoparticle uptake and processing 
Most NPs enter the cell through the process of endocytosis. Some exceptions can be found 
as for phagocytic cells phagocytosis remains the main uptake mechanism.167 Wang et al. 
furthermore observed QD uptake by passive diffusion in red blood cells.168 But this must be 
put into perspective, as red blood cells are not capable of endocytosis.  
The uptake mechanism is highly important as it determines the intracellular location of the 
NPs. NPs entering the cell by passive diffusion will directly interact with the cytosol, while 
NPs taken up by endo- or phagocytosis are retained in vesicles, which can be distributed 
throughout the cytoplasm or localized in a specific cellular region.168, 169  
The uptake kinetics and intracellular location were compared in different cell types since 
they are important determinants for the final response. For example, the uptake of 1.9 nm 
diameter AuNPs was found to be higher in human prostate and breast cancer cell lines 
(DU154 and MDA-MB231) than in a human lung epithelium long-lived cell line (L132).170 Diaz 
et al. compared the uptake of five different NPs in normal human monocytes, lymphocytes 
and erythrocytes, mouse macrophages and four human cancer cell lines: a myeloid-
monocytic cell line (U937), a T-cell line (Jurkat), a B-cell line (HMY) and a prostatic cancer cell 





macrophages showed an even higher uptake, which was comparable to the uptake in PC3 
cells. The monocytic cell line did not show NP internalization, which is in conflict with results 
from other studies showing a higher uptake capacity for cancer cell lines.170-172 As all other 
cell types tested did not show significant NP uptake, the authors have put the phagocytic 
machinery in combination with the cell type forward as predominant factors for NP 
uptake.173 This is the general belief and is supported by several studies.174  
Regarding intracellular localization of the same particles in different cell types, widely 
varying results have been obtained. PEGylated micelles, for example, were shown to have 
similar distributions in a human lung cancer cell line and long-lived cell line (A549 and MRC-
5) and a human kidney epithelium long-lived cell line (293T).162 However, Barua and Rege 
observed significant variations in intracellular localization of QDs in three phenotypically 
closely related human prostate cancer cell lines (Figure 5.2). It was observed that the QDs 
were trapped in lysosomes scattered throughout the cytoplasm in PC3 cells, localized at a 
single juxtanuclear location in PC3-PSMA cells and a combination of both was found in PC3-
flu cells.175 They coupled these observations to (i) the loss of polarity in malignant cells 
influencing the sorting and trafficking potency of the cells, (ii) the slight differences in 
receptor expression profiles and (iii) a disruption of the microtubule network in PC3 cells 
impeding further trafficking to the juxtanuclear region.175 
It is clear that the cell type is an important factor to NP uptake, influencing both the uptake 
mechanism as well as the extent, with cancer cell lines mostly showing higher uptake levels 
when compared to uptake in long-lived cell lines and primary cells. Intracellular distribution 
also appears to be cell type dependent and has even been found to differ substantially 
between phenotypically closely related cell lines. Therefore these findings underscore the 
importance of selecting a representative cell type that mimics the in vivo situation as closely 
as possible, as toxicity is logically related to NP uptake, determining the cellular dose and 
location of the NPs. 
 




Figure 5.2. The effect of cell phenotype on NP processing as illustrated by the clear differential 
intracellular localization patterns of QDs in highly similar, but slightly differing human PC3 cells. (a) 
PC3, (b) PC3-flu, (c) PC3-PSMA. This figure is reproduced with permission from Barua and Rege.176 © 
Wiley-VCH 2009. 
 
3.2. Effect of the cell type on NP toxicity 
Only recently more awareness was raised on cell type-dependent effects being one of the 
factors leading to discordant in vitro nanotoxicity data. Since the use of cell lines for in vitro 
nanotoxicity assessment has been put to question, several groups compared the effects of 
NP exposure in cell lines to those in primary or stem cells representing the same tissue. In 
various cases, the primary cells and stem cells have been found to be less sensitive to NP 
toxicity than long-lived cancer cell lines.164, 176 For instance, Hanley et al. found two human 
T-cell lymphoma cell lines (Jurkat and Hut-78) to be respectively 28- and 35-fold more 
sensitive to ZnONP exposure than human primary T-cells (Figure 5.3A).177 In contrast, Bregoli 





after antimony oxide NP exposure while the proliferative capacity of none of the seven 
hematopoietic (cancer and long-lived) cell lines tested was affected.165 Likewise, three 
independent groups found normal bronchial epithelial cells to experience more acute 
toxicity following NP exposure than the A549 cancer cell line or 16HBE immortalized cell 
line.122-124 In contrast, Kermanizadeh et al. found similar responses to different NPs in both 
primary human hepatocytes and the hepatoma C3A cell line, indicating that certain cell lines 
can be applied to model nanosafety.178 Hence, this body of data warrants the careful 
selection of a cell model and a case-by-case evaluation of the applicability of a certain cell 
line. 
 
Figure 5.3. The effect of cell phenotype on NP toxicity as illustrated by (A) differential viability after 
ZnONP exposure of Jurkat and Hut-78 cancer cell lines and normal human T lymphocytes and (B) 
differential viability after ZnONP exposure for unactivated and activated human T lymphocytes. This 
figure is reproduced with permission from Hanley et al.178 © IOP Sciences 2008. 
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As the focus of in vitro toxicity testing is shifting to the use of primary cells, it was put to 
question whether cellular differentiation has an influence on the induced toxicity. Several 
studies show a higher sensitivity towards nanotoxicity for differentiated cells, which can be 
explained by the fact that undifferentiated cells adapt better to new conditions than 
differentiated cells.179, 154 Accordingly, Saretzki et al. found the stress defence mechanism 
(antioxidant capacity and DNA repair mechanism) in murine embryonic stem cell to be 
superior to that of various differentiated murine cells (fibroblasts, hematopoietic progenitor 
cells and 3T3 fibroblast long-lived cell line).180  
A number of groups furthermore tried to elucidate the mechanisms causing various cell 
types to react differently to NP exposure. First of all the physiological cell function appears 
to be important. For instance, macrophages and monocytes are involved in the clearing of 
xenobiotics as they can ingest many compounds in high quantities by phagocytosis, which 
explains the higher uptake levels and susceptibility to nanotoxicity.173, 174, 181 A second factor 
is the variation in proliferative capacity of different cell types: rapidly proliferating cells can 
experience less toxicity due to the fast dilution of the cellular NP contents with every cell 
division. Indeed, Chang et al. found three epithelial cancer cell lines (A549, MKN-28 and HT-
29, average doubling time 23h) to be less prone to silica (SiO2)NP-induced injury than three 
long-lived fibroblast cell lines (WS1, CCD-966sk and MRC-5, average doubling time 128.4h). 
This was explained by the higher cell division rate of the former and the associated dilution 
of cellular NP levels.182 Additionally, NP uptake depends on the cell cycle phase, being 
maximal in the G2/M phase. Therefore, rapidly proliferating cells may experience more 
cytotoxicity due to higher NP uptake levels. This was demonstrated by Hanley et al. as 
activated primary human T lymphocytes showed a higher susceptibility to ZnONP-induced 
injury in comparison to resting human T lymphocytes due to the preferential targeting of the 
actively proliferating cells (Figure 5.3B).177 A final factor is intrinsic variations between cell 
types such as their natural anti-oxidative capacity. For instance, Mukherjee et al. accounted 
the stronger ROS induction and GSH depletion by AgNPs in HeLa cells compared to the 







Overall, the response to NP exposure is highly cell type-dependent and the observed 
differences in sensitivity may largely be explained by variations in cell function influencing 
NP uptake, metabolic activity, natural antioxidant activity and proliferative capacity. These 
data underscore the importance of selecting a relevant cell system for NP hazard 
assessment, which is a balancing act since both primary cells and cell lines show specific 
advantages and major shortcomings. Therefore, further research is needed in order to 
determine proper cell models and according cell culture protocols.  
4. THE EFFECT OF NP AGGLOMERATION AND SEDIMENTATION  
Initially it was assumed that the NP dose to which cells are exposed, is accurately 
represented by the concentration of the NP dispersion since NPs were believed to be evenly 
dispersed by Brownian motion.34 This appeared not to be true, as NPs in dispersion are 
additionally subject to agglomeration or aggregation and sedimentation.110, 184 It is 
important to note the difference between agglomeration and aggregation since both terms 
are often confused: aggregates are formed by covalent bonds and are therefore not as easy 
to break as agglomerates, which are held together by van der Waals forces, hydrophobic 
interactions and/or hydrogen-bonds.185 The formation of agglomerates originates from the 
pursuit of a state with a lower free surface energy and is strongly promoted by the 
hydrophobic nature of most NPs.173, 185 Thus, agglomeration occurs in media when attractive 
forces overpower the electrostatic or steric repulsion between NPs.186 Since both diffusion 
and sedimentation are influenced by agglomeration, the latter is expected to have a major 
impact on NP uptake and toxicity.187 Therefore the concept of dose is more complex and 
dynamic for NPs and requires the modeling of the NP behavior in dispersion.110, 144 
Several NP- and medium-related factors have been shown to influence NP agglomeration. 
Parameters in the first category are the NP surface charge, size and shape. For example 
nanorods and –fibers agglomerate more easily than spheres and smaller NPs typically 
aggregate more than their larger counterparts at similar mass doses, which can be explained 
by the higher number density.188, 189 Several medium-related parameters like pH, salt 
composition and ion concentration were also suggested to potentially influence NP 
agglomeration.186, 190, 191 Additionally, the presence of proteins has been shown to be a very 
important factor.186 Yet, its effect on NP agglomeration is not fully understood as several 
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groups obtained conflicting data, showing either less or more agglomeration in serum 
containing media.192, 193 However, several groups recently showed that mixing the NPs with 
serum protein prior to the addition to culture medium, stabilizes the final NP dispersion.184, 
194, 195 
It is crucial to take the influence of NP agglomeration on diffusion and sedimentation and 
subsequently on NP uptake and toxicity into account when evaluating nanosafety. Certainly 
since agglomerates or aggregates show altered kinetics when compared to their single NP 
counterparts with the same size.186 However, evaluating NP agglomeration in the applied 
cell medium or biological fluid is not an easy task. Dynamic light scattering is a commonly 
used technique but is limited to samples in simple or diluted media as other light scattering 
components, such as serum proteins, can interfere with the measurements.196 To overcome 
these obstacles, alternative methods have been put forward, such as the use of fluorescence 
correlation spectroscopy or fluorescent single particle tracking, which allow the accurate and 
precise determination of the size distribution of fluorescent NPs in undiluted biological 
fluids.196, 197 Additionally, UV spectroscopy can be applied to evaluate the dispersion state of 
NPs with a surface plasmon resonance.194 
This section provides an overview of studies evaluating the influence of NP sedimentation on 
uptake and toxicity as well as innovative setups to avoid the effect of sedimentation during 
in vitro nanosafety assessments. 
4.1. Effect of nanoparticle agglomeration and sedimentation on NP uptake 
Several studies showed that the impact of agglomeration is not straightforward, as 
aggregates show either enhanced or impeded uptake when compared to single NPs.188, 189, 
192, 194, 195 The higher uptake levels for aggregates can be explained by the fact that they 
reach the cells more rapidly by sedimentation, while the transport rate of single NPs is 
limited by diffusion.189 In contrast, agglomerates have a fractal structure and thus a lower 
mass density compared to a solid NP of a similar size, which reduces the sedimentation rate 
and potentially NP uptake.144 Hence, agglomerates will not necessarily behave as a NP of the 
same size, further complicating nanosafety assessments.106 Indeed, Hirsh et al. found 65 nm 
AuNPs to be more rapidly and extensively taken up by HeLa cells than agglomerates at least 





than the cell itself, uptake is impeded by physical restrictions to the uptake processes.188, 192 
These observations support the assumption that larger aggregates do not enter the cell via 
the same mechanism as single NPs or small agglomerates, as most common endocytosis 
routes like clathrin- or caveolin-mediated endocytosis are limited to the uptake of materials 
with dimensions of maximally 120 nm.192  
From the available (conflicting) data it cannot be concluded whether single NPs or small 
agglomerates/aggregates are taken up to a greater or lesser extent, but we do hypothesize 
that following factors are equally important; (i) the extent of agglomeration/aggregation, (ii) 
the size and density of the NPs/agglomerates/aggregates and (iii) the cellular uptake 
mechanism. The extent of agglomeration and the size of the agglomerates will not only 
determine the rate of sedimentation, and hereby the rate of NP transport towards the cells, 
but also the way in which the cells will handle these materials. Non-specialized cells will 
typically prefer smaller NPs, while cells capable of ingesting larger materials will take up 
higher levels of agglomerates. As such, it is clear that agglomeration and sedimentation have 
an influence on NP uptake that cannot be neglected.  
4.2. Effect of nanoparticle agglomeration and sedimentation on NP toxicity 
Similar to NP uptake, the influence of agglomeration/aggregation on nanotoxicity is not 
straightforward. On the one hand, clear correlations have been found between NP 
concentration, aggregation, precipitation and cell injury for ZnONPs, QDs and carbon 
nanotubes (CNTs).36, 195, 198 On the other hand, several studies show reduced cytotoxicity for 
agglomerated NPs, due to the fact that smaller entities are in general taken up more avidly 
by non-specialized cells and more easily reach intracellular structures such as the cell 
nucleus or mitochondria, which are less accessible to larger NPs or agglomerates.188, 199, 200 
Yoon et al. further hypothesized that adherent cells might be more affected by NP 
deposition through sedimentation than cells in suspension and therefore compared 
aluminum oxide NP and agglomerate toxicity in suspension cells (THP-1) and three adherent 
cell lines (A549, 293T and J774A-1: a mouse macrophage cancer cell line). Toxicity was 
observed in the THP-1, A549 and 293T cell lines, but only in the A549 and 293T cell lines was 
time dependent toxicity witnessed that could be related to sedimentation of the 
agglomerates, which confirmed their hypothesis.201 Likewise, Anders et al. observed 
increased and reduced nanotoxicity in suspension and adherent cultures, respectively when 
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exposed to stable NP dispersions compared to dispersions containing agglomerates.195 In 
addition, agglomerate size is an influencing factor, as Sharma et al. found smaller IONP 
agglomerates to induce more severe effects than their larger counterparts at similar cellular 
mass doses.106 
These data highlight the influence of NP sedimentation on in vitro nanotoxicity studies and 
indicate that it can result in either underestimated or exaggerated toxicity estimations. 
Therefore, in order to reduce the in vitro-in vivo gap, there is a need for novel models in 
which the effect of NP sedimentation can be avoided. Such models should provide results 
that are more relevant to the applied NP dose rather than reaching unrealistically high cell 
exposure levels due to NP sedimentation.  
4.3. New model systems to minimize sedimentation effects 
Since sedimentation is not observed in vivo and was demonstrated to affect nanotoxicity in 
vitro, several groups have tried to develop novel model systems such as inverted cultures, 
flow models and microfluidic systems in which the influence of sedimentation can be 
reduced or completely avoided.  
4.3.1. Inverted models 
Cho et al. developed an inverted cell model in which they evaluated the influence of 
sedimentation on uptake of Au nanospheres, -cages and -rods in human breast cancer cells 
(SK-BR-3). This is an elegant and straightforward cell model in which sedimentation itself is 
not avoided but will not result in increased cellular exposure levels for cells that are cultured 
in the inverted configuration (cells grown on an insert at the top of the medium, facing 
downwards). The authors observed much more avid NP internalization in classical cell 
cultures in comparison to cells cultured in the inverted configuration (Figure 5.4). However, 
no variations were observed in toxicity: cell viability remained approximately 90% of the 
control values in all conditions tested, but this may be due to the type of material and the 
limited concentration range tested. Overall, the differential uptake in upright or inverted 
configuration depended on the NPs physical properties and was most distinct for NPs with a 







Figure 5.4. The effect of cell culture configurations (normal horizontal (= upright) versus hanging 
down (= inverted)) on the uptake of various types of NPs. Differential uptake of (a) 15 nm 
nanospheres (120 pM); (b) 54 nm nanospheres (20 pM); (c) 100 nm nanospheres (2.8 pM); (d) 62 nm 
nanocages (20 pM); (e) 118 nm nanocages (2.6 pM); and (f) nanorods (20 pM) in the upright and 
inverted configuration. This figure is reproduced with permission from Cho et al.34 © Nature 
Publishing Group 2011. 
 
4.3.2. Flow and microfluidic models 
More complicated models are flow or microfluidic systems where gravitational setting is 
impeded or even completely avoided. The applied flow also assists in acquiring a more 
homogeneous NP distribution and alters the cell-NP contact time.36, 121 Additionally, applying 
a flow implies the continuous renewal of culture medium, which ensures a sustained supply 
of nutrients and a constant pH.35 To us, the main advantage is that cells show a more in vivo-
like behavior as a laminar flow can activate endothelial cells and suppress proliferation, 
apoptosis and ROS induction.202 Cellular morphology is also altered as the shear stress (SS) 
induces elongation of endothelial cells in the direction of the applied flow and formation of 
actin stress fibers, which cluster around the nucleus to protect the cells from hemodynamic 
damage.202-204 Finally, Samuel et al. observed membrane blebbing under flow conditions, 
whereas cells under static conditions showed a smooth and flattened membrane.204  
Several groups compared NP uptake under flow and static conditions. Samuel et al. observed 
uptake of untargeted NPs in cells from a HUVEC cell line (CRL-1730) under flow conditions 
but not in the classical static 2D cultures. They also did not find any difference in NP uptake 
in activated or unactivated CRL-1730 cells.204 In contrast, most other groups typically found 
higher uptake levels under static conditions, due to the contribution of NP agglomeration 
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and sedimentation.203, 205, 206 In addition, most studies clearly show higher uptake levels for 
targeted NPs in activated endothelial cells.203, 204, 205 
Subsequently the influence of the level of applied SS on NP uptake was explored. Most 
studies found the highest uptake under the lowest SS, as NPs are more likely to sediment on 
top of the cells under these conditions, which prolongs the cell-NP contact time.207,208  
As uptake is significantly altered under flow conditions it is expected that the same will be 
true for nanotoxicity. On the one hand Mahto et al. observed significantly higher levels of 
QD toxicity in 3T3 fibroblasts in static configuration following a 12h exposure time: cells in 
static condition showed approximately 30% cell viability whereas the percentage of living 
cells under SS remained as high as 75% and significantly fewer cells were deformed or 
detached.35 Kim et al. on the other hand found significant levels of toxicity under high SS 
conditions whereas HUVECs under static conditions or low SS did not show significant 
toxicity after 2h exposure to unmodified SiO2NPs. They accounted this difference to the 
possible activation of the HUVECs under higher SS,121 while we believe that the shorter 
incubation time must also be taken into account.  
Interestingly the application of shear stress was also shown to alter NP agglomerate size and 
the polydispersity of the NP dispersion.209 Finally, Braun et al. reported that shear flow alters 
the protein corona as the protein concentration present on PEG- and tannic acid-coated 
AuNPs subjected to flow was increased with ˜25% compared to the protein corona present 
on the same NPs in the same medium under static conditions. This observation was 
explained by the increased possibility for NP-protein interactions leading to a greater 
number of proteins adsorbed onto the NP surface.210  
It is clear from these data that toxicity levels found in classical 2D monocultures are either 
exaggerated or underestimated in comparison to levels obtained from in vitro experiments 
where (the effect of) sedimentation is avoided. When NP toxicity is evaluated in a flow 
system an extra level of complexity is added as the induced SS has an impact on the NP 
dispersion characteristics, the protein corona and cell behavior, which in turn influence NP 
uptake and toxicity. It is observed that targeted NPs are taken up more avidly under flow 
conditions, while non-functionalized NPs show higher uptake under static conditions. 





this subject yet. However, as toxicity levels measured in these novel model systems 
significantly differ from those obtained from classical static 2D monocultures, which are 
believed to be less in vivo-like, we believe that flow models should be optimized and that 
their use should be promoted.  
5. THE EFFECT OF CELL COMMUNICATION 
Another important shortcoming of the monoculture model is the lack of intercellular 
communication. This crosstalk between different cell types is known to be vital in sustaining 
homeostasis and in complicated processes like the processing of xenobiotics, inflammation 
and immune responses. Such events can consequently hardly be accurately mimicked in 
simplified monocultures.211, 212  
Several groups have focused on establishing co-culture models in order to overcome this 
shortcoming and bridge the in vitro-in vivo gap. Multiple types of co-cultures can be set up 
representing various tissues. Here, two or more cell types are combined and cells can be 
cultured either in direct contact or be separated by culture inserts. Cells co-cultured on 
culture inserts show a more differentiated phenotype, develop tight and adherent junctions 
and are polarized, implying that the cells have an apical and basolateral membrane with a 
distinct composition.213, 214 Thus, these models mimic the in vivo environment more closely 
and are therefore assumed to have a higher predictive power. This section provides an 
overview of studies evaluating NP uptake and toxicity in these novel model systems.  
5.1. Effect of intercellular communication on NP uptake 
Since it is well known that the majority of the NPs are rapidly taken up by the reticulo-
endothelial system after intravenous administration, it was investigated whether the same 
trend could be observed in vitro in co-cultures of epithelial and phagocytic cells. Indeed, the 
highest and lowest uptake levels were respectively found in the macrophages and epithelial 
cells.215 Furthermore, Rothen-Rutishauer et al. evaluated uptake of polystyrene beads, 
AuNPs and TiO2NPs in a co-culture consisting of A549 cells, human monocyte derived 
macrophages (MDM) and human monocyte derived dendritic cells (MDDC). They observed 
preferential uptake of all NPs in the MDMs and the lowest uptake levels in A549 cells (Figure 
5.5). Compared to the MDDCs, uptake in MDMs was twice as high, which was explained by 
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its 2-fold greater phagocytic capacity.216 Likewise, when exposing mixed cultures of primary 
neural cells, microglia – the brain’s macrophages – were shown to preferentially internalize 
NPs.215 As previously mentioned, co-culturing cells can result in more differentiated and 
polarized cells that show a more barrier-like phenotype, which impedes NP uptake.213  
Overall, NP uptake is significantly altered in co-cultures with the two main factors 
determining NP uptake being (i) the level of cellular differentiation and (ii) the combination 
of cell types and their preferential uptake mechanism, especially when phagocytic cells are 
included.  
 
Figure 5.5. Preferential uptake of fluorescent polystyrene beads in human monocyte derived 
macrophages (MDM) in co-culture with A549 cells (EP) and human monocyte derived dendritic cells 
(MDDC). This figure is reproduced with permission from Rothen-Rutishauser et al.217 © Biomed 
Central 2007. 
 
5.2. Effect of intercellular communication on NP toxicity 
Many studies on co-cultures apply models representing alveolar tissue since the lung is 
expected to be one of the major target organs for NP-induced toxicity following the 
inhalation of airborne NPs. In this regard, particulate matter (PM10) treatment was shown to 
cause a co-culture to secrete more cytokines than the sum of the cytokine secretion 
observed in the corresponding monocultures.217, 218 This increased cytokine production can 
in turn render cells more susceptible to NP-induced damage. For instance, Kim et al. 
observed that the NP-induced tumor necrosis factorα (TNFα) release by RAW264.7 cells in a 
RAW264.7/MLE12 (murine alveolar long-lived cell line) co-culture rendered this co-culture 






Another popular co-culture model consists of alveolar epithelial and microvascular 
endothelial cells to mimic the air-blood-barrier. Culture inserts separate the two cell types 
and only the epithelial cells (representing the apical membrane) are typically exposed to 
NPs. Various studies revealed that this type of co-culture is more resilient towards 
nanotoxicity in terms of acute toxicity but shows an increased inflammatory response.213, 214, 
220 In turn, Ramos-Godinez et al. did not find any changes in cytokine release by a 
A549/HUVEC co-culture due to TiO2NP exposure. However, HUVECs from the co-culture did 
show a significant increase in adhesion molecules, a 3 to 4-fold increase in monocyte 
adhesion and a 2-fold increase in nitric oxide production. These results were comparable to 
HUVECs directly exposed to NPs, implying that endothelial cells were activated via 
intercellular communication.221 Recently, this phenomenon was confirmed by Sisler et al. 
who observed actin remodeling, ROS induction and inflammation in HMVEC cells following 
NP exposure of the co-cultured small airway epithelial cells.222 Importantly, in none of these 
studies the NPs were found to cross the culture insert, possibly due to the barrier formed by 
the epithelial cells or NP agglomeration, confirming that endothelial cells were activated 
through intercellular communication after NP exposure of the epithelial cells.  
The activation status of macrophages in co-culture has also been shown to influence 
nanotoxicity: non-activated macrophages act as a reservoir, thus performing a protective 
function, while activated macrophages elicit secondary toxicity in the accompanying cell 
type via cytokine secretion.223, 224 According to van Berlo et al. the protective or aggravating 
effect towards NP toxicity furthermore depends on the combination of cell types as they 
found macrophages to protect A549 cells against oxidative DNA damage whereas the 
neutrophils aggravated the effects.225  
The complexity of the model can further be increased via the introduction of additional cell 
types. For example, Alfaro-Moreno et al. evaluated the effects of PM10 in several 
combinations of cell lines: A549/HMC-1, THP-1/HMC-1, A549/THP-1/HMC-1 and A549/THP-
1/HMC-1/EAhy296. They found that all cultures had a distinct cytokine excretion profile with 
the cytokine production being either amplified or mitigated in co-culture, which was 
confirmed by Napierska et al.226, 227 This was explained by the differential expression of cell 
surface receptors depending on the cell type or changes in crosstalk between the cells by 
adding of an extra cell type.226 Besides the cytokine excretion, Müller et al. also found the 
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total antioxidant capacity to be modulated in an A549, MDC and MDDC co-culture.228 Finally, 
Clift et al. investigated the effect of CNT on 16HBE, MDM, MDDC monocultures and their 
triple culture. They found the TNFα secretion to be highest in both MDM and MDDC 
monocultures, the interleukin (IL)8 secretion to be less pronounced in the 16HBE 
monoculture than the triple culture and the effect on ROS production to vary in all four 
models.229 
Besides models representing the lung, additional co-culture models were established to 
mimic various tissues or barriers. For instance, Lui et al. combined HUVEC and THP-1 cells 
and found the NP-exposed co-culture to secrete higher cytokines levels than the 
monocultures and found the monocytes to activate the HUVECs, concurrent to observations 
in the lung.230 In turn, Xu et al. modeled the blood brain barrier (BBB) through the 
combination of primary rat microvascular endothelial cells, pericytes and astrocytes. Upon 
exposure to AgNPs, they observed an increased blood brain barrier permeability, reduced 
gap junctions, a reduced anti-oxidative capacity, an inflammatory response and apoptosis.231 
The gastro-intestinal (GI) tract can furthermore be modeled by combining the Caco-2/TC7 
and the mucus secreting HT29-MTX colon carcinoma cell lines. The mucus was shown to 
have a protective effect towards NP-induced damage and the co-culture again responded 
differently towards AgNP exposure than the corresponding monocultures.232 Additionally, 
Walczak et al. applied the Caco-2 cell line as a monoculture and in co-cultures combined 
with HT29-MTX alone or HT29-MTX and M-cells to evaluate NP translocation. The secreted 
mucus in the Caco-2/HT29-MTX co-culture reduced NP translocation whereas results from 
the triple and monoculture were quite similar.233  
In summary, cells respond differently to NP exposure in a mono- or co-culture setup. Apart 
from some exceptions, co-cultures are generally found to be more resilient to acute toxicity 
but show a significant increase in cytokine release, indicative of an inflammatory response. 
Hence, co-culture models allow the study of effects that could not be picked up in 
monoculture experiments. However, given that the observed effect depends on the applied 
combination of cell types and can be altered by the addition of an extra cell type, 
standardization is required. In addition, the predictive power of these models should be 
confirmed, certainly since Braakhuis et al. unexpectedly found the best correlation with in 





6. THE EFFECT OF A 3D ENVIRONMENT 
The loss of the specific 3D tissue architecture and cell polarization is a final major 
shortcoming of monocultures. This can be overcome by applying 3D cultures, where cells 
show a more in vivo-like phenotype as well as ECM production. Additionally, the cell-cell and 
cell-matrix communication is promoted due to the tighter packing of the cells in a 3D setup. 
In turn, the enhanced communication influences a number of important cellular functions 
such as migration, invasion, proliferation, apoptosis and differentiation.235 Consequently, 
cells cultured in a 3D setup are able to acquire tissue-like organization and differentiation to 
levels that have thus far been impossible to reach in a classical 2D setting.129, 236 Thus, 
cellular responses to NP exposure in a 3D model are expected to be significantly different 
from those observed in a monolayer culture.127  
Furthermore, the cultivation time of cells in 3D models can be prolonged, which enables 
long(er)-term in vitro experiments.237 Hence, 3D models allow the evaluation of cumulative 
effects of repeated NP exposure, which is less feasible in 2D cultures since cells do not 
survive longer cultivation periods, dedifferentiate or rapidly divide causing dilution of the 
NPs and an associated dilution of possible effects. 
A number of 3D systems have been developed of which the multicellular spheroid models, 
mimicking solid tumours, are most widely used. Another approach is the use of natural or 
synthetic hydrogels as a scaffold in which cells can be seeded.238 However, hydrogel-based 
scaffolds are likely to be less useful for nanosafety studies as thick scaffolds may limit NP 
diffusion towards the cells. The recent use of 3D models to assess nanosafety is discussed in 
this section.  
6.1. Effect of a 3D environment on NP uptake 
Since cells cultured in spheroids are known to produce a more dense and complex ECM, 
several groups compared NP uptake in a 2D and 3D setting. In comparison to classical 2D 
monocultures where NPs are taken up by all cells, an uneven distribution and limited 
penetration is obtained in spheroids.235, 239, 240 Consequently, NP uptake is generally lower 
and found to be restricted to the peripheral layers of the spheres.235, 240 An interesting study 
by Huang et al. compared 2, 6 and 15 nm AuNP uptake in an MCF-7 monolayer, spheroid 
model and mouse breast tumors in vivo. The spheroids and tumors showed similar trends in 
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tissue penetration as 2 and 6 nm NPs could penetrate the deeper regions of the cell mass, 
but 15 nm NPs were only found in the periphery. In contrast, all NPs were evenly distributed 
throughout the monolayer.241 Thus, NP distribution is generally less homogeneous in 3D 
cultures and the ECM hampers NP penetration into a 3D matrix. This limits NP uptake to the 
cells in the peripheral layers of the 3D culture, especially for larger NPs.  
6.2. Effect of a 3D environment on NP toxicity 
Subsequently, several groups compared NP-induced toxicity in 2D and 3D cultures. In 
general, the toxicity induced by NP enclosed anti-cancer agents was found to be significantly 
lower (5- to 20-fold) in spheroid models than in the classical monolayer.235, 239 Concurrently, 
various groups confirmed that this paradigm also accounts for inorganic NPs, as for instance 
CdSe/ZnS QD-, IONP- and SiO2NP-induced toxicity in HeLa microspheres was radial and lower 
in the 3D setup.128, 240, 242  
In one of the first studies using 3D models for nanotoxicity purposes Lee et al. evaluated 2.9 
nm QD and 3.5 nm AuNP toxicity in HepG2 2D and spheroid cultures and found a 
substantially lower toxicity in the latter. The number of dead cells was significantly lower in 
the 3D setup and most dead cells were found in the periphery of the sphere, creating a 
rugged surface (Figure 5.6). Longer exposure times induced more severe damage to the cells 
in periphery of the sphere while the interior remained unimpaired. When the same 
incubation conditions were applied to 2D cultures, they overall observed more cell death 
(Figure 5.7). The core of the sphere remained unaffected due to the protective effect of the 
barrier created by the ECM and the dead cells remaining on the exterior of the sphere due to 
the initial tight packing, thereby temporarily enhancing the efficiency of the barrier.243 Chia 
et al. obtained similar results upon exposing a colon cell spheroid culture to ZnONPs. 
However, they noted only a temporary protective effect of the outer layer consisting of the 
ECM and dead cells.244 In addition, they observed different modes of ZnONP-induced cell 
death for cell cultured in a monolayer or a spheroid and the cytokine production by the 
outer cells of the sphere was shown to induce an inflammatory response in the core cells.244 
In correspondence to many studies, AgNPs, SiO2NP and ZnONPs induced more severe 
toxicity in a 2D HepG2 culture. Of note, the outcome in the 3D model depended on the 
matrix material applied to create the spheroid culture, as for all NPs tested HepG2 cells in 





warrants the need for further optimization of 3D spheroid models as well as the 
confirmation of the predictive value towards in vivo adverse outcomes. 
 
Figure 5.6. The effect of NP toxicity in both a 2D and 3D cellular environment. Confocal images of 
live/dead (red)-stained normal (E) 2D and (G) 3D spheroid cultures and after QD exposure in (F) 2D 
and (H) 3D spheroid cultures. This figure is reproduced with permission from Lee et al.243 © Wiley-VCH 
2009. 
 
Figure 5.7. Effect of NPs on cell morphology on 2D and 3D cell cultures. SEM images of 2D and 3D 
spheroid cultures before and after CdTe QD exposure. Typical morphology of (A) 2D and (D) 3D 
spheroid cultures after 5 days without CdTe QD exposure. Representative morphology of (B) 2D and 
(E) 3D spheroid cultures after 12 h of CdTe QD treatment. Morphological change of (C) 2D and (F) 3D 
spheroid cultures after 24 h of CdTe QD exposure. This figure is reproduced with permission from Lee 
et al.243 © Wiley-VCH 2009. 
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In conflict with most observations, Sambale et al. did not observe significant differences in 
ZnONP-evoked cell injury in NIH-3T3 spheroid cultures. Additionally, A549 spheroids were 
more severely affected than the corresponding monolayer, which was explained by the 
loose confirmation of the spheroid.245 Likewise, Yu et al. found 5 and 30 nm IONPs to cause 
more severe toxicity to porcine aortic endothelial cells in a 3D alginate matrix than in a 
conventional monolayer. However, it must be noted that cells were unable to divide once 
added to the matrix while cells in 2D culture retained their proliferative capacity. Since 
toxicity was measured after 72h exposure time, cells in 2D cultures were likely to be exposed 
to lower IONP doses as the NPs were diluted upon cell division. This protective effect was 
likely to be impeded in the 3D setup, possibly causing the cells to show higher stress levels 
and toxicity.246  
In conclusion, culturing cells in a 3D setup has a major influence on the phenotype and cell 
function and provides different insights on NP-induced damage, which could not be 
retrieved from the corresponding monolayer cultures. Importantly, most studies show 
hampered NP penetration through the ECM barrier and altered cellular uptake. 
Subsequently, toxicity is generally less pronounced and limited to the outer layers of the 
sphere. Overall, we believe that the development of 3D models is a recent milestone in 
bridging the in vitro-in vivo gap and that these models are likely to gain importance in the 
coming years.  
7. ALTERNATIVE CELL MODELS 
Since the cell model was shown to have a major impact on nanosafety studies, alternative or 
even more complex cell models were recently applied, of which several examples are 
discussed in this section.  
Susewind et al. developed a 3D co-culture model that represents the intestinal mucosa. 
Hereto the THP-1 and MUTZ-3 (human dendritic cells) cell lines were cultured in a collagen 
scaffold which remained separated from the Caco-2 cell line via a Transwell insert. They 
observed less acute toxicity and increased IL8 release in the 3D co-culture model than in the 
corresponding monocultures, which is in line with previously discussed results.247 In turn, 





achieve a 3D orientation. Uptake of aerosolized SiO2NPs at the air-liquid interface was only 
observed in the THP-1 cells and ROS levels were significantly lower in their model compared 
to the respective monocultures.248 Furthermore, the lung can be represented by the 
commercially available human primary bronchial epithelial 3D MucilAirTM model. CeO2NP 
uptake in this model was found to be hindered by the presence of respiratory mucus due to 
NP aggregation and NP removal by mucociliary clearance. In consequence no CeO2NP–
related toxicity was observed in this model in contrast to A549 and BEAS-2B 
monocultures.249 Furthermore, precision cut lung slices were combined with a human 
macrophage cell line (AMJ2-C11) to allow the evaluation of the role of macrophages on 
injury at the organ level.250 Kermanizadeh et al. in turn established the applicability of a 
commercially available 3D liver microtissue model to evaluate nanosafety. This model allows 
repeated exposure experiments, which were shown to elicit more severe effects than a 
single NP exposure, with the toxicity not being limited to the outer layer of the model.178 
Finally, Esch et al. applied a body-on-a-chip system to evaluate the potential toxicity of 
AgNPs. Hereto the GI-tract and liver were mimicked by the Caco-2/HT29-MTX and 
HepG2/C3A co-cultures respectively and connected in a microfluidic device. They observed 
that ˜9% of the NPs could pass through the GI barrier as single NPs or small aggregates. The 
latter in turn induced more severe liver injury than expected based on exposure of the liver 
co-culture alone.251  
Overall, more complicated cell models allow evaluation of more intricate events, which 
cannot be mimicked in an oversimplified monoculture and thereby provide valuable 
information on NP-mediated adverse events. However, such models are more labor 
intensive and are therefore currently less applicable for the screening of large sets of NPs. In 
addition the predictive value of most proposed models should be assessed to identify the in 
vitro models showing the best in vitro-in vivo correlation for future use.   
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8. CONCLUSION & PERSPECTIVES 
The present chapter provides an overview of several strategies that have recently been put 
forward in order to try and optimize cell models for more robust and reliable in vitro analysis 
of NP uptake and toxicity prior to any in vivo applications. Where the field of nanotoxicology 
is advancing fast, it is still lagging behind the rapid developments in the field of 
nanotechnology. The thorough evaluation of nanomaterial-cell or –tissue interactions is 
greatly impeded by the numerous types of NPs (each with their specific features) and the 
heavy impact of even the most miniature changes to a single physicochemical parameter on 
the NPs interaction with biological entities,  
The most used in vitro model, namely the classical 2D monoculture, is a very reductionist 
approach were most complexity of the in vivo situation is lost. Therefore, results from in 
vitro studies often did not relate very well to findings obtained in in vivo studies. Several 
groups have therefore made substantial efforts in trying to optimize the current in vitro 
models to mimic the in vivo conditions more closely. Inverted cell cultures, flow models, co-
cultures, 3D cell cultures or combinations all have specific advantages for NP uptake and 
toxicity studies when compared to the classical 2D monolayers as described in the various 
sections above. 
Since the field of nanotechnology keeps blooming and the safety of nanomaterials remains 
questionable as we are all being exposed more and more, it is expected that all these models 
will gain more importance as more robust rapid screening tools. Based on the data obtained 
with these models, better predictions on NP safety should be possible as well as a better 
selection of materials that are more interesting to further in vivo evaluation. However, 
further optimization is needed to fully exploit the benefits of these models. Ideally, these 
novel models would be adapted to a high content setting as to date they are rather labor 
intensive. For instance, using co-culture or 3D models combined with flow models in a HCS 
setting would enable these methods to be used as rapid screening tools. Of note, the 
predictive power of the proposed models towards in vivo adverse outcomes should be 






Given the rapid developments in the field of nanotoxicology and the on-going maturation of 
this niche area into a full scientific discipline, more relevant in vitro models such as the ones 
described in the present review will become increasingly important in various research areas 
that are linked to the use of nanomaterials in biological settings. Considering that most of 
these models have only recently been introduced, it is to be expected that more optimized 
models such as combinations of the ones mentioned will have big impacts on our 
understanding of how nanosized materials interact with cells and tissues under 
physiologically relevant conditions. 
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While nanotechnology is advancing rapidly, nanosafety tends to lag behind since general 
mechanistic insights into cell-nanoparticle (NP) interactions remain rare. To tackle this issue, 
standardization of nanosafety assessment is imperative. In this regard, we believe that the 
cell type selection should not be overlooked since the applicability of cell lines could be 
questioned given their altered phenotype. Hence, we evaluated the impact of the cell type 
on in vitro nanosafety evaluations in a human and murine neuroblastoma cell line, neural 
progenitor cell line and in neural stem cells. Acute toxicity was evaluated for gold, silver and 
iron oxide (IO)NPs, and the latter were additionally subjected to a multiparametric analysis 
to assess sublethal effects. The stem cells and murine neuroblastoma cell line respectively 
showed most and least acute cytotoxicity. Using high content imaging, we observed cell 
type- and species-specific responses to the IONPs on the level of reactive oxygen species 
production, calcium homeostasis, mitochondrial integrity and cell morphology, indicating 
that cellular homeostasis is impaired in distinct ways. Our data reveal cell type-specific 
toxicity profiles and demonstrate that a single cell line or toxicity end point will not provide 
sufficient information on in vitro nanosafety. We propose to identify a set of standard cell 
lines representing different target organs for screening purposes and to select cell types for 







In recent years, many inorganic nanoparticles (NPs) have made their way to the market as 
they are being incorporated into various consumer products.1 Moreover, their unique 
properties are being extensively explored for various biomedical applications. For instance, 
gold NPs (AuNPs) and iron oxide NPs (IONPs) hold great promise as theranostic agents for 
cancer treatment through hyperthermia combined with tumour detection via respectively 
photoacoustic or magnetic resonance imaging.2 Additionally, silver NPs (AgNPs) are good 
candidates for wound dressings and antibacterial coatings of medical devices due to their 
enhanced antimicrobial properties.3 However, to date only a few nano-enabled products 
were successfully translated into the clinic. Besides general targeting issues, this can 
primarily be attributed to their elusive safety profiles.4 Despite extensive efforts, a general 
paradigm on how inorganic NPs are able to affect homeostasis on the level of the cell, organ 
or organism and to which physicochemical NP properties this can be attributed, is largely 
lacking.5  
In general, nanosafety evaluations struggle with two important obstacles. The first is the fast 
pace at which nanotechnology keeps advancing, leading to the development of a plethora of 
NPs with distinct physicochemical properties, which should ideally undergo safety evaluation 
prior to their (biomedical) implementation. The second is the lack of standardization of in 
vitro nanosafety studies, as various groups apply different assays on various cell types. This 
results in low inter-study comparability and the publication of conflicting data, which 
complicates the elucidation of general paradigms on NP-cell interactions.6, 7  
The first hurdle can be overcome by implementing high throughput or high content 
techniques in order to speed up in vitro nanosafety testing.8, 9 Secondly, much effort is being 
put into the standardization of various factors of in vitro nanosafety studies.10, 11 In this 
regard, we believe that the cell type selection should receive equal attention. In most 
studies a cell line is selected since they are in general more readily accessible, less expensive 
and easier to cultivate when compared to primary cells.7, 12 However, cancer cell lines have a 
disturbed anti-apoptotic balance as well as an altered metabolism to sustain their high 
proliferation rate.13 The phenotype expressed by immortalized cells is in turn not entirely 
stable and might undergo changes due to the extensive in vitro manipulation or the initial 
immortalization.14 Hence, a shift towards the use of primary or stem cells as well as more 




complex cell culture models for in vitro nanosafety testing strategies has been recently 
noted. In contrast, primary cells can suffer from clonal variations and have a limited lifespan 
in vitro, making rational cell type selection a balancing act.7  
Subsequent to the realization that the cell type could be of substantial importance, several 
groups have shown that NP-induced effects vary in cell lines retrieved from different tissues 
or species.15-18 However, only a few studies compared NP effects in a cancer or immortalized 
cell line versus primary cells representing the same tissue and species.19, 20 Unfortunately, 
available data contrast one another wherefore no unambiguous conclusions could yet be 
formulated on whether cell lines can generally be applied as a reliable model for in vitro 
nanosafety studies. In addition, many of the abovementioned reports choose to either focus 
on interspecies variations or cell-type related differences in NP-evoked effects and do not 
address both factors in a single study.  
Here, we present a side-by-side comparison of NP-evoked effects in six related neural cell 
types thereby evaluating the extent of both species and cell type related variations in NP-
induced cytotoxicity. We selected a neuroblastoma cell line, neural progenitor cell line and 
neural stem cells derived from either humans or mice (Table 6.1) and purposely applied the 
optimal culture conditions for each cell type. These cell types were selected as potential 
models to assess the safety of neural stem cells labelling with nanosized contrast agents 
prior to transplantation in the context of regenerative medicine.21-23 In turn, the synthesized 
AuNPs, AgNPs and IONPs with a diameter below 10 nm make them good candidates for the 
proposed application.24  
Table 6.1. Cell types applied in this study. 
 Stem cells Progenitor cell line Cancer cell line 
Human hNSC 25 ReNcell 26 LA-N-2 27 
Mouse mNSC 25 C17.2 28 Neuro-2a 29 
 
First, we surveyed the acute toxicity of AuNPs, AgNPs and IONPs in all cell types. 
Subsequently we selected the IONPs for further evaluation given the minor acute toxicity. 
Hereto we applied a validated multiparametric approach, using automated imaging, to 





the calcium (Ca2+) homeostasis, mitochondrial health and cell morphology.30 Importantly, 
our data reveal distinct and cell type specific toxicity profiles that warrant careful selection 
of appropriate cell models for future nanosafety studies, taking both species and target 
tissue into account, and caution misinterpretation of experimental results based on a single 












2. MATERIALS & METHODS 
2.1. NP synthesis and characterization  
AuNPs, AgNPs and IONPs were synthesized, coated with the polymer poly(isobutylene-alt-
maleic anhydride) (PMA) grafted with dodecylamine and characterized by the lab of Prof. 
W.J. Parak. Detailed information on the synthesis and characterization procedures is 
provided in Appendix A. 
2.2. Cell culture 
The human neural stem cells (hNSCs) required the culture plates to be coated with 10 µg/mL 
poly-L-ornithin and 6 µg/mL laminin (Sigma, Belgium) in phosphate buffered saline (PBS) 
prior to use. Complete cell medium consisted of KnockOutTM Dulbecco’s modified Eagle’s 
medium (DMEM)/F12 supplemented with StemPro® NSC FSM supplement, basic fibroblast 
growth factor (FGF) recombinant protein, epidermal growth factor (EGF) recombinant 
protein, 2 mM L-Glutamine and 2% penicillin/streptomycin (Gibco, Invitrogen, Belgium). 
Similar as for the hNSCs, culture plates for the murine neural stem cells (mNSCs) were 
coated with poly-L-ornithin and laminin before use. Complete cell medium was prepared by 
freshly adding 20 ng/mL FGF, 20 ng/mL EGF and 2 µg/mL heparin (Millipore, Belgium) to 
Neural Stem Cell Expansion Medium (Millipore, Belgium) containing 2% 
penicillin/streptomycin. For the ReNcell VM cell line, plates were coated with 20 µg/mL 
laminin in DMEM/F12 (Invitrogen, Belgium) and cells were cultured in cell medium 
consisting of ReNcell NSC maintenance medium (Millipore, Belgium) with 2% 
penicillin/streptomycin. Again, 20 ng/mL FGF and 20 ng/mL EGF were added freshly to 
complete the cell medium. The C17.2 progenitor cell line did not require culture plates to be 
coated. By adding 10% fetal bovine serum (FBS, Invitrogen, Belgium), 5% horse serum 
(Invitrogen, Belgium), 2 mM L-Glutamine and 2% penicillin/streptomycin to DMEM 
(Invitrogen, Belgium) complete cell medium was prepared. The culture medium for the 
human neuroblastoma cell line, LA-N-2, was prepared by mixing 43.5% Eagle’s minimal 
essential medium (Sigma, Belgium), 43.5% HAM F12 (Sigma, Belgium), 10% FBS, 2% 
penicillin/streptomycin and 2 mM L-Glutamine. Finally, for the murine neuroblastoma 
Neuro-2a cell line complete medium contained 43% DMEM, 42% Opti-MEM (Invitrogen, 





For acute toxicity experiments, all cell types were seeded at the density of 25000 cells/well. 
For further cell experiments we determined appropriated seeding densities in 24-well plates 
for each cell type individually. In the interest of cell segmentation during data analysis, the 
optimal seeding density was defined as the density that rendered approximately 80% 
confluency at the end point of the assay. The volume of cell medium applied for seeding and 
IONP incubation was adapted to the initial density.  
The cells were cultured at 37 °C in a humidified atmosphere completed with 5% CO2. Cell 
medium was renewed every other day and cells were split after reaching 80% confluency. 
Here, the cells were dissociated with 0.05% trypsin–EDTA (Invitrogen, Belgium), after which 
the cells were centrifuged (4 minutes, 300 g), resuspended in fresh culture medium and 
seeded at appropriate densities. 
2.3. Cytotoxicity  
All cell types were seeded at 25000 cells per well in opaque 96-well plates and were allowed 
to settle overnight. Thereafter the cells were incubated with 2.5, 5, 10, 25, 50 and 100 nM of 
the AuNPs and AgNPs and 3.5, 7, 14, 35, 70 and 140 nM of the IONPs for 24 hours at 37 °C 
(5% CO2). After 24h NP incubation, the CellTiter-GLO
® assay (Promega, Belgium) was 
performed according to the manufacturer’s instructions. In short, 100 µL of the assay buffer 
was added to each well. Plates were shaken during two minutes after which a 10-minute 
incubation period was respected. Finally, the signal was measured using a GloMax® 96 
Microplate Luminometer (Promega, Belgium). Experiments were performed in triplicate and 
the data are represented as the mean ± the standard error to the mean (SEM). 
2.4. High content imaging  
For the multiparametric analysis, cells were seeded in 24-well plates and were allowed to 
attach overnight. Optimal seeding cell densities were identified for each cell type 
individually. The optimal seeding density was defined as the density that would result in an 
80% confluent cell layer in the untreated control at the end point of the assay. In order to 
preserve the cell density/cell medium volume ratio for all cell types, we varied the latter 
according to the optimal cell seeding density (Table 6.2). 
 




Table 6.2. Seeding density and incubation volume/well. 
 hNSC mNSC ReNcell C17.2 LA-N-2 Neuro-2a 
Cell density 35000 17500 17500 15000 50000 15000 
Volume (µL) 700 350 350 300 1000 300 
 
For the evaluation of effects on ROS production and [Ca2+]c 7, 14, 35, 70 and 140 nM IONP 
dispersions were applied, whereas for the effects on cell morphology and the mitochondria 
3.5, 7, 14, 35 and 70 nM were tested as effects on cell function were expected to occur 
starting from lower NP doses. As the volume of cell medium used for incubation was 
adjusted according to the cell density, the NP number/volume cell medium/cell number 
remained equal in all high content experiments. Similar to acute toxicity experiments, the 
cells were incubated with the IONPs for 24 hours at 37 °C in an atmosphere containing 5% 
CO2 after which staining and analysis were performed. This set of data is presented as mean 
± SEM from two independent replicates.  
2.5. Reactive oxygen species and cytoplasmic calcium levels 
To allow detection of reactive oxygen species (ROS) the general ROS marker CellROX® green 
probe (Molecular Probes, Invitrogen, Belgium) was selected. The latter was combined with 
the Rhod-2 AM (Molecular Probes, Invitrogen, Belgium), which becomes strongly fluorescent 
upon interaction with free Ca2+ in the cytoplasm.  
The IONP containing medium was discarded subsequent to 24 hours exposure and the cells 
were washed once with PBS with Ca2+ (PBS+, Invitrogen, Belgium). To allow visualization of 
reactive oxygen species (ROS), the cells were labeled with 5 µM CellROX® green (Molecular 
Probes, Belgium) in cell medium (250 µL/well). Following a 30 minute incubation period at 
37 °C, the probe was removed and cells were washed once with PBS+. The following 30 
minutes cells were stained with a 5 µM Rhod-2 AM (Molecular Probes, Belgium) solution in 
PBS+ (250 µL/well). After discarding the Rhod-2 AM and washing the cells with PBS+, the cells 
were fixed with 4% paraformaldehyde. Following a 15-minute incubation period at room 
temperature the fixative was removed, cells were washed once with PBS without Ca2+ (PBS-, 






During data acquisition the FITC/FITC excitation/emission (ex/em) filter combination was 
applied to visualize ROS whereas the Ca2+ signal was detected using the Cy3/Cy3 ex/em 
filters. Using a 20x magnification, a minimum of 5000 cells was imaged in at least 60 fields in 
two independent wells. The IN Cell Developer Toolbox software (GE Healthcare Life Sciences, 
Belgium) was applied to develop protocols and analyze the obtained images. The total cell 
number could be counted in the FITC/FITC images after defining the nuclei. Subsequent to 
determining the basal ROS levels, induction or reduction of ROS production (respectively 
cells with a ROS signal above or below background level) could be determined. In the 
Cy3/Cy3 images the signal area and total cell area were determined to quantify the effect on 
cytoplasmic free Ca2+.  The Ca2+ signal area was divided by the total cell area and the values 
for treated cells were normalized against the untreated control cells. 
2.6. Effect on mitochondrial health and cell morphology  
The mitochondria were labelled with Mitotracker® CMX-ROS Red (Molecular Probes, 
Invitrogen, Belgium), which specifically accumulates in the mitochondria based on its 
membrane potential. To allow evaluation of cell morphology the HCS CellMask™ Blue probe 
(Molecular Probes, Invitrogen, Belgium) was applied.  
Following 24 hours exposure to the IONPs, the IONP containing medium was removed. Cells 
were washed once with PBS with Ca2+ (PBS+, Invitrogen, Belgium) and incubated 30 minutes 
at 37 °C with 250 µL of a 250 nM Mitotracker® CMX-ROS Red (Molecular Probes, Invitrogen, 
Belgium) solution in cell medium. Following removal of the dye, the cells were washed once 
with PBS+ and fixed with 4% paraformaldehyde during 15 minutes at room temperature. 
After discarding the fixative and washing the cells with PBS-, we applied 5 µg/mL HCS 
CellMask™ Blue (Molecular Probes, Invitrogen, Belgium) in PBS- to label the cell cytoplasm. 
Subsequent to a 10-minute incubation period at room temperature, the label was removed 
by aspiration. Finally, the cells were washed with PBS- and stored in 500 µL PBS-/well at 4 °C 
and protected from light until analysis with the IN Cell Analyser 2000.  
The mitochondria were detected with the TexasRed/TexasRed and Dapi/Dapi ex/em filters 
were used to record the CellMask™ Blue signal. Similar as before, minimum 5000 cells were 
imaged per condition in 60 fields per well (in two independent wells) using a 20x 
magnification lens. The obtained images were analyzed with in-house developed protocols 




with the IN Cell Developer Toolbox software. Since the HCS CellMask™ Blue preferentially 
resides in the nucleus, the total cell number could be obtained from the Dapi images by 
defining and counting the nuclei. Subsequently, cells touching the image borders were 
excluded from analysis of cell morphology parameters. Next, cells were segmented based on 
the nuclei, the cytoplasm was recognized based on signal intensity and eventual holes were 
filled. For each condition, the average cell area was determined and normalized against the 
untreated control. In addition, the cell circularity was determined for each cell individually. 
The latter is a value between zero and one, with one representing a perfect sphere. Images 
in the orange channel provided information on the mitochondria. These organelles were 
defined based on the signal intensity and the mitochondrial signal area the within the total 
cell area was determined and normalized against the untreated control.  
2.7. Statistics  
Acute toxicity data are expressed as mean ± SEM (n=3). IN Cell data are presented as mean 
values normalized against the untreated control ± SEM (n=2). Statistical analysis was 





3. RESULTS & DISCUSSION 
3.1. Synthesized inorganic NPs display similar physicochemical characteristics  
AuNP, AgNP and IONP synthesis was initiated with the aim of obtaining a similar core 
diameter. All NPs had a mean core diameter around 3.8 nm, as measured by transmission 
electron microscopy. Subsequently all NPs were coated with poly(isobutylene-alt-maleic 
anhydride) grafted with dodecylamine (PMA), which was selected as it ensures colloidal 
stability over a wide pH range and a uniform coating of the different core materials.31 
Dynamic light scattering measurements in water showed a hydrodynamic diameter of 9.0 
nm, 8.9 nm and 12.3 nm and a negative zeta-potential around -45 mV, -35 mV, and -54 mV 
for the coated AuNPs, AgNPs and IONPs respectively. All obtained values correspond well to 
data reported on the characterization of NPs synthesized via similar protocols.32, 33 The NPs 
were synthesized with the intention of obtaining similar physicochemical properties so that 
discrepancies in cell responses could be related to variations between the cell types.  
3.2. Cytotoxicity depends on both the NP core material and the cell type 
In initial cell experiments, we evaluated cell viability following 24 h NP exposure with the 
CellTiter GLO® assay. In Figure 6.1 a general concentration-dependent decrease in ATP signal 
can be observed for every evaluated NP–cell type combination. Although the extent of this 
decrease clearly varies, the onset of this downward trend depended on both the applied NP 
and the cell type. In all cell types, the most severe effect was observed following AuNP 
treatment, while the cells were least affected by the IONPs. The toxicity observed for the 
AgNPs can likely in part be explained in terms of Ag+-ion leaching.34 In turn, the severe acute 
cytotoxicity induced by the AuNPs could possibly be attributed to genotoxicity due to direct 
interactions between the 3.8 nm diameter AuNPs and DNA.35 In addition, note that 
determining NP concentrations is not straightforward, as various methods/models need to 
be applied for different NP materials (Appendix A). This may affect the comparison of 
absolute concentrations of NPs of different materials and may additionally explain the 
severe toxicity observed here for the AuNPs. Given the limited loss of cell viability observed 
for the IONPs, the latter were selected for further evaluation of sublethal effects.  





Figure 6.1. A concentration-dependent decrease in ATP content, as measured via the CellTiter GLO® 
assay, is observed for every NP-cell type combination tested. Results for the AuNPs (yellow), AgNPs 
(blue) and IONPs (red) are represented as mean ± standard error of the mean (SEM, n=3). Statistical 
significance is indicated when appropriate for each type of NP in the corresponding color of the 
graphs (* p<0.05, AuNPs (yellow), AgNPs (blue) and IONPs (red)).  
 
Independent of the core material, the Neuro-2a cells were least susceptible to NP exposure 
whereas the hNSC, followed by the mNSC, were most sensitive. The susceptibility ranking for 
the other cell types varied with the NP core material. This greater sensitivity of the NSC, as 
found under the conditions reported here, is dissimilar to several studies where cell lines 
were found to be more susceptible to NP-induced acute cell injury.18, 19 However, our data 
correlate well with previous work from Bregoli et al. who did not observe any toxic effects in 
several hematopoietic cell lines while primary bone marrow cells were clearly affected.14 Of 
note, Wilkinson et al. and Schlinkert et al. independently found normal bronchial epithelial 
cells to experience more acute toxicity than the A549 cancer cell line.36, 37  
3.3. ROS induction is observed in two out of six cell types  
Since we found the IONPs to induce the least acute cell damage, it was decided to probe for 
sublethal effects caused by these NPs using a multiparametric methodology. The evaluation 
of effects on cell function has become crucial, as it is generally recognized that nanosafety 
evaluations should go beyond live/dead scoring in order to establish a more predictive 





vivo adverse outcomes. For instance, NP-promoted reactive oxygen species (ROS) 
production in pulmonary cells has been linked to acute inflammation in the lung.39, 40 ROS 
induction is also stated to be the main mechanism via which metallic NPs induce cell stress. 
Persisting ROS induction can subsequently lead to oxidative stress and damage cellular 
components such as DNA, proteins and membrane lipids.6  
Upon IONP treatment, we observed an increased ROS production in two out of six cell types, 
namely the mNSC and human ReNcells (Figure 6.2). ROS production was significantly 
reduced in the other four cell types. Notably, for both the reduced or increased ROS levels, 
the effect was most prominent in the NSC. Again the murine neuroblastoma cell line (Neuro-
2a) was least affected in terms of ROS. Given the variable effects, no general statements can 
be made on whether the human or murine cell types were more severely affected than their 
counterparts. 
 
 Figure 6.2. Effects on ROS production following IONP exposure visualized with the CellROX® green 
probe. A significant induction of ROS production was observed in the mNSC and human ReNcells. In 
the other four cell types a significant reduction was observed. Statistical significance is indicated 
when appropriate (* p<0.05). (NTC = not treated control) 
 
Although ROS induction by IONPs is often observed,19, 39, 41 NP-induced cytotoxicity cannot 
always be attributed to an increased ROS production.42 Interestingly, Harris et al. also 
witnessed reduced ROS levels in their high content analysis of IONP-induced effects on a 




mammalian fibroblast cell line.6 Additionally, IONPs can exhibit an intrinsic peroxidase-like 
activity in mesenchymal stem cells and thus reduce the cellular ROS content, especially of 
H2O2.
43, 44 As this effect was only witnessed when IONPs remained intact, IONP 
biocompatibility is presumably to a large extent affected by the intracellular location and the 
way the cell processes the IONPs. In confirmation, Sabella et al. found greater cell 
perturbation by metallic NPs when they were trafficked to the acidic lysosomes in 
comparison to the same NPs present in the cytosol, due to the enhanced degradation in the 
acidic compartments.45 Indeed, this degradation will be accountable for an increased 
amount of free iron ions, which may in turn enhance ROS production via for instance Fenton 
chemistry.6, 46 A final factor that could clarify our observation is the intrinsically different 
anti-oxidative capacity of the various cell types.15, 17 Thus, the cell itself likely determines NP 
biocompatibility to a large extent.   
3.4. IONP exposure perturbs cellular calcium homeostasis  
Subsequently, we evaluated the effect of IONP exposure on Ca2+ homeostasis. The 
intracellular free Ca2+ concentration ([Ca
2+]c) is a valuable toxicity marker since Ca
2+ is 
involved in a plethora of processes such as cell proliferation, mitochondrial function and 
gene expression.47, 48 Ca2+ is furthermore of ultimate importance for proper cell function in 
neural cells, as it is required for neurotransmitter release and cellular excitability.8, 49 
Additionally, Ca2+ is since long known to be an important regulator of cell death, where a 
significant increase in [Ca2+]c is noted.
47 A mild reduction can on the contrary be correlated 
with an impaired cell function due to enhanced intracellular Ca2+ storage or efflux in an 
effort to retain cell homeostasis, while cell lysis is correlated to a more severe decrease.48, 50  
On the one hand, a significant concentration-dependent increase in [Ca2+]c was observed in 
the hNSC, ReNcells, and C17.2 cells (Figure 6.3). The effect was more severe in the 
progenitor cell lines compared to the hNSC and the ReNcells showed the highest [Ca2+]c. On 
the other hand, a decline of the [Ca2+]c was detected in the mNSC, LA-N-2 and Neuro-2a 
cells. In contrast to previous parameters, the Neuro-2a cells showed more severe effects in 
terms of the perturbation of the calcium homeostasis. Again, no unambiguous conclusions 







Figure 6.3. Effect on [Ca2+]c as determined following labelling with Rhod-2 AM. A significant increase 
in [Ca2+]c was observed in the hNSC and both progenitor cell lines whereas a significant reduction was 
observed in the remaining three cell types (p<0.05). Statistical significance is indicated when 
appropriate (* p<0.05). (NTC = not treated control) 
 
Multiple studies investigating the influence of NP exposure on the Ca2+ homeostasis also 
found [Ca2+]c to be augmented.
51 Since this response could be interpreted as a cell death 
signal, this outcome could be correlated to the initially observed acute toxicity (Figure 6.1).47, 
52 Although we would have expected to observe a greater increase in [Ca2+]c in the hNSC 
when compared to the ReNcells based on the acute toxicity data, the opposite was true. In 
line with the observed decline in [Ca2+]c in three out of six cell types, Haase et al. 
documented diminished Ca2+ responses at cytotoxic NP doses in mNSC.3 This observation 
could on the one hand be explained in terms of cell lysis. On the other hand, stressed cells 
can maintain their Ca2+ homeostasis by elevating Ca2+ efflux via the plasma membrane Ca2+ 
ATPase pump.50 We hypothesized that this occurred in the neuroblastoma cell lines where 
ATP levels were to a minor extent reduced and thus still allowed sufficient pump function.  
In general, two groups could be distinguished based on the elevation or diminution of 
[Ca2+]c. Even though similar trends were retrieved in each group, it is clear that the extent of 
the perturbation of cellular Ca2+ homeostasis varied with the cell type. Since Ca2+ 
homeostasis is significantly altered upon cell transformation or immortalization in favour of 




cell proliferation,53 it was not surprising that NP exposure variably altered the [Ca2+]c. 
Notably, cell type specific toxicity profiles started to emerge as various combinations of the 
thus far evaluated effects were obtained.   
3.5. Mitochondria are affected by IONP loading  
Next, the effect of IONP exposure on mitochondrial homeostasis was evaluated. The 
mitochondria are interesting organelles as they are the cell’s main energy suppliers, involved 
in programmed cell death, an important source of ROS and to a large extent regulated by 
Ca2+.52, 54 This Ca2+-mediated regulation is furthermore influenced by external stimuli: in 
combination with a stress inducer Ca2+ promotes ROS production and possibly cell death, 
whereas under physiological conditions Ca2+ stimulates the oxidative respiration in the 
mitochondria and thus ATP production.52 Interestingly, the importance of oxidative 
respiration for overall cellular ATP production varies with the cell type: both cancer cells and 
stem cells rather rely on cytosolic glycosylation for their ATP production.54, 55 Hence, it is 
conceivable that mitochondria will not only be differentially affected, but also that the 
impact of mitochondrial perturbation on overall cell homeostasis will vary in the different 
cell types.  
To visualize the mitochondria, we selected a probe that specifically labels the organelles 
based on their membrane potential (ΔΨm). Loss of this potential, as a result of mitochondrial 
membrane permeabilization, will render the organelle undetectable and has been 
associated with cytochrome C release and cell death initiation.52, 56 During data analysis, 
such events could be detected as a reduction of the relative mitochondrial area. Figure 6.4 
shows that all cell types, except the Neuro-2a cells, showed significant mitochondrial 
damage. Accordingly, the loss of ΔΨm following NP exposure has already been described in 
multiple studies for several NPs in cell types from various lineages and species.8, 9, 42 In the 
NSC all IONP doses caused a decreased signal area, though the effect was only significant 
starting from 7 nM. In contrast, the affected cell lines (ReNcell, C17.2 and LA-N-2) were 
significantly affected by all IONP doses. The effects were most outspoken in the ReNcells, 
closely followed by the hNSC and mNSC. The mitochondria in the C17.2 and LA-N-2 cell lines 
were perturbed to a lesser extent. Notably, the human cell types were more severely 
affected than the murine counterpart. In addition, the neuroblastoma cell lines were most 





mitochondria in transformed cells to be less sensitive to perturbation due to an intrinsically 




Figure 6.4. Effects on the mitochondria labelled with Mitotracker® CMX-ROS in terms of the relative 
signal area representing the size of the mitochondrial compartment relative to the total cell area. 
Except for the Neuro-2a cell line, all cell types showed a significant decrease in mitochondrial area. 
Statistical significance is indicated when appropriate (* p<0.05). (NTC = not treated control) 
 
3.6. IONP loading affects cell morphology  
Lastly, we examined alterations in cell morphology following IONP exposure. Cell 
morphology is a convenient parameter, especially for neural cells given their intricate 
architecture.8 Moreover, numerous NPs have been shown to alter cell morphology as a 
secondary effect of ROS induction or via direct interactions with elements of the 
cytoskeleton.58, 59 In addition to the changes in the morphological appearance, certain cell 
functions that require signalling via these components can subsequently be impaired.59, 60 
Thus, subtle effects on cell morphology can indirectly herald perturbation of cell function 
whereas severe morphological alterations, i.e. cell rounding and shrinking, can be 
interpreted in terms of cell death.47  




After staining the entire cell cytoplasm, the impact of IONP exposure on cell morphology was 
quantified via two parameters: cell area and cell circularity. The latter is applied as a 
measure of cell spreading and is a value between zero and one, where one represents a 
perfect sphere. Although the extent of neurite outgrowth is often applied to evaluate the 
morphology of neural cells,61 this parameter was not selected for this work, as several cell 
types are not capable of forming neurites.  
While only a significantly decreased cell area was noted for the C17.2 cell line, both a 
reduced cell area and an increase in circularity were observed in the NSC, ReNcells and 
Neuro-2a cells (Figure 6.5). Thus, the cells became both smaller and more spherical in a 
concentration-dependent fashion, which was most outspoken in the ReNcells. Such loss of 
specific morphological features and cell shrinking has already been described in numerous 
studies for multiple NPs and cell types.3, 8, 22, 42 Since it is known that cell transformation or 
immortalization affects cell morphology, it is not surprising that morphology was also 
differentially affected in the various cell types. For instance the mNSCs were more strongly 
affected in terms of morphology whereas only minor effects were observed in the C17.2 or 
Neuro-2a cell line (Figure 6.6). Since stem cells have a more intricate architecture in 
comparison to most cell lines, it was not surprising that the morphology of the former was 
impaired more extensively. Finally, as the LA-N-2 cells tend to grow in clusters we evaluated 
effects on cell morphology in terms of the total cluster area and number of cells per cluster, 
which both showed a similar concentration-dependent decrease starting from 3.5 nM IONPs. 
Since the decrease in cluster area was slightly more severe than the number of cells per 
cluster, we concluded that the cell area also decreased with every dose tested.  
Overall, we observed similar effects on cell morphology (cell rounding and shrinking) in the 
various cell types in contrast to previously evaluated parameters. However, the exact trends 
and extent of the responses clearly differed. Importantly, these variations could not 
unequivocally be linked to one or a specific combination of responses observed for the other 
toxicity parameters investigated in this study, underscoring the cell type specific nature of 






Figure 6.5. IONP-induced alterations in cell area (grey bars) and cell circularity (orange lines) 
visualized after labelling of the cytoplasm with the CellMask™ Blue probe for the NSC, progenitor cell 
lines and murine neuroblastoma cell line. Cell circularity is a measure of cell spreading and is a value 
between zero and one, where one represents a perfect sphere. LA-N-2 cell morphology was analysed 
in terms of cluster area (grey bars) and number of cells per cluster (orange bars). A decreased cell 
area and increased cell circularity were detected in the NSC, ReNcell and Neuro-2a cell line. For the 
C17.2 cells only a diminution in cell area was detected. In the LA-N-2 cell line a reduction in cells per 
cluster and cluster size were observed. Statistical significance is indicated when appropriate (* 
p<0.05), in black for the cell area and orange in case of the cell circularity (respectively cluster area 
and cells per cluster in case of the LA-N-2 cell line). (NTC = not treated control) 





Figure 6.6. Representative images of untreated mNSCs (A), ReNcells (C) and C17.2 cells (E) as well the 
morphological alterations induced by exposure to 70 nM IONP (B, D & F). The mNSCs are clearly 
affected in terms of both cell area and circularity. The altered circularity in the ReNcells is less 
outspoken as initial morphology is less complex. Finally IONP treatment only caused a reduction in 






3.7. Multiparametric analysis reveals cell type-specific toxicity profiles  
In general, our data set reveals that each cell type reacted in a specific way to IONP exposure 
in terms of both extent and nature of the responses (Table 6.3). This could not have been 
deduced from the acute toxicity assessment (Figure 6.1) but became increasingly clear with 
every additionally evaluated parameter. Furthermore, the obtained profiles would likely 
become increasingly complex with the addition of supplementary end points such as the 
influence on autophagy, induction of endoplasmic reticulum stress or genotoxicity. Note that 
it was not the primary objective of this study to unravel the underlying toxicity mechanisms. 
Additional experiments should therefore be performed, for instance on the type of cell 
death or gene expression. Instead, the aim was to clearly show the impact of both the 
species and the cell type, under its optimal cell culture conditions on the nanotoxicity profile 
within one single study. We show that for 3 different, though related neural cell types (stem 
cells, immortalized cells and cancer cells) the effects in the human cells were often more 
outspoken than the murine alternative. In addition, we found the NSC from each species to 
be more sensitive to IONP exposure than the cell lines.  
Table 6.3. Cell type-specific nanotoxicity profiles induced by 24h exposure to 70 nM IONPs. 
 
ROS Ca2+ Mitochondria 
Cell morphology 
Area Circularity 
hNSC ↓ ↑ ↓ ↓ ↑ 
mNSC ↑ ↓ ↓ ↓ ↑ 
ReNcell ↑ ↑ ↓ ↓ ↑ 
C17.2 ↓ ↑ ↓ ↓ = 
LA-N-2 ↓ ↓ ↓ (*) (*) 
Neuro-2a ↓ ↓ = ↓ ↑ 
 
The observed variations in cell responses can be explained in several possible ways. One may 
argue that variations in NP uptake in the various cell types will be an important factor. In this 
regard, dose heterogeneity at single cell level due to variations in NP uptake in the same 
population will also lead to response heterogeneity.62 In addition, NP uptake is related to the 
colloidal stability in the applied cell culture media. Although we did not evaluate the 




abovementioned parameters in detail, it was previously shown that PMA-coated NPs show 
good stability in biological media and that they are taken up well by various cell types.30, 63 
Besides the extent of NP uptake, we believe that the cellular response is strongly related to 
the intracellular NP processing. This will in part depend on the uptake pathway since the 
latter will co-determine the intracellular trafficking route and the ultimate intracellular 
location. Indeed, as previously mentioned when NPs are present in the acidic and degrading 
environment of the endo-lysosomes, stronger cytotoxicity is observed than when the NPs 
reside in the cytosol.45 In addition, the variations in intrinsic cell properties, such as the anti-
oxidative capacity, metabolic rate (e.g. Ca2+ homeostasis) and mitochondrial activity, are to a 
large extent accountable for the revealed divergent toxicity profiles. Combined, these 
elements advocate an in vitro toxicity profiling that takes intrinsic cell properties and 
variations in the studied cell population into account. Indeed, to understand the intrinsic 
cellular capacity to traffic and handle exogenous materials could be of key importance to 
anticipate NP-evoked effects.  
Furthermore, our data indicate that it is imperative to apply multiparametric methods that 
look beyond live/dead scoring. Notably, even when only minor variations could be detected 
in the cell viability, as for instance for the Neuro-2a and ReNcells, cellular homeostasis was 
distinctly altered. In addition, minor cell viability alterations for the ReNcells did not imply 
that the cell homeostasis was not impaired. Accordingly, Ge et al. found IONPs to evoke 
important effects on cell function without affecting cell viability.64 Also, toxicity endpoints 
included in nanosafety screens should be carefully selected, as some are more sensitive or 
indicative of the induced damage. An example of the latter is the use of cell area and 
circularity as parameters to describe alterations in cell morphology. Although effects on cell 
circularity occurred sooner, the impact on cell area was more outspoken and illustrative for 
the extent of the actual damage in cell types without a complex architecture. Finally, the 
safety of the coating should be investigated in further detail to determine its possible 
contribution to some of the observed effects.  
Notably, we found that none of the cell types included in this work would be a suitable 
substitute for any other tested. In contrast, other groups did succeed in identifying a cell line 
alternative for primary cells based on similar cellular responses to NP exposure.12 In such 





lines should be approached with caution, especially when performing a detailed toxicity 
profiling to elucidate the mechanisms via which NPs alter cell homeostasis. Indeed, cell lines 
are not always ideal candidates for the analysis of cell function and may not be 
representative in terms of discrete cell perturbation.19 Thus, it would be fitting to select a 
cell type based on the expected exposure and/or intended application of the NPs. We also 
propose to cautiously apply non-human cell types since we, as well as several other groups, 
have observed notable interspecies variations.15, 16  
For screening purposes the selection of a proper cell type is a balancing act. Indeed, primary 
cells can suffer from several drawbacks like an often limited availability, specific cultivation 
requirements, a limited life-span, and possible inter-batch and –individual variations, which 
possibly limit the throughput.7, 12 Hence, cell lines are still the preferred candidates when 
performing a large-scale screening of numerous NPs. For this reason and because it is highly 
unlikely that one single cell type will emerge as a universal model, we strongly believe that 
the definition of a set of standard cell lines would constitute a definite asset in standardizing 
nanosafety assessments. The selected cell types would preferably be known to mimic 
responses observed in primary cells and would ideally be thoroughly characterized in terms 
of their intrinsic properties in order to enhance our understanding of the NP-induced effects. 
The standard cell lines should provide models for relevant target organs or tissues and the 














In this work, we investigated the effect of both species and cell type related variations on 
NP-evoked responses in six related neural cell types via a multiparametric approach. 
Interestingly, the observed impact on cellular health varied widely in each cell type in terms 
of both the nature and extent of the analyzed effects and cell type-specific nanotoxicity 
profiles were obtained. Hence, conclusions on the safety of a NP should preferably not be 
based on the evaluation of a single toxicity end point in a single cell type. We propose to 
rationally select a cell model based on the envisioned (biomedical) application and/or 
exposure scenario, especially when performing an extensive in vitro toxicity assessment with 
the aim of unveiling mechanisms via which the NPs inflict cell injury. Finally, with regard to 
standardization of in vitro nanosafety evaluations, we strongly believe that for the safety 
screening of large sets of nanomaterials the selection of a set of standard cell types, 
representing relevant target tissues, from which a cell line could be selected for a specific 
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Currently, there is a large interest in the labeling of neural stem cells (NSCs) with iron oxide 
nanoparticles (IONPs) to allow MRI-guided detection after transplantation in regenerative 
medicine. For such biomedical applications, excluding nanotoxicity is key. Nanosafety is 
primarily evaluated in vitro where an immortalized or cancer cell line of murine origin is 
often applied, which is not necessarily an ideal cell model. Previous work revealed clear 
neurotoxic effects of PMA-coated IONPs in distinct cell types that could potentially be 
applied for nanosafety studies regarding neural cell labeling. Here, we aimed to assess if 
DMSA-coated IONPs could be regarded as a safer alternative for this purpose and how the 
cell model impacted our nanosafety optimization study. Hereto, we evaluated cytotoxicity, 
ROS production, calcium levels, mitochondrial homeostasis and cell morphology in six 
related neural cell types, namely neural stem cells, an immortalized cell line and a cancer cell 
line from human and murine origin. The cell lines mostly showed similar responses to both 
IONPs, which were frequently more pronounced for the PMA-IONPs. Of note, ROS and 
calcium levels showed opposite trends in the human and murine NSCs, indicating the 
importance of the species. Indeed, the human cell models were overall more sensitive than 
their murine counterpart. Despite the clear cell type-specific nanotoxicity profiles, our 
multiparametric approach revealed that the DMSA-IONPs outperformed the PMA-IONPs in 
terms of biocompatibility in each cell type. However, major cell type-dependent variations in 







Nanotechnology yields numerous nanomaterials with interesting properties, which can be 
exploited in a plethora of possible applications. The biomedical field, for instance, aims to 
apply these materials to develop novel or improve existing diagnostic and/or therapeutic 
strategies.1-4 
A category of inorganic nanoparticles (NPs) for biomedical use that has received much 
attention over the last two decades, are iron oxide (IO)NPs.5 By creating nanosized iron 
oxide particles, the material acquires superparamagnetic properties, which allows its 
implementation in biomarker and pathogen detection assays6-8, protein sequestration8, cell 
sorting9, drug delivery10 and cancer treatment through hyperthermia.5, 11 Importantly, IONPs 
can also be applied as contrast agents for magnetic resonance imaging (MRI).12, 13 In this 
regard, FDA-approved dextran-coated IONPs (USA: Feridex®, EU: Endorem®) have been 
clinically applied for the MRI-guided detection of liver lesions and tumors, before the 
production was discontinued in 2009.14, 15 This MRI susceptibility can furthermore be 
exploited for regenerative cell therapy, where stem cells are transplanted into damaged 
tissues to replace the latter or promote cell survival and tissue repair via the secretion of 
specific factors.16, 17 To monitor the cell distribution and engraftment, such therapies require 
a non-invasive method to track the transplanted cells in vivo, which can be accomplished by 
ex vivo cell labeling prior to the transplantation.16, 18 
In the context of regenerative medicine, there is a large interest in IONP labeling of neural 
stem cells before transplantation into the neural trauma site.17, 19, 20 Since cell survival is an 
inherent drawback to this therapeutic modality and IONPs should persist inside the cells to 
allow long-term cell tracking, the IONPs should not negatively affect cellular homeostasis.18 
Hence, IONP optimization in terms of nanosafety is of key importance. Previous work from 
our group on IONPs coated with poly(isobutylene-alt-maleic anhydride) grafted with 
dodecylamine (PMA) (Figure 7.1) showed a disturbed cellular homeostasis at sublethal 
doses, making this construct less ideal for the labeling of neural cells.21 Coating with the 
ligand 2,3-meso-dimercaptosuccinic acid (DMSA) (Figure 7.1) could be a valuable alternative 
to improve the nanosafety profile. Indeed, DMSA is an FDA-approved chelator applied in 
case of lead intoxication and DMSA-IONPs show good biocompatibility both to neural cells in 
vitro and neural tissue in vivo.22-24 




In general, many hazard identification studies are initially performed in vitro applying cell 
lines given their easy accessibility and applicability.25-28 However, we and other groups have 
demonstrated that primary cells or stem cells often respond differently to NP exposure as 
compared to the cell line counterpart.21, 29-31 In addition, murine cell types are regularly 
applied despite reported species-related variations in NP-induced effects, which impede the 
extrapolation of results towards possible human scenarios.32-34 Although several groups 
investigated either the species or cell type associated diversity in NP-evoked responses,35-37 
such studies remain rare for neural cell types. Previous work from our group revealed cell 
type specific neurotoxicity profiles in response to PMA-IONPs.21 Given the clear perturbation 
of cell homeostasis, the PMA-IONPs were considered less fit for neural stem cell labeling in 
the context of regenerative medicine. Hence, we set out to optimize the IONPs by applying a 
different coating. To investigate whether the cell type equally impacts nanosafety 
optimization studies we compared the nanosafety profile of DMSA-coated IONPs to the 
previously applied PMA-IONPs. Please note that the same PMA-IONP sample was applied as 
described in our previous work.21 In short, we evaluated the cellular responses in neural cell 
types that could possibly be selected as an in vitro model for neural stem cell labeling prior 
to transplantation in regenerative medicine, namely neural stem cells (NSCs), a neural 
immortalized (progenitor) cell line and neuroblastoma (cancerous) cell line from both 
humans and mice.25-27 This setup will allow us to rationally guide the cell type selection for 





2. MATERIALS & METHODS 
2.1. IONP synthesis and characterization 
The lab of Prof. W.J. Parak synthesized and coated the IONPs with either the meso-2,3-
dimercaptosuccinic acid (DMSA) ligand or the polymer poly(isobutylene-alt-maleic 
anhydride) (PMA) grafted with dodecylamine.21, 24, 38-40 IONP synthesis and characterization 
occurred as described in Appendix A.  
2.2. Cell culture 
The same cell types and cell culture protocol were applied as described in Chapter 6.  
2.3. NP-cell interactions 
A similar method was applied as detailed in Chapter 6. In short, the investigated parameters 
were cell viability, ROS production, mitochondrial and calcium homeostasis and cell 
morphology. Cell viability was assessed with the CellTiter GLO® assay (Promega, Belgium) 
whereas the other parameters were evaluated with high content imaging upon labeling with 
appropriate probes. In this case data were obtained with the IN Cell Analyzer 2000 and 
analysed with the IN Cell Developer Toolbox software. Detailed information on the staining 
procedure, data acquisition and data analysis is provided Chapter 6.   
2.4. Statistics 
Cytotoxicity data are expressed as the mean ± standard error of the mean (SEM, n=3). IN Cell 
data are presented as the mean normalized against the untreated control ± SEM for two 
independent replicates, with a minimum of 10000 cells being analysed per replicate. 
Statistical analysis was performed using the 6th version of the GraphPad Prism software. 
Treated samples were compared with the untreated control by means of one-way ANOVA 
combined with the post-hoc Dunnett test. Additionally, responses induced by the differently 
coated IONPs were compared with two-way ANOVA followed by the Bonferroni post-hoc 
test.   





3.1. IONP characterization 
The core diameter (dc) of the synthesized IONPs was quantified with transmission electron 
microscopy (TEM), which showed a mean value of 3.8 nm (Figure 7.1c & 7.1d). Next, the 
IONPs were coated with a ligand or polymer, respectively meso-2,3-dimercaptosuccinic acid 
(DMSA) and poly-(isobutylene-alt-maleic) anhydride grafted with dodecylamine (PMA).21 As 
measured with dynamic light scattering, the hydrodynamic diameter in number distribution 
(dh) was 11.83 ± 0.61 and 12.33 ± 0.75 nm with a polydispersity index of 0.185 and 0.308 for 
the DMSA- and polymer-coated IONPs, respectively. In addition, both IONPs showed a 
strong, negative charge of -55.5 ± 0.9 mV for the IONP-DMSA and -54 ± 2.2 mV for the IONP-
PMA.21  
 
Figure 7.1. (a) DMSA-IONPs, (b) PMA-IONPs, (c) TEM image (scale bar corresponds to 20 nm) of the 







In a first set of cell-based experiments we evaluated the IONP-induced cell injury. Upon 
exposure to higher doses, several cell types experienced cell damage, which was most 
pronounced in the hNSCs (Figure 7.2). In contrast, the murine Neuro-2a neuroblastoma cell 
line was most resilient to IONP exposure, as only the highest dose of PMA-IONPs evoked a 
minor, though significant, effect. In the majority of the cell types (the hNSCs, mNSCs and the 
murine C17.2 and Neuro-2a cell lines), the PMA-IONPs induced more severe effects than the 
DMSA-IONPs. However, in the ReNcell and LA-N-2 cell line, the opposite was true. Finally, 
when comparing the human cell types to their murine counterpart, the former appeared to 
be more sensitive, irrespective of the coating. 
 
Figure 7.2. Cytotoxicity as determined with the CellTiter GLO® assay following 24 hours exposure to 
DMSA- (black) and PMA-coated (white) IONPs. Statistical significance with regard to the untreated 
control is indicated when appropriate (* p < 0.05) in black for the DMSA-IONPs and grey for the PMA-
coated IONPs. (NTC = not treated control) 
 
3.3. ROS production 
To assess whether IONP exposure could affect the cell homeostasis at sublethal doses, we 
first looked into the effect of ROS production via staining with the CellROX® green probe.41 
This is especially important in neural cells since (i) ROS is a key player in the initiation and 




progression of several neurodegenerative disorders and (ii) neural cells are especially 
sensitive to oxidative stress given their high metabolic rate and low anti-oxidative capacity.42  
Three responses could be distinguished; an increase, a decline or a steady state (Figure 7.3). 
In case of the first two responses, the induced effects were IONP-concentration dependent. 
Similar to the cell damage, the observed changes in ROS levels were most pronounced in the 
NSCs. For instance, in the hNSCs the DMSA-coated IONPs evoked a three-fold ROS induction 
at the highest concentration tested, whereas a decline was induced by the IONP-PMA. 
Notably, exact opposite trends were obtained in the mNSCs, indicating species-specific 
effects. Likewise, in the human progenitor cell line (ReNcell), both IONPs caused ROS 
induction whereas a decline was seen in the murine counterpart (C17.2). In contrast, in both 
neuroblastoma cell lines only the PMA-coated IONPs significantly reduced ROS. Overall, the 
PMA-IONPs evoked more severe effects in the included cell lines but no general statements 
can be made on the interspecies variations. 
 
Figure 7.3. The influence of 24 hours DMSA-IONP (black bars) and PMA-IONP (white bars) exposure 
on reactive oxygen species (ROS) production as detected with the CellROX® green probe, with the 
latter generally evoking stronger responses. When appropriate, statistical significance with respect to 
the untreated control is indicated in grey for the PMA-IONPs and in black for the DMSA-IONPs (* p < 






3.4. Cytoplasmic calcium signal 
Next, we evaluated the Ca2+ homeostasis in terms of the cytosolic free calcium 
concentration ([Ca2+]c) through Rhodamine-2 AM staining.
41 The latter is an important 
indicator of cell function, especially in neural cells, given its involvement in numerous 
intracellular processes (metabolic activity, gene expression, neurotransmitter release, cell 
proliferation and cell death, etc.).43-46  
Similar to the results on ROS production, we found either a concentration dependent decline 
or augmentation in [Ca2+]c or no significant changes (Figure 7.4). In both NSCs and the C17.2 
cell line, the differentially coated IONPs induced opposite effects. Where the PMA-IONPs 
caused an elevated [Ca2+]c in the hNSCs and C17.2 cells, a significant decrease was noted for 
the DMSA-IONPs. Again, the opposite was true for the mNSCs. In the human progenitor cell 
line (ReNcell), Ca2+-levels were significantly elevated by both IONPs and the PMA-IONPs, 
which once more evoked stronger responses. In the murine Neuro-2a cell line, both IONPs 
induced a significant decline, which was significantly greater for the IONP-DMSA. In the  
LA-N-2 cell line this response was only observed for the PMA-IONPs, as the DMSA-IONPs did 
not induce a significant effect. Here, less pronounced responses were detected in the 
murine NSCs and C17.2 cell line compared to their human counterparts. 
 
 





Figure 7.4. The cytosolic free calcium concentration ([Ca2+]c) was visualized with Rhod-2 AM following 
24 hours exposure to DMSA-IONPs (black bars) and PMA-IONPs (white bars). Grey and black * 
represent significant alterations when compared to the untreated control (* p < 0.05) induced by 
respectively PMA-IONPs and DMSA-IONPs. (NTC = not treated control) 
 
3.5. Mitochondrial homeostasis 
In turn, the mitochondria provide the bulk of the cellular energy, require Ca2+ signaling for 
their function, produce significant amounts of ROS and are associated with programmed cell 
death.47, 48 In addition, the ΔΨm is a known effector in neurodegenerative disorders.
49 When 
the ΔΨm is compromised, the mitochondria fail to produce ATP and cytochrome C can be 
released, followed by the initiation of apoptosis.47, 50 These organelles were labeled with 
Mitotracker® CMX-ROS Red, which accumulates in the organelle based on the mitochondrial 
membrane potential (ΔΨm). When the ΔΨm is compromised due to NPs directly interacting 
with the mitochondrial membrane or ROS-induced membrane damage, the dye can no 
longer accumulate and the mitochondrial signal area relative to the total cell area 
decreases.51  
Figure 7.5 shows the relative signal area to be reduced or unaffected by IONP exposure. The 
latter was true for both IONPs in the Neuro-2a cell line and the C17.2 cells exposed to DMSA-
IONPs. In all other cases the IONPs significantly reduced the ΔΨm. Notably, the ReNcells were 





observations, the human cell types were more sensitive to IONP exposure than the murine 
counterparts. On the whole, the onset of the effect occurred at lower doses for the IONP-
PMA and effects were significantly more severe as compared to the DMSA-IONPs, except in 
the LA-N-2 neuroblastoma cells where no significant differences were detected between 
both IONPs.  
 
Figure 7.5. DMSA-IONP (black bars) and PMA-IONP (white bars) induced effects on mitochondrial 
homeostasis in terms of the relative mitochondrial area as visualized with Mitotracker® CMX-ROS. 
Statistical significance with regard to the untreated control is indicated when appropriate (* p < 
0.05), in black for significant effects evoked by IONP-DMSA and in gray for the PMA-coated IONP. 
(NTC = not treated control) 
 
3.6. Cell morphology 
Following cell labeling with HCS CellMask™ Blue, cell morphology was evaluated in terms of 
cell area and cell circularity.21 The latter is defined as a value between zero and one, with 
one representing a perfect sphere. Thus, a lower value corresponds to a more complex cell 
morphology whereas an increase due to IONP exposure points to cell rounding and loss of 
specific morphological features, such as neurite outgrowths.21 Cell morphology is a 
convenient parameter to include in a multiparametric analysis, as cell death has specific 
morphological features whereas minor alterations to cytoskeleton building blocks can impair 
cell functions that require signaling via these components.42, 44, 52, 53  




Figure 7.6 and 7.7 reveal that the effect of the PMA-IONPs on cell morphology was overall 
more severe, with the exception of the mNSCs. In the latter, both cell area and circularity 
were significantly affected by the lowest and highest dose of DMSA-IONPs and PMA-IONPs, 
respectively. Likewise, the hNSCs and ReNcells became smaller and more spherical starting 
from 14 nM PMA-IONPs, whereas DMSA-IONPs only significantly altered morphology at 70 
nM. Cell circularity of the C17.2 cells was not significantly affected but the PMA-IONPs and 
DMSA-IONPs did reduce the cell area starting from the lowest and highest dose tested, 
respectively. The cell circularity of the Neuro-2a cells was elevated by both IONPs, while only 
the PMA-IONPs reduced the cell area at higher doses.  
Figure 7.6. The effect on cell morphology of 24 hours exposure to DMSA-IONPs (top row) and PMA-
IONPs (lower row) represented as changes in relative cell area (black bars) and cell circularity (blue 
lines). In general cell circularity is a more sensitive parameter and DMSA-IONPs induce least severe 
effects. Statistical significance with regard to the untreated control is indicated when appropriate in 







Figure 7.7. Representative images of HCS CellMask™ Blue-labeled untreated cells and cells treated 
with 70 nM DMSA-IONPs or PMA-IONPS. The scale bar corresponds to 100 µm. 
 




Finally, since LA-N-2 cells tend to grow in clusters, the morphology was analyzed in terms of 
cluster area and cells per cluster. Here, the PMA-IONPs caused a significant concentration 
dependent decrease in both the average cluster area and number of cells per cluster at 
lower doses compared to the DMSA-IONPs (Figure 7.8). 
 
 
Figure 7.8. The effect of both IONPs on the LA-N-2 cell line in terms of the total cluster area (black 
bars) and cells per cluster (white bars). Grey and black * represent significant alterations when 
compared to the untreated control (* p < 0.05) for respectively cluster area and cells per cluster. (NTC 






4. DISCUSSION  
In this study, we evaluated the extent at which DMSA- and PMA-coated IONPs induced 
adverse effects in six neural cell types, namely NSCs, a progenitor cell line and a cancer cell 
line from murine and human origin. Please note that the same PMA-IONP sample was 
applied as in previous work, where we observed clear dose- and cell type-dependent 
neurotoxicity.21 The specific aim of this work was to evaluate if such adverse effects could be 
similarly alleviated in the distinct cell types by applying a different coating strategy. The cell 
types were selected based on an important future application of the IONPs, i.e. neural cell 
labeling to allow MRI-guided in vivo cell tracking following transplantation in the context of 
regenerative cell therapy for neural lesions. Multiple studies regarding this topic apply 
various cell models without clearly specifying the species and or cell type (immortalized or 
cancer cell line, primary cells, stem cells).25-27 Since NP-evoked effects can differ widely 
amongst various cell models32, 34, we evaluated the impact of the cell model on nanosafety 
optimization studies. Hereto, we looked into the impact of both the cell type and species in 
one single study in contrast to previous reports focusing on a single variable.33, 36, 37  
IONP characterization showed that DMSA- and PMA-IONPs had similar basic 
physicochemical properties, in line with previous reports.21, 24, 38, 54 This was desirable as 
potentially distinct cell responses could be explained in terms of how the cell models 
interact with the NPs, rather than by the intrinsic physicochemical properties of the IONPs. 
Overall, we found the DMSA-IONPs to evoke less extensive responses than the PMA-IONPs. 
In four out of six cell types DMSA-IONPs induced less cytotoxicity than the PMA-IONPs, as 
expected based on recent literature.22-24 However, the observed toxicity for DMSA-IONPs 
was slightly more severe than anticipated possibly due to the greater sensitivity of neural 
cells towards NP exposure in general.16 Cell homeostasis was furthermore perturbed at 
sublethal IONP doses in nearly all combinations tested. Indeed, in correspondence with 
previous reports, we witnessed decreased, induced or unaffected ROS levels.49, 55, 56 In case 
of ROS induction or scavenging, the PMA-IONPs evoked more severe effects. The latter 
response can be explained in terms of the intrinsic scavenging potential of intact IONPs.57, 58 
The steady state observed for DMSA-IONPs in the cancer cell lines can be contributed to the 
chelating capacity of DMSA, preventing leached iron ions from inducing ROS.14, 22, 24 Still, the 
DMSA-IONPs were found to significantly induce ROS in the hNSCs and ReNcells, possibly 




indicating that the extent of ion leaching outweighed the DMSA chelating capacity or that 
ROS induction in part occurred through alternate mechanisms. In addition, the DMSA-IONPs 
most often showed less pronounced responses on the level of the calcium and mitochondrial 
homeostasis and cell morphology. Since all responses can to a certain extent be correlated 
to ROS production,59, 60 the chelating capacity of DMSA may in part be accountable for the 
improved nanosafety profile. However, the capacity of DMSA to chelate iron ions is limited 
compared to its propensity to bind lead and cadmium ions. The capacity to catch iron ions 
may further be reduced by the ominously present calcium ions, although it slightly prefers to 
bind iron ions.61 Hence, the exact mechanism of the improved biocompatibility of the DMSA-
IONPs warrants further research.   
From the multiparametric data set in each cell type alone it would be concluded that the 
DMSA-IONPs are the preferred candidate for further optimization since they generally 
evoked less severe effects, regardless of the distinct culture medium composition for the 
different cell types. The cell media could potentially influence IONP uptake through an 
impact on colloidal stability and the formation of a protein corona.62, 63 The latter 
parameters were not investigated in detail in this work as we focused on investigating how 
various cell models (i.e. the cell type and its optimal medium) would respond to IONP 
exposure. Furthermore, adequate IONP uptake and colloidal stability were previously 
documented for the applied coating materials.23, 41, 64 Nevertheless, further characterization 
of the protein corona and IONP uptake in the applied cell models would improve our 
understanding of the observed adverse events.65  
Most importantly, a correct conclusion on the preferable IONP coating for the envisioned 
application could only be reached when a multiparametric approach was applied, as in rare 
cases the DMSA-IONPs more severely perturbed cell homeostasis.  
Overall, a distinct nanotoxicity profile was obtained in each applied cell model. The 
sensitivity of the cell model was furthermore clearly species-related, as human cell types 
were more sensitive towards DMSA-IONP-induced effects. Likewise, Zhang et al. found 
human macrophages to be more sensitive towards DMSA-IONPs than the murine 
alternative.66 Secondly, the cell type was a major factor since for both the human and 





the cancer cell lines were most resilient. This is in agreement with the observation that 
tumor cells have several characteristics making them less prone to NP-induced effects, as 
cell transformation or immortalization is accompanied by phenotypical changes on the level 
of cell morphology, metabolic rate, proliferation rate, etc.32, 67 Finally, not all cell models 
showed a similar sensitivity on all evaluated end points. For instance, no significant 
differences could be detected in IONP-induced mitochondrial damage in the cancer cell 
lines, while this was true for all other cell types. Hence, nanosafety screenings to define 
suitable NPs for a certain application should be performed in a multiparametric fashion 
evaluating sensitive and informative end points in sufficiently sensitive cell types.  
Prior to the possible application of the investigated DMSA-IONPs, further testing would be 
required to (i) certify that a sufficient MRI signal could be detected at non-toxic doses, (ii) 
establish the importance of the detected adverse events on long-term cell function (e.g. 
differentiation in case of pluripotent stem cells) and (iii) rule out delayed cytotoxicity, as this 
was previously observed for the DMSA-IONP labeling of primary neurons.68 Based on our 
observations we suggest that NSCs are the preferred model for further investigation given 
the selected application. In preference the hNSCs should be applied since both NSCs showed 
opposite effects on the level of ROS and Ca2+ in response to DMSA-IONP labeling. Finally, it 
would be interesting to compare the obtained responses to those evoked by commercially 
available IONPs, as clinical translation of the latter for a novel application might be more 
efficient than for novel IONPs.  





IONPs are of interest as MRI contrast agents for the labeling of transplanted neural stem 
cells (NSCs), albeit that nanotoxicity remains a concern. Cell-nanoparticle interactions of 
DMSA- and PMA-coated IONPs were investigated in human and murine NSC, neural 
progenitor and neuroblastoma cells. The overall nanosafety profile of the DMSA-IONPs was 
superior compared to the PMA-IONPs. Importantly, a multiparametric approach was 
required to reach this conclusion. In the cell lines we predominantly found both IONPs to 
evoke similar responses. In contrast, clear interspecies variations were detected on ROS 
production and Ca2+ homeostasis in the NSCs, where both IONPs were found to evoke 
opposite effects. This is an important observation, as the hNSCs are considered to be the 
most representative model for the envisioned application. Thus, the DMSA-coating could not 
in all cell types equally alleviate the induced nanotoxicity compared to the PMA-IONPs. 
Overall, sufficiently sensitive cell lines can be applied when performing a multiparametric 
screening to define suitable candidates for a certain biomedical application. However, 
further thorough safety evaluations should be performed on a non-cancerous human cell 
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In the first part of this thesis we showed that by repurposing cationic amphiphilic drugs, 
siRNA-mediated gene silencing could significantly be improved upon nanogel transfection. In 
the second part of this thesis we focused on the impact of the cell model on the in vitro 
hazard assessment of inorganic nanoparticles. In short, we showed that the cell model 
selection in terms of the cell type and species influences the outcome of nanotoxicity 
evaluations and should not be overlooked in the optimization and standardization of in vitro 
nanosafety testing. In this final chapter we discuss the broader international context of our 
findings, the relevance of the work and the future perspectives. Hereto we first look into the 
commercial development of siRNA, RNAi therapeutics and inorganic nanoparticles. Secondly, 
we focus on the current clinical development of RNAi therapeutic en inorganic nanoparticles. 
Since we repurpose cationic amphiphilic drugs to improve siRNA delivery, both the concept 
of drug repurposing and combining drugs with siRNA to obtain an improved therapeutic 
outcome are discussed. Finally, we identify unmet challenges and suggest how research on 
both topics should be continued, with a focus on the importance of bridging the in vitro-in 





1. NANOTECHNOLOGY  
Nanotechnology has become indispensable to technological advances in the 21st century. By 
fabricating constructs in the nanometer range, many materials acquire unique and hard to 
obtain properties thereby unlocking a whole new world of novel applications and/or product 
improvements. Through the enlarged surface area, nanoparticles (NPs) may for instance 
contain improved catalytic properties (gold NPs), increased strength (graphene) and 
augmented antibacterial action (silver NPs) compared to their bulk materials. Semiconductor 
nanocrystals furthermore show excellent conducting properties and iron oxide NPs are 
superparamagnetic.1 Upon the discovery of these unique nano-features, NPs became the 
driving force behind the rapid progress of various sectors in the past decade, such as the 
chemical, energy and electronics industry.2, 3 As of today, nanotechnology has reached the 
consumer through various products, with many more still on the way. A general inventory of 
NP-containing consumer products can be found on the website of the Project on Emerging 
Nanotechnologies (www.nanotechproject.org).4 
Besides the avid use in consumers products, various NPs are being developed for distinct 
biomedical applications.5 In this regard, organic NPs are often applied as nanocarriers for 
macromolecules or molecules with a limited solubility. Several inorganic NPs are similarly 
being tested for their delivery potential, whereas their unique properties furthermore allow 
their development as contrast agents or radioenhancers in cancer therapy (section 3.1), 
besides improved biomarker detection.  
2. NANOCARRIERS FOR siRNA DELIVERY 
2.1. The industry perspective on siRNA therapeutics 
The pharmaceutical industry connection with RNA interference (RNAi) could be perceived as 
a love-hate relationship. In retrospect four phases can be noted6, 7: 
- 2002 – 2005  the RNAi discovery phase 
- 2005 – 2008  the boom of RNAi 
- 2008 – 2012  the burst of the RNAi bubble and the funding crisis 
- 2012 – now  the reinforced interest in RNAi 




RNAi was first reported in C. elegans in 1998 by Fire and Mello.8 Soon afterwards evidence of 
RNAi in mammalian and human cells was reported concurrent to the elucidation of the 
molecular RNAi pathway and how this pathway can be harnessed using RNAi triggers.9, 10 
This set of seminal data revealed the great potential of RNAi as a lab tool and as a 
therapeutic agent for a myriad of disorders. Indeed, theoretically any disease-causing gene 
could be silenced with high specificity and selectively.11, 12 Hence, it was even proposed that 
RNAi would allow personalized cancer treatment.13 In these early days, risk taking 
biotechnology companies such as Tekmira and Silence Therapeutics invested in the 
commercial development of the RNAi technique. In addition, the current leading RNAi 
company, Alnylam, was founded in the initial RNAi discovery phase.6 
The interest in RNAi as a therapeutic modality fiercely increased upon the positive in vitro 
and in vivo proof-of-concept data and the first successful clinical study where naked siRNA 
was intravitreally injected for the treatment of age-related macular degeneration.10, 11, 14, 15 
Up until then the big pharmaceutical companies (Big Pharma) mainly regarded RNAi as a 
research tool, but now companies like Merck, Roche and Novartis invested large amounts in 
both the intellectual property and therapeutic development of RNAi.16 Big Pharma was no 
longer watching from the side lines, but invested an estimated US$ 2.5 – 3.5B.6 In retrospect, 
the expectations of Big Parma were unrealistically high, as it was anticipated that the 
development of an RNAi therapeutic would take no longer than 15 months.17 Thus, Big 
Pharma envisioned RNAi to quickly boost their pipeline and thereby be a ‘magic’ solution to 
the ever-increasing cost and time required for drug development. In this enthusiasm it was 
even anticipated that RNAi therapeutics would rival with monoclonal antibodies.6, 18  
Disillusionment soon followed since technical barriers to successful therapeutic RNAi 
applications were initially largely underestimated. Indeed, the initial wave of clinical trials 
did not yield marketable products, but revealed issues of delivery, safety and selectivity.19 
Since the anticipated quick return of investments held off, RNAi became a bad career 
strategy in Big Pharma. This was consolidated by a report stating that the positive effects 
observed in the 2004 trial on age-related macular degeneration was a consequence of the 
immune response to the injected siRNA rather than a sequence-specific RNAi effect.20 At this 





development. Roche, Pfizer and Abbott Labs terminated their in-house RNAi development, 
whereas Merck and AstraZeneca strongly reduced their activities.6  
In turn, smaller biotech companies and academia did not lose their faith in RNAi. For one, 
the siRNA structure was engineered to reduce immunogenicity and improve target 
specificity.21 The inclusion of a 2’OH methyl group enhanced the stability and reduced the 
chances of an innate immune response. Off-target effects of the guide strand were reduced 
by applying asymmetric siRNA molecules with less thermodynamically stable base pairs at 
the 5’ end.21 Smaller biotechnology companies further recognized poor siRNA delivery as a 
main factor holding back therapeutic RNAi development and refocused their actions on the 
development of more efficient delivery platforms.6 Tekmira for instance developed stable 
nucleic acid lipid nanoparticles (SNALP) and Alnylam established the GalNAc-conjugate with 
enhanced stabilization chemistry (ESC-)siRNA.19, 22 Although various successful delivery 
strategies were developed, it is recognized that only a small fraction of the internalized dose 
is active inside the cytosol and that the delivery work should not be halted at this stage. 
Various formulations are currently evaluated in clinical trials (Table 8.1). Consequently, it is 
expected that the first FDA-approved RNAi therapeutic will enter the market before 2020.23 
Although it may not be likely that RNAi therapeutics will immediately rival with monoclonal 
antibodies, such as Humira® and Remicade® (two of the currently largest selling drugs), as 
first anticipated, the RNAi market is expected to grow with the approval of the first RNAi 
therapeutic.18, 24 In this regard, it should be kept in mind that monoclonal antibodies 
required several waves of innovation prior to the development of marketable products, 
similar to the situation RNAi therapeutics are currently facing. The enhanced clinical pipeline 
and overall quality of the RNAi science indeed fanned renewed interest into RNAi as a 
therapeutic modality. To ensure their share when RNAi therapeutics hit the market, Big 
Pharma players entered into collaborations with smaller biotech companies to outsource 
R&D activities on delivery strategies and siRNA therapeutics.6  
A final note should be made on the rivalry between the RNAi and clustered regularly 
interspaced short palindromic repeats (CRISPR) technology, as both can be applied to 
sequence specifically silencing genes. Some anticipate that CRISPR may overrule RNAi as it 
has the potential to create stable gene knockouts whereas transient gene silencing is 




obtained through RNAi.25 This is potentially an exaggerated statement, as it is expected that 
both techniques will coexist with each their specific therapeutic applications. Certainly since 
CRISPR mediated gene silencing is less homogeneous compared to RNAi. Hence, CRISPR may 
pose advantages in chronic genetic diseases or in the context of cancer immunotherapy. 
CRISPR may for instance be the weapon of choice to tackle Duchenne muscular dystrophy 
where partial reversal of the diseased phenotype leads to muscle recovery. In contrast, RNAi 
would be beneficial as a temporary treatment for transient disorders (e.g. asthma) or if more 
homogeneous gene silencing is required (e.g. in endothelial cells).25 The development of 
CRISPR is furthermore not as advanced as for RNAi.14, 26 Although CRISPR may be delivered 
through similar delivery strategies as RNAi, delivery challenges for CRISPR may be even 
greater since both a ˜100 nucleotide single stranded RNA molecule and a Cas9-expressing 
mRNA or pDNA need to be delivered and translocated to nucleus. Hence, it is expected that 
RNAi therapeutics will be applied sooner and will create sufficient revenue prior to potential 
overruling by CRISPR therapeutics, for which clinical evaluation is yet to commence.25  
2.2. Clinical development of siRNA therapeutics 
The first clinical trial with an RNAi therapeutic candidate was conducted in 2004 where 
naked siRNA was injected intravitreally. The siRNA targeted the vascular endothelial growth 
factor (VEGF) to treat age-related macular degeneration. This product was successful in 
Phase I to III trials with the anti-angiogenic effect of the anti-VEGF siRNA leading to improved 
vision. However, Kleinman et al. showed that this was not an siRNA sequence-specific effect, 
as scrambled control siRNA and anti-luciferase siRNA induced similar improvements. In turn, 
the anti-angiogenic effect was related to the induction of an innate immune response upon 
siRNA recognition by toll like receptor 3.20 On second thought, this observation was not 
surprising since naked siRNA shows poor uptake and can consequently not effectively alter 
VEGF expression.  
A first wave of clinical trials evaluating RNAi therapeutics was initiated in 2008. These initial 
trials generally applied naked siRNA and failed to render marketable therapeutics.13 
However, they provided valuable information on the major obstacles towards efficient RNAi 
therapies being safety, efficacy and delivery.19 Subsequent innovations on the siRNA 
structure and delivery modalities led to a second wave of clinical trials, which is anticipated 





therapeutics are being evaluated in Phase I to III clinical trials (Table 8.1).19, 27 The majority of 
the RNAi therapeutic candidates are investigated in the context of hereditary diseases, viral 
infections and cancer. Most therapeutics target hereditary orphan diseases given the 
advantageous FDA and EMA fast track for approval.27 It is expected that a successful delivery 
method should fairly easy be repurposed for a different disorder in the same target tissue. 
Hence, once an RNAi therapeutic is approved for an orphan disease, applications for more 
generally occurring disorders in the same tissue may soon follow. However, this may be a 
simplistic view since alterations in the siRNA sequence may in turn be responsible for 
unexpected adverse events.  
The organs that are currently most targeted in RNAi trials are the eye and the liver. The eye 
is a privileged site given its low nuclease activity and immunosensitivity.19 At the time of 
writing, 4 ongoing trials are evaluating naked siRNA administered either topically or through 
intravitreal injections.19, 28 However, the current absolute n° 1 target organ for RNAi therapy 
is the liver, which can chiefly be attributed to the preferential hepatic accumulation of the 
applied constructs.27 The majority of the clinical trials for hepatic targets evaluate products 
developed by Alnylam to treat hypercholesterolemia, hemophilia, hepatic porphyria and 
paroxysmal nocturnal hemoglobinurua.29-31 Alnylam’s current lead component is Patisiran. 
This LNP containing transthyretin (TTR)-targeting siRNA is applied in familial amyloidotic 
polyneuropathy due to TTR amyloidosis and is currently tested in Phase III studies.19 In 
contrast, the Phase III trial for Revusiran (a GalNAc conjugate applied for familial amyloidotic 
cardiomyopathy) was prematurely terminated, as reanalysis of the Phase II data revealed 
more deaths in the Revusiran treated group.32 Besides Alnylam, Arrowhead and Nitto Denko 
are evaluating their RNAi therapeutics for alpha-I trypsin deficiency and hepatic fibrosis, 
respectively.19 Further studies evaluate the safety and potency of RNAi therapeutics in the 
context of cancer immunotherapy or as a direct anti-cancer agent.19, 33 A final set of hepatic 
RNAi indications for which RNAi therapeutics are currently clinically evaluated are viral 
infections, such as Ebola and Hepatitis B and C.34-36 




Table 8.1. siRNA therapeutic candidates in clinical evaluation. (Adapted from 19) 





Dry eye TRPV1 
Topical 
Naked siRNA 
Phase I/II Sylentis 
Ocular hypertension, open-angle glaucoma ADRB2 
Topical 
Naked siRNA 
Phase II Sylentis 
Angle closure glaucoma CASP2 
Intravitreal injection 
Naked siRNA 
Phase II/III Quark 














Subcutaneous injection  
ESC-siRNA-GalNAc  
Phase I  Alnylam 
Hepatic porphyrias ALAS1 
Subcutaneous injection  
ESC-siRNA-GalNAc 
Phase I  Alnylam 
Paroxysmal nocturnal hemoglobinuria C5 
Subcutaneous injection  
ESC-siRNA-GalNAc 
Phase I /II Alnylam 
Familial amyloidotic polyneuropathy 
(Patisiran) 
TTR 
IV infusion  
LNP 
Phase I-III Alnylam 
Alpha-1 antitrypsin deficiency AAT 
Subcutaneous injection  
ESC-siRNA-GalNAc 
Phase I /II Alnylam 
Alpha-1 antitrypsin deficiency AAT 
IV injection  
DPC 
Phase I Arrowhead 
Hepatic fibrosis HSP47 
IV injection  
vitamin A targeting LNP 
Phase I/II Nitto Denko 
Advanced/ metastatic cancer STMN 
Intratumoral injection  
LNP 





Advanced recurrent cancer EPHA2  
IV injection  
DOPC LNP 
Phase I MD Anderson 
Hepatitis B 
Three conserved 
regions of HBV 
IV infusion  
LNP 




IV injection  
DPC 
Phase II Arrowhead 
Hepatitis C 
Three conserved 
regions of HCV 
IV infusion  
AVV 
Phase I/II Benitec 
Ebola 
VP24; VP35; Ebola 
L-polymerase 
IV infusion  
LNP 





IV infusion of ex vivo 
electroporation 




IV infusion of ex vivo 
electroporation 
Phase III Gradalis 
Neural endocriene cancer PLK1 
IV infusion  
LNP 
Phase I/II Arbutus 
Pancreatic cancer KRAS-G12D 
Surgical implementation 
 LODER-polymer 
Phase II/III Silenseed 
Solid tumor, melanoma, lymphoma MYC 
IV infusion  
LNP 
Phase I/II Dicerna 
Skin 
Pachyonychia congenita K6a 





Scar prevention, keloid formation CTGF 
Intradermal injection  
rxRNA 
Phase II Rxi Pharmaceuticals 
GI tract Familial adenomatous polyposis Beta-catenin 
Oral administration of bacteria 
(trans kingdom RNAi) 






With several RNAi candidates in Phase III studies, it will likely only be a matter of time before 
the first one is granted FDA-approval. Current applications are mainly limited to easily 
reachable tissues by local application (eye, skin, mucosa) and the liver upon systemic 
administration.19, 27 Hence, the need for additional delivery methods able to target more 
difficult to access organs could not be more stringent. Since nanomedicines show 
preferential hepatic accumulation and targeting efforts towards extra-hepatic tissues have 
limited success37, the focus of delivery research may benefit from a switch towards siRNA-
conjugates, being an order of magnitude smaller in size than most nanocarriers. Ideally, such 
conjugates would target an ominously expressed receptor that quickly recycles back to the 
cell surface, after release of its ligand, to ensure maximal internalization of the conjugate.27 
Given the smaller size of the conjugates, tissue penetration might be less troublesome as for 
nanomedicines.7 In any case, the development of more stable and potent delivery systems is 
required to enhance the efficiency of siRNA therapeutics. Here, our proposed adjuvant 
strategy might pose a solution.  
2.3. Drug repurposing and drug-siRNA combinations 
2.3.1. Drug repurposing 
Ashburn and Thor were the first to apply the term drug repurposing in 2004, although 
various cases were described by that time.38 In the context of drug repurposing, also known 
as drug repositioning or rescue, approved, withdrawn or abandoned drugs or drug 
candidates are evaluated for different indications than they were initially developed for.38, 39 
Thus, drug candidates previously underwent at least Phase I clinical investigations and data 
regarding the pharmacokinetics, drug safety and possible interactions are already available. 
Furthermore, potential issues with bulk manufacturing and formulation were often 
previously dealt with.40 Based on this foreknowledge, drug repurposing is generally 
considered a risk- and cost-cutting strategy with a more rapid turnout.38, 41 Currently, de 
novo drug discovery and development requires approximately 15 years and several billion 
US$. The upward trend in cost and development time does not coincide with an increasing 
amount of drugs reaching the market. In contrast, a historically low 6% of all investigated 
compounds reaches the market, with the development mainly being discontinued in late 
phase clinical assessments. Drug repurposing is expected to boost the product pipelines, as 





Before 2011, drug repurposing was mainly based on serendipitous clinical observations. 
Probably the most well-known example is sildenafil (Viagra®), which was developed to treat 
angina pectoris but is now applied for erectile dysfunctions.38 From 2011 onwards, drug 
repurposing became an independent drug development strategy, driven by the availability 
of novel screening techniques and appropriate compound libraries.40 The boom in drug 
repurposing can be clearly recognized by the vast increase of publications on the subject, 
with a record of nearly 500 reports published in 2016.  
Currently, most repurposing strategies focus on repositioning drugs for oncologic 
applications39, 43, 44, with the star of the show being metformin. The latter is an orally applied 
biguanide for the treatment of type II diabetes, as it reduces gluconeogenesis and insulin 
resistance. Nowadays metformin is tested in combination with available chemotherapeutic 
agents given its anti-mitotic, anti-angiogenic and anti-inflammatory actions.43 In addition, 
many efforts focus on drug repositioning to treat infectious diseases, such as Zika virus45, 46, 
Ebola virus47, tuberculosis48, 49 and other bacterial and parasite infections.50 Further efforts 
are reported on drug repurposing for neurological disorders, inflammatory disorders (IBD, 
COPD), etc.39, 51-54 Finally, various groups evaluated new drug combinations to meet the 
shortcoming of the low potency of newly identified hits. Sun et al. for instance suggested 
treating Ebola with a mixture of three lysosome-targeting compounds to reduce viral 
replication.47  
In the current optimistic spirit, it is anticipated that 30% of the yearly FDA-approved 
products will stem from drug repurposing.42 However, repurposing may, just like RNAi, not 
be the magical solution Big Pharma is hoping it to be. Indeed, many identified hits suffer 
from relatively weak efficiencies and will therefore potentially not outperform current 
standard treatments in clinical investigations.40 In turn, not all repurposing strategies may be 
desirable. For instance, certain adverse effects may be acceptable in the context of an anti-
cancer strategy but not when treating a chronic disorder.40 Finally, repurposing does not 
always imply that preliminary clinical testing can be skipped. When different doses , 
formulations or novel drug combinations are applied, Phase I clinical trials are still 
required.38, 40 Overall, drug repurposing will not replace the development of new 
compounds, but both strategies will continue to be applied to nourish Big Pharma’s 
pipelines. 




Our proposed adjuvant approach also fits in this context of drug repurposing. Of utmost 
interest, several cationic amphiphilic antihistamines (loratidine and ebastine) were recently 
shown to improve sensitivity towards chemotherapy and reduce multidrug resistance in 
Danish patients with non-small cell lung carcinoma.44 Although similar clinical results were 
not observed for desloratadine, this compound may still be an applicable delivery adjuvant. 
In any case will the application of known CADs be advantageous in respect to both time and 
costs when bringing our concept from bench to bedside.  
2.3.2. Drug-siRNA combinations 
In the first section of this thesis, small molecules were applied to improve the nucleic acid 
therapeutic potential. In addition, a significantly larger amount of studies report on the 
combination of siRNA and small molecular drugs, where siRNA is applied to enhance the 
therapeutic potential of an anti-cancer treatment. The most reported combinations 
comprise doxorubicin or paclitaxel with a specific siRNA based on the tumor type.55-57 In 
addition, the low molecular weight drug can be either administered as a free drug, in a 
nanocarrier or co-included with siRNA in the same carrier.58 
The rationale to apply siRNA can be two-fold. On the one hand, siRNA can silence multidrug 
resistance proteins thereby increasing the drug concentration at the target site and ensuring 
enhanced tumor killing efficacy. On the other hand, a synergetic apoptotic effect can be 
obtained when applying siRNA targeting anti-apoptotic proteins or proteins involved in cell 
cycle regulation or cell proliferation.57, 58 If apoptosis can be induced by the siRNA through a 
different pathway than the drug-induced apoptosis, a synergistic effect may be obtained. A 
second advantage to this strategy is that required doses of the chemotherapeutic may be 
reduced. Since these compounds often suffer from a narrow therapeutic range, adverse 
effects could potentially be scaled down.57 Ideally a combination strategy is applied where 
the therapeutic anticancer agent enhances siRNA delivery, which in turn boosts the small 







2.4. Where to go from here with the adjuvant concept 
2.4.1. How do CADs promote siRNA-mediated gene silencing? 
We previously showed that the apparent endo-lysosomal volume increases upon CAD 
treatment, most likely as a consequence of phospholipid accumulation, which was in turn 
correlated to enhanced siRNA-mediated gene silencing (Chapter 3). This Niemann-Pick 
disease-like phospholipidosis phenotype is in all probability induced through CAD-mediated 
acid sphingomyelinase (ASM) inhibition, although this was not experimentally verified. Sahay 
et al. showed that the Niemann-Pick C1 (NPC1) cholesterol transporter protein has a major 
role in retrograde transport and exocytosis. Indeed, LNP exocytosis in NPC1-/- cells was 
blocked, which significantly improved the LNP transfection efficiency.59 However, our 
sequential CAD treatment, which causes secondary cholesterol accumulation through NPC2 
inhibition, did not have a similar potentiating effect on LPS delivery. Both differences in 
carrier (lipidoid LNP vs LPS) and incubation schemes (NPC1-/- vs phenotype induction post 
transfection) could be responsible for this discrepancy. Despite the fact that Sahay et al. 
showed a clear impact on LNP trafficking in NPC1-/- cells59, we were not yet able to evaluate 
whether sequential CAD treatment alters siNG trafficking. Such observations might enhance 
our understanding of the mechanism(s) through which CADs may improve siRNA delivery. It 
would furthermore we interesting to evaluate if CAD treatments prior to transfection could 
improve LPS-mediated siRNA delivery as observed in NPC1-/- cells. Further investigation of 
the effect of CAD pre- or co-incubation on nanocarrier uptake and siRNA-mediated gene 
silencing could provide valuable information on the mechanism of action and guide the 
definition of in vivo dosing schemes. 
Based on the data presented in Chapter 3, we assumed that the improved cytosolic release 
occurred through lysosomal membrane permeabilization (LMP). However, this remains to be 
experimentally verified. Here, experiments should be performed to confirm the lysosomal 
lipid accumulation and LMP. In addition, siramesine should be applied as a control as this 
CAD is reported to induce LMP in cancer cells both in vitro and in vivo. However, improved 
siRNA release was not correlated to severe cytotoxicity. This suggests that the ˜34 kDa 
cathepsins often responsible for lysosomal cell death mainly retained their lysosomal 
localization, while the ˜12 kDa siRNA managed to escape. Cathepsins may in turn leak to the 
cytosol concurrent to the siRNA, although to a limited extent with cytosolic cathepsins levels 




not saturating the cytosolic hydrolase inhibitors and inducing cytotoxicity.60 Immunostaining 
of cathepsins would provide clarification on this topic. In any case, the hypothesis of minor 
LMP furthermore implies that only free siRNA (i.e. siRNA detached from its carrier) can 
transfer from the lysosomal to the cytosolic compartment upon CAD treatment. It would be 
interesting to probe the effective size of macromolecules for which CADs may enhance 
cytosolic delivery. 
It would be equally interesting to further assess the impact of CADs on the lysosomal 
compartment. Uncertainty for instance lingers around their effect on the lysosomal pH.61-64 
Interestingly, lysosomal lipid accumulation may equally affect the lysosomal pH, depending 
on the phospholipidosis phenotype.61, 62 It would furthermore be interesting to understand 
how lipid accumulation affects lysosomal membrane stability to promote cytosolic release. 
Finally, we solely applied our adjuvant method to a single cancer cell line in this thesis. 
Preliminary experiments revealed that the CAD adjuvant approach was effective in the 
SKOV-3 and HeLa cancer cell lines (data not shown). By testing additional cancer cell lines we 
could establish if the CADs can generally be applied as adjuvants in cancer cells. Several 
reports furthermore state that cancer cell lysosomes are more easily perturbed and that 
CADs selectively induce LMP in cancer cells.44, 64-66 Hence, it would be highly interesting to 
confirm whether this is also true for our adjuvant method by comparing the CAD effect in 
cancer cell lines and primary cells, thereby establishing the therapeutic indication(s) where 
this CAD strategy could be of use.   
2.4.2. Applicable small molecules and their combinations 
In Chapter 3, we showed that four CADs improved siRNA-mediated gene silencing in a 
similar concentration-dependent way (Figure 3.4C). However, not all CADs are expected to 
be active in the same dose range since higher and lower doses of dextromethorphan (Figure 
3.5C) and terfenadine (data not shown) respectively provided similar adjuvant effects as the 
first four molecules. The doses applied in Chapter 3 are relatively high, which may limit their 
applicability. Hence, more potent FIASMAs should be identified via a larger scale screening. 
An additional strategy might be to evaluate chemical inhibitors of ASM since lower 
concentrations are potentially required to directly inhibit ASM through the key-lock 





stated that bisphosphonates directly inhibit ASM in cell lysates. However, zolendronate was 
not as successful as our CADs in preliminary tests (data not shown), which may be attributed 
to the unfavorable properties for uptake trough passive diffusion. In any case, further 
experiments are required to confirm this observation.  
Various compounds are furthermore reported to negatively influence the lysosomal 
membrane stability. Compounds that induce lysosomal membrane permeabilization without 
severe concurrent cytotoxicity due to cathepsins release may be equally applicable delivery 
adjuvants. In the general context of drug repurposing it would be interesting to screen larger 
commercially available libraries to identify additional delivery enhancers, which may act 
through distinct mechanisms. Subsequently, we should evaluate drug combinations, as 
synergetic combinations may be identified.40 In this case, lower doses of each component 
would be required, thereby reducing the risk of adverse effects. 
2.4.3. Applicable nanocarriers  
In this thesis we showed that the proposed adjuvant strategy can strongly potentiate siRNA-
mediated gene silencing upon NG transfection (Chapter 3), but not upon transfection with 
LPS or commercial lipid formulations (Chapter 4). Hence, it would be highly interesting to 
combine our adjuvant strategy with distinct polymer-based carriers to truely establish the 
broader applicability in terms of the nanocarrier. It would furthermore be of utmost interest 
to evaluate if CAD adjuvants can potentiate the effect of clinically tested formulations, such 
as SNALP and dynamic polyconjugates (DPC). If this were true, required siRNA doses and 
potential off-target effects could be dramatically reduced. 
As previously noted, we expect that solely siRNA detached from its carrier is able to transfer 
from the lysosomal to the cytosolic compartment. Hence, carrier degradation and/or siRNA 
release are potentially of key importance to our adjuvant method. This should be confirmed 
by combining non-biodegradable NGs or enzyme resistant cyclodextrins with a sequential 
CAD treatment, where we would not expect to witness improved transfection efficiencies. 
This feature may indeed explain why our approach worked well for the biodegradable NGs, 
but not for the lipid-based formulations. Unfortunately, relatively little is known regarding 
the degradation of lipid-based carriers in the lysosomal compartment. However, it is 
generally assumed that carrier and cargo face degradation since the lysosomes are regarded 
as the cell’s ‘stomach’. Liposomal lipids are most likely digested by lysosomal lipases, such as 




phospholipase A2 (PLA2), which are known to have a preference for phosphatidylcholine 
(PC) and –ethanolamine (PE) moieties.67 The kinetics of this degradation process are 
potentially of key importance to our sequential adjuvant approach. Indeed, sufficient 
amounts of free (nuclease-stabilized) siRNA need to be present when initiating the 
sequential adjuvant treatment. Thus, the timing of the latter could be optimized based on 
degradation kinetics of the lipid nanocarrier. An additional solution could be to apply 
bioresponsive carriers - such as PLA2 sensitive LPS68-70 - or biodegradable carriers (f.i. SNALP, 
Lipidoids, PLGA)15, 71, 72. In general a more in depth understanding of intracellular trafficking, 
the mechanism of escape and carrier degradation would stimulate the rational combination 
of nanocarriers and small molecular adjuvants.    
2.4.4. New constructs 
Two main strategies can be envisioned for the development of new constructs based on our 
adjuvant approach. The first implies the co-encapsulation of siRNA and small molecules in a 
single carrier, whereas the second focusses on the synthesis of CAD-siRNA conjugates. 
The main advantage of introducing the small molecular adjuvant into the formulation is the 
reduction of the total required dose. In a first attempt, where we prepared DOPE:NT LPS 
(Figure 4.9), no beneficial effect of the NT could be detected since it was not able to induce a 
PLD phenotype. Hence, the challenge will be to prepare a formulation where both the CAD 
and siRNA are released in the lysosomal compartment, which may for instance be achieved 
through pH sensitive linkers. 
Secondly, effort should be put into the synthesis of a CAD-siRNA conjugate in analogy with 
the GalNAc conjugate. This conjugate shows high hepatic transfection efficiency and is easier 
and cheaper to produce than nanocarrier alternatives. In addition, such conjugates are 
regarded as relatively save, although a Phase III clinical trial on GalNAc conjugates was 
recently halted.32 Still such conjugates are dwarfed by nanocarriers and may show improved 








2.4.5. A final critical note 
A shortcoming to the presented work may be the lack of an in vivo proof-of-concept 
experiment. As discussed in Chapter 3 it is not straightforward to evaluate our adjuvant 
approach in an in vivo setting. For one, the applied NGs are not stable upon systemic 
administration. Thus the use of NGs to deliver siRNA would solely be feasible through 
intratumoral injections, which are very rarely applied in the clinic. In addition, intratumoral 
injections are most often administered to xenograft tumors, which may not be an ideal 
model given the poor representation of human solid tumors.73 Thus, we should first identify 
a suitable carrier both able to transport siRNA throughout the body and sensitive to our CAD 
adjuvant approach, and identify a more complex and representative tumor model to 
evaluate our approach in vivo. When performing an in vivo evaluation of our concept it 
would be advisable to include siramesine as a control in both the in vitro and in vivo 
experiments since this molecules was shown to induce LMP in both models.64  
The safety of our current approach may be one of the biggest hurdles towards translation, as 
the in vitro effective doses can maybe not be achieved in vivo with therapeutic CAD doses, 
despite the large distribution volumes, preferential accumulation at acidic tumor sites and 
successful LMP induction by siramesine in vivo.44, 64 Careful modeling of the pharmacokinetic 
profile of the adjuvant and safety assessments could provide clarification. In addition, one 
needs to be sure that other CADs consumed by the patient will not impact the siRNA release, 
as excess siRNA release would increase the risk of off-target effects and immune responses. 
On the other end of the spectrum, it should be ensured that the CAD does not negatively 
affect (off-)target tissue(s).  
The majority of the current clinical trials locally apply siRNA formulations to the eye or skin 
or target the liver upon systemic administration. Despite research efforts in the past 20 
years, little progress has been achieved on targeted delivery, as nanocarriers still 
predominantly accumulate in the liver. A sobering report by Chan’s group revealed that a 
median 0.7% of the nanocarrier dose reaches solid tumor cells.37 Although a recent 
communication stated that we should not as much look at the numbers but rather focus on 
the benefits for patients74, we should still aim higher by developing more efficient delivery 
approaches able to target difficult to reach target tissues. In this regard, we may need a 
different approach to delivery keeping simplicity at the front of our minds.75 According to 




Haussecker: “Small polyconjugates bringing together active endosomal release chemistries 
and RNAi-triggers may strike the balance between size and cell penetration though at the 
cost of adding further chemical complexity.”7 In this view we believe that a CAD-siRNA 
conjugate may be an important strategy to explore.  
3. INORGANIC NANOPARTICLES IN MEDICINE 
3.1. Clinical use and development of inorganic nanoparticles 
At the time of writing, approved biomedical applications of inorganic NPs are chiefly limited 
to diagnostic tools. In this regard, various NPs (gold NPs, silver NPs, iron oxide NPs, quantum 
dots etc.) are applied to enhance the signal read-out or to improve bioseparation to ensure 
pathogen or biomarker detection with improved specificity and sensitivity.76, 77 While such 
applications were initially developed by academia, various big pharmaceutical and medical 
device companies soon showed interest by investing in large R&D initiatives to develop 
nano-enabled in vitro and ex vivo diagnostic tools.78 In contrast, inorganic NPs are as of 
today rarely applied for therapeutic purposes or in vivo imaging-mediated diagnostic 
strategies, despite numerous proof-of-concept studies.79 Overall, the uncertainty regarding 
the safe use of inorganic NPs does not favor regulatory agencies to move an investigational 
new drug into clinical evaluation or to approve a new drug application. Consequently, the 
return of investments is highly insecure and investment in inorganic NP-based 
nanomedicines remains low. Several discontinued NP-containing contrast agents and 
imminent issues with bulk manufacturing further hinder the commercial incentive.80-82  
The sole inorganic nanomaterial that managed to reach the clinic is iron oxide (Table 8.2). 
The best known application of iron oxide (IO)NPs is as an MRI contrast agent, where IONPs 
were administered systemically to image liver lesions or lymphatic abnormalities83, 84 or 
orally as a gastro-intestinal contrast agent.85, 86 Despite the clinical approval, many of the 
contrast agents failed to reach widespread use and production was discontinued by 2009.87 
The intraveneous injection of carbohydrate-coated IONPs is in contrast still successfully 
applied for the management of chronic anemia in chronic kidney disease.88, 89 Aminosilane-
coated IONPs are a final IONP-formulation that obtained EU approval and is applied to treat 





An additional material currently proceeding in clinical evaluations is nano-sized gold. 
Interestingly, colloidal gold has since long been used in the treatment of rheumatoid arthritis 
before being outclassed by newer drugs.92, 93 Currently, AuNPs coupled to tumor necrosis 
factor alfa (TNFα) are evaluated for the treatment of solid tumor metastasis.
94 Silica-Au 
nanoshells coated with PEG are in turn investigated as a hyperthermia agent.76, 95 Finally, the 
local application of silica-Au nanoshells, followed by low frequency ultrasound and laser 
irradiation, is investigated for the treatment of severe acne.96 Cornell dots (silica NPs) can 
furthermore enhance PET imaging and are evaluated for the imaging of metastatic 
melanoma and the intraoperative mapping of sentinel lymph nodes.97 Finally, hafnium oxide 
nanocrystals (NBTXR3) are investigated for their potential as radioenhancing agents in soft 
tissue sarcoma and head and neck cancer.98, 99 
Table 8.2. Clinical use and development of inorganic nanoparticles. 








IV Liver Discontinued 
Combidex 
Sinerem 
IV Lymphography Discontinued 
Gastromark 
Lumirem 
Oral Upper GI tract Discontinued 
Ferristene Oral GI tract Discontinued 
Iron supplement Feraheme IV 
Chronic anemia in chronic 
kidney disease 
Available 
Hyperthermia NanoTherm IT Glioblastoma Available 
AuNP 
TNFα delivery Aurimune IV Solid tumor metastasis Phase I 
Hyperthermia AuroLase IT 
Recurrent head & neck cancer Phase I 
Primary & metastatic lung 
cancer 
Phase I 
Acne Sebashells Local Skin Phase I 
Silica NP PET Imaging Cornell dots 
Local Metastatic melanoma Phase I 
IT Sentinel lymph node mapping Phase I 
Hafnium 
oxide NP 
Radioenhancer NBTXR3 IT 
Soft tissue sarcoma Phase I 
Head and neck cancer Phase I 




Although the current perception may not be in favor of a widespread use of inorganic NPs 
for biomedical applications, a solution may be found in altering the delivery method. 
Nanotoxicity can indeed nearly completely be circumvented by delivering NPs directly into 
the cytosol.100, 101 When the NPs are not exposed to the acidic environment of the endo-
lysosomes they are less prone to dissolution – which is a main determinant to NP toxicity – 
and can potentially be safely applied.102, 103 Hence, scientists seeking to biomedically apply 
inorganic NPs may also need to identify efficient cytosolic delivery strategies. 
3.2. How to advance in the field of in vitro nanotoxicology 
In the first phase of research into nanotechnology, scientists mainly focused on the 
discovery of the unique nano-features and their potential implementation. In a second 
phase, concerns were raised regarding increasing exposure to inorganic NPs given the ever 
increasing number of NP-containing consumer products entering the market.80 
Consequently, scientists started looking into the safety of NPs. Initially, nanotoxicology was a 
small niche within the general toxicology field, but it soon became a discipline on its own 
and started to boom.104 Due to this sudden explosion of reports, consistency in terms of 
dose metrics, NP characterization, applied assays etc. was staggeringly low. Currently, we 
face an enormous pool of uncorrelated nanosafety data from which little general 
conclusions are to be drawn. On the upside, this explosion in nanotoxicology data did reveal 
important weaknesses to the in vitro nanohazard assessment paradigm. At this stage, in vitro 
nanotoxicology should enter a new phase of harmonization where efforts are truly focused 
on the development, evaluation, standardization and implementation of appropriate 
methods. A set of standard NPs should furthermore be defined, which can subsequently be 
included as controls in the optimization and validation of in vitro methods.  
The issue of inconsistent data troubles biomedical scientist seeking to rationally design a NP, 
but also hinders regulatory bodies aiming to ensure safe NP use. In the past decades, 
regulatory bodies and concerted multicenter projects therefore aimed to standardize 
nanohazard testing, exposure evaluation and risk assessment schemes. The NANoREG 
project, for instance, provided standard operating protocols for NP characterization and NP 
dispersion preparation, guidelines on harmonized data reporting and risk assessment 
schemes. Their highly concerted action in terms of applied NPs, methods, cell models and 





testing in the context of regulatory nanosafety testing were established and made available 
to the public. In addition, the organization for economic cooperation and development 
(OECD) enumerates which toxicological end points require investigation (f.i. skin and eye 
irritation105, 106, chronic toxicity107, carcinogenicity108 etc.) by which assays and in which 
(animal) model(s) in the context of hazard assessment. These guidelines were initially 
developed for chemical compounds, but were found appropriate for NP hazard assessment 
upon minor adaptations of the methods. Thus, although these methods were developed to 
evaluate NP toxicity in the context of risk assessment, many of these methods will be 
appropriate to evaluate the toxicity of NPs for biomedical applications. These methods and 
guidelines must therefore increasingly clearly be communicated to the nanotoxicology 
community to urge harmonization. Journal boards should play their part by applying stricter 
guidelines on the minimum set of NP characterization data required for correct data 
interpretation and harmonized data representation. This would allow future meta-analysis 
and may prevent the pool of uncorrelated data from overflowing. On the downside, many of 
the OECD methods involve animal testing. To enable more rapid safety screening during NP 
optimization, credible scientific bodies should provide harmonized guidance on in vitro 
assays in terms of how NP dispersions should be prepared, the dose metric and which 
endpoints to study through which (combination of) assay(s) in which cell models. Although 
the field would significantly benefit from more harmonized research, scientists should never 
be discouraged to identify further shortcomings and file for additional improvements to the 
methodologies in place.  
It is clear that nanotoxicology is becoming an increasingly complex field. Therefore, we 
believe that the field would benefit from the establishment of multidisciplinary knowledge 
centers who apply standardized methods in compliance to regulatory guidelines. A recent 
example is the European Nanomedicine Characterization Laboratory, where selected 
promising NP samples can be sent to for standardized characterization and safety testing.109 
Since the number of NPs that are selected for analysis is limited, more knowledge centers 
should be created, as we believe it would be challenging to bring all this knowledge and the 
required high end equipment together in an academic setting.  
The setting where in vitro evaluations can be of use should finally be defined. We envision 
that in vitro tests may provide a first indication of NP cytotoxicity and allow NP ranking, since 




in vitro evaluations largely neglect potential systemic interactions. However, at this point in 
vitro data are often questioned due to the in vitro-in vivo gap. Hence, current in vitro 
methods require further adaptations to enhance their predictivity, which is not 
straightforward when the true toxicity of the tested NP is uncertain.110 Hence, it may be 
necessary to perform in vivo studies to acquire knowledge on the in vivo behavior of NPs. 
With such data sets, scientists can go back to the drawing board to develop reliable 
predictive in vitro models while balancing throughput and model complexity. At this point, 
the nanotoxicology community should more closely inspect the work of in vitro toxicologists, 
whom are often quite advanced in the development of in vitro models to evaluate the 
toxicity of chemical compounds. With several adaptations, such models may also be 
applicable to estimate NP toxicity. 
4. BRIDGING THE IN VITRO-IN VIVO GAP 
Research on both topics discussed in this thesis was performed on in vitro cell models, more 
specifically 2D cell monolayers. The latter are often selected for preliminary proof-of-
concept studies given their simplicity and convenience. However, when applying such 
simplified models the question remains how the obtained data can be extrapolated first to in 
vivo effects and subsequently to observations in humans. The discrepancy between in vivo 
data and effects in humans is for instance largely responsible for the many compounds 
failing in late stage clinical trials. Similarly, effects obtained in vitro will not necessarily 
correlate with in vivo responses given the in vitro-in vivo gap.  
It is proposed that the use of more complex models could provide a bridge between in vitro 
and in vivo studies given the improved representation of the in vivo environment.111 Such 
models include co-cultures, 3D spheroids, organoids, histocultures etc. As mentioned in 
Chapter 5, the use of more complex models indeed allows an improved evaluation of 
intricate processes, such as inflammation and the metabolization of xenobiotic. In addition, 
the predictive value of such models must be validated by side-by-side comparisons with in 
vivo data. An interesting approach could be to first assess NP toxicity in vivo and go back to 
the drawing board to develop reliable predictive in vitro models while balancing throughput 





Besides the use of more intricate models, it is of utmost important to build bridges between 
in vitro and in vivo models through the definition of correlations between in vitro end points 
and in vivo observations. This is true for both simplified 2D models and intricate 3D models. 
Zhang et al. for instance showed that ROS production in a 2D pulmonary cell model can be 
correlated to inflammation in the lung.112 Similar correlations should increasingly be 
identified. However contrary to the 3R principle by Russel and Burch, it may thus again be 
necessary to first perform in vivo studies to understand the in vivo NP behavior and 
interactions. Next, relevant in vitro end points could be defined and analyzed to potentially 
identify correlations. Of note, various groups showed that the success of identifying 
correlations may be linked to the use of proper dose metrics.113, 114 When correlations were 
defined using specific compounds or NPs, at least one of them should be applied as a 
positive control in subsequent experiments. This way, the extent of the potential in vivo 
effects could be estimated based on the in vitro result. In case of nanotoxicity assessments, 
standard NPs should ideally be applied as positive and negative controls. In case of 
therapeutic approaches, the optimal experiment would include a comparison between the 
proposed therapeutic and the current therapeutic standard for the specific disease. Many 
drug candidates fail in late phase clinical testing, as they do not outperform the therapeutic 
standard. This number may be reduced by earlier direct comparisons between the standard 
and proposed therapy. In our case specifically, it would be interesting to evaluate the effect 
of siramesine in vitro, as this compunds has been shown to induce LMP in vivo. At lower 
doses, siramesine may be applicable as a delivery adjuvant. The use of the same biomarkers 
in in vitro and in vivo experiments may furthermore reduce the in vitro-in vivo gap. The 
replication of relevant exposure scenario’s may furthermore aid this process. When NPs are 
for instance expected to be inhaled it is more representative to apply an aerosol exposure 
than to simple add NPs to the culture medium of submerged lung cells.115 Finally, physiology 
based pharmacokinetic modeling will provide information on the in vivo distribution of the 
of the novel drug or nanocarrier, which will allow more rational design of the in vivo 
experiment in terms of dosing schemes. 
Overall, bridging the in vitro-in vivo gap can be achieved by increasing the model complexity 
but mainly by identifying correlations between effects observed in both model systems, 
which can be obtained through side-by-side comparisons.  





Nanoparticles (NPs) are avidly investigated in the context of biomedical application. In the 
first part of this thesis we provided an in vitro proof-of-concept that CAD adjuvants can 
significantly enhance siRNA-mediated gene silencing upon nanogel-mediated transfection. 
However, further research is required to (i) identify CADs with greater functionality and/or 
additional delivery enhancers that can be applied either alone or combined with CADs, (ii) 
establish the importance of the carrier degradation and siRNA release and the subgroup of 
nanocarriers to which our approach is applicable and (iii) create new nanocarriers with both 
the CAD and siRNA present as cargo or synthesize CAD-siRNA conjugates, which may more 
easily reach extra-hepatic tissues. Although a long road still lies ahead, the great potential of 
our adjuvant approach warrants further investigation. The repurposing strategy may lead to 
accelerated approval especially when our strategy would combine well with currently 
clinically evaluated delivery platforms. Finally, it may strongly enhance the efficiency of 
siRNA therapeutics through lowering the required siRNA dose, thereby significantly 
improving the safety profile. Clinical translation of inorganic NPs is on the contrary severely 
limited by their ambiguous safety profile. Overall, the main challenge to nanotoxicology 
remains the harmonized implementation of characterization and testing guidelines to 
reduce the generation of conflicting data. Both in the development of nanocarriers and 
nanosafety studies, the question remains how the obtained in vitro data will translate to in 
vivo responses. In the interest of bridging the in vitro-in vivo gap, more complex in vitro 
models are being applied to evaluate responses in models that more closely represent the in 
vivo microenvironment. Most importantly, future side-by-side comparisons should be 
performed to define correlations between in vitro and in vivo parameters to improve the 
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1. MATERIALS & METHODS  
1.1. Nanoparticle (NP) synthesis 
1.1.1. AuNP synthesis 
The synthesis of gold nanoparticles (AuNPs) was performed according to previously reported 
protocols 1, 2. First, 0.300 g of the aqueous gold precursor, chloroauric acid (HAuCl4, Alfa 
Aesar, USA), was dissolved in 35 mL Milli-Q water. 80 mL of a 27.125 mg/mL 
tetraoctylammonium bromide (TOAB, Sigma-Aldrich, USA) solution in toluene was added 
and the mixture was vigorously stirred during 5 minutes to ensure gradual transfer of the 
AuCl4







                         




After carefully discarding the aqueous solution and transferring the organic phase to a 250 
mL round bottom flask, 25 mL of a 13.36 mg/mL sodium borohydride (NaBH4, Roth, 
Germany) solution was added drop-wise under vigorous stirring.  This caused an immediate 
reduction of the gold precursor, which could be observed by a color shift from light orange 




        +3 𝑒−          
→          𝐴𝑢𝑜𝑟𝑔𝑎𝑛𝑖𝑐 +  4 · 𝐶𝑙𝑎𝑞𝑢𝑒𝑜𝑢𝑠
−  
Following one hour of additional stirring to allow complete reduction of the remaining Au+ 
ions, the solution was transferred to a separation funnel. Here, the resulting AuNPs were 
washed under vigorous shaking with 25 mL 0.01 M HCl to remove the excess NaBH4. After 
removal of the aqueous solution the same procedure was repeated with 25 mL 0.01 M 
NaOH (Roth, Germany) in order to eliminate the remaining acid. Finally, the AuNPs were 
washed up to four times with Milli-Q water to dispose residual salts created in the previous 
washing steps. In the interest of obtaining a thermodynamically stable size distribution, the 
obtained dispersion was stirred overnight to allow the Ostwald ripening process to take 
place. Next, 10 mL of the surfactant 1-dodecanethiol was added and the resulting mixture 
was placed at 65 °C for 3 hours to allow the attachment of the 1-dodecanethiol ligand to the 
AuNP surface. This occurred via the high affinity of the thiol groups for the AuNP surface, 





centrifuging at 1000 rpm, followed by precipitation via methanol addition and a second 
centrifugation step at 1000 rpm to obtain the AuNP precipitate. This precipitate, containing 
dodecanethiol-coated AuNPs, was dispersed in chloroform and stored at room temperature 
until further use. 
1.1.2. AgNP synthesis  
Silver nanoparticles (AgNPs) were synthesized as previously reported 3,4. First, the stabilizer 
sodium S-dodecylthiosulfate, was synthesized by adding 25 mmol sodium thiosulfate 
pentahydrate (Sigma-Aldrich, USA) in Milli-Q water to a solution of 25 mmol 1-
bromododecane (Sigma-Aldrich, USA) in 50 mL ethanol, which was prepared at 50 °C. This 
solution was stirred and refluxed at 50 °C for 3 hours after which it was kept at 4 °C 
overnight. A white precipitate was formed and isolated via filtration and vacuum drying.  
In order to synthesize the AgNPs, 1.68 mmol AgNO3 (Aldrich, USA) was added to 1.26 mmol 
of sodium S-dodecylthiosulfate that was previously dissolved in ethanol at 50 °C. This 
mixture was stirred for 10 minutes, during which the solution became light brown. Next, a 
solution of 8.4 mmol NaBH4 in 15 mL ethanol was added. As the Ag
+ ions were reduced by 
NaBH4, a coating of the dodecylthiol ligand was formed around the AgNPs, which was visibly 
detected by the glooming of the dispersion into a dark brown shade. After a 5 minute 
incubation period, 0.42 mmol ascorbic acid (Sigma-Aldrich, USA) was added and the 
resulting dispersion was stirred for 3 hours. Next, the sample was slowly cooled down to 
room temperature and the resulting AgNPs were collected via centrifugation (15 minutes at 
3000 rpm). After being washed with Milli-Q water, ethanol and acetone, the AgNPs were 
dried under vacuum and conserved dried until further use. 
1.1.3. IONP synthesis 
Iron oxide nanoparticles (IONPs) were synthesized according to the method described by 
Sun et al. 5. In short, 2 mmol of the metal precursor, iron (III) acetylacetonate Fe(acac)3 
(Sigma-Aldrich, USA), was mixed with 10 mmol 1,2-hexadecanediol (Chemos GmbH, 
Germany) in the presence of 6 mmol oleic acid (Sigma-Aldrich, USA), 6 mmol oleylamine 
(Aldrich, USA) and 20 mL phenyl ether (Sigma-Aldrich, USA). The resulting mixture was 
stirred in water-free and oxygen-free conditions and consequently heated up to 200 °C 
during 30 minutes. Next, the temperature was increased to 265 °C for an additional 30 




minutes. During the heating Fe(acac)3 was reduced to IONPs via thermal decomposition, 
with 1,2-hexadecanediol acting as a reducing agent. Oleic acid and oleylamine were in turn 
applied as surfactants to stabilize the particles during the decomposition process. The 
resulting dispersion was slowly cooled down to room temperature and removed from the 
water- and oxygen-free glove box. Subsequently, 80 mL ethanol (Roth, Germany) was added, 
which resulted in the precipitation of a black NP powder that was separated via 
centrifugation at 4000 rpm for 40 minutes. Next, the NP powder was dissolved in 20 mL of 
an organic mixture consisting of hexane with 1 vol% oleic acid and 1 vol% oleylamine after 
which centrifugation during 30 minutes at 4000 rpm was applied to remove undispersed 
aggregates. Next, ethanol was added to the supernatant to precipitate the IONPs, which 
were concentrated in a third 30-minute centrifugation step at 4000 rpm. Finally, the 
resulting pellet was redispersed in hexane and stored until further use. 
1.1.4. Synthesis of the amphiphilic polymer (PMA) 
The amphiphilic polymer poly(isobutylene-alt-maleic anhydride)-graft-dodecyl (PMA), which 
is capable of transferring hydrophobic nanoparticles from an organic to an aqueous phase, 
was prepared according to a previously published protocol 6. This polymer, of which the 
structure is depicted in Figure S1, consists of a poly(isobutylene-alt-maleic anhydride) 
hydrophilic backbone (6 kDa/mol, 531278, Sigma-Aldrich, USA) that has been modified with 
hydrophobic dodecylamine chains (D222208, Sigma-Aldrich, USA), which ensure linkage to 
the hydrophobic NPs. The dodecylamine chains were added in an amount that would ensure 
covalent binding with 75% of the anhydride rings of the poly(isobutylene-alt-maleic 
anhydride) via its amine groups. Note that covalent linkage is assumed, but not 
experimentally verified.  
 
Figure S1. Structure of the amphiphilic poly(isobutylene-alt-maleic anhydride)-graft-dodecyl (PMA) 
with the green poly(isobutylene-alt-maleic anhydride) hydrophilic backbone and bordeaux 





In short a solution of 2.70 g (15 mmol) dodecylamine (Sigma-Aldrich, USA) in 100 mL 
tetrahydrofuran was added to 3.084 g (20 mmol monomer) of poly(isobutylene-alt-maleic 
anhydride) (Sigma-Aldrich, USA) powder in a round bottom flask. The resulting mixture was 
stirred until the solution became clear and subsequently heated to 60 °C under stirring 
conditions during two hours. Next, the solution was concentrated under vacuum to a final 
volume of approximately 40 mL, which was left at 55 °C under stirring conditions overnight. 
This volume decrease was necessary to allow the interaction between the anhydride rings 
and the amino groups. The following day the solution was dried and the powder was 
redispersed in 40 mL chloroform to a final concentration of 0.5 M. 
1.1.5. Polymer coating of the NPs 
The amount of PMA monomer required to coat the NP surface was determined via the 
following equation:  
Vpolymer  =  
π ∙ deff
2 ∙ cNP ∙ VNP ∙ Rp/area
cpolymer
 
with deff being the effective diameter of the NP, which is defined as the sum of the NP core 
diameter (dc) as determined by transmission electron microscopy (TEM), and two times the 
estimated thickness of the surfactant molecule layer (lsurf = 1.2 nm; deff  = dc +2•lsurf ).
6 cNP 
and cpolymer respectively correspond to the NP and the PMA monomer concentration. Each 
PMA molecule comprises on average 39 monomer units. The concentration determination of 
the NPs is explained in detail in section II.2.  VNP and Vpolymer stand for the volume of NP 
sample solution and polymer solution, respectively. Rp/area refers to the amount of PMA 
monomers that have to be added per effective NP surface area in monomer units per nm2 
(in this study the value of 200 monomers PMA per nm2 NP surface was used, which was 
experimentally optimized). The calculated volume Vpolymer was subsequently added to the 
preset amount of NPs in a 25 mL round bottom flask. Subsequent to the slow removal of the 
solvent under vacuum, 20 mL chloroform was added, which was repeated twice. After the 
third cycle, the dried PMA-coated NPs were dispersed in a 50 mM pH 12 sodium borate 
buffer (SBB 12). The opening of the anhydride rings and the origination of carboxylic groups 
in this basic environment ensured complete dispersion in an aqueous medium, as illustrated 
in Figure S2. 





Figure S2. When the PMA polymer is added to the NPs, the dodecylamine chains (bordeaux) 
hydrophobically interact with the surfactant (black) on the NP surface. By adding sodium borohydrate 
buffer (pH = 12) the anhydride rings on the poly(isobutylene-maleic acid) backbone (green) are 
opened and carboxylic groups are formed. Hence, the NPs acquire hydrophilic properties and are 
transferred to the aqueous phase. 6  
 
1.1.6. Ligand coating of the IONPs 
To coat the IONPs by the specific ligand of choice, in this case meso-2,3-dimercaptosuccinic 
acid (DMSA, #D7881, Sigma Aldrich, USA), a ligand exchange was performed, where the 
ligand applied during the IONP synthesis was replaced by DMSA. Hereto, 50 mg of the IONPs 
were dispersed in 10 mL chloroform. Subsequently, the IONPs were purified by the addition 
of 20 mL ethanol, vigorous shaking, and sonication during 3 minutes followed by a magnetic 
separation of the IONP aggregates.7 After discarding the supernatant, the procedure was 
repeated until the supernatant became colorless. Consequently, the IONPs were dried under 
vacuum and redissolved in 20 mL toluene. Next, 90 mg DMSA was dissolved in 5 mL DMSO 
(#D4540, Sigma Aldrich, USA) to which the IONP dispersion in toluene was added. Following 
a 5-minute sonication of the resulting dispersion, it was left stirring on a rotary shaker for 4 
days. During this period, the DMSA ligand was coupled to the IONP surface and the phase 





phase containing the precipitated IONPs and a clear brownish supernatant. The latter was 
discarded and the IONPs were washed with 10 mL ethanol. Subsequently, the dispersion was 
placed in an ultrasonic bath and centrifuged at 9000 rpm during 20 minutes. These washing 
steps were repeated until the supernatant became colorless. Next, the IONPs were dried 
under vacuum. After redispersion in Milli-Q water, a heterogeneous dispersion was obtained 
that was homogenized by slowly raising the pH to 10 with diluted NaOH. Finally, a 3-day 
dialysis with a 50 kDa MWCO membrane was performed against Milli-Q water to remove the 
excess ligand and the sample was stored in Milli-Q water until further use. 
1.1.7. Purification of the NPs 
Subsequently the aqueous PMA-coated NP dispersions were concentrated by the use of 
centrifuge filters (100 kDa MWCO) for 30 minutes at 3000 rpm. Then, the NPs were injected 
in a 2% agarose gel in a Tris-Borate-EDTA buffer (TBE 0.5x) to remove empty polymer 
micelles from the samples via gel electrophoresis 8. Before injection, a mixture of glycerol 
and orange G in a 1:8 proportion (v:v, glycerol + orange G solution: PMA-coated NPs) was 
added to improve injection into the wells of the gel (i.e. due the viscosity of glycerol) and to 
allow spotting of the front of the samples while running through the gel (i.e. due to the color 
of orange G). Once the gel was placed in the tray of the electrophoresis set-up and fully 
covered with TBE 0.5X, the NP samples were injected in the well and an electric field of 15 
V/cm was applied during 60 minutes. The resulting NP bands on the gel (Figure S3 & S4) 
were cut away and transferred to a dialysis membrane (50 kDa molecular weight cut-off 
(MWCO)) with fresh TBE 0.5X. By applying the electric field for an additional 20 minutes the 
NPs were transferred out of the gel pieces into the TBE 0.5X solution. Subsequently, they 
were collected and washed 5 times via centrifugation at 3000 rpm for 20 minutes using 
centrifuge filters with 100 kDa MWCO membranes and Milli-Q water to remove the salts 
from TBE 0.5X solution. Finally, the NP dispersions were filtered with 0.2 µm syringe filter 
and stored in Milli-Q water until further use. Note that in our hands gel electrophoresis has 
so far turned out to be the best option to remove empty PMA micelles from PMA-coated 
NPs. However, some residual PMA micelles as impurities in the NP samples cannot be 
excluded. 





Figure S3. Image of a gel in which AuNPs, AgNPs and IONPs had been run with gel electrophoresis. (1) 
10 nm phosphine-coated AuNPs used as a control, (2) PMA-coated AuNPs, (3) PMA-coated AgNPs and 
(4) PMA-coated IONPs after 1 hour gel electrophoresis in a 2% agarose gel 9. The yellow band 
corresponds to the loading buffer orange G used as gel front line. Due to their negative charge the 
NPs run towards the plus pole. 
 
 
Figure S4: Image of (1) PMA-coated IONPs and (2) DMSA-coated IONPs after 1h of gel electrophoresis 
in a 2% agarose gel.9  
2. RESULTS 
2.1. Nanoparticle characterization 
2.1.1. Transmission electron microscopy (TEM) 
With the aim of obtaining the inorganic core diameter (dc) of each batch of NPs, 
transmission electron microscopy (TEM) measurements were performed using a Jeol 





coating) was added to a TEM grid and slowly dried. Finally, pictures were recorded and 
analyzed using Image J to obtain a dc histogram of each sample (Figure S4). For all three NP 
samples a mean core diameter of dc = 3.8 nm was achieved. Note that core diameters with 
exactly the same mean value of the 3 different NP types were obtained by chance (i.e. our 
synthesis does not allow to tune the NP diameter with a tenth of nm precise) and the values 
have to be seen in respect to the relatively broad size distributions (Figure S5). 
 
Figure S5. TEM images of (a) AuNPs, (c) AgNPs, and (e) IONPs, and the corresponding size 
distribution histograms N(dc) (respectively (b), (d) and (f)). For all NPs a mean dc of 3.8 nm 
was obtained. Note that due to the width of the bars in the histograms the accuracy in the 
determination of the dc is limited to 0.5 nm. For TEM pictures, the scale bar corresponds to 
20 nm. 
 




2.1.2. Inductively coupled plasma mass spectrometry (ICP-MS) 
The concentrations of the prepared NP dispersions were measured via inductively coupled 
plasma mass spectrometry (ICP-MS, 7700 Series ICP-MS from Agilent Technologies). For 
concentration determination, the aqueous samples were mixed with aqua regia (1:10, Vaqua 
regia : VNP) and subsequently incubated at room temperature for 3 hours. These mixtures 
were further diluted 1:10 (Vmixture : VHCl) in 2% HCl in water and the elemental concentrations 
(cM) of the metals Au, Ag, and Fe were measured directly with ICP-MS. Subsequently the 
elemental metal concentrations (i.e. Au, Ag, or Fe) were converted into NP concentrations 
(cNP). For this purpose the mass of a single NP core (mNP) was first calculated via the 
equation below: 
𝑚𝑁𝑃 = 𝜌𝑀 · 𝑉𝑐,𝑁𝑃 
in which ρM corresponds to the theoretical density of the NP core material (being 19.3 g/cm
3 
for gold; 10.49 g/cm3 for silver; and 5.18 g/cm3 for iron oxide) and Vc,NP  refers to the volume 
of one NP core: VNP=(4/3)·π·(dc/2)
3. The molar NP concentration (cNP) of the NP samples 
[mol/L] was obtained by dividing the elemental mass concentration [g/L] of the metals as 
obtained by ICP-MS (cM) by the mass of one mole of NPs (referred as the Avogadro constant, 
NA multiplied by the mass of a single core NP, mNP). An additional factor F was added to the 
equation. For both pure metal nanoparticles (AuNPs and AgNPs) F corresponds to one. In the 
case of IONPs, F is the ratio of the molecular weight of iron oxide (231.53 g/mol) and the 
multiplication of the molecular weight of iron (55.84 g/mol)  and the molar conversion factor 
3 (3 moles of Fe per mol of Fe3O4). Thus for the IONPs the value of F is 1.38 
(F=231.53/(55.84·3)=1.38).  
𝑐𝑁𝑃  =  
𝑐𝑀
𝑚𝑁𝑃 · 𝑁𝐴
· 𝐹  
The concentrations of the NP stock dispersions as determined by ICP-MS can be found in 
Table S1.  
Table S1. NP dispersion concentration as determined via ICP-MS. 









2.1.3. UV/Vis absorption spectroscopy 
UV/Vis absorption spectra were recorded with an Agilent 8453 UV-visible Spectroscopy 
System, which allowed the identification of the surface plasmon resonance (SPR) peaks for 
the AuNPs and AgNPs in Milli-Q water (cf. Figure S6). As expected, the data depicted in 
Figure S6 show that surface plasmon peaks were found in the AuNP and AgNP samples 
around 517 nm and 430 nm, respectively, while no peak was observed in the IONP 
absorption spectrum. 
 
Figure S6. UV/Vis absorption spectra of the various NP dispersions in Milli-Q water.  
 
Figure S7 shows that the coating did not have a major influence on the spectral properties 
since a good spectral overlap is observed for the differently coated IONPs. 
 
































For further characterization, series of minimum 4 dilutions were prepared for each NP type 
and analyzed with both UV/Vis absorption spectroscopy and ICP-MS, in order to 
experimentally determine of the extinction coefficients (εNP) of the NPs (Table S2). For 
AuNPs and AgNPs UV/Vis absorption measurements were performed at the SPR peak 
wavelength, namely 517 nm and 430 nm respectively, while a wavelength of 450 nm was 
selected for the IONPs. The εNP were retrieved from the slopes of the linear fittings of the 
molar NP concentrations (cNP), as determined via ICP-MS (Table S1), and absorption values 
(A) measured in the same sample (with a cuvette of l = 1 cm path length). The linear fittings 




Figure S8. Linear fitting of NP absorbance measured at 517 nm, 430 nm, and 450 nm for the AuNPs, AgNPs, and 
IONPs, respectively, versus the molar concentration for different NP dispersion dilutions. According to the 
Lambert Beer law the slope A/(cNP•1cm) = εNP represents the εNP value for (a) AuNPs, (b) AgNPs, (c) PMA-IONPs 
and (d) DMSA-IONPs. R
2
 is the coefficient of determination of the linear regression fit, which is an indication of 







y = 9.508.876,1473x - 0,0038 









a)                                      AuNP-PMA 
y = 14967785,8780x - 0,0916 









b)                                    AgNP-PMA 
y = 398604,0532x + 0,1639 









c)                                       IONP-PMA 
A450 = 600712.2427 M
-1xCIONP + 0.0442 


























2.1.4. Dynamic light scattering (DLS) and laser Doppler anemometry (LDA) 
The NP hydrodynamic diameter (dh) was measured via dynamic light scattering (DLS), while 
the zeta potential was measured via laser Doppler anemometry (LDA). Both measurements 
were performed in a Zetasizer Nano ZS (Malvern Instruments). The samples were filtered 
and diluted to a concentration of 10 nM in Milli-Q water. Samples were then equilibrated for 
2-5 minutes at 25 °C to avoid interferences in NP movement due to temperature gradients. 
Measurements were performed in triplicates and the results are shown as the mean ± 
standard deviation (SD). 
2.2. Cell-NP interactions 
2.2.1. Cell morphology 
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Nanotechnology is one of the key enabling technologies of the 21st century. Various 
inorganic and organic materials show unique properties when engineered at the nanoscale, 
which opens up a myriad of novel applications. In the context of medicine, organic 
nanoparticles (NP) are often applied as carriers for insoluble drugs or macromolecules, such 
as nucleic acids (NA). The latter require packaging into a nanocarrier to ensure 
transportation to the target tissue and cellular internalization, while maintaining their 
functionality. In this regard, both viral and non-viral vectors were explored in parallel. Non-
viral delivery vehicles are considered relatively safe but generally fall short in terms of 
transfection efficiency given the many extra- and intracellular barriers limiting NA delivery. 
At the intracellular level, endosomal escape is regarded to be the major bottleneck. Even for 
state-of-the-art carriers, a minor fraction of the internalized NA dose escapes to the cytosol 
whereas the bulk of the NA cargo is trafficked to the lysosomal compartment for 
degradation. Hence, current strategies aim to improve endosomal escape from the early or 
late endosomal compartment to avoid lysosomal entrapment. In contrast to this paradigm, 
we set out to specifically target the lysosomes to induce release of the accumulated NA 
cargo. In particular, we aimed to improve the cytosolic delivery of small interfering (si)RNA 
upon nanogel (NG)-mediated transfection using approved low molecular weight drugs, 
namely cationic amphiphilic drugs (CADs), which functionally inhibit acid sphingomyelinase 
(FIASMA). A general introduction into the use of siRNA to trigger the RNA interference 
pathway, nanogels as non-viral nanocarriers and FIASMAs as lysosomal delivery enhancers is 
provided in Chapter 1.  
Since the early days of plasmid (p)DNA delivery through lipid-based nanocarriers, scientists 
explored the use of small molecules to boost the delivery potential. Our literature study 
(Chapter 2) revealed adjuvants can enhance tumor penetration or cellular internalization. In 
turn, some adjuvants boost endosomal escape, alter intracellular trafficking or directly 
promote the transgene expression of successfully delivered pDNA. Several small molecules 
can furthermore improve the transfection efficiency by reducing the innate immune 
response or facilitating pDNA nuclear entry. Finally, pleiotropic molecules such as 
SUMMARY & CONCLUSION 




chloroquine, dexamethasone and other steroids, improve NA transfection by simultaneously 
influencing various delivery-related processes. Overall, this overview underscores the 
diversity small molecular adjuvant approaches to stimulate NA delivery. Of note, the activity 
of several adjuvants is limited to specific NA and/or nanocarriers and the moment of the 
adjuvant treatment relative to the transfection. Hence, further insights into nanocarrier 
uptake, intracellular trafficking and endosomal escape should allow to rationally combine 
adjuvants, NA and carriers in the future. 
The data presented in Chapter 3 show that the FIASMAs induce the accumulation of 
phospholipids, cholesterol and sphingomyelin. This transient phospholipidosis (PLD) 
phenotype was suggested to reduce the lysosomal membrane stability, leading to enhanced 
transfer of siRNA from the lysosomes into the cytosol. Of note, this assumed improved siRNA 
delivery drastically enhanced the gene silencing potential of the siRNA-loaded NGs. In 
addition, we showed that the lysosomes could be applied as a depot for prolonged and 
controlled siRNA release, underscoring the great potential of the CAD adjuvant approach. In 
Chapter 4 we explored the broader applicability of this adjuvant strategy. First, we showed 
that the induction of PLD through mechanisms other than acid sphingomyelinase inhibition, 
does not necessarily improve siRNA delivery. In turn, distinct adjuvants might too greatly 
affect the lysosomal membrane stability wherefore the stimulated cytosolic siRNA release 
coincides with significant cytotoxicity. In addition, messenger (m)RNA delivery could not to a 
similar extent be improved and the delivery of siRNA by lipid-based transfection reagents 
was less prone to the FIASMA adjuvant effect.  
In conclusion, we showed that a sequential FIASMA treatment is able to markedly improve 
the therapeutic potential of siRNA-loaded NGs. However, this effect was both carrier- and 
NA-dependent since neither mRNA delivery nor transfection by lipid-based carriers could 
equally be enhanced. Research on the subject could be continued by identifying more 
potent adjuvants through large-scale compound screenings. A more detailed elucidation of 
the cellular FIASMA effects will in turn clarify to which subgroup of NA and carriers this 
method can be applied. Finally, the co-inclusion of the FIASMA and NA into the nanocarrier 
or the synthesis of FIASMA-NA conjugates should be explored.  




In addition to the use of organic nanocarriers as delivery vehicles for NA, inorganic NPs are 
being explored in a biomedical setting, with their unique properties allowing improvements 
to current detection and/or treatment strategies or the development of novel biomedical 
applications. Iron oxide (IO)NPs for instance allow magnetism-guided delivery, magnetic 
resonance imaging (MRI) and cancer treatment through hyperthermia. Despite extensive 
proof-of-concept studies, few inorganic NPs are currently clinically applied, which can largely 
be attributed to their elusive safety profiles given the inconsistent nanotoxicity data. 
Chapter 5 summarizes cell-NP interactions suggested to elicit nanotoxicity, the current in 
vitro approaches to study nanotoxicity and their major limitations. We discuss novel 
methods and show that the complexity of the cell model influences NP uptake and toxicity, 
highlighting the need for optimization and standardization of the in vitro nanotoxicity testing 
paradigm. 
In Chapter 6, we assessed how IONPs interact with six related neural cell types, namely 
murine and human neural stem cells (NSC), neuroblastoma and immortalized neural 
progenitor cells. Besides species-specific variations, the neuroblastoma cell line and NSCs 
were respectively least and most affected. Of note, we obtained cell type-specific 
nanotoxicity profiles in terms of the extent and nature of the effects, indicating that a single 
toxicity end point will not provide sufficient information on in vitro nanotoxicity. In a follow-
up study (Chapter 7), we reported on the influence of the cell type on the optimization of 
NPs for biomedical applications. We showed that DMSA-coated IONPs outperformed PMA-
coated IONPs in the same six neural cell types, although the differentially coated IONPs 
again elicited cell-type specific toxicity profiles. Hence, the major cell type-dependent 
variations in the observed effects warrant the use of relevant human cell models that mimic 
the envisioned target cells as closely as possible.   
Overall, the optimization and standardization of in vitro hazard evaluations would 
significantly improve the quality of in vitro nanotoxicity research, which could boost the 
clinical development of inorganic NPs. In analogy with guidelines on in vivo methods 
established by regulatory bodies, a consensus should be reached on how to assess 
nanotoxicity in vitro. We showed that the cell type is a critical factor that should not be 
overlooked in the standardization process. Most importantly, correlations should be 




established between in vitro effects and in vivo adverse events to allow extrapolation to 






Nanotechnologie is één van de drijfveren achter vele technologische ontwikkelingen in de 
21ste eeuw. Vele anorganische en organische materialen vertonen immers unieke 
eigenschappen op nanoscopische schaal, hetgeen de deur opent naar nieuwe innovatieve 
producten. Op medisch vlak, worden organische nanopartikels (NPs) veelal gebruikt as 
dragers voor weinig oplosbare moleculen of marcomoleculen, zoals nucleïne zuren (NZ). 
Deze laatste groep wordt verpakt in nanoscopische dragers om transport tot zijn doelwit 
orgaan en opname in de cel te bewerkstelligen zonder verlies van NZ functie. In deze context 
werden zowel virale als niet-virale dragers in parallel ontwikkeld. Niet-virale dragers worden 
als relatief veilig beschouwd maar worden gekenmerkt door een beperkte transfectie 
efficiëntie door vele extra- en intracellulaire barrières die een efficiënte NZ aflevering 
belemmeren. Endosomale ontsnapping van de NZ wordt beschouwd als het belangrijkste 
intracellulaire knelpunt. Zelfs ingeval van transfectie met zeer efficiënte dragers, kan slecht 
een beperkte fractie van de NZ cargo in het cytoplasma afgeleverd worden. Het leeuwendeel 
van de NZ cargo wordt immers naar de lysosomen geleid, waar ze ten prooi vallen van 
degraderende enzymen. Om deze afbraak te voorkomen, focussen de meeste recente 
strategieën op het vermeiden van de lysosomen door vrijstelling van de NZ vanuit de vroege 
of late endosomen te faciliteren. In tegenstelling tot deze algemene trend, ontwikkelden wij 
een methode om NZ vrijstelling vanuit de lysosomen te bekomen. Meer specifiek, trachtten 
we om de afgifte van klein interfererend (si)RNA na transfectie met nanogelen (NG) te 
bevorderen met behulp van kationische amfifiele geneesmiddelen, meer specifiek 
functionele inhibitoren van het zure sphingomyelinase (FIASMAs). In Hoofdstuk 1 werden 
siRNA, NZ aflevering met behulp van NG en het gebruik van FIASMAs als adjuvans uitgediept.  
Initieel werd plasmide (p)DNA afgeleverd via liposomale formulaties. Sinds het gebruik van 
deze methode werd geëxperimenteerd met adjuvantia om de pDNA afleveringsefficiëntie te 
verhogen. In Hoofstuk 2 werden zowel de initiële als recente studies belicht die gebruik 
maken van een adjuvans strategie. Bepaalde adjuvantia verbeteren de penetratie van de 
drager in de tumor, terwijl de cellulaire opname eveneens verbeterd kan worden. Enkele 
andere moleculen zullen specifiek de endosomale vrijstelling verbeteren, interfereren met 
de intracellulaire verdeling of rechtstreeks de transgen expressie van het afgeleverde pDNA 
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stimuleren. Twee bijkomende klassen van ajduvantia kunnen de immuun respons reduceren 
of pDNA translocatie naar de kern begunstigen. Finaal, zijn er bepaalde pleiotrope 
moleculen (chloroquine, dexamethason en andere steroïden) die simultaan verschillende 
processen beïnvloeden. Dit overzicht toont duidelijk de diversiteit van de adjuvans strategie 
aan hoewel het effect van bepaalde adjuvantia sterk afhangt van het NZ, de drager en het 
moment van toediening ten opzichte van de transfectie. Verdere inzichten in opname, 
intracellulaire verdeling en endosomale vrijstelling zullen in de toekomst toelaten om 
rationeel adjuvantia, NZ en dragers te combineren.  
In Hoofdstuk 3 werd aangetoond dat FIASMAs de accumulatie van fosfolipiden, cholesterol 
en sphingomyeline induceren. Deze kortstondige inductie van een fosfolipidosis fenotype 
zou vervolgens de stabiliteit van de lysosomale membraan verminderen, waardoor siRNA 
kan worden vrijgesteld in het cytosol. De vooropgestelde verbeterde afgifte van siRNA naar 
het cytosol zorgde op zijn beurt voor een sterke verhoging van het therapeutisch potentieel 
van de siRNA-beladen NG. Verder toonden we aan dat de lysosomen als depot voor 
gestimuleerde en verlengde siRNA vrijstelling konden dienen. In Hoofdstuk 4 werd de 
bredere toepasbaarheid van de FIASMA adjuvans methode bestudeerd. Ten eerste 
bemerkten we dat een molecule die fosfolipidosis induceert, niet noodzakelijk een 
functioneel adjuvans is. Verder kunnen bepaalde moleculen de lysosomale membraan 
mogelijkst te sterk beschadigen waardoor verhoogde siRNA vrijstelling gepaard gaat met 
cytotoxiciteit. Verder kon de vrijstelling van mRNA niet in een zelfde mate verbeterd worden 
en waren lipide-gebaseerde transfectie methoden minder gevoelig voor het FIASMA effect.  
Samengevat, hebben we aangetoond dat FIASMAs het therapeutisch potentieel van siRNA-
belanden NG sterk verhogen maar dat dit effect zowel drager- als NZ-afhankelijk is. Een 
volgende stap in dit onderzoek is mogelijks het aanduiden van meer potente adjuvantia met 
behulp van een grootschalige screening. Verder kan de opheldering van het mechanisme 
waardoor de FIASMAs siRNA aflevering verbeteren uitsluitsel geven over voor welke NZ en 
dragers deze methode toepasbaar is. Een laatste element dat verder onderzoek vergt is de 
co-inclusie van zowel het adjuvans als het NZ in eenzelfde drager of de synthese van 
adjuvans-NZ conjugaten.  




Naast het gebruik van organische nanoscopische dragers, worden mogelijke biomedische 
toepassingen van inorganische NPs uitgebreid bestudeerd. Bepaalde NPs kunnen immers 
toegepast worden om bestaande detectiemethoden of therapieën te verbeteren of om 
nieuwe biomedische applicaties te ontwikkelen. Ijzer oxide (IO)NPs kunnen bijvoorbeeld 
gebruikt worden in magnetisch-geleide aflevering van medicijnen, beeldvorming met 
magnetische resonantie en de bestrijding van kanker via hyperthermie. Ondanks de vele 
proof-of-concept studies worden slecht weinig anorganische NPs klinisch toegepast. Dit is in 
grote mate te wijten aan de onzekere veiligheid van anorganische NPs door de vele 
contradictorische resultaten van nanotoxiciteitsstudies. In Hoofdstuk 5 werden NP-
interacties op celniveau besproken die tot nanotoxiciteit kunnen leiden. Verder werden de 
meest gebruikte in vitro methoden en hun tekortkomingen aangehaald. Nieuwe methoden 
werden geïntroduceerd en we toonden aan dat de complexiteit van het in vitro cel model de 
NP opname en toxiciteit beïnvloed, hetgeen het belang van optimalisatie en standaardisatie 
van in vitro methoden benadrukt.  
In Hoofdstuk 6 bestudeerde we hoe IONPs interageren met zes neuronale celtypes, namelijk 
humane en muriene neuronale stam cellen (NSC), een geïmmortaliseerde neuronale 
progenitor cellijn en een neuroblastoma kankercellijn. Naast species-specifieke variaties, 
bemerkten we dat de kanker cellijn en NSC respectievelijk het minst en meest uitgesproken 
reageerden op de IONPs. Meer nog, elk celtype vertoonde een uniek toxiciteitsprofiel 
waarbij de mate en het type effect verschilden. Hieruit blijkt dat een enkel eindpunt 
onvoldoende informatie biedt omtrent de in vitro nanotoxiciteit. Vervolgens (Hoofdstuk 7) 
rapporteerden we hoe het celtype de optimalisatie van NPs kan beïnvloeden. Hoewel de 
DMSA-gecoate IONPs in het algemeen minder toxisch bleken dan de PMA-gecoate IONPs 
werd in elk celtype opnieuw een uniek nanotoxiciteitsprofiel bekomen. Daarom is het 
belangrijk om een celmodel te gebruikten dat de doelwitcel zo dicht mogelijk benaderd.     
In het algemeen zou de optimalisatie en standaardisatie van in vitro nanohazard evaluaties 
de kwaliteit van nanotoxiciteisonderzoek sterk bevorderen. Hierdoor zou eveneens de 
klinische toepassing van NPs een boost kunnen krijgen. Naar analogie met richtlijnen 
omtrent in vivo experimenten, zouden regulatoren een consensus moeten bieden over hoe 
nanotoxiciteit in vitro geëvalueerd dient te worden. In dit werk hebben we aangetoond dat 
het celmodel een belangrijke invloed heeft en dat deze factor niet vergeten mag worden in 




de optimalisatie en standaardisatie. Daarnaast dienen bruggen gebouwd te worden tussen 
in vitro toxiciteitseindpunten en in vivo waarnemingen aangezien dit zou betere extrapolatie 
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Nu rest er enkel nog een woord van dank, want een doctoraat succesvol tot een einde 
brengen dat doe je ten slotte niet alleen. 
Stefaan, jou wil ik in de eerste plaats bedankt voor de kans die je me gegeven hebt om in je 
lab van start te kunnen gaan. Ik heb ik veel opgestoken van de wijze waarop jij met een open 
en verwonderde blik naar wetenschap (en de wereld in het algemeen) kijkt en complexe 
materie in heldere metaforen giet. Daarnaast bewonder ik hoe jij het lab runt, op tijd en 
stond een luisterend oor biedt en ons al eens belangrijke levenslessen meegeeft. De 
bemoedigende woorden en het vertrouwen dat ik van je kreeg tijdens de eindspurt van dit 
doctoraat deden wonderen. Je oprechte interesse in de persoon en de wens dat je 
studenten goed terecht komen sieren je als persoon. Ik mag hopen dat ik in mijn verdere 
loopbaan het geluk heb zulke people managers te treffen. 
Koen, bedankt om me bijna halfweg mijn doctoraat te adopteren. Het was een plezier om 
vanaf dan jouw inventieve FIASMA concept uit te werken. Jij bent een vat vol ideeën en bezit 
een enorme kennis omtrent de onderwerpen van je studenten. Via je zeer nauwgezette 
begeleiding zet je jouw studenten aan om de beste wetenschapper in hun naar boven te 
halen. Nu de samenwerking op zijn einde loopt, hoop ik dat jij even trost bent als ik op de 
resultaten die we samen bereikt hebben. Verder is je benoeming niet minder dan verdiend 
en wens ik je het allerbeste toe in je verdere academische carrière. 
Kevin, ik hou goede herinneringen over aan de samenwerking omtrent de (as)symmetrische 
nanopartikelverdeling. We hebben een belangrijk nieuw inzicht kunnen aanleveren en ik ben 
trost dat ik mijn steentje hieraan heb kunnen bijdragen! Daarnaast heb ik zowel van jou als 
Jo belangrijke steun gekregen tijdens het eerste jaar van mijn doctoraat. In de monday 
meetings samen met Stefaan (DS) leerden jullie me dat er van een correcte hypothese 
vertrokken moet worden en het belang van het definiëren van het juiste experiment met de 
correcte controles. Katrien en Ine ook jullie wil ik bedanken voor de wetenschappelijke 
suggesties tijdens o.a. discussion groups. Daarnaast wil ik elk van jullie bedanken om het 






studenten zeker niet aan kansen ontbreekt en de gecombineerde expertises een brede 
ondersteuning bieden.   
Katharine en Ilse, voor alle administratieve beslommeringen kon ik steeds jullie terecht. 
Oprecht bedankt om het ‘minder fijne’ papierwerk over te nemen en om steeds de bareel te 
openen als ik mijn batch weer eens vergeten was. Dan zijn er misschien wel dé meest 
onmisbare personen als het over praktische aangelegenheden gaat: Bart & Hilde. Ik denk 
dat we maar half beseffen hoeveel jullie doen om het lab draaiende te houden. Hilde, jouw 
hulp in het cellab is alleszins een geschenk uit de hemel. Bart, ik heb ontelbare keren aan 
jouw deur gestaan om een of ander ‘probleem’ te melden. Bovendien kon je me steeds uit 
de nood helpen als ik (weer net te laat) iets wou bestellen. Je staat verder steevast klaar met 
advies of het nu gaat over praktische of persoonlijke zaken. Laatst heb ik mogen 
ondervinden dat je ook nog is een absolute pro bent in het inbinden van thesissen! Die vier 
jaar hebben me geleerd dat je een prachtige persoon bent met het hart op de juiste plek en 
daarom terecht een steunpilaar voor velen als het even (experimenteel) niet mee wil. Toon, 
ook jij mag in dit rijtje niet ontbreken. Jij bent absoluut de reddende engel voor velen van 
ons. Ook ik heb menig maal gebeld omdat ik een probleem met één van de microscopen zelf 
niet opgelost kreeg. Je bent oprecht een aanwinst voor het lab. 
Wat heb ik geluk gehad dat ik in een labo met zo’n TOP mensen terecht gekomen ben. Ik had 
me geen leukere bende kunnen wensen om deze vier jaar THUNDER mee te gaan. De 
jaarlijkse weekendjes, vele concerten, ongeplande uitstapjes naar de bar des amis & de 
charlatan, afterwork feestjes, housewarmings, uitgelopen traktaties en alles wat ik hier nu 
nog vergeet, hebben ervoor gezorgd dat jullie meer zijn geworden dan collega’s. 
First things first, second things second, third things third and the rest you can count on your 
own. Om te beginnen zijn er natuurlijk de bureau-maatjes. Koen, jij zat er al even toen Elisa 
en ik toekwamen. De Wim Helsen one-liners wilden al wel eens door de bureau vliegen en 
het was al snel duidelijk dat we over veel zaken op dezelfde lijn zitten. Het was dan ook 
onwennig toen je stoel een tijdje leeg bleef. Anderzijds ben ik content dat je een fijne 
nieuwe uitdaging gevonden hebt en ik wens jou en Suus een prachtige reis toe. Al kom ik 
graag eerst nog eens langs voor dat goed glas rood. Elisa, I will certainly remember your 




wish you the best of luck with everything life has in store for you now. Lotte, natuurlijk zal ik 
jou associëren met de manke swept field, maar er is veel meer dan dat. We hebben elkaar 
tonnen advies gegeven over experimenten, posters, presentaties, figuren etc. Belangrijker 
dan dat, we waren elkaars steun en toeverlaat en de gezellige babbels zal ik ontzettend 
missen. Ik wens je een beter vervolg van 2017 en daarna ontzettend veel succes met het 
afronden van je doctoraat! (Je hebt mijn nr als je raad nodig hebt .) Aranit, Ik wens je toe 
dat je verder groeit in je onderzoek. Felix, I want to thank you a lot for the encouraging 
gestures during these final months. I wish you the best of luck with your FRAP-eye project 
and your further career.   
Dan zijn er natuurlijk de (ex-)leden van Team Koen. Lynn, jou wil ik oprecht bedanken  voor 
het delen van jouw kennis over de nanogelen. Zonder jouw expertise en advies had ik een 
hele tijd lopen klungelen. Ook nadien kon ik met al mijn vragen bij jou terecht. Je bent met 
stip één van de meest behulpzame personen van het lab. Nog zo iemand is Laura. Als ik jou 
in drie worden zou moeten omschrijven zouden het behulpzaam, zachtaardig en precies zijn. 
Ik heb sowieso goede herinneringen aan de vele momenten samen in het cellab, telkens op 
onze zelfde plek meezingen met de radio of met Roland Garros of De Tour op de 
achtergrond. Stephan (aka complex), ook bij jou kon ik steeds terecht voor advies over van 
alles en nog wat. Daarnaast ben je ook een echte doorzetter. Ik denk dat weinigen het je 
nadoen om zo’n werkijver aan de dag te blijven brengen terwijl de resultaten niet steeds 
meevallen. Ik moet toegeven, jouw thesis was mijn voorbeeld tijdens het schrijven van deze 
thesis. Pieterjan, ik denk niet dat ik al ooit iemand ontmoet heb die zo ‘droog’ is als jij. Ook 
jou wil ik bedanken voor de aanmoediging de laatste maanden. Daarnaast wou ik je dit nog 
meegeven: “Experience is what you obtain, when you don’t achieve what you want”. Jelter, 
Laura nr 2 en auteur van ‘the rising of a new star…’. Je bent misschien niet de meest 
uitbundige persoon maar kan onverwacht grappig uit de hoek komen: dat pipet mysterie 
heeft toen echt mijn dag gemaakt! Thijs, ik denk dat het FIASMA project bij jou zeker in 
goede handen is. Succes ermee! Finally, Roberta and Arianna: the Italian reinforcements. I 
wish you both the best of luck in the four years to come.  
“Like the legendary feeling” of “Like the legend of the phoenix”? Karen, wij zijn er 4 jaar 
geleden samen aan begonnen. Bijna hadden we elkaar al eerder gekend als we samen met 





noot vergeten. Jij die ’s morgens niet uit je woorden komt en ik die voor de eerste koffie nog 
niet echt veel kan verdragen: top combo! In de eerste twee jaar hebben we ook op 
wetenschappelijk vlak enorm veel aan elkaar gehad. Daarna heb jij je oogproject uit de 
grond gestampt, waar ik tonnen respect voor heb. Ik had het je niet nagedaan. Nu begint het 
ook voor jou te korten. Geniet nog met volle teugen van Canada voor je aan de eindspurt 
begint! Rita, I truly admire your focus and persistence. No wonder you’re office buddies call 
you ‘the machine’. I’m sure you will do great in Portugal and I can’t wait to come to your 
defense in September . Eline, nog zo’n harde werker, jij lijkt altijd alles onder controle te 
hebben en je project lijkt als een sneltrein te gaan. Ik heb veel respect voor de wijze waarop 
jij door je doctoraat lijkt te fietsen en je bijna eeuwig optimisme. Gaëlle, de nieuweling in de 
VNB groep, jou wens ik veel succes met je project.  
Heleen, ook jij bent er al van het begin bij. Als een onwetende jonkie kon ik steeds bij jou 
terecht. Maar ook daarbuiten waren er vele leuke momenten; samen trainen voor de 
ekiden, I Love Techno, de labo-biochemie-doos,… Merci voor alles! Joke, de absolute 
sfeermaker en het nieuwe prijsbeest van het lab. Samen met Karen vorm je een top-oog-
team. Laurens, de eerste die liever naar MNM luistert dan StuBru. Gelukkig komen we in 
zake wijn beter overeen. Alleszins merci voor de info omtrent CRISPR/Cas9. Ranhua I 
enjoyed our collaboration and trips to Leuven and am very happy with the result of our 
collaboration. Rein, jij bent zo mogelijk de meest gezapige mens die ik ken. Daarbuiten ben 
je oprecht geïnteresseerd in mensen en weet je wanneer een schouderklopje of 
bemoedigend woordje op zijn plaats is. Juan, you have such a bubbly personality! Your joy, 
optimism, Laura Pausini imitations and love for karaoke were exactly what the group 
needed. Silke, ik apprecieer je eerlijkheid en de wijze waarop je er de sfeer steeds weet in te 
houden. Ik duim mee dat je het noorderlicht ziet in IJsland! Heyang, I was truly surprised 
when I found out you like football! By the way, you and Jing make delicious dumplings. 
Molood, I wish you the best of luck with your project.  
Thomas, Katrien, Ine DC en George jullie hebben het lab al een tijdje of pas sinds kort 
verlaten. Ook jullie wil ik bedanken voor de vele goede herinneringen. Thomas zijn (soms 
flauwe) grappen, Katrien haar photoshop kunsten, Ine haar kaasgunstigheid en George zijn 




Next, I wish to thank the collaborators with whom I worked together during the past four 
years. Prof. Préat and Chiara, thank you for the nice collaboration on the FIASMA project. I 
furthermore want to thank Prof. Parak, Béatriz and Daniel for the synthesis and 
characterization of the applied inorganic nanoparticles and straightforward communication 
afterwards. Finally, I thank Prof. Doak for the opportunity to perform research and use the 
IN Cell Analyzer at the DNA damage group at Swansea University. 
Natuurlijk behoort ook een woord van dank toe aan al mijn lieve vrienden: de SNOW 
vrienden, de altijd-feest vriendinnetjes en aanhang, de VUB-vrienden en al degenen die niet 
in een vakje te schuiven zijn. Bedankt voor jullie interesse, het aanhoren van de vele 
verhalen en frustraties, de steun in de laatste maanden en zo veel meer…  
Mama, papa jullie wil ik bedanken voor de kansen en steun die jullie me altijd gegeven 
hebben. Thomas, merci om te komen luisteren. Dit is normaal gezien de laatste keer dat je 
naar iets van mij zal moeten komen kijken ;).  Ook aan de Wilgenhof-clan, merci. 
Adriaan, ik weet niet of je beseft hoe groot jouw positieve impact op me is geweest de 
voorbije jaren. Toen ik me in het begin van mijn PhD dreigde te verliezen in de 
experimenten, vertelde je me het verhaal van het glas, de stenen, de keitjes en het zand. De 
moraal van het verhaal: “ No matter how full the jar of life may seem, there is always room 
for a couple of beers with some friends”. Hoewel dit de laatste maanden misschien minder 
het geval was, was het de voorbije jaren wel steevast het devies en zal het vanaf nu opnieuw 
zijn ingang nemen. Daarvoor alleen al kan ik je niet genoeg bedanken. We hebben samen 
vier prachtige jaren achter de rug met Laos, Cambodia, Southport Weekender, Namibië, 
Lapland en de aanschaf van ons appartement als absolute hoogtepunten. Nooit gedacht dat 
we na 9 jaar op dit punt zouden staan. Maar kijk, jij maakt me gelukkig. Je wenste me de 
laatste dagen voor het indienen telkens weer succes. Je brengt me aan het lachen, zet mijn 
favoriete nummers op als ik er nood aan heb, hebt een glas wijn voor me uitgeschonken als 
het een rotdag was… Je bent de laatste vier jaar mijn grootste steun en toeverlaat geweest 
en ik hoop dat je dat nog heel lang zal blijven.  
 
Aan iedereen: carrément merci      (-> zo gebruik je het dus Stephan) 
 
Freya
 
 
 
 
 
